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(who  may  have  got  it  right  for  selenium  and  cancer  prevention) Abstract 
Prospective  studies  and  recent  intervention  trials  suggest  that  the  risk of  some  cancers  may 
be  inversely  related  to  selenium  intake  and  this  is  supported  by  strong  experimental 
evidence  from  animal  cancer  models.  How  this  cancer-protective  effect  is  mediated  is 
unclear  but  interference  with  the  balance  of  growth/apoptosis  during  tumor  outgrowth  is  a 
likely  hypothesis.  In  general,  there  is  a  correlation  between  the  effectiveness  of  selenium 
compounds  as  chernopreventive  agents  in  vivo  and  their  ability  to  inhibit  cell  growth  and 
induce  apoptosis  in  vitro.  As  processes  of  cellular  growth  regulation  are  intimately 
regulated  by  intracellular  signalling,  this  study  has  investigated  the  signal  transduction 
pathways  affected  by  selenium  compounds  in  several  cell  culture  systems. 
Using  the  cervical  carcinoma  cell  line,  HeLa,  molecular  mediators  of  selenium-induced 
apoptosis  were  investigated.  These  studies  were  later  extended  to  biopsies  of  normal 
human  oral  mucosa  cells  (NOMCs)  and  human  oral  carcinoma  cells  (SCCs),  using  a 
primary  culture  system.  Two  selenium  compounds  were  tested:  selenodiglutathione  (SDG), 
the  primary  metabolite  of  selenite,  the  most  commonly  used  cancer-protective  selenium 
compound  in  animal  models,  and  the  synthetic  compound,  1,4-phenylenebis 
(methylene)selenocyanate  (pXSQ,  one  of  the  most  potent  chernopreventive  selenium 
compounds.  Both  compounds  induced  apoptosis  in  the  cells  tested  and  this  was  associated 
with  a  strong  induction  of  Fas  ligand  (Fasl).  Blocking  Fas  activation  resulted  in  inhibition 
of  apoptosis.  Activities  of  stress  kinases  JNK  (c-jun  N-terminal  kinase)  and  p38  were  also 
induced  on  selenium  treatment  and  intervention  studies  using  specific  chemical  inhibitors 
and/or  dominant  negative  mutants  suggested  that  JNK,  but  not  p38,  was  functionally 
important  for  the  induction  of  apoptosis  and  Fasl.  The  relative  levels  of  induction  of  JNK 
activity  and  Fasl  also  correlated  with  the  extent  of  apoptosis  observed.  On  treatment  with 
SDG,  but  not  pXSC,  SCCs  were  found  to  preferentially  activate  the  JNK/Fasl  pathway 
compared  to  NOMCs  and  this  correlated  with  enhanced  sensitivity  of  SCCs  to  SDG- 
induced  apoptosis.  Both  SDG  and  pXSC  also  appeared  to  modulate  activities  of  other 
signalling  proteins  like  extracellular  regulated  kinases  (ERKs)  1,2  &5  and  Akt.  However, 
functional  interference  with  these  pathways  using  specific  chemical  inhibitors  or 
constitutively  activated  mutants  revealed  either  none  or  a  small  effect  on  apoptosis- 
induction.  One  exception  was  the  activation  of  Akt  by  SDG  in  SCCs:  inhibiting  its  activity 
sensitised  the  cells  to  apoptosis  significantly.  Finally,  preliminary  xenograft  studies  have 
confirmed  the  induction  of  apoptosis  in  vivo,  using  chernopreventive  dietary-levels  of 
selenium. iv 
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AIF  apoptosis  inducing  factor 
ASK1  apoptosis  signal-regulated  kinase  1 
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FGF  fibroblast  growth  factor 
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G2  gap/growth  phase  2 
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GFP  green  fluorescent  protein 
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GPx  glutathione  peroxidase 
GST  glutathione-S-transferases xiv 
HEPES  N-(2-hydroxyethyl)  piperazine-N'-(2-ethanesulphonic  acid) 
IgG  immunoglobulin  G 
11,2  interleukin-2 
JNK  c-jun  N-terminal  kinase 
kb  kilobases 
kDa  kilodalton 
M.  month/s 
M  molar 
MAPK  mitogen  activated  protein  kinase 
[tci  microcurie 
mg  milligram 
Rg  microgram 
min  minute/s 
ml  millilitre 
Rl  microlitre 
mm  millimeter 
mm  millimolar 
[LM  micromolar 
MNU  methy1nitrosourea 
MMP  matrix  metalloproteinase 
mRNA  messenger  ribonucleic  acid 
NADPH  nicotinamide  adenine  dinucleotide  phosphate 
NaF  sodium  fluoride 
NK  cells  natural  killer  cells 
NNK  4-(methylnitrosoamino)-l-(3-pyridyl)-l-butanone 
NOMC  human  normal  oral  mucosa-derived  cell 
N-terminal  amino  terminal 
02  oxygen 
OD  optical  density 
o/n  overnight 
PARP  poly(ADP-ribose)polymerase 
p38  p38  kinase 
PBS  phosphate  buffered  saline 
PDGF  platelet-derived  growth  factor 
PI  propidium  iodide 
PKA  protein  kinase  A xv 
PKC  protein  kinase  CII 
PMA  phorbol  12-myristate  13-acetate 
PMSF  phenylmethylsulphonyl  fluoride 
PPM  parts  per  million 
PXSC  1,4-phenylene-bis-(methylene)selenocyanate 
Rb  retinoblastorna  protein 
RNA  ribonucleic  acid 
ROS  reactive  oxygen  species 
RT-PCR  reverse  transcription-polymerase  chain  reaction 
S  synthesis  phase 
SAC  Se-allylselenocysteine 
ScC  human  squamous  cell  carcinoma  cell 
SDS  sodium  dodecylsulphate 
SDS-PAGE  SDS-polyacrylamide  gel  electrophoresis 
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SECIS  selenocysteine  insertion  sequence 
SM  selenomethionine 
SMC  Se-methylselenocysteine 
SSB  single  strand  breaks 
TEMED  N,  N,  N',  N'-Tetramethyl-ethylenediamine 
TNFa  tumour  necrosis  factor-cc 
TPA  tetradecanoyl  phorbol-  13  -acetate 
TPS  triphenylselenoniurn  chloride 
tRNA  transfer  RNA 
TR  thioredoxin  reductase 
Trx  thioredoxin 
TUNEL  terminal  deoxynucleotidyl  transferase-mediated  dUTP  nick  end- 
labelling 
U  unit 
UV  ultraviolet  radiation 
V/V  volume  for  volume 
W/V  weight  for  volume 
y  year/s I 
1  Selenium  in  Biology  and  Disease 
1.1  Introduction 
Selenium  has  been  puzzling  researchers  ever  since  its  discovery  in  1817.  In  biology,  it  was 
long  considered  to  be  toxic  (Franke,  1934)  until  it  was  identified  as  growth  factor  in  certain 
bacteria  (Pinsent,  1954)  and  an  essential  trace  element  in  rats  (Schwarz  and  Foltz,  1957); 
regarded  as  a  potential  carcinogen  for  years  but  now  widely  accepted  as  a  potential  anti- 
tumorigenic  agent  (Combs  Jr  et  al.,  2001);  extensively  used  as  an  antioxidant,  but  has  also 
been  noted  to  undergo  pro-oxidant  redox  cycling  (Seko  and  Imura,  1997);  an  functional 
component  of  peroxidases  but  also  shown  to  use  peroxides  to  form  cellular  structures 
(Ursini  et  al.,  1999). 
Study  of  biological  roles  played  by  selenium  started  in  the  1930's  when  it  was 
demonstrated  to  be  the  dietary  component  responsible  for  certain  diseases  in  animals 
grazing  in  specific  areas  of  the  American  grasslands  (reviewed  in  (Hatfield,  2000)).  This 
prompted  the  United  States  Department  of  Agriculture  (USDA)  to  map  the  selenium 
content  of  forage  in  the  USA  and  it  was  shown  that  selenium  content  of  the  plants  vary 
according  to  where  they  were  grown.  Thus  effectively  identifying  selenium-deficient  areas 
in  the  USA.  Later,  the  identification  of  selenium  as  an  essential  nutrient  prompted 
investigations  into  several  veterinary  diseases,  like  white  muscle  disease  in  sheep,  endemic 
to  the  low-selenium  areas.  Supplementation  of  selenium  not  only  had  a  positive  response  in 
these  diseases  but  also  on  disease  previously  related  to  vitamin  E  deficiency,  like  mulberry 
heart  disease  of  pigs,  suggesting  for  the  first  time  that  selenium  may  function  as  an 
antioxidant  (reviewed  in  (Hatfield,  2000)). 
The  evidence  for  selenium  as  a  micronutrient  in  humans  came  from  studies  in  China 
investigating  the  childhood  cardiomyopathy,  Keshan  disease  (Gu,  1983).  The  disease  was 
endemic  to  certain  regions  and  the  veterinary  history  of  these  areas  showed  similar 
diseases  in  cattle  as  those  caused  by  selenium  deficiency.  Supplementation  of  selenium  to 
affected  children  protected  them  from  the  ravages  of  the  disease,  thus  identifying  selenium 
deficiency  with  increased  susceptibility  to  cardiornyopathy  in  humans  (Gu,  1983). 
These  studies  proved  to  be  a  turning  point  in  selenium  research  as  the  focus  now  shifted, 
from  mechanisms  of  toxicity,  to  its  role  in  normal  biochemistry.  This  effort  led  to 
identification  of  selenoproteins,  the  major  agents  underlying  the  role  of  selenium  in Chapter  1 
promoting  health.  Research  over  the  last  3  decades  has  unequivocally  implicated  selenium 
to  be  an  essential  nutrient  of  fundamental  importance  to  human  physiology  and  the  role  of 
selenoproteins  in  maintaining  human  health  has  become  more  apparent. 
Selenium  is  a  component  of  selenoproteins  as  the  21't  amino  acid,  selenocysteine 
(Chambers  et  al.,  1986;  Zinoni  et  al.,  1986).  It  is  now  clear  that  several  of  these 
selenoenzymes  are  selenium-dependent  as  selenocysteine  forms  a  critical  component  of 
their  catalytic  sites  (Chambers  et  al.,  1986;  Zinoni  et  al.,  1986). 
Additionally,  selenium  also  influences  other  major  human  health  issues  like,  cancer 
prevention  and  tumour  cell  surveillance  but  these  are  not  likely  to  be  mediated  exclusively 
by  selenoprotein  activities  (reviewed  in  (Rayrnan,  2000)). 
1.2  Acute  selenium  deficiency  and  health  conditions 
Selenium  enters  the  food  chain  through  plants,  which  enrich  it  from  the  soil.  Low  soil 
selenium  content,  or  soil  low  in  bio-available  selenium  due  to  complex  formation  with 
metals,  reduce  the  selenium  content  of  plants  growing  in  these  conditions.  The 
consequences  are  primarily  observed  in  livestock  grazing  in  such  areas  and  also  in  humans 
predominantly  reliant  on  local  produce. 
Animal-deficiency  diseases  have  been  extensively  identified  since  the  discovery  that 
selenium  was  a  trace  nutrient  necessary  for  anaerobic  growth  of  E.  coli  on  glucose  and  in 
the  prevention  of  liver  necrosis  in  rats  (Pinsent,  1954;  Schwarz  and  Foltz,  1957).  Selenium 
deficiency-related  pathologies,  like  reproductive  defects  and  white-muscle  disease,  had 
such  a  severe  impact  on  the  economy  that  selenium  supplementation  of  high-risk  animals 
is  now  routine  (Combs  and  Combs  Jr,  1986).  Recent  studies  have  also  implicated  the 
incidence  of  transmissible  spongiform  encephalopathy  (TSE)  in  cattle  to  be  partially 
related  to  selenium  deficiency  (Purdey,  2000). 
In  humans,  the  major  conditions  recognised  to  stem  from  selenium-deficiency  are  the 
endemic  cardiomyopathy,  Keshan  disease  and  Kashin-Beck  disease  -a  debilitating 
osteoarthropathy.  Both  were  first  identified  in  an  area  of  China  with  extremely  low 
selenium  content  in  the  soil  (Cheng  et  al.,  1990;  Gu,  1983;  Li  et  al.,  2000). 
As  discussed  in  detail  later,  low  selenium  status  has  also  been  associated  with  a 
significantly  increased  risk  of  cancer  incidence.  A  2-6  fold  (depending  on  the  study) Chapter  13 
increased  risk  has  been  identified  in  the  cohort  with  lowest  serum  selenium  concentrations 
(Rayman,  2000). 
1.3  Health  effects  of  mild  selenium  deficiency 
A  large  body  of  evidence  has  accumulated  suggesting  mild  selenium  deficiency  can 
adversely  affect  health  and  enhance  disease  susceptibility.  One  of  the  confounding  factors 
in  such  analyses  is  that  while  selenium  may  directly  affect  the  disease  process,  it  may  also 
be  an  outcome  of  the  condition  itself,  perhaps  aiding  disease  progression.  However, 
carefully  controlled  clinical  and  prospective  trials  can  effectively  discriminate  between 
these  alterations.  Selenium  status  appears  to  influence  a  large  number  physiological 
activities  with  profound  implications  on  human  health,  some  of  the  major  issues  are 
discussed  next. 
1.3.1  Reproduction 
Selenium  deficiency  has  been  recorded  to  be  associated  with  incidence  of  miscarriage  in 
livestock  and  selenium  supplementation  appears  to  prevent  early  pregnancy  loss  (Stuart 
and  Oehme,  1982).  In  humans,  an  association  between  low  serum  selenium  and  first 
trimester  and  recurrent  miscarriages  have  been  reported  (Barrington  et  al.,  1996).  This  is 
thought  to  be  associated  with  a  reduced  protection  from  oxidative  damage  resulting  from 
diminished  activity  of  glutathione  peroxidases  (GPx),  the  first  selenoprotein  to  be 
characterised  (Barrington  et  al.,  1996).  A  later  study,  however,  did  not  find  differences  in 
selenium  levels  between  the  control  group  and  non-pregnant  women  with  a  history  of 
recurrent  miscarriage  (Nicoll  et  al.,  1999).  However,  as  this  study  did  not  exclude  women 
who  had  had  a  miscarriage  from  the  control  group,  it  is  possible  that  this  may  have 
confounded  the  result. 
Male  fertility  is  affected  by  selenium  as  it  is  required  for  formation  of  testosterone  and 
normal  development  of  spermatozoa  (Behne  et  al.,  1996).  A  trial  held  in  Scotland  found 
supplementation  of  sub-fertile  men  with  100[tgIday  selenium  for  3  months  significantly 
increased  sperm  motility  and  reproductive  success  (Scott  et  al.,  1998).  However,  a  similar 
trial  in  Poland  on  sub-fertile  men  using  200[ig/day  for  3  months  found  no  association  with 
supplementation  and  sperm  motility  (Iwanier  and  Zachara,  1995). 
A  mechanistic  explanation  for  these  findings  came  from  studies  on  rat  spermatogenesis. 
Typically,  the  mid-piece  of  the  sperm  which  embeds  the  helix  of  mitochondria  in  a  keratin- Chapter  14 
like  material,  is  morphologically  altered  in  selenium  deficiency;  not  only  is  sperm  motility 
decreased,  but  the  head  and  the  tail  may  become  disconnected  because  of  fractures  of  the 
midpiece  material  (Wu  et  al.,  1973).  In  selenium-sufficient  animals  the  element  is 
associated  with  the  mitochondrial  capsule  material,  which  becomes  fragile  on  selenium 
deficiency  (Ursini  et  al.,  1999).  It  was  demonstrated  that  an  isoform  of  GPx,  phospholipid 
hydroperoxide  GPx  (PHGPx  or  GPx4),  is  abundantly  expressed  in  spermatids  and  protects 
them  from  oxidative  damage.  However,  in  fully  mature  spermatozoa  it  was  found  to  have 
no  peroxidase  activity  and  was  transformed  to  an  insoluble  structural  protein  accounting 
for  almost  50%  of  all  proteins  in  the  capsule  (Ursini  et  al.,  1999).  This  polymerisation, 
conceivably,  confers  the  structural  stability  required  for  normal  sperm  activity. 
1.3.2  Immune  function 
Selenium  deficiency  has  been  strongly  associated  with  loss  of  immunocompetence  and  is 
attributed  to  attenuated  cell-mediated  immunity  and  B-cell  function  (Spallholz  et  al., 
1990).  Supplementation  with  seleniumP  has  a  significant  immunostimulatory  effect, 
including  clonal  expansion  of  activated  T  cells  (Kiremidjian-Schumacher  et  al.,  1994).  For 
example,  supplementation  with  200[tg/day  selenite  resulted  in  enhanced  response  of 
leukocytes  to  antigen  stimulation,  development  of  cytotoxic  T  cells  and  destruction  of 
tumour  cells  (Kiremidjian-Schumacher  et  al.,  1994).  The  activity  of  natural-killer  cells 
(NK-cells)  was  also  increased  on  selenium  supplementation  (Kiremidjian-Schumacher  et 
al.,  1996). 
The  explanation  for  these  effects  may  be  as  follows.  Activated  lymphocytes  and  NK-cells 
require  interleukin-2  (IL-2)  stimulation  for  clonal  expansion  and  differentiation  to 
cytotoxic  T  cells.  Selenium  is  thought  to  promote  IL,  2  stimulation  directly  by 
transcriptionally  upregulating  the  IL-2  receptors  in  these  cells  (Roy  et  al.,  1992;  Roy  et  al., 
1994),  thus  providing  a  possible  mechanistic  explanation  for  immunostimulatory  effects  of 
selenium.  There  are  indications  that  selenium  may  have  more  diverse  roles  in  regulating 
the  immune  system.  For  example,  several  T-cell  associated  genes  are  putative 
selenoproteins  and  this  is  complemented  by  an  increased  selenophosphate  synthetase  (a 
crucial  enzyme  involved  in  selenocysteine  synthesis)  activity  in  activated  T  cells 
(Guimaraes  et  al.,  1996;  Taylor,  1995). Chapter  1 
1.3.3  Viral  Infection 
A  newly  emerging  area  of  selenium  research  is  regarding  its  role  in  viral  infection  where  it 
has  been  implicated  in  the  occurrence,  virulence  and  disease  progression  (Beck,  2000).  The 
best  evidence  comes  from  studies  on  the  coxsackie  virus,  which  is  thought  to  be  a  co-factor 
in  the  endemic  cardiomyopathy,  Keshan  disease  (Beck,  2000).  Injection  of  selenium- 
deficient  mice  with  a  benign  strain  of  the  coxsackie  virus  resulted  in  mutations  in  the  viral 
genome  resulting  in  a  cardiovirulent  form  that  caused  myocarditis  (Beck  et  al.,  1995). 
However,  this  was  not  seen  in  selenium-sufficient  mice,  but  when  the  virus  isolated  from 
selenium-deficient  mice  showing  cardiornyopathy  was  introduced  to  selenium-sufficient 
mice,  it  still  induced  heart  damage  (Beck  et  al.,  1995).  Further  studies  in  GPx-1  knockout 
mice  revealed  that  this  enzyme  was  critical  in  avoiding  mutations  in  the  viral  genome 
(Beck  et  al.,  1998).  Thus  it  appears  that  selenium-deficiency  may  affect  viral  genomes, 
presumably  due  to  enhanced  oxidative  stress  inducing  mutations,  resulting  in  emergence  of 
virulent  forms.  In  this  context,  it  is  intriguing  to  note  the  emergence  of  several  new  strains 
of  influenza  from  the  selenium-deficient  regions  in  China  and  the  evidence  that  the  first 
putative  crossing-over  of  HIV  to  humans  occurred  in  a  selenium-deficient  population  in 
Zaire  (Beck  et  al.,  1995;  Rayman,  2000). 
Plasma  selenium  has  recently  been  demonstrated  to  be  a  strong  predictor  of  the  outcome  of 
HIV  infection.  Individuals  with  plasma  selenium  concentrations  below  85[tg/l  were  found 
to  be  20  times  more  likely  to  succumb  to  HIV-related  causes  than  those  with  adequate 
levels  (Baum  et  al.,  1997).  In  fact,  low  plasma  selenium  was  shown  to  be  a  greater  risk 
factor  (by  a  factor  of  16)  for  mortality  than  low  helper-T-cell  count.  In  infected  individuals, 
low  plasma  levels  were  significantly  related  to  mortality  and  accelerated  disease 
progression  (Campa  et  al.,  1999).  This  data,  together  with  reports  of  concomitant  reduction 
in  plasma  selenium  with  loss  of  helper-T-cells  suggest  that  selenium-deficiency  is  a  major 
risk  factor  for  the  outcome  of  HIV  infection  (Beck,  2000).  Similar  data  for  a  protective  role 
of  selenium  in  the  progression  of  hepatitis  B  and  C  infection  to  liver  cancer  (Yu  et  al., 
1999;  Yu  et  al.,  1997)  and  for  infection  with  the  Ebola  virus  have  been  reported 
(Ramanathan  and  Taylor,  1997). 
Thus,  it  appears  that  maintenance  of  proper  redox  processes  and  immunocompetence  by 
selenium  may  be  the  critical  mechanisms  mediating  its  anti-viral  effect.  Selenium  may  be 
selectively  incorporated  by  the  viral  proteins  resulting  in  a  decrease  in  available  selenium 
in  the  host  as  described  for  HIV,  coxackie  virus,  hepatitis  and  measles  viruses  (Zhang  et 
al.,  1999a;  Zhang  et  al.,  1999b;  Zhao  et  al.,  2000).  It  has  been  suggested  by  the  Taylor Chapter  16 
group  (Zhao  et  al.,  2000)  that  with  adequate  selenium  the  host  immunity  will  be  optimal 
and  consequently  the  host  cell  is  less  likely  to  die  as  a  result  of  the  infection.  In  this 
situation  the  best  viral  strategy  is  to  replicate  at  low  levels  and  maintain  a  persistent 
disease.  However,  on  selenium  depletion,  the  resulting  diminished  immunocompetence, 
increased  oxidative  stress  and  enhanced  host  cell  apoptosis  and  forces  the  virus  to  replicate 
faster  leading  to  exacerbated  disease  progression. 
1.3.4  Cardiovascular  disease 
Several  studies  have  shown  that  selenium  may  have  a  protective  effect  against 
cardiovascular  disease  (Neve,  1996).  A  2-3  fold  risk  of  cardiovascular  mortality  was  found 
to  be  associated  with  serum  selenium  concentrations  below  45[tg/l  (Salonen  et  al.,  1982). 
Another  study  found  a  significant  inverse  correlation  between  toenail  selenium  content  and 
the  risk  of  myocardial  infarctions,  but  only  in  the  population  with  the  lowest  level  of 
selenium  (Kardinaal  et  al.,  1997).  An  inverse  association  between  risk  of  ischaernic  heart 
disease  and  serum  selenium  concentration  below  79[tg/l  was  reported  from  another  study 
on  Danish  men  (Suadicani  et  al.,  1992).  A  few  studies  have  failed  to  find  a  significant 
correlation,  but  most  of  these  included  either  none  or  very  few  people  with  low 
plasma/toenail  selenium  concentrations  (Neve,  1996;  Salvini  et  al.,  1995).  It  may  well  be 
that  a  significant  effect  is  detectable  only  when  low  selenium  status  (and  not  moderate)  is 
compared  with  higher  levels.  The  levels  of  other  antioxidants  may  also  be  a  complicating 
factor. 
As  the  transformation  of  macrophages  to  foam  cells  and  the  proliferation  smooth  muscle 
resulting  from  their  uptake  of  oxidised  low-density  lipoprotein  (oxLDL)  are  considered  to 
initiate  artherogenesis,  and  antioxidants  may  be  able  to  inhibit  this  process  by  blocking 
1DL  oxidation  (Neve,  1996).  This  makes  selenoproteins  with  antioxidant  activities,  like 
GPx's,  attractive  targets  for  mediating  the  protective  effects  of  selenium.  Selenium 
deficiency  has  been  shown  to  modulate  the  eicosanoid  metabolism  and  induce  preferential 
production  pro-coagulant  thromboxanes  over  the  anti-clotting  prostacyclins  (Neve,  1996). 
This  may  result  in  platelet  aggregation  and  vasoconstriction  and  consequently  lead  to 
cardiovascular  diseases:  this  is  suggested  by  a  study  in  Finland  which  reported  an  inverse 
association  between  platelet  aggregability  and  selenium  status  in  individuals  suffering  from 
ischaernic  heart  disease  (Salonen  et  al.,  1988). Chapter  1 
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Since  the  brain  is  deficient  in  catalase  activity,  selenoproteins  with  antioxidant  functions 
are  critical  to  the  removal  of  damaging  peroxides  in  this  organ  (Ramaekers  et  al.,  1994). 
This  crucial  role  is  reflected  in  the  observation  that  during  selenium  deficiency,  the 
selenium  supply  to  the  brain  receives  priority  (Hawkes  and  Hornbostel,  1996). 
Supplementation  with  selenium  has  been  shown  to  reduce  epileptic  seizures  in  children 
(Weber  et  al.,  1991)  and  neurotransmitter  cycling  is  also  affected  in  selenium  deficiency 
(Castano  et  al.,  1997).  Alzheimer's  patients  have  been  reported  to  have  significantly 
reduced  selenium  content  in  the  brain  (Hawkes  and  Hornbostel,  1996)  and  selenium 
deficiency  is  also  associated  with  accelerated  cognitive  decline  in  the  elderly  (Berr  et  al., 
2000;  Hawkes  and  Hornbostel,  1996). 
Several  studies  have  revealed  a  significant  association  of  selenium  deficiency  with 
negative  mood  states  (Hawkes  and  Hornbostel,  1996).  Individuals  fed  low  selenium  diets 
for  15  weeks  showed  significantly  decreased  positive  mood  indicators,  like 
'clearheaded/confused'  and  'elated/depressed'  ratios  (Finley  and  Penland,  1998). 
Individuals  on  high  selenium  diets  had  more  positive  overall  mood  indicators,  for  example 
improved  'confident/unsure',  'composed/anxious'  and  'clearheaded/confused'  subscores 
(Finley  and  Penland,  1998).  Selenium  supplementation  has  also  been  shown  to  decrease 
anxiety,  tiredness  and  depression,  the  effect  being  greatest  in  individuals  on  lowest 
selenium  diets  (Benton  and  Cook,  1990). 
1.3.6  Other  health  issues 
Glutathione  peroxidase  (GPx)  activity  in  essential  in  the  thyroid  gland  to  prevent 
oxidation-induced  toxicity  (Coppinger  and  Diamond,  2000).  Also,  the  production  of 
thyroid  hormones  are  dependent  upon  the  catalytic  activities  of  iodothyronine  deiodinases, 
which  are  selenoproteins  (Coppinger  and  Diamond,  2000).  Selenium  therefore  regulates 
thyroid  hormone  metabolism  and  consequent  endocrine  effects.  Supplementation  with 
selenium  increases  deiodinase  activity  and  enhanced  production  of  the  active  hormone 
(Coppinger  and  Diamond,  2000).  Symptoms  of  hypothyroidism  are  aggravated  by 
selenium  (and  iodine)  deficiency  as  reported  from  selenium-deficient  areas  (Vanderpas  et 
al.,  1990). 
The  ageing  process  is  associated  with  accumulation  of  oxidative  damage,  reduced 
effectiveness  of  the  immune  system  and  endocrine  dysfunction.  As  discussed  earlier, Chapter  18 
selenium  can  conceivably  influence  all  these  factors.  In  fact  recent  reports  have  noted 
longevity  in  areas  with  selenium-rich  soils  and  has  been  hypothesised  that  areas  of  the 
world  with  higher  lifespan  than  average  are  those  where  bioavailable  soil  selenium  is high 
(McKenzie  et  al.,  2000).  Indicators  of  lipid  peroxidation  from  elderly  patients  show  a 
inverse  correlation  with  plasma  selenium  content  and  lowered  GPx  activity  is  found  in 
neutrophils  from  elderly  individuals  (McKenzie  et  al.,  2000).  In  a  study  of  individuals  aged 
between  96-106  years,  the  percentage  of  NK-cells  in  circulation  was  related  to  the 
selenium  status  (Ravaglia  et  al.,  2000).  Finally,  it  has  been  suggested  that  telomere  length, 
which  progressively  shortens  with  every  cell  division,  may  also  be  maintained  by  enhanced 
GPx  activity  (Serra  et  al.,  2000). 
Selenium  also  affects  several  human  conditions  associated  with  oxidative  stress  and 
inflammation.  While  oxidative  stress  is  managed  by  antioxidant  activities  of  several 
selenoproteins,  inflammatory  responses  may  be  regulated  by  the  influence  of  selenium  on 
cycloxygenase  and  lipoxygenase  pathways  resulting  in  reduced  production  of 
inflammatory  leukotrienes  and  prostaglandins.  This  may explain  why  selenium  status  has 
been  inversely  associated  with  relative  risk  and/or  severity  of  diseases  like  asthma, 
pancreatitis  and  arthritis  (Hasselmark  et  al.,  1993;  Knekt  et  al.,  2000;  McCloy,  1998). 
1.4  The  eukaryotic  selenoproteome 
Proteins  containing  the  21't  amino  acid,  selenocysteine  (Sec),  which  is  cotranslationally 
incorporated  and  is  coded  by  the  UGA  codon  are  termed  selenoproteins  (Chambers  et  al., 
1986;  Zinoni  et  al.,  1986).  Eukaryotic  selenoproteins  have  no  sequence  homology  to 
prokaryotic  selenoproteins  apart  from  selenophosphate  synthetase,  which  itself  participates 
in  Sec  biosynthesis  (Gladyshev,  2000).  This  suggests  independent  origins  of  these  two 
selenoproteomes  (i.  e.  all  selenoproteins  in  an  organism).  The  eukaryotic  selenoproteins  of 
known  functions  participate  in  predominantly  redox  reactions  which  are  crucial  to  normal 
physiology.  The  incorporation  of  selencysteine  in  the  active  sites  of  these  proteins  render 
them  uniquely  suited  to  participate  in  redox  pathways. 
1.4.1  Selenoproteins 
The  22  known  selenoproteins  can  be  classified  into  groups  based  on  the  location  of  Sec  on 
the  polypeptide.  The  two  major  groups  emerge  from  such  analysis  are  the  GPx  group  and 
the  thioredoxin  reductase  (TR)  group.  The  GPx  group  is  by  far  the  most  abundant  and 
includes  proteins  in  which  Sec  is  located  in  the  N-terminal  region.  Several  members Chapter  19 
contain  UXXC  or  CXXU  motifs  (U,  See;  C,  cysteine  and  X,  any  amino  acid)  that  resemble 
active  eentres  of  thioredoxins  and  glutaredoxins.  Predicted  structures  in  this  group  indicate 
presence  of  both  ct-helices  and  P-sheets  and  most  appear  to  have  the  thioredoxin  fold. 
During  catalysis,  the  See  in  these  proteins  is  oxidised  to  selenic  acid  or  forms 
selenosulphide  bonds.  The  TR  group  has  See  located  in  the  C-terminal  regions  and  this 
positioning  in  the  conformationally  flexible  C-terminus  ensures  accessibility  of  this 
residue.  All  other  selenoproteins  are  placed  in  group  3  and  are  often  characterised  by  a 
CXU  or  UXC  motif.  In  most  selenoproteins,  in  all  three  groups,  the  Sec-flanking 
sequences  are  abundant  in  glycine,  cysteine  (Cys)  and  basic  amino  acids.  The  functional 
significance  of  this  remains  unclear. 
Unlike  the  prokaryotic  selenoproteins  only  a  few  physiological  functions  of  selenoproteins 
in  humans  is  well  characterised.  Broadly,  these  activities  include  prevention  of  oxidative 
damage,  control  of  cellular  redox  processes,  involvement  in  spermatogenesis  and 
modulation  of  thyroid  hormones.  Since  a  recent  review  (Gladyshev,  2000)  has 
exhaustively  discussed  the  functions  of  selenoproteins,  a  short  summary  of  the  major 
mammalian  selenoproteins  is  presented  in  Table  1.4.1. 
1.4.2  Selenocysteine:  function  and  evolution 
See  and  Cys  and  Serine  (Ser)  differ  by  only  one  atom.  However,  their  properties  vary 
greatly,  since  at  physiological  pH,  serine  is  completely  protonated,  the  majority  of 
cysteines  are  also  protonated  but  See  remains  ionised  (Stadtman,  1996).  This  property  and 
the  lower  redox  potential  confers  Sec  its  special  properties  as  reflected  in  the  inability  of 
Cys  to  functionally  replace  Sec  in  known  selenoproteins.  Enzyme  kinetic  comparison 
between  selenoproteins  and  their  naturally  occurring  Cys-containing  counterparts  reveal 
the  considerably  higher  k,  "  for  selenoproteins  (Stadtman,  1996). 
While  selenoproteins  are  found  in  all  three  major  groups  of  life  forms  (archaea,  bacteria 
and  eukaryotes)  several  species  in  each  of  these  groups  lack  genes  for  selenoproteins.  The 
evolutionary  implications  of  this  observation  are  unclear.  Sec  could  have  been  encoded  by 
UGA  in  primitive  anerobic  organisms,  where  it  was  found  in  abundance.  However,  with 
the  advent  of  oxygen  in  the  atmosphere  the  selection  pressure  may  have  turned  against  its 
use  because  of  its  lability  in  aerobic  conditions.  Some  organisms,  presumably  with 
enhanced  oxidant  defences,  could  have  retained  Sec  and  its  insertion  machinery.  The 
aerobic  lability  of  Sec  and  the  development  of  the  specific  Sec  insertion  system  may  have 10 
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then  left  UGA  without  an  overt  function,  perhaps  resulting  in  its  evolution  as  a  termination 
signal. 
1.4.3  Selenocysteine  incorporation 
Unlike  the  other  20  naturally  occurring  amino  acids,  selenocysteine  is  synthesised  on  its 
tRNA  and  is  coded  for  by  the  'stop'  codon  UGA  (Bock,  2000;  Stadtman,  1996).  This 
enigmatic  dual  function  of  the  UGA  codon  has  resulted  in  a  lot  of  interest  directed  towards 
elucidating  the  molecular  mechanisms  involved  in  selenocysteine  incorporation.  The 
molecular  mechanisms  mediating  selenocysteine  incorporation  in  prokaryotes  are 
extensively  characterised  and  recently  reviewed  in  detail  (Bock,  2000).  This  section  will 
therefore  primarily  deal  with  recent  developments  in  the  field  of  selenocysteine 
incorporation  in  eukaryotes. 
Sec  incorporation  occurs  co-translationally  at  the  UGA  codon.  Specific  secondary  stem- 
loop  structures  in  the  selenoprotein  mRNA,  called  the  Sec  insertion  sequences  (SECIS), 
have  been  defined  by  mutational  analysis  that  signal  the  recoding  of  the  UGA  codon  from 
translation  termination  to  Sec  insertion  (Martin  III  and  Berry,  2000).  In  E.  coli,  the  selC 
tp  gene  codes  for  the  'NA[Ser]Sec  ,  which  has  an  anticodon  complementary  to  UGA  and  is 
initially  charged  with  serine  by  seryl-tRNA  synthetase.  Sec  synthase,  encoded  by  the  selA 
gene,  later  converts  this  seryl-tRNAls"]Sec  to  selenocysteyl_tRNAjS,,  jsec.  The  activated 
selenium  donor  species  is  monoselenophosphate  which  is  produced  by  the  activity  of  the 
sell)  gene  product,  selenophosphate  synthetase  (Bock,  2000). 
tp  In  order  to  prevent  'NA[Ser]Sec  from  functioning  as  an  ubiquitous  UGA  suppressor,  the 
presence  of  specific  structural  features  make  it  unrecognisable  by  the  standard  elongation 
factor  (EF).  A  specific  Sec  elongation  factor,  SELB  binds  selenocysteyl-  tRNA[ser]Se'  and 
_tp  to  the  SECIS  element  but  not  the  precursor  seryl  'NA[Ser]Sec,  thus  tethering  the 
selenocysteyl-  tRNA[Ser]s'c  and  the  mRNA  in  the  ribosome  (Bock,  2000). 
Unlike  prokaryotes,  eukaryotes  have  the  SECIS  elements  located  in  the  Y-untranslated 
region  (3'-U'IR)  and  these  can  recode  any  upstream,  in  frame  UGAs  in  the  entire  mRNA, 
as  long  as  a  minimum  distance  criteria  is  met  (Martin  et  al.,  1996).  Eukaryote  SECIS 
elements  contain,  among  other  features,  an  A-G  tandem  purine  pair  at  the  base  of  the  stem- 
loop  structure  which  is  required  for  Sec  insertion  (Mansell  and  Berry,  2000).  Recently  a 
mammalian  protein,  SECIS-binding  protein  2  (SBP2),  has  been  characterised  which 
specifically  binds  to  the  purine  pair  and  immunodepletion  of  SBP2  has  been  shown  to Chapter  1  12 
abolish  Sec  incorporation  (Copeland  and  Driscoll,  1999;  Copeland  et  al.,  2000).  Addition 
of  recombinant  SBP2  restores  Sec  incorporation  demonstrating  that,  at  least  in  vitro,  SBP2 
is  required  for  the  insertion  of  Sec  (Copeland  et  al.,  2000).  However,  SBP2  was  found  to 
have  no  detectable  EF  activity  (Copeland  et  al.,  2000). 
Taking  note  of  the  identification  of  a  Sec-specific  EF  in  the  archaeon  Methanococcus 
jannaschii,  which,  while  showing  specificity  for  selenocysteyl-  tRNAise,  3sec,  did  not  bind 
SECIS  elements,  researchers  started  to  look  for  a  putative  mammalian  Sec-specific  EF  that 
showed  specificity  towards  selenocysteyl-  tRNA[ser3Sec  but  did  not  have  a  SECIS-binding 
domain.  Finally  by  sequential  database  searches  with  the  putative  archaeal  SELB 
sequence,  the  mammalian  EF  specific  to  Sec  incorporation,  eEFSec,  was  identified  (Berry 
et  al.,  2001;  Dennis,  1997). 
Thus  the  current  model  in  eukaryotes  (Fig  1.4.1)  suggest  that  the  presence  of  SECIS 
elements  in  the  3'-UTRs  of  selenoproteins  signals  the  binding  of  SBP2  to  these  specialised 
structural  elements.  This  is  followed  by  the  recruitment  of  eEFSeC_tRNA[serisec  to  the 
SECIS-SBP2  complex.  Assembly  of  the  complex  at  the  SECIS  element,  followed  by 
delivery  of  eEFSeC_tRNA[Ser]Sec  to  a  UGA  codon  occupying  the  ribosomal  A  site  would 
allow  translation  of  all  in  frame  UGAs  in  the  open  reading  frame  as  Sec  (Fig  1.4.1). 
What  still  remains  obscure  is  the  interaction  of  eEFSec-selenocysteyl-tRNAESerlSec  with 
translation  release  factors  (eRF1  and  3)  which  bring  about  termination.  The  simple  model 
of  the  UGA  codon  at  the  ribosomal  A  site  being  decoded  by  either  the  release  factors  or 
eEFSec-selenocysteyl_tRNA[serisec  would  have  predicted  some  sort  of  competition  where 
increase  in  eRF1  or  eRF3  would  favour  termination.  However,  recent  evidence  suggests 
that  overexpression  of  both  eRF1  and  eRF3  result  in  increased  Sec  incorporation 
(Grundner-Culemann  et  al.,  2001).  This  may  point  towards  non-canonical  regulation  of 
termination  in  ribosomes  translating  selenoprotein  mRNAs;  perhaps  the  presence  or 
absence  of  SBP2  dictating  whether  UGA  will  be  read  as  a  Sec  insertion  codon  or  a 
termination  signal.  Other,  as  yet  unidentified,  proteins  may  also  be  involved  in  specifying 
the  fate  of  the  UGA  codon. 
1.4.4  Identification  of  new  selenoproteins 
With  the  sequencing  of  several  genomes,  the  time  is  appropriate  to  use  database  screens  to 
identify  novel  selenoproteins  which  can  be  later  characterised.  Since  the  characteristic  of 
selenoprotein  genes  is  the  sequence  specifying  the  SECIS  elements  in  the  3'-UTR  of  the 13 
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Fig  1.4.1  Model  for  eukaryotic  selenocysteine  insertion  (Mansell  and  Berry,  2000). 
A  model  of  the  current  mechanisms  believed  to  mediate  Sec  incorporation.  The  figure  shows  a 
mRNA  molecule  with  the  SECIS  elements  as  a  stem-loop  structure.  SBP2  and  eEFSec  interact 
with  this  structure  and  recruit  selenocysteyl-tRNA  which  incorporates  a  Sec  residue  in  the 
nascent  polypeptide  at  the  UGA  'termination'  codon.  Translation  termination  is  brought  about 
by  either  as  yet  unidentified  factors  or  non-canonical  regulation  of  eRFI  and  eRF3.  Additional 
factors  required  for  the  formation  of  this  complex,  association  with  ribosomes  and  regulation  of 
release  factor  are  as  yet  unidentified.  Putative  activities  are  marked  with  '?  '. Chapter  1  14 
corresponding  mRNA,  this  has  been  successfully  utilised  to  identify  novel  selenoproteins 
in  silico  (Gladyshev,  2000).  An  algorithm  that  scans  database  ribonucleotide  sequences  for 
SECIS  elements,  called  SECISearch,  has  been  recently  developed  based  on  primary 
sequence  identification,  secondary  structure  prediction  and  estimation  of  minimum  free 
energy  (Kryukov  et  al.,  1999).  Using  this  a  number  of  hitherto  unknown  bona-fide 
selenoproteins  have  been  identified  in  different  eukaryotic  organisms  (Gladyshev,  2000; 
Martin-Romero  et  al.,  2001). 
1.5  Selenium  metabolism 
Selenium  metabolism  has  been  extensively  reviewed  recently  (Ganther,  2000;  Ganther, 
2001;  Harrison  et  al.,  1997),  therefore  only  a  brief  overview  will  be  presented.  Mammals 
have  limited  body  stores  of  selenium,  and  require  a  regular  supply  of  the  element  through 
their  diet  and/or  water.  The  nutritional  role  of  selenium  is  expressed  not  by  the  element  per 
se,  but  through  the  biochemical  functions  of  a  number  of  selenium-containing  proteins. 
Animals  synthesise  selenoproteins  from  hydrogen  selenide  after  activation  to 
selenophosphate.  Reduction  of  inorganic  salts  like  sodium  selenite  is  a  source  of  hydrogen 
selenide  (Fig  1.4.2).  In  this  process  glutathione  conjugation  with  selenite  results  in  the 
formation  of  selenodiglutathione  (SDG)  which  undergoes  further  reduction  to  form 
hydrogen  selenide.  Another  source  of  hydrogen  selenide  is  via  the  liberation  of  selenium 
from  organoselenium  compounds  by  scission  of  C-Se  bonds.  The  metabolism  of 
selenomethionine  requires  the  conversion  to  selenocysteine,  via  the  transsulphuration 
pathway,  before  the  release  of  inorganic  selenium  by  selenocysteine  lyase  (Fig  1.4.2). 
Hydrogen  selenide  is  toxic,  but  only  small  quantities  are  needed  for  selenoprotein 
synthesis.  Any  excesses  are  rapidly  methylated  to  form  less  toxic  species  which  are 
eliminated  from  the  body  mainly  in  the  form  of  trimethylselenonium  in  the  urine  and/or 
exhaled  as  dimethylselenide  (Fig  1.4.2).  Monomethylated  methylselenol  can  also  be 
formed  directly  from  Se-methylselenocysteine  (one  of  the  major  components  in  plants)  and 
selenobetaine  (a  synthetic  compound)  (Andreadou  et  al.,  1996b).  In  this  case  the  inorganic 
pool  is  bypassed,  however  sufficient  demethylation  to  inorganic  selenium  may  occur  to 
maintain  selenoprotein  biosynthesis. 
Hydrogen  selenide  is  methylated  by  S-adenosylmethionine  in  three  successive  reactions. 
The  first  two  steps  are  catalysed  by  an  arsenite-sensitive  microsomal  enzyme,  thiol  S- 
methyltransferase,  forming  dimethylselenide  (Hsieh  and  Ganther,  1977;  Mozier  et  al., 
1988).  The  final  step  is  catalysed  by  thioester  S-methyltransferase  and  may  become  rate 
limiting  as  the  rate  of  methylation  decreases  with  the  increase  in  the  degree  of  methylation 15 
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Fig  1.4.2  Schematic  representation  of  selenium  metabolism  (adapted  from  Harrison  et  al, 
1997  and  Ganther,  2000) 
Plants  supply  animals  with  methylated  selenoarninoacids.  Conversion  to  inorganic  selenium  is 
necessary  for  selenoprotein  synthesis  while  excess  of  hydrogen  selenide  is  detoxified  by 
methylation  and  subsequently  excreted.  TMT,  thiol  S-methyltransferase;  TEMT,  thioester  S- 
methyltransferase.  Compounds  marked  with  asterisk  are  synthetic. Chapter  1  16 
(Mozier  et  al.,  1988).  At  normal  dietary  levels  of  selenium,  monomethylated  forms  are  the 
major  metabolites  (Vadhanavikit  et  al.,  1993).  At  chemopreventive  levels  monomethylated 
forms  increase  along  with  trimethylselenonium.  At  the  highest  levels  of  intake,  dimethyl 
selenide  (excreted  in  the  breath)  equals  monomethyl  selenium  and  surpasses 
trimethylselenoniurn  levels. 
1.6  Biochemical  reactions  of  low  molecular  weight  selenium 
compounds 
As  discussed  in  Section  1.2,1.3  and  the  next  chapter,  low  molecular  weight  selenium 
compounds  have  a  profound  influence  on  preserving  normal  health  and  protecting  against 
disease  incidence,  like  cancers.  It  is  therefore  pertinent  to  discuss  the  various  biochemical 
reactions  of  these  compounds  that  might  modify  proteins  and  have  a  major  impact  on 
disease  prevention. 
Research  on  biochemical  reactions  of  selenium  compounds  have  been  mainly  directed 
towards  protein  thiols,  and  four  types  of  reactions  identified  (reviewed  in  (Ganther,  1999)): 
Type  1,  formation  of  selenenylsulphide  bonds  (S-Se); 
Type  2,  formation  of  selenotrisulphide  bonds  (S-Se-S); 
Type  3,  formation  or  disruption  of  disulphide  bonds; 
Type  4,  formation  of  diselenide  bonds  (Se-Se) 
Types  1  and  2  are  the  most  commonly  characterised  and  several  examples  are  known. 
Recent  work  on  proteins  with  cysteine  clusters  in  their  active  sites,  like  protein  kinase  C 
(PKC)  have  underscored  the  importance  of  these  reactions  as  selenite  has  been  shown  to 
inhibit  the  activities  of  such  proteins  but  not  those  lacking  such  clusters  (Gopalakrishna  et 
al.,  1997).  With  selenium  metabolites  that  are  further  reduced,  like  SDG,  inhibitory  effects 
on  thiol  containing  proteins  are  more  pronounced  (Spyrou  et  al.,  1995).  Selenium  adduct 
formation  on  critical  thiol  containing  residues  can  inactivate  proteins,  including 
transcription  factors,  and  may  thereby  influence  cellular  processes  (Kim  and  Stadtman, 
1997;  Spyrou  et  al.,  1995). 
Selenium  may  act  as  an  catalyst  in  formation  or  breakage  of  disulphide  bonds  without 
actually  getting  incorporated  (Type  3  reaction).  Catalytic  amounts  of  selenite  have  been 
demonstrated  to  initiate  rapid  disulphide  formation  leading  to  restoration  of  ribonuclease 
activity  (Lundstrom  et  al.,  1992).  SDG,  in  turn,  can  efficiently  oxidise  reduced  thioredoxin Chapter  1  17 
by  promoting  disulphide  bond  formation  (Ren  et  al.,  1993).  It  has  also  been  shown  that 
selenium  can  catalyse  intramolecular  disulphide  bond  and  thereby  inactivate  PKC 
(Gopalakrishna  et  al.,  1997). 
While  there  is  no  direct  biological  evidence  of  type  4  reactions,  it  remains  an  interesting 
possibility  that  may  help  identify  the  biochemical  basis  of  selenoprotein  action  and  other 
selenium  mediated  activities. 
1.7  Conclusion 
Over  the  last  50  years  compelling  evidence  has  accumulated  for  the  beneficial  role  of 
selenium  in  human  health.  It  appears  that  the  activities  of  this  trace  nutrient  impinge  on 
several  major  health  issues  and  its  thought  that  selenium  exerts  its  influence  primarily 
through  selenoprotein  activity.  While  the  molecular  mechanism  underlying  Sec 
incorporation  in  mammals  is  gradually  becoming  clear,  the  functions  of  the  majority  of  the 
selenoproteins  remain  obscure.  For  most  of  the  health  issues  discussed  in  this  chapter,  data 
suggesting  strong  associations  is  rapidly  accumulating,  but  the  biological  underpinnings  of 
the  role  of  selenium  in  animal  health  remain  poorly  defined.  What  has  been  achieved, 
however,  is  an  appreciation  of  the  fundamental  role  of  selenium. 
It  has  been  realised  that  the  biological  activities  of  selenium  are  properties  of  its  various 
compounds  and  not  of  the  element  per  se.  This  means  that  additional  research  employing 
various  metabolites  and  synthetic  compounds  of  selenium  needs  to  be  carried  out  to 
identify  the  active  metabolites.  The  next  section  discusses  the  role  of  selenium  in 
prevention  of  cancer,  where  low  molecular  weight  selenium  compounds,  rather  than 
selenoproteins,  appear  to  be  the  key  mediators. 18 
2  Selenium:  an 
Agent 
2.1  Introduction 
Anti-cancer,  Chemopreventive 
Evidence  from  several  lines  of  investigation  indicates  that  selenium  may  affect  cancer 
incidence.  Epidemiological  evidence  generally  shows  an  inverse  correlation  between 
dietary  selenium  intake  and  cancer  risk.  The  limited  number  of  intervention  trials 
conducted  so  far  have  also  been  supportive  of  this  claim.  A  large  number  of  studies  on 
laboratory  animals  have  repeatedly  demonstrated  supranutritional,  but  non-toxic,  levels  of 
selenium  intake  to  be  associated  with  reduced  tumorigenesis.  It  should  be  noted  that  while, 
for  reasons  of  convenience,  the  word  'selenium'  is  used  the  biological  effects  of  selenium 
are  due  to  particular  chemical  forms  of  selenium  and  not  the  element  per  se. 
While  nutritional  functions  of  selenium  are  thought  to  be  largely  mediated  by  the  activities 
of  several  selenoproteins,  there  is  only  limited  evidence  that  these  are  important  mediators 
of  the  anti-cancer  activities  of  selenium  compounds.  There  is  convincing  evidence, 
however,  suggesting  anti-cancer  activities  mediated  by  selenium  compounds  in  individuals 
in  whom  the  activities  of  selenoproteins  are  already  maximal.  It  appears  that  several 
selenium-metabolites  are  the  key  players  in  anti-cancer  activities  though  actual 
mechanisms  are  not  known.  It  may  well  be  that  selenium  deprivation  may  increase  cancer- 
risk,  though  little  evidence  is  forthcoming,  but  there  is  more  widespread  acceptance  of  the 
inverse  association  of  supranutritional  selenium  exposure  and  cancer  incidence.  These 
hypotheses  are  perhaps  not  mutually  exclusive  and  both  nutritional  and  supranutritional 
modes  influence  the  anti-cancer  action  of  selenium. 
Whereas  evidence  supporting  selenium  as  an  anti-cancer,  chernopreventive  agent  is 
substantial,  our  understanding  of  molecular  and  cellular  mechanisms  mediating  these 
activities  remains  sketchy.  This  chapter  discusses  the  evidence  implicating  selenium  as  a 
potent  modifier  of  cancer  risk  and  the  potential  mechanisms  that  may  be  involved. 
2.2  Evidence  in  humans 
Evidence  for  selenium  as  a  cancer  risk  modifier  in  humans  has  come  from  ecological, 
epidemiological  and,  most  recently,  intervention  trials. Chapter  2 
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The  initial  clue  indicating  a  possible  inverse  correlation  based  on  geographic  association 
found  the  risk  of  mortality  attributed  to  cancers  of  the  lung,  breast,  gastrointestinal  tract 
and  peritoneum  and  lymphomas  to  be  significantly  lower  for  Americans  living  is  areas  of 
high  to  moderate  forage  selenium  levels  compared  those  low  in  forage  selenium  content 
(Shamberger  and  Willis,  1971).  Later,  a  reanalysis  of  the  same  data  extended  the  same 
conclusion  to  colorectal,  ovarian  and  bladder  cancers  (Clark  et  al.,  1991).  Both  total  cancer 
mortality  and  age-corrected  mortality  due  to  leukaemia,  lung,  breast,  ovarian  and  colorectal 
cancers  were  estimated  to  be  inversely  related  to  the  per  capita  intake  of  selenium  in  a 
study  comparing  27  different  countries  (Schrauzer  et  al.,  1977).  Similar  data  was  also 
reported  from  China  (Yu  et  al.,  1985). 
Several  epidemiological  studies  have  since  noted  that  cancer  patients  generally  have  a  low 
selenium  status  compared  to  healthy  individuals,  as  assessed  by  plasma/serum 
concentrations  (summarised  in  Table  2.2.1  and  reviewed  in  (Combs  and  Gray,  1998; 
Vinceti  et  al.,  2000b)).  These  studies  are  often  complex  to  interpret  due  to  methodological 
issues  and  variations  in  assessment  techniques.  The  evaluation  of  selenium  exposure  is 
complicated  by  the  fact  that  it  is dependent  on  the  type  of  food  and  where  it  was  produced. 
Also,  tissue  selenium  content  can  be  affected  by  the  disease  stage  and  treatment.  Therefore 
in  the  most  valid  assessments,  selenium  exposure  is  based  on  biological  parameters  from 
prediagnostic  samples,  commonly  toenail  clippings  and  blood  plasma  and  serum. 
However,  even  these  are  not  always  accurate  as,  for  example,  blood  selenium  levels  vary 
between  fasting  and  morning  blood  collection,  presumably  because  bolus  doses  of 
selenium  causes  transient  increases  in  blood  selenium  (Patterson  et  al.,  1989).  Toe  nail 
clippings,  on  the  other  hand,  give  an  estimate  of  average  selenium  levels  over  a  longer 
period  of  time  (-6  months:  the  average  time  between  initial  nail  formation  and  clipping). 
The  situation  may  be  further  confounded  if  the  individuals  have  access  to  multiple  sources 
of  selenium  like  high-selenium  foods  and  other  dietary  supplements.  Other  problems  often 
plaguing  some  of  these  studies  are  variation  of  selenium  status  within  the  population  and 
low  incidence  of  cancers  in  general,  all  of  which  affect  the  statistical  power  of  the  studies. 
Notwithstanding  such  complications,  several  studies  have  provided  interesting  evidence.  A 
decade  long  prospective  study  in  America  found  that  initial  plasma  selenium  concentration 
was  inversely  correlated  to  the  later  risk  of  colonic  adenomatous  polyps  and  non- 
melanoma  skin  cancer  (Clark  et  al.,  1993).  Patients  with  plasma  selenium  level  less  than 
the  population  median  were  4  times  more  likely  to  have  one  or  more  adenomatous  polyps 
and  had  more  than  three  times  the  number  of  polyps  per  person.  Eight  independent  cohort 20 
Study  Population  (cases)  Follow-up  RR  (95%  Cl) 
Willett  et  al.,  1983  USA,  (111)  5  0.5  (0.3-0.9) 
Salonen  et  al.,  1984  Finland  (128)  6  0.3  (0.1-0.7) 
Peleg  et  al.,  1985  Georgia  (130)  12  1.0 
Salonen  et  al.,  1985  Finland  (51)  4  0.2  (0.03-0.8) 
Fex  et  al.,  1987  Swedish  men  (35)  8  0.3,  p  trend=0.05 
Kok  et  al.,  1987  Holland 
males  (40)  9  0.4  (0.2-0.8) 
females  (29)  9  0.7  (0.2-2.0) 
Nomura  et  al.,  1987  Japanese  men  in  11  0.8,  p  trend  =  0.61 
Hawaii  (280) 
Virtarno  et  al.,  1987  Finnish  men  (109)  9  0.9  (0.5-1.5) 
Coates  et  al.,  1988  USA  (154)  12  1.0  (0.5-1.8) 
Ringstad  et  al.,  1988  Norway(60)  6  0.7  (0.3-1.7) 
Knekt  et  al.,  1990  Finland 
males  (597)  10  0.4,  p  trend  =  <0.001 
females  (499)  10  0.9,  p  trend  =  0.6 
Garland  et  al.,  1995  US  females  (934)  3.5  1.2  (0.9-1.7) 
Table  2.2.1  Summary  of  major  cohort  studies  on  the  relation  between  selenium  and  overall 
cancer  risk  (adapted  from  Vinceti  et  al.,  2000  and  unpublished  work  of  Dr  P.  R.  Harrison). 
Major  cohort  studies  investigating  the  relationship  between  selenium  intake  and  overall  cancer- 
risk  are  surnmarised  in  the  table.  The  number  of  actual  cases  and  the  length  of  the  follow  up 
time  (in  years)  is indicated.  The  results  expressed  in  terms  of  relative  risk  (RR),  usually  for  the 
highest  to  lowest  quintiles  of  plasma  selenium  and  are  corrected  for  the  common  confounding 
factors  like  age  and  smoking.  95%confidence  limits  are  indicated  beside  the  RR  in  parentheses. Chapter  2  21 
studies  failed  to  detect  any  significant  association  with  colorectal/gastrointestinal  cancer 
risk  and  plasma  selenium  level  but,  interestingly,  all  of  them  found  that  individuals  who 
did  develop  cancers  had  lower  initial  plasma  levels  than  those  remaining  healthy  (Knekt  et 
al.,  1988;  Nomura  et  al.,  1987;  Peleg  et  al.,  1985;  Ringstad  et  al.,  1988;  Salonen  et  al., 
1985;  Schober  et  al.,  1987;  Virtamo  et  al.,  1987;  Willett  et  al.,  1983).  A  meta-analysis  of 
these  data  should  be  very  illuminating.  Several  other  prospective  cohort  studies  have, 
however,  shown  prediagnostic  serum  selenium  levels  to  be  significantly  lower  in  cases  of 
cancer  than  in  disease-free  controls  (Coates  et  al.,  1988;  Fex  et  al.,  1987;  Salonen  et  al., 
1984)  (summarised  in  Table  2.2.1). 
Several  studies  have  demonstrated  protective  effects  of  selenium  against  epithelial  cancers 
including  bladder  (Helzlsouer  et  al.,  1989),  ovary  (Helzlsouer  et  al.,  1996),  pancreas 
(Burney  et  al.,  1989),  thyroid  (Glattre  et  al.,  1989),  lung  (Knekt  et  al.,  1990)  and  stomach 
cancers  (Knekt  et  al.,  1990).  Protection  from  oesophagus  (Jaskiewicz  et  al.,  1988),  lung 
(Gerhardsson  et  al.,  1985),  melanoma  skin  cancer  (Reinhold  et  al.,  1989),  head  and  neck 
cancers  (Westin  et  al.,  1989),  gastric  (Caygill  et  al.,  1989)  and  prostate  cancers  (Criqui  et 
al.,  1991)  have  been  noted  in  other  studies.  A  recent  study  has  showed  a  strong  inverse 
dose  response  association  between  toe-nail  selenium  level  and  prostate  cancer  incidence 
(Yoshizawa  et  al.,  1998). 
While  the  positive  evidence  from  epidemiology  and  animal  experiments  is  significant, 
several  studies  have  failed  to  find  any  association  of  selenium  with  total  cancer  risk  and 
cancers  of  the  stomach,  bladder,  lung,  cervix,  oral  cancer  and  colon-rectum  (reviewed  in 
(Vinceti  et  al.,  2000b)).  A  recent  study  found  a  positive  association  of  toenail  selenium 
with  cancer  risk  though  not  with  an  unadjusted  analysis  (Garland  et  al.,  1995).  However, 
this  study  was  fraught  with  several  methodological  problems  particularly  changing  levels 
of  selenium  within  the  cohort  over  time  and  possible  overadjustment  for  smoking.  Reports 
from  a  'natural  experiment'  in  Italy,  on  a  population  accidentally  exposed  to  high  doses  of 
selenium  from  their  drinking  water  have  also  argued  the  case  for  an  elevated  cancer  risk 
(Vinceti  et  al.,  2000a;  Vinceti  et  al.,  1998). 
Gender  specific  effects  have  been  note  in  several  studies,  generally  in  favour  of  men  (Kok 
et  al.,  1987a;  Kok  et  al.,  1987b;  Rogers  et  al.,  1991).  This,  however,  is  not  reflected  in 
geographical  studies  and  the  biological  basis  remains  obscure.  There  is  extensive  evidence 
in  animals  showing  that  selenium  supplementation  reduces  the  incidence  of  carcinomas  of 
the  breast,  however,  epidemiological  data  have  almost  consistently  failed  to  find  such  an 
association  (van  den  Brandt  et  al.,  1994;  van  I  Veer  et  al.,  1996;  van  I  Veer  et  al.,  1990). Chapter  2  22 
Taken  together,  the  data  from  epidemiological  studies  indicate  significant  inverse 
correlation  between  selenium  level  and  gastrointestinal,  oesophageal,  stomach,  prostate, 
upper  respiratory  tract  and  lung  cancers,  and  also  possibly  thyroid  and  pancreatic  cancers. 
There  is  no  suggestion  of  a  link  with  breast  cancer  and  evidence  is  also  weak  for  colon 
cancer  risk  (though  the  length  of  follow  up  for  the  largest  studies  were  quite  short). 
Supplementation  trials  of  cancer  patients  with  selenium  have  not  been  extensively 
reported.  However,  one  study  found  selenium  supplementation  reduced  bone  marrow 
suppression  and  kidney  damage  induced  by  cisplatin  (Hu  et  al.,  1997).  There  is  also  animal 
data  suggesting  reduction  of  cardiac  toxicity  induced  by  adriamycin  therapy,  on  selenium 
supplementation  (Boucher  et  al.,  1995).  Thus,  epidemiological  evidence  suggests  that 
selenium  is  a  likely  cancer  risk  modifier,  and  appears  to  be  protective  against  certain 
cancers,  particularly  those  of  epithelial  origin. 
2.2.2  Intervention  trials 
Intervention  using  selenium  has  been  reasonably  limited  (summarised  in  Table  2.2.2). 
These  trials  have  not  only  used  different  selenium  sources  (like  selenite,  selenized  yeast, 
selenomethionine  or  selenate),  sometimes  in  combination  with  other  vitamins  and 
minerals,  the  populations  are  also  quite  variable  in  terms  of  risk  factors  and  geography. 
The  two  studies  conducted  in  China,  in  Quidong,  Shandong  Province,  have  only  been 
reported  in  English  very  recently.  One  employed  the  use  of  a  daily  supplement  of  200[ig 
selenised  yeast  and  concluded  that  almost  complete  prevention  of  liver  cancer  could  be 
achieved  among  carriers  of  hepatitis  surface  antigen  (otherwise  with  1.58%  incidence  risk) 
(Yu  et  al.,  1997).  It  also  reduced  the  incidence  of  liver  cancer  among  first-degree  relatives 
by  approximately  60%.  The  other  study  used  table  salt  fortified  with  sodium  selenite  and 
reported  attenuation  of  liver  cancer  incidence  by  37%  (Yu  et  al.,  1991).  It  should  be 
cautioned  that  these  studies  suffered  from  several  methodological  and  quality  control 
issues. 
The  third  study,  in  Linxian  county,  China  was  technically  sound  employing  a  double-blind, 
placebo-controlled,  randomised  design  in  a  region  where  oesophageal  and  stomach  cancer 
causes  a  third  of  all  deaths.  Using  a  combination  of  50  [tg  selenium  (as  selenised  yeast), 
vitamin  E  and  P-carotene  (all  administered  at  -twice  their  Recommended  Dietary 
Allowances  -  RDA)  for  5  years,  a  protective  effect  was  observed  against  mortality  from 
total  cancer  (13%;  RR=0.87  (0.75-1.00))  and  stomach  cancer  (21%;  RR=0.79  (0.64-0.99)), 23 
No.  Dose  and  form  of  Se  Population  Cancer  type  (outcome) 
1  200pg  Se/day  as  selenised  Hepatitis  surface  antigen  Liver  cancer  (1) 
yeast  carriers 
2  Table  salt  fortified  with  Hepatitis  surface  antigen 
15mg/kg  Se  as  selenite  carriers 
3  50ýLg  Se/day  as  selenised  General  population 
yeast 
4  50pg  Se/day  as  selenate  Oesophageal  dysplasia 
5  1  OOpg  Se/day  and  50tig 
Se/day  as  selenomethionine  Reverse  smokers 
6  200pg/day  as  selenised  Patients  with  prior 
yeast  resected  adenomatous 
polyps 
7  200pg  Selday  as  selenised  Patients  with  prior  skin 
yeast  cancer 
Table  21.2  Intervention  trials  employing  selenium. 
Liver  cancer  (1) 
Stomach  cancer  (1) 
Oesophageal  cancer  (NE) 
Oral  lesions  (1) 
New  adenomatous  polyps  (1) 
Basal  or  squamous  cell 
carcinoma  (NE);  lung  (1); 
colorectal  (1);  prostate  (1) 
Summary  of  intervention  trials  employing  selenium  (Se)  either  alone  or  in  combination  with 
other  minerals  and  vitamins.  In  study  3,  selenium  was  used  in  combination  with  f3ýcarotene  and 
vitamin  E.  In  study  4,  selenium  was  used  in  combination  with  25  other  minerals  and  vitamins.  In 
study  5,  selenium  was  used  in  combination  with  zinc  and  vitamin  A  and  riboflavin.  In  study  6, 
selenium  was  used  in  combination  with  vitamins  A,  C,  E  and  zinc.  I:  statistically  significant 
inhibition  and  NE:  no  effect. Chapter  2  24 
and  well  as  total  mortality  (9%)  (Blot  et  al.,  1993).  However,  no  protection  from 
oesophageal  cancer  was  conferred  when  selenium  (as  50[tg  sodium  selenate/day)  was 
given  in  combination  with  25  other  vitamins  and  minerals  (Li  et  al.,  1993). 
A  placebo-controlled  trial  in  India,  on  reverse  smokers  diagnosed  with  premalignant  oral 
lesions  showed  57%  remission  in  the  treatment  group  (8%  in  placebo  group)  on 
supplementation  with  a  cocktail  vitamin  A,  riboflavin,  zinc  and  selenomethionine  (100  and 
50[tg/day)  (Krishnaswamy  et  al.,  1995;  Krishnaswamy  et  al.,  1993). 
A  recent  study  in  Italy,  using  a  randomised,  double  blind  cancer  prevention  trial  on  patients 
with  prior  resected  adenomatous  polyps  noted  a  44%  reduction  in  the  incidence  of  new 
polyps  using  selenium  (200[tg/day  as  selenised  yeast)  along  with  zinc  and  vitamins  A,  C 
and  E  (Bonelli,  1998). 
A  pivotal  prospective,  double-blind,  placebo-controlled,  randomised  selenium 
chemoprevention  study,  the  Nutritional  Prevention  of  Cancer  (NPC)  trial,  was  conducted 
in  the  US  (Clark  et  al.,  1996).  1312  subjects  with  a  previous  history  of  basal  or  squarnous 
cell  carcinoma  of  the  skin  were  randomised  and  the  treatment  group  supplemented  with 
200[tg  of  selenium  (as  selenised  yeast)  per  day  for  an  average  of  4.5  yrs  and  followed  up 
for  6.4  years.  While  selenium  supplementation  did  not  affect  the  recurrence  of  skin  cancer, 
it  was  associated  with  a  statistically  significant  decrease  in  several  secondary  endpoints: 
total  cancer  incidence  (RR=0.63  (0.47-0.85))  and  incidence  of  lung,  colorectal  and  prostate 
cancers  (17able  2.2.3).  The  study  also  reported  a  decrease  in  the  total  cancer  mortality  in  the 
supplementation  arm  (RR=0.50(0.31-0.80)).  Recent  updates  on  this  trial  have  shown  that 
men  with  the  lowest  baseline  selenium  blood  levels  prior  to  supplementation  had  the 
greatest  reduction  in  cancer,  especially  so  for  prostate  cancer  (Clark  et  al.,  1998;  Combs  Jr, 
2000).  It  should  be  noted  that  none  of  the  subjects  had  plasma  serum  levels  below  60ng/ml 
and  that  very  few  had  levels  below  80ng/ml;  thus  this  cohort  was  selenium-adequate  and 
the  cancer  protection  was  shown  by  supranutritional  levels  of  selenium.  Yet,  subjects  with 
initial  plasma  selenium  levels  less  than  106ng/ml  showed  not  only  the  highest  rates  of 
cancer  in  the  placebo  group  but  also  the  strongest  protective  effects  of  supplementation 
with  selenium  (Fig  2.2.1A)  (Clark  et  al.,  1998;  Combs  Jr,  2000).  Individuals  with  plasma 
selenium  level  above  121ng/ml  showed  no  cancer-protective  of  selenium  supplementation. 
Prostate  cancer,  in  particular,  demonstrated  this  trend  most  clearly  (Fig  2.2.113)  (Clark  et 
al.,  1998;  Combs  Jr,  2000). 25 
Cancer  Site  Selenium  Placebo  RR  P  value 
Lung  17  31  0.54  0.04 
Prostate  13  35  0.37  0.002 
Colorectal  8  19  0.42  0.03 
Total  carcinomas  59  104  0.55  <0.001 
Total  cancer 
incidence  77  119  0.63  0.001 
Total  cancer 
mortality  29  57  0.50  0.002 
Table  21.3  Cancer  incidence  and  cancer-related  mortality  in  the  NPC  study  (adapted 
from  Clark  et  al.,  1996). 
Summary  of  cancer  incidence  and  cancer-related  mortality  found  in  the  NPC  trial.  The  numbers 
in  the  selenium  and  placebo  columns  indicate  the  number  of  cancer  cases  in  the  selenium 
supplemented  and  placebo  administered  cohorts,  respectively.  RR:  relative  risk  and  P  value  is 
calculated  from  log  rank  tests.  Total  cancers  include  both  carcinomas  and  non-carcinomas  like 
melanomas,  leukaemia,  lymphoma  etc. 26 
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Fig  21.1  Effect  of  selenium  on  total  cancer  risk  and  prostate  cancer  risk  by  tertile  of 
baseline  plasma  selenium  (adapted  from  Clark  et  al.,  1998  and  Combs,  2000). 
Follow  ups  and  reanalysis  of  data  from  the  NPC  trial  showed  that  the  strongest  effect  against 
total  cancer  (A)  and  prostate  cancer  (B)  risk  was  seen  in  people  in  the  lowest  tertile  of  plasma 
selenium  content.  Cases  indicated  are  the  actual  number  of  individuals  diagnosed  with  cancer. 
<106  106-121  >121 
baseline  plasma  selenium  level,  ng/ml 
<1  06  106-121  >121 
baseline  plasma  Se  level,  ng/ml Chapter  2  27 
Thus  selenium  supplementation  appears  to  protect  against  certain  types  of  human  cancers: 
prostate,  lung,  colorectal,  oesophagal,  gastrointestinal,  oral  and  liver.  However,  no 
protection  is  apparent  for  breast  and  skin  cancers.  The  encouraging  evidence  from  the  last 
few  years  has  emphasised  the  need  for  detailed,  better  controlled,  large-scale  trials.  One 
such  trial,  the  Selenium  and  Vitamin  E  Chernoprevention  Trial  (SELECT),  to  be  performed 
in  North  America  has  already  started  recruiting  volunteers.  It  plans  to  enrol  32,400  healthy 
men  without  a  prior  history  of  prostate  cancer.  The  individuals  will  be  randomised  into 
four  arms  and  supplemented  daily  with  200[tg  selenium  (as  selenomethionine),  400mg 
vitamin  E,  both  selenium  and  vitamin  E,  or  placebo,  for  7  years.  The  total  follow  up  time  is 
currently  scheduled  as  11yrs  (Miller,  2001).  A  Canadian  trial  will  be  addressing  similar 
questions  randomising  both  male  and  female  subjects  having  successful  resection  of  stage 
IA  non-small  cell  lung  carcinoma  to  receive  200[tg  selenium  as  selenised  yeast  or placebo 
daily  for  4  years.  Another  large  trial  is  also  planned  in  Europe  in  4  countries  including  the 
UK  This  Prevention  of  Cancer  by  Intervention  by  Selenium  (PRECISE)  trial  is  scheduled 
to  recruit  about  50,000  subjects  of  both  sexes  and  selenium  supplementation  is  planned  for 
6.5  years  (M.  Rayman,  personal  communication). 
2.3  Evidence  from  experimental  carcinogenesis  models 
Several  laboratory  models  of  carcinogenesis  have  demonstrated  the  ability  of  a  variety  of 
selenium  compounds  to  inhibit/retard  turnorigenesis  (extensively  reviewed  in  (Combs, 
1989;  Combs  Jr,  1997;  Ip,  1998)).  It  was  estimated,  in  1986,  that  among  the  100+  studies 
performed  until  then,  about  two-thirds  showed  reductions  in  tumour  production  and/or 
preneoplastic  endpoints  and  half  showed  reductions  of  50%  or  more  (Combs  and  Combs 
Jr,  1986).  Since  then,  several  further  studies  have  found  similar  reductions  tumour  yield  or 
experimental  metastasis  using  supranutritional  levels  of  selenium,  and  only  a  limited 
number  (Appel  et  al.,  1996)  have  found  such  treatments  ineffective.  It  is  generally  accepted 
that  exposure,  at  higher  levels  than  those  required  to  support  maximal  selenoenzyme 
expression,  to  some  selenium  compounds  can  be  anti-tumorigenic. 
In  contrast  to  the  vast  body  of  experiments  indicating  otherwise,  four  studies  indicate 
selenium  supplementation  to  enhance  tumorigenesis.  Each  of  these  used  sodium  selenite  at 
supranutritional  doses.  Three  of  these  found,  upon  selenium  treatment,  reduction  of  tumour 
yields  at  one  site  while  enhancing  them  at  a  different  site  (Ankerst  and  Sjogren,  1982; 
Dorado  et  al.,  1985;  Nakadaira  et  al.,  1996).  The  fourth  reported  enhanced  incidence  of 
papillomas  only  when  the  carcinogen  was  administered  in  small  multiple  doses  but  not Chapter  2  28 
with  a  single  large  dose  (Perchellet  et  al.,  1987).  These  studies  may  reflect  changes  in 
tumour-site  specificity  rather  than  enhanced  turnorigenesis  per  se. 
Compared  to  the  large  number  of  studies  that  have  examined  the  contribution  of 
supranutritional  levels  of  selenium,  relatively  few  have  addressed  the  complementary 
question  of  selenium  deficiency  potentially  enhancing  tumorigenesis.  Literature  here  is 
inconsistent  (reviewed  in  (Combs  and  Gray,  1998));  12  studies  have  found  no  effect  while 
10  suggested  selenium  deficiency  increased  tumour  yield.  5  studies  have  reported  reduced 
turnorigenesis  on  selenium  deficiency.  It  also  appears  that  selenium  deficiency  may  result 
in  increased  risk  depending  on  the  carcinogen  used  (Nelson  et  al.,  1996b).  Thus  the  present 
evidence  is  insufficient  to  determine  unequivocally  whether  nutritionally  suboptimal 
selenium  status  increases  cancer  risk  in  animal  models.  ' 
2.4  Effects  of  selenium  on  various  stages  of  carcinogenesis 
As  protective  effects  have  been  observed  in  different  phases  of  carcinogenesis,  in  different 
models,  it  is  not  clear  if  anti-cancer  activities  of  selenium  are  stage  specific.  It  may  well  be 
that  different  mechanisms  of  action  (see  Section  2.6)  are  of  varying  influence  during 
different  stages  of  carcinogenesis. 
For  example,  protection  from  oxidative  damage  by  selenium-dependent  enzymes  like 
GPx's  and  TR  or  carcinogen  detoxificatiorn  (discussed  in  Section  2.6.1)  may  play  a  role  in 
inhibiting  the  initiation  phases  of  cancer  by  removing  potentially  genotoxic  free  radicals. 
In  support  of  this,  selenite  (only  when  administered  during  the  initiation  stage)  have  been 
shown  to  protect  from  dimethylhydrazine-  (DMH)  induced  colon  tumours  in  mice  (Temple 
and  Basu,  1987),  7,12-dimethylbenz[a]anthracene-  (DMBA)  induced  mammary  tumours 
(Thompson  et  al.,  1982)  and  aflatoxin  induced  hepatic  lesions  in  rats  (Baldwin  and  Parker, 
1987).  Similar  data  has  been  obtained  during  the  initiation  of  DMBA-induced  mammary 
turnours  in  rats  supplemented  with  a  number  of  aliphatic  selenocyanates  (Ip  et  al.,  1995) 
and  1,4-phenylene-bis-(methylene)  selenocyanate  (pXSC)  (el-Bayoumy  et  al.,  1992). 
Other  studies  suggest  that  the  effects  of  selenium  may  not  be  stage-specific.  Selenium 
treatment  after  the  initiation  phase  is  also  protective  in  several  models  of  hepatic,  colonic 
and  mammary  cancers  (Curphey  et  al.,  1988;  Ip  and  Ganther,  1992b;  Thompson  et  al., 
1981).  One  study  of  azoxymethane-induced  colon  turnours  has  reported  selenite  to  be 
effective  only  in  the  post-initiation  phases  (Reddy  et  al.,  1988),  while  in  DMBA-induced 
mammary  cancers  in  rats,  the  optimal  effect  is  obtained  when  selenium  is  present Chapter  2  29 
continuously,  starting  during  initiation  Qp  and  Daniel,  1985).  Studies  on  experimental 
metastasis  would  suggest  selenium  to  be  capable  of  exerting  protection  against  these  later 
stages  of  carcinogenesis  (Tanaka  et  al.,  2000;  Yan  et  al.,  1999).  The  dose  (perhaps  also 
type)  of  carcinogen  used  may  be  a  contributory  factor,  as  higher  doses  of  DMBA  appear  to 
shift  the  anti-cancer  activities  of  selenium  to  the  post-initiation  stages  (Ip  and  Daniel,  1985; 
Ip  et  al.,  1981). 
It  is  pertinent  to  note  that  the  intervention  trials  in  humans  discussed  earlier  detected 
protective  effects  of  selenium  supplementation  within  relatively  short  time  periods, 
suggesting  that  selenium  prevents  development  of  malignancy  in  already  initiated 
preneoplastic  cells.  In  fact,  in  the  NPC  trial,  the  authors  reported  that  reduction  in  the 
incidence  of  prostate  cancer  among  selenium-treated  subjects  was  observed  in  each  year, 
except  the  very  first  (Combs  Jr,  2000).  This  also  suggests  selenium  treatment  to  be 
effective  in  the  later  stages  of  carcinogenesis. 
2.5  Chemical  form,  dose  and  chemopreventive  efficacy 
The  biological  effects,  including  anti-cancer  activities,  of  selenium  appear  to  be  properties 
of  its  various  compounds  and  not  of  the  element  per  se.  Therefore,  study  of  form  and  dose 
of  selenium  compounds  is  essential  to  understand  its  chernopreventive  activity. 
Z5.1  Active  selenium  metabolites 
As  discussed  in  Section  1.5,  selenium  compounds  undergo  extensive  metabolism. 
Evidence  suggests  that,  while  various  chemical  sources  of  selenium  may  vary  in  their 
efficiency  of  absorption  and/or  retention,  the  biochemical  basis  for  the  anti-tumorigenic 
effects  may  reside  in  certain  selenium  metabolites  produced,  following  absorption,  from 
those  sources. 
Most  commonly,  selenite  and  selenomethionine  (abundant  in  foods  and  feedstuff,  and  in 
selenised  yeast)  have  been  used  in  animal  studies  because  of  their  commercial  availability, 
and  both  these  have  been  shown  to  suppress  carcinogenesis  in  many  different  models 
without  affecting  animal  health  adversely.  The  first  indication  that  metabolism  of  primary 
sources  of  selenium  is  required  for  selenium-mediated  chernopreventive  effects  came  from 
the  observations  that  selenomethionine  was  generally  less  effective  as  a  anti-cancer  agent 
than  selenite,  although  tissue  selenium  concentrations  were  higher  in  animals  given 
selenomethionine  (Ganther  and  Lawrence,  1997).  At  the  same  time,  it  was  noted  that Chapter  2  30 
chernopreventive  activity  of  selenomethionine  could  be  significantly  reduced  by  a  low 
methionine  diet  (1p,  1988).  This  suggested  that  limiting  methionine  resulted  in  diverting 
the  selenomethionine  to  be  non-specifically  incorporated  into  body  proteins  thereby 
sequestering  it  away  from  its  metabolic  pathway  (Fig  1.4.2). 
Employing  a  strategy  of  delivering  selenium  at  specific  points  along  the  metabolic 
pathway,  using  specific  precursor  compounds,  the  active  metabolites  involved  in  cancer 
protection  could  be  identified.  Extensive  use  of  this  approach  by  the  Ganther  and  lp  groups 
(extensively  reviewed  in  (Ganther  and  Lawrence,  1997;  Ip,  1998))  has  led  to  the 
suggestion  that  the  active  ingredient  is  downstream  of  hydrogen  selenide  (H2Se).  Thus, 
while  selenite  is  more  active  than  selenomethionine  (SM),  Se-methylselenocysteine  (SMC) 
is  about  two  times  more  effective  than  selenite  (Ip  and  Hayes,  1989).  Other  methylated 
forms  of  selenium  and  their  precursors,  like  selenobetaine,  that  by-pass  H2Se  formation 
also  shows  chernopreventive  activity  Qp  and  Ganther,  1992a;  Ip  and  Ganther,  1990;  Ip  et 
al.,  1991).  Thus  delivery  of  selenium  in  a  pre-methylated  form,  by-passing  H2Se,  may 
avoid  the  putative  non-specific  toxicity  associated  with  H2Se  presumably  via  superoxide 
generation  (Garberg  et  al.,  1988;  Wilson  et  al.,  1992;  Yan  and  Spallholz,  1993).  While 
ROS  generation  and  subsequent  non-specific  toxicity  of  inorganic  forms  of  selenium  has 
been  demonstrated  in  vitro,  these  compounds  remain  very  effective  chemopreventive 
agents,  in  vivo,  and  are  not  associated  with  any  adverse  side  effects.  Presumably,  entry  via 
the  inorganic  pool  at  in  vivo  supplementation  levels,  leads  to  the  formation  of  the  active 
metabolites  reasonably  efficiently  without  the  associated  superoxide  mediated  damage 
seen  in  vitro. 
Three  types  of  selenium  metabolites  (see  Fig  1.4.2)  merit  special  mention:  a) 
selenodiglutathione  (SDG),  the  reductive  metabolite  of  inorganic  salts  (selenite  and 
selenate);  b)  H2Se,  the  common  intermediate  of  the  reductive  pathway  and  the  catabolic 
pathway  for  selenium-containing  amino  acids  and,  c)  methylated  metabolites  of  selenide 
([CH3],,  Se). 
SDG  has  been  shown  to  inhibit  (more  effectively  than  selenite)  development  of 
transplantable  turnours  in  vivo  (Milner,  1985;  Milner,  1986;  Poirier  and  Milner,  1983)  and 
inhibit  cell  growth  in  vitro  (Fleming  et  al.,  2001;  Ghose  et  al.,  2001a;  Lanfear  et  al.,  1994). 
It  is  unlikely  to  be  the  active  metabolite  per  se  since  it  is  rapidly  metabolised  to  other 
metabolites  like  H2Se.  However  SDG  shows  marked  differences  to  its  precursor 
compound,  selenite,  including  considerably  enhanced  ability  to  mediate  apoptosis  and 
inhibit  cell  growth  in  vitro  (Fleming  et  al.,  2001).  As  tyrosine  phosphorylation  patterns  of Chapter  2  31 
SDG  are  dissimilar  to  those  of  oxidants  (Fleming  et  al.,  2001),  this  suggests  that  SDG  may 
have  substantially  diminished  non-specific  toxicity. 
H2Se  may  also  contribute  to  anti-carcinogenic  activity  by  undergoing  oxidative  metabolism 
and  producing  superoxides  and  H202,,  which  may  stimulate  apoptosis  induction  (Lu  et  al., 
1995b;  Spallholz,  1994;  Zhu  et  al.,  1996).  Though  demonstrated  in  tissue  culture  cells, 
ROS  generation  has  not  been  shown  in  vivo.  H2Se  mediated  increase  in  selenoprotein 
activity  may  also  have  a  chernoprventive  function.  Moreover,  recent  work  has,  indirectly, 
implicated  H2Se  as  being  crucial  for  apoptosis  generation  by  both  inorganic  selenium 
compounds  and  SMC  (A-S.  Chung,  personal  communication).  This  study  has  revealed  that 
treatment  with  non-toxic  doses  of  Hg  2+ 
.  which  is  a  specific  selenide  trapper,  inhibits 
apoptosis  induction  not  only  by  selenite  and  SDG,  but  also  SMC.  Thus  selenide  appears  to 
be  a  key  metabolite  involved  in  a  critical  step  in  apoptosis-induction  by  various  selenium 
compounds.  If  this  were  indeed  the  case,  then  routeing  of  SMC  for  demethylation  to 
selenide  would  appear  to  play  a  major  role  in  chernoprevention  by  methylated  selenium 
compounds. 
Methylation  products  of  H2Se  are  also  known  to  possess  anti-cancer  activities.  The 
Ganther  and  lp  laboratories  have  shown  methylselenols  and  its  derivatives  are  potently 
anti-carcinogenic  (reviewed  in  (1p,  1998)).  Using  methylselenol  precursors,  selenobetaine 
and  SMC,  they  have  demonstrated  that  these  compounds  have  enhanced  anti-tumour 
activities  than  selenite  (Ip  and  Ganther,  1992a;  Ip  and  Ganther,  1990;  Ip  et  al.,  1991). 
However,  dimethylselenoxide  which  gets  metabolised  rapidly  to  dimethylselenide,  was 
very  poorly  chernopreventive  possibly  because  of  its  prompt  excretion  (lp  et  al.,  1991). 
Similar  lack  of  chemopreventive  efficacy  was  noted  for  trimethylselenonium  (Ip  and 
Ganther,  1992a).  This  reduced  activity  can  also  be  partially  attributed  to  the  diminished 
reactivity  of  the  Se  bound  to  two  or  three  carbon  atoms.  At  doses  used  in  the  experiment 
both  the  compounds,  however,  were  able  to  support  maximum  GPx  expression, 
presumably  by  feeding  back  into  the  H2Se  pool  (Ip  et  al.,  1991;  Vadhanavikit  et  al.,  1993). 
This  suggests  the  reversibility  of  the  methylation  pathway  to'  the  H2Se  pool  may  be 
essential  to  maintain  optimal  selenoprotein  expression,  however,  it  may  also  be  necessary 
for  chemopreventive  action  but  this  possibility  has  not  been  investigated  in  detail. 
At  low  doses,  arsenic  competitively  inhibits  H2Se  methylation  and  methylselenol  (and 
analogous  di-  or  tri-methylated  species)  demethylation.  Selenite-mediated,  but  not 
methylated  selenium  compound-  mediated,  chernoprevention  is  inhibited  when  animals  are 
exposed  to  low  doses  of  arsenic  (which  have  no  chernopreventive  activity  itself)  (lp  et  al., Chapter  2  32 
1991).  Thus  methylselenol,  its  precursors  and  derivatives,  appear  to  have  anti-carcinogenic 
activity  distinct  from  those  associated  with  the  inorganic  selenium  pool.  This  implies  that 
the  inorganic  selenium  pool  needs  to  be  metabolised  to  methylated  derivatives  to  have  any 
chemopreventive  activity. 
Z5.2  Other  selenium  compounds 
Since  methylselenol  precursor,  methylselenocyanate,  demonstrated  chernopreventive 
activity,  an  examination  of  a  series  of  aliphatic  selenocyanates  with  increasing  lengths  of 
the  carbon  side  chain  suggested  the  chernopreventive  potencies  as: 
heptyl=pentyl>propyl>methyl  (lp  et  al.,  1995).  Thus  longer  the  alkyl  chains  better  the 
efficacy  of  selenocyanates. 
SMC  (a  common  constituents  of  food  and  feedstuff  and  selenised  yeast)  is  readily 
metabolised  to  mono-,  di-  and  tri-methylated  species  of  selenium  in  animals  primarily  by 
scission  to  methylselenol  by  cysteine  conjugate  P-lyase,  which  also  shows  considerable 
activity  with  other  Se-alkylcysteine  derivatives,  therby  releasing  the  active  Se-alkyl  moiety 
(Andreadou  et  al.,  1996a).  Accordingly,  Se-methyl-,  Se-propyl-  and  Se-allyl-derivatives 
have  been  tested  for  chemopreventive  activity  and  while  the  first  two  gave  about  50% 
reduction  in  tumour  yield,  Se-allyl  derivatives  inhibit  tumour  formation  by  almost  90%  (lp 
et  al.,  1999). 
Sulphur  analogues,  such  as  S-allylcysteine  and  related  allylsulphides,  occur  in  abundance 
in  garlic.  Therefore,  growth  of  garlic  in  high  selenium  medium  results  in  selenium- 
enriched  garlic  by  substitution  of  sulphur  by  selenium  in  these  compounds.  These 
selenium-derivatives  of  sulphur  compounds  from  selenium-enriched  garlic  when  tested  on 
laboratory  models  of  carcinogenesis  showed  strong  chernopreventive  activity  that  was 
about  twice  that  shown  with  selenised  yeast  (Ip  and  Lisk,  1995;  lp  et  al.,  1996).  Recent 
analysis  has  revealed  y-Glutamyl-Se-methylselenocysteine  (GGSMC)  to  be  the  major 
chemical  form  of  selenium  (-73%)  in  selenium-enriched  garlic  (Ip  et  al.,  2000a). 
Experiments  suggest  that  GGSMC  may  serve  as  a  carrier/precursor  for  SMC  since  the 
biological  activities  of  the  two  compounds  (including,  chernopreventive  efficacies,  tissue 
accumulation,  excretion  and  gene  expression  patterns)  appear  to  be  similar  (Dong  et  al., 
2001b).  It  is  interesting  to  note  that  both  SMC  and  GGSMC  when  administered  to  animals 
for  a  short  period  (4  weeks)  immediately  after  carcinogen-dosing,  provides  lasting 
protection  from  methylnitrosurea  induced  mammary  lesions  (Dong  et  al.,  2001b).  This Chapter  2  33 
would  suggest  that  these  compounds  cause  irreversible  damage  to  the  transformed  cells, 
possibly  by  inducing  apoptosis  although  this  is  yet  to  be  demonstrated. 
Selenium-enriched  garlic  has  potentially  several  advantages  over  other  methods  of 
selenium  supplementation  in  the  general  population.  As  it  is  mainly  used  for  flavouring, 
overconsumption  is  less  likely.  At  nutritional  levels,  it  supports  optimal  selenoprotein 
expression  and  at  higher  doses  has  a  strong  chernopreventive  action.  However,  it  has 
reduced  toxicity  as  its  active  constituent,  SMC,  is  prevented  from  accumulation  by 
methylation  to  di-  and  tri-methylated  excretion  products.  High-selenium  broccoli  also 
exhibits  strong  chernopreventive  activity  in  rodent  models  (Finley  et  al.,  2000). 
Research  into  developing  aromatic  selenium  compounds  was  pioneered  by  Dr  Karam  El 
Bayourny  at  the  American  Health  Foundation,  New  York,  with  a  view  to  develop  novel 
reagents  with  lower  toxicity.  p-Methoxybenzeneselenol  was  the  first  aromatic  selenium 
compound  synthesised  which  showed  inhibiton  of  tumour  yield  at  liver,  kidney  and  colon 
on  treatment  with  the  carcinogen  azoxymethane  (Reddy  et  al.,  1985;  Tanaka  et  al.,  1985). 
Benzy1selenocyanate  (BSC)  was  another  successful  compound  which  showed  anti- 
tumorigenic  activities  in  various  different  models  of  cancer  utilising  different  carcinogens 
(el-Bayoumy,  1985;  Nayini  et  al.,  1989;  Nayini  et  al.,  1991).  However,  BSC  has  a  very 
pungent  odour  which  reduced  the  food  intake  of  animals  resulting  in  growth  depression. 
Therefore,  to  reduce  its  volatility,  a  second  methylselenocyanate  group  was  added  in  the 
para  position  resulting  in  1,4-phenylene-bis-(methylene)selenocyanate  (pXSC;  used  in  this 
study).  This  compound  had  significantly  less  toxicity  than  BSC  and  subsequently  was 
shown  to  possess  the  highest  chernopreventive  index  (defined  as  the  highest  cancer 
inhibitory  activity  in  relationship  to  its  toxicity  in  vivo)  for  selenium  compounds  to  date 
(Conaway  et  al.,  1992;  el-Bayourny  et  al.,  1992). 
pXSC  was  shown  to  inhibit  DMBA-induced  mammary  carcinogenesis  by  interfering  with 
DNA  adduct  formation  (el-Bayourny  et  al.,  1992),  to  have  an  anti-initiation  effect  in  the 
azoxymethane  colon  cancer  model  (Reddy  et  al.,  1992)  and  also  inhibit  mammary  and 
colon  carcinogenesis  at  post-initiation  phases  Qp  et  al.,  1994a;  Reddy  et  al.,  1992).  In 
contrast  to  selenite,  which  does  not  effect  4-(methylnitrosoamino)-l-(3-pyridyl)-l- 
butanone  (NNK)  induced  lung  cancer,  pXSC  strongly  inhibited  turnorigenesis  in  this 
cancer  model  (el-Bayoumy  et  al.,  1993).  This  finding  is  particularly  relevant  as  NNK  is 
strongly  implicated  in  pathogenesis  of  tobacco-related  lung  cancers  in  humans  (Hecht  and 
Hoffmann,  1988).  Later  studies  have  also  revealed  inhibition  of  lung  metastasis  of 
melanoma  cells  in  mice  treated  with  pXSC  (Tanaka  et  al.,  2000). Chapter  2  34 
It  is  clear  that  pXSC  and  related  compounds  release  some  selenium  to  the  inorganic 
selenide  pool,  leading  to  the  nutritional  bioavailability  of  selenium  from  these  compounds 
(Ip  et  al.,  1994a).  However,  the  rate  of  selenium  release  cannot  entirely  explain  the 
chernopreventive  properties  of  these  compounds:  10ppm  of  selenium  as  pXSC  is 
equivalent  to  3pprn  of  selenium  as  selenite  in  the  efficacy  of  cancer  protection;  yet  only 
1pprn  of  selenium  as  pXSC  can  replete  GPx  in  a  selenium-deficient  animal  as  opposed  to 
O.  1pprn  selenium  as  selenite  Qp  et  al.,  1994a).  Thus  the  relative  selenium  concentration 
required  for  anticancer  activity  compared  to  that  required  to  replete  GPx  for  pXSC  is  10 
while  it  is  30  for  selenite,  suggesting  that  the  pXSC  molecule  has  some  inherent  anti- 
cancer  activity  that  is  independent  of  the  release  of  selenium  from  the  parent  molecule. 
Very  recently,  glutathione  conjugates  of  compounds  like  pXSC  (pXSSG)  have  been 
developed  and  strong  cancer  inhibitory  activities  demonstrated  (Rao  et  al.,  2001).  It 
appears  that,  as  with  selenite,  glutathione  conjugation  may  be  the  first  metabolic  step 
undergone  by  pXSC  (Rao  et  al.,  2001).  Interestingly,  while  the  chernopreventive  efficacies 
of  pXSSG  and  pXSC  are  similar,  the  sub-chronic  maximum  tolerated  dose  of  pXSSG  is  4 
times  higher  than  that  of  pXSC  indicating  reduced  toxicity  (Rao  et  al.,  2001).  It  would  be 
interesting  to  see  the  efficacy  of  this  class  of  aromatic  selenium  compounds  in  clinical 
trials. 
Selenium  bonded  directly  to  a  benzene  ring  has  provided  another  class  of  low  molecular 
weight  selenium  compounds.  This  bonding  is  very  stable  and  less  of  selenium  is  released 
during  metabolism  from  these  compounds  and  subsequently-  these  are  not  efficient  in 
repleting  GPx  in  deficient  animals  (Ip  et  al.,  1998a).  Of  the  different  compounds  in  this 
group,  triphenylselenonium  chloride  (TPS)  shows  the  most  promise  as  an  anti-cancer  agent 
(lp  et  al.,  1994b).  TPS  had  potent  chernopreventive  activity  at  5ppm  but  no  detectable 
influence  on  selenoprotein  expression  at  30ppm,  and  even  at  200pprn  no  toxic  effects  were 
observed  (lp  et  al.,  1998a).  This  observation  also  underscores  the  suggestion  that 
selenoproteins  may  not  be  involved  in  cancer  preventive  activities  and  in  the  case  for  TPS 
there  appears  to  be  a  particularly  distinct  separation  of  bioavailability,  anti-cancer  activity 
and  toxicity. 
To  put  this  discussion  in  perspective,  one  should  note  that  the  NPC  trial  used  a  complex 
selenium  source,  selenised  yeast  (Clark  et  al.,  1996).  Until  recently,  it  has  been  assumed 
that  the  major  component  of  selenised  yeast  was  selenomethionine  (SM).  However, 
development  of  new  analytical  techniques  have  revealed  that  selenomethionine  accounts 
for  only  -20%  of  all  selenium  containing  material  (Bird  et  al.,  1997).  Another  -20%  is  in 
the  form  of  SMC,  selenocystine  and  selenoethionine,  while  the  remaining  40-50% Chapter  2  35 
comprises  a  combination  of  hitherto  unidentified  compounds  (Bird  et  al.,  1997).  As  there  is 
no  evidence  how  these  unidentified  compounds  may  have  differing  effects  on  the  multistep 
process  of  carcinogenesis,  our  current  knowledge  cannot  entirely  explain  the  biological 
basis  of  the  cancer-inhibitory  effect  observed  by  Clark  et  al.  (1996).  Curiously  a  later 
paper,  using  the  same  techniques  and  having  some  of  the  investigators  in  common,  have 
again  re-established  the  abundance  of  selenomethionine  as  the  major  constituent  of 
selenised  yeast  (-85%),  most  of  it  immobilised  in  proteins  (Ip  et  al.,  2000b). 
Again,  until  very  recently,  it  was  assumed  that  all  selenium  in  the  plasma  is  protein-bound. 
New  techniques  have  now  revealed  that  a  small  fraction  (2-5%)  of  selenium  in  plasma  is 
non-covalently  bound  to  proteins  (Combs  Jr,  2000).  Given  the  assumption  that 
intermediates  of  selenium  metabolism  discharge  the  anti-cancer  activities,  this  fraction  is 
likely  to  contain  such  species:  thus  it  would  be  valuable  to  resolve  this  fraction  to 
individual  components  as  they  may  have  tremendous  implications  for  developing  effective 
biomarkers  of  the  critical  selenium  metabolites  responsible  for  selenium-mediated 
chemoprevention. 
In  conclusion,  it  appears  that  normal  products  of  metabolism  of  both  inorganic  and  organic 
forms  of  selenium  have  anti-carcinogenic  potentials,  as  does  several  synthetic  compounds. 
While  inorganic  selenium  salts  would  yield  SDG,  further  metabolism  would  produce 
selenide,  which  is  also  the  metabolic  fate  SM,  and  SMC  (Fig  1.4.2).  Selenide  itself  may 
exert  major  anti-cancer  activities,  but  when  accumulated  in  sufficient  quantities  may 
produce  apparently  anti-carcinogenic  metabolites  like  methylselenols  (and  its  derivatives). 
ROS  produced  by  selenide  may  also  directly  contribute  to  chernoprevention  by  inducing 
apoptosis  in  preneoplastic  cells.  Such  a  central  role  for  selenide  indicates  that  though  dose 
efficiencies  may  vary,  both  inorganic  and  organic  selenium  compounds  can  be  anti- 
tumorigenic.  Synthetic  compounds  like  pXSC,  TPS  and  BSC,  which  appear  to  release  their 
selenium  very  slowly  for  general  metabolism,  may  employ  more  direct  effects  (perhaps  as 
very  effective  analogs  of  the  natural  anticarcinogenic  metabolities)  to  mediate  their 
chernopreventive  effects. 
2.5.3  Selenium  dose  and  anti-carcinogenic  effect 
Anti-tumorigenic  effects  observed  for  various  selenium-compounds  require  exposure  to 
supranutritional  doses,  typically,  for  laboratory  animals,  >1mg  selenium/kg  diet  or  0.7mg 
selenium/l  drinking  water.  These  are  5-10  times  the  level  required  to  prevent  clinical  signs 
of  selenium  deficiency  and  support  maximal  selenoprotein  (known)  expression  (no  greater Chapter  2  36 
than  0.5mg  selenium/kg  of  diet).  On  a  unit  body  weight  basis,  this  is  also  greater  than  those 
experienced  by  most  people,  which  is  rarely  greater  than  200[tg/person/day. 
It  has  been  estimated  that  maximum  expression  of  GPx  and  selenoprotein  P  in  plasma 
would  yield  a  plasma  selenium  concentration  of  80ng/ml,  a  level  that  can  be  supported  by  a 
daily  dietary  selenium  intake  of  30-40[tg/day  (Combs  Jr,  2000;  Yang  et  al.,  1989).  The 
baseline  plasma  selenium  concentration  of  patients  entering  the  NPC  trial  was 
114:  t23ng/ml,  equivalent  to  a  daily  intake  of  >85[tg  from  dietary  sources  (Clark  et  al., 
1996;  Clark  et  al.,  1998).  It  is  therefore  interesting  to  note  that  use  of  200[tg/day  was 
associated  with  reductions  in  cancer  risk,  although  it  did  not  increase  plasma  GPx  activities 
or  alter  Thyroxine:  3,5,3'-Triiodothyronine  ratios  (a  measure  of  selenoprotein  deiodinase 
activity)  (Clark  et  al.,  1996;  Clark  et  al.,  1998;  Combs  Jr,  2000). 
This  makes  it  very  unlikely  that  anti-cancer  activities  of  selenium  compounds  can  be 
completely  explained  by  the  involvement  of  known  selenoenzymes.  Selenium-deficiency 
may,  however,  limit  the  activity/s  of  one  or  more  selenoproteins  and  enhance  cancer  risk. 
Therefore,  depending  on  dose,  selenium  may  play  different  roles  in  cancer  prevention,  viz., 
deficient  individuals  may  benefit  from  supplementation  by  optimal  expression  of 
selenoproteins  and  selenium-replete  individuals  may  benefit  from  diverting  selenium 
resources  to  other  metabolic  routes. 
From  the  above  discussion  on  dose  and  form  of  selenium  (and  with  reference  to  particular 
biological  responses  mediating  chernopreventive  effects  of  selenium  dicussed  later  - 
Section  2.6),  it  appears  that  selenium  has  two  basic  roles  in  cancer  prevention:  a)  as  a 
component  of  antioxidant  enzymes,  and  b)  as  anticarcinogenic  metabolites.  This  has  led  to 
the  proposal  of  a  2-stage  model  (Fig  2.5.1)  for  role  of  selenium  in  cancer  prevention 
(Combs  and  Gray,  1998).  According  to  this  model,  different  selenium-induced  biological 
activities  are  induced  at  different  doses.  These  activities  are  mediated  through  either  the 
functions  of  specific  selenium-dependent  enzymes  or  of  certain  selenium  metabolites 
produced  in  large  amounts  at  relative  high  doses  (supranutritional)  of  the  elements.  The 
cumulative  effect  of  all  these  anti-cancer  activities  is  proposed  to  account  for  the  robust 
chemopreventive  action  seen  at  supranutritional  doses  of  selenium.  The  model  predicts  that 
set  of  anti-cancer  activities  involved  in  protecting  a  nutritional  deficient  individual,  on 
supplementation  with  nutritionally  adequate  doses,  is  likely  to  be  different  from  those 
conferring  a  cancer-protective  action  at  supranutritional  levels. 37 
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Fig  2.5.1  Two-stage  model  for  roles  of  selenium  in  cancer  prevention  (adapted  from 
Combs  and  Gray,  1998) 
This  model  shows  that  selenium  has  two  essential  roles  in  chernoprevention,  viz.,  regulation  of 
antioxidant  activity  of  selenoproteins  and  regulation  of  biological  responses  by  selenium 
metabolites.  Biological  responses  are:  AP,  antioxidant  protection;  CM,  carcinogen  metabolism; 
IE,  immune  enhancement;  CC/PCD,  cell  cycle  alterations  and  induction  of  programmed  cell 
death  (apoptosis);  IS,  enhanced  immune  surveillance  and  cell-mediated  turnouricidal  activity; 
NA,  inhibition  of  neoangiogenesis;  T,  non-specific  toxicity. Chapter  2  38 
2.6  Candidate  mechanisms  mediating  anti-cancer  activities  of 
selenium  compounds 
While  a  huge  amount  of  data  has  accumulated  over  the  years  establishing  selenium 
compounds  as  potent  anti-cancer  agents,  little  is  known  of  the  biological  mechanisms  that 
mediate  this  cancer-inhibitory  activity.  A  particular  problem  has  been  the  inability  to 
address  several  of  these  issues  in  a  clinical  setting;  therefore  researchers  are  reliant  on  in 
vitro  cell  culture  experiments  and  studies  on  laboratory  animals. 
2.6.1  Alteration  of  carcinogen  action 
Though  no  universal  role  has  been  delineated,  selenium  may  exert  some  of  its 
chernopreventive  actions  by  altering  carcinogen  action.  Chernopreventive  doses  of  selenite 
and  selenocyanates,  but  not  selenomethionine,  have  been  demonstrated  to  inhibit  the 
formation  of  DNA-adducts  by  carcinogens  like  DMBA  and  bis(2-oxypropyl)nitrosamine 
(Ejadi  et  al.,  1989;  el-Bayourny  et  al.,  1992;  lp  et  al.,  1995).  While  Phase  I  xenobiotic 
enzymes  generally  do  not  appear  to  be  affected  by  selenium  (reviewed  in  (Ip,  1986)), 
Phase  II  enzymes,  like  glutathione-S-transferases  (GST)  and  uridine  5'-diphosphate- 
glucuronyltransferase,  are  induced  in  the  liver  and  kidney  upon  selenium  treatment  at 
chernopreventive  levels  (Chidambaram  and  Baradarajan,  1996;  lp  and  Lisk,  1997). 
Consistent  with  this,  some  GSTs  are  upregulated  in  selenium-resistant  variant  cell  lines 
(Wu  et  al.,  1995b).  However,  as  both  chernopreventive  and  nutritionally  repleting  doses  of 
selenium  induce  these  enzymes  to  similar  levels,  their  role  in  mediating  the  anti-cancer 
activities  of  selenium  is  debatable. 
While  selenite  has  been  shown  to  suppress  DNA  adduct  formation  by  aflatoxin  in  the  chick 
(Chen  et  al.,  1982b),  the  similar  dietary  levels  do  the  opposite  in  rats  (Chen  et  al.,  1982a), 
suggesting  a  species-specific  effect.  Effect  of  azoxymethane  is  altered  by  selenium, 
possibly  by  increasing  its  hydroxylation  and  subsequent  oxidation  (Fiala  et  al.,  1991). 
Promotion  of  ring  hydroxylation  of  the  carcinogen  2-acetylaminofluorene  by  selenium  is 
thought  to  diminish  the  carcinogenic  potential  of  this  compound  (Besbris  et  al.,  1982).  The 
production  of  mutagenic  metabolites  in  the  liver,  by  carcinogens  such  as  DMBA,  2- 
acetylarninofluorene  and  benzopyrene,  is  also  reduced  by  dietary  selenium 
supplementation  in  rats  (Gairola  and  Chow,  1982;  Schillaci  et  al.,  1982). Chapter  2  39 
In  summary,  while  considerable  variation  with  respect  to  carcinogen  type  and  host  species 
is  observed,  chemopreventive  levels  of  selenium  can  affect  carcinogen  action  and  may 
therefore  influence  the  initiation  phase  of  carcinogenesis. 
Z6.2  Enhancement  of  immune  surveillance 
Selenium-deficiency  has  long  been  shown  to  impair  T-  and  B-cell  immune  responses  in 
animals.  Antibody  dependent  cytotoxicity  has  been  found  not  to  be  affected  by  selenium 
deprivation  but  some  reports  indicate  that  natural  killer  (NK)  cell-dependent  cytotoxicity  is 
susceptible  to  selenium  deficiency  (Talcott  et  al.,  1984).  Selenium  deprivation  has  also 
been  reported  to  affect  splenocyte  differentiation  and  attenuated  proliferative  responses  of 
T-cells  on  mitogenic  stimulation  (Chang  et  al.,  1994;  Finch  and  Turner,  1989). 
Supranutritional  levels  of  selenium  have  been  found  to  stimulate  cytotoxic  activities  of 
NK-cells  (Kiremidjian-Schumacher  et  al.,  1994;  Kiremidjian-Schumacher  et  al.,  1996; 
Petrie  et  al.,  1989)  and  lymphokine  activate  killer  cells  in  humans  (Kiremidjian- 
Schumacher  et  al.,  1996),  though  similar  effects  have  not  been  reproduced  in  animals  (Nair 
and  Schwartz,  1990).  Supplementation  with  200[ig  of  selenium/day,  a  dose  equivalent  to 
that  used  in  the  NPC  trial,  though  the  form  of  selenium  was  different,  was  found  to 
promote  destruction  of  tumour  cells  by  cytotoxic  lymphocytes  and  macrophages 
(Kiremidjian-Schumacher  et  al.,  1994;  Roy  et  al.,  1994).  Selenium  exposure  also  leads  to 
an  increased  production  of  high-affinity  IL,  2  receptor  subunits  (Roy  et  al.,  1992;  Roy  et 
al.,  1994)  which  may,  conceivably,  lead  to  accelerated  clonal  expansion  of  IL-2 
stimulation-induced  cytotoxic  effector  cells.  Recently,  investigations  into  several  T-cell 
associated  genes,  like  CD4,  CD8  HLA-DR,  have  revealed  the  presence  of  open  reading 
frames  similar  to  selenoprotein  P,  potential  SECIS  elements  and  Sec  insertion  sequences  in 
their  mRNA  (Guimaraes  et  al.,  1996;  Taylor,  1995).  This  raises  the  intriguing  possibility 
that  these  may  be  functional  selenoproteins  that  may  confer  an  additional  level  of 
selenium-mediated  regulation  of  the  immune  system. 
Z6.3  Inhibition  of  angiogenesis  and  invasion 
Growth  of  capillary  blood  vessels  from  existing  ones,  i.  e.,  angiogenesis  is  essential  for  the 
growth,  progression  and  metastasis  of  solid  turnours  (Folkman,  1971).  Selenite,  selenium- 
enriched  garlic  and  SMC  have  all  been  shown  to  inhibit  angiogenesis  and  tumour-induced 
neovascularisation  in  animal  models  (Jiang  et  al.,  2000;  Jiang  et  al.,  1999;  Lu,  2001; 
Schumacher  et  al.,  2001).  Whilst  the  molecular  mechanisms  involved  in  this  process  are Chapter  2  40 
not  clear,  in  vitro  data  suggests  that  reduction  in  the  expression  of  a  potent  angiogenic 
growth  factor,  the  vascular  endothelial  growth  factor  (VEGF),  may  be  responsible  (Jiang  et 
al.,  2000;  Lu,  2001).  pXSC  has  also  been  reported  to  inhibit  VEGF  and  basic  fibroblast 
growth  factor  (bFGF)-induced  angiogenic  sprouting  in  an  in  vivo  model  (Schumacher  et 
al.,  2001). 
Selenium  compounds  have  also  been  reported  to  modulate  the  activities  of  matrix 
metalloproteases  (MMP),  which  mediate  the  degradation  of  the  extracellular  matrix,  a 
prerequisite  for  cellular  invasiveness  and  movement  (McCawley  and  Matrisian,  2000). 
Inhibition  of  MMP-2  and  MMP-9  gelatinolytic  activities  has  been  reported  following 
selenium  treatment  (Jiang  et  al.,  2000;  Jiang  et  al.,  1999;  Yoon  et  al.,  2001).  Selenite  has 
also  been  shown  to  increase  the  production  of  tissue  inhibitor  of  matrix  metalloprotease-1 
(TIMP-1),  an  inhibitor  of  MMP  activity  (Yoon  et  al.,  2001).  These  observations  raise  the 
possibility  that  modulation  of  cellular  movement  via  alteration  of  MMP  activities  may 
contribute  to  angiogenic  sprouting.  Endothelial  cells  (lining  capillaries)  are  sensitive  to 
selenium-induced  apoptosis;  this  may  also  be  causally  related  to  inhibition  of  neo- 
angiogenesis  (Lu,  2001). 
Reports  of  modulation  of  MMP  activities  suggest  that  these  may  contribute  to  reducing 
tumour  invasiveness  and  metastasis.  Several  selenium  compounds,  including  pXSC,  inhibit 
experimental  metastasis  in  animal  models  (Tanaka  et  al.,  2000).  In  vitro,  selenite  has  been 
shown  to  retard  migration  of  turnour  cells  through  a  collagen  matrix  (Yoon  et  al.,  2001). 
Cellular  attachment  and  motility  of  HeU  cells  is inhibited  by  non-growth  inhibitory  doses 
of  selenite  (Gong  and  Frenkel,  1994;  Yan  and  Frenkel,  1992).  Though  this  is  a  newly 
emerging  aspect  of  selenium  biology,  evidence  suggests  selenium  may  contribute  directly 
to  inhibit  neo-angiogenesis  and  tumour  invasiveness. 
Z6.4  Protection  from  oxidative  damage 
As  the  aetiology  of  several  cancers  is  thought  to  involve  mutagenic  oxidative  stress,  the 
antioxidant  activities  of  selenoproteins,  such  as  GPxs,  have  been  proposed  to  mediate 
chernopreventive  effects  of  selenium.  It  is  thought  that  these  may  operate  by  removing 
genotoxic  H202  and  lipid  hydroperoxides,  by  blocking  the  production  of  ROS  and 
malonyldialdehyde.  Indeed,  the  production  of  UV-B  and  phorbol  ester  induced  skin 
turnours  in  rat  was  inhibited  by  selenite  and  this  correlated  with  increased  GPx  activity  in 
the  skin  (Pence  et  al.,  1994;  Perchellet  et  al.,  1987).  Several  other  studies  on  rodents,  using 
selenite,  BSC,  pXSC,  selenomethionine  and  the  synthetic  selenium  compound  ebselen  and Chapter  2  41 
have  shown  inhibition  of  oxidative  stress  induced  damage  to  DNA,  lipids  and  proteins  (El- 
Bayoumy  et  al.,  2000;  Fiala  et  al.,  1997;  Roussyn  et  al.,  1996;  Takada  et  al.,  1992). 
However,  there  is  evidence  that  at  least  the  cytosolic  GPx  (GPx1)  is  not  involved  since 
GPxl-null  mice  do  not  show  any  abnormal  histoPathologies  up  to  15  months  age  (Cheng  et 
al.,  1997;  Ho  et  al.,  1997)  although  they  are  more  sensitive  to  exogenous  oxidative  stress 
(de  Haan  et  al.,  1998).  In  fact,  GPxl-transgenic  mice  are  actually  more  sensitive  to 
DMBA/TPA-induced  skin  cancer,  rather  than  the  reverse,  hypothetically  because  the 
generation  of  tumor-promoting  lipoxygenase-derived  peroxides  is  increased  (Lu  et  al., 
1997). 
The  anti-carcinogenic  response  seen  in  selenium-replete  animals  supplemented  with 
supranutritional  doses  of  selenium  (>lppm)  cannot  involve  the  known  selenoproteins,  as, 
animals  show  maximal  GPx  activities  in  most  tissues  at  dietary  levels  of  -0.2ppm. 
Accordingly,  the  studies  on  selenium  mediated  inhibition  of  UV  induced  oxidative  damage 
in  rodents  typically  observed  the  said  effect  at  dose  ranges  of  0.1-0.5ppm  (Pence  et  al., 
1994).  Also,  reports  suggesting  chernopreventive  doses  (1.5ppm)  of  selenium  reduce  lipid 
peroxidation  only  slightly  (Lane  and  Medina,  1985)  or  not  at  all  (Horvath  and  lp,  1983) 
also  go  against  this  hypothesis. 
2.6.5  Redox  regulation  and  the  thforedoxin  system 
Redox  signalling  is  critical  to  the  growth  of  several  cancers  and  its  modulation  may  be 
another  underlying  mechanism  of  cancer-inhibitory  effects  of  selenium.  Thiol  residues  on 
critical  regulators  and  effectors,  like  transcription  factors,  are  known  to  be  involved  in  their 
regulation  in  response  to  changes  in  redox  potential  in  the  cell  (Kamata  and  Hirata,  1999; 
Sun  and  Oberley,  1996).  Selenium  influences  redox  signalling  in  two  ways;  first,  it  may  be 
a  component  of  these  active  centres  as  selenocysteine  and  directly  participate  in  redox 
reactions,  secondly,  selenium  may  modulate  the  activities  of  redox  regulatory  proteins  by 
forming  covalent  adducts  and  catalysing  thiol/disulphide  reactions  with  crucial  cysteine  or 
Sec  residues  (as  described  in  Section  1.6). 
In  vitro,  low  concentrations  of  selenite  and  SDG  have  been  shown  to  inhibit  PKC  activity 
by  covalently  modifying  catalytic  cysteine  clusters  (Gopalakrishna  et  al.,  1997).  Thiol- 
dependent  modification  is  also  implicated  in  the  inhibition  of  UV-induced  stress-kinase 
activation  by  selenium  (Park  et  al.,  2000b).  Cysteine  modification  is  also  the  proposed 
mechanism  for  inhibition  of  the  transcription  factor  NF-KB  (Kim  and  Stadtman,  1997). Chapter  2  42 
Thus,  these  activities  could  profoundly  modulate  redox  signalling  and  subsequently  affect 
cellular  homeostasis.  Such  activities  have  been  extended  to  a  model  (Ganther,  2000)  where 
selenium  may  regulate  redox  signalling  independently  of  its  capacity  to  directly  modulate 
changes  in  peroxide/ROS  levels  and  the  cellular  redox  potential.  Redox-regulated 
transcription  factors  can  have  two  states,  ON  and  OFF,  that  differ  by  the  oxidation  state  of 
regulatory  cysteines  that  often  involve  presence  or  absence  of  intramolecular  disulphide 
bonds,  as  in  the  OxyR  transcription  factor  (Zheng  et  al.,  1998).  Selenium  can  reversibly 
catalyse  redox-changes  in  these  proteins  by  reversing  or  promoting  the  formation  of 
disulphide  bonds  (type  3  mechanism,  see  Section  1.6),  leading  to  resetting  the  protein 
activity  to  the  basal  state.  Thus,  by  altering  the  redox  state  of  important  targets  selenium 
may  influence  the  activity  of  these  molecules. 
A  recent  report  has  shown  that  benzeneselenic  acid  can  displace  zinc  from  tightly  bound 
zinc-sulphur  clusters  in  metallothionein  (Jacob  et  al.,  1999).  This  mechanism  can  form  the 
basis  for  removal  of  zinc  by  selenium  ftom  zinc-finger  of  transcription  factor  and  other 
signalling  proteins  and  could  be  a  putative  chernopreventive  mechanism.  Selenite  has  also 
been  shown  to  inactivate  the  c-myc  oncogene  in  hepatoma  cells  leading  to  the  loss  of  its 
transforming  potential  (Yu  et  al.,  1990).  This  appears  to  be  mediated  by  the  competition  of 
selenium  with  zinc  on  the  c-myc-activating  zinc-finger  (Maz)  protein  (Nelson  et  al., 
1996a).  Curiously,  cysteine  proteases  like  caspases  have  inhibitory  zinc  atoms  blocking  the 
active  site  cysteine.  Thus  direct  displacement  of  this  zinc  molecule  by  selenium 
compounds  can  conceivably  activate  the  caspases  and  induce  apoptosis. 
A  prime  candidate  likely  to  have  a  significant  influence  on  redox  modulation  by  selenium 
is  the  selenoprotein  thioredoxin  reductase  (TR).  TR  and  thioredoxin  (Trx)  form  a  redox 
system  and  have  diverse  functions,  like  regulating  transcription  factor  activities  and 
providing  reducing  equivalents  for  DNA  synthesis  (recently  reviewed  in  (Holmgren, 
2000)).  While  TR  expression  is  low  in  many  normal  tissues,  it  is  overexpressed  in 
transformed  cells  (Powis  and  Montfort,  2001).  In  fact,  selenite  and  SDG  are  highly 
efficient  oxidants  of  Trx  and  substrates  for  TR  (Bjornstedt  et  al.,  1992;  Kumar  et  al.,  1992) 
and  so  it  has  been  proposed  that  the  inhibitory  effects  of  selenite  and  SDG  on  cell  growth 
may  involve  competitive  inhibition  of  the  thioredoxin  system  and  oxidation  of  structural 
cysteines  in  Trx  to  disulphides  (Ganther,  1999). 
In  cancer  cell  lines  and  animals,  supranutritonal.  doses  of  selenium  as  selenite,  increases  the 
activity  of  TR  (Berggren  et  al.,  1997).  Interestingly  such  changes  have  not  been  observed 
in  vitro  with  SMC  and  SM  and  in  general  appear  to  be  specific  to  epithelial  cells  (Ganther, Chapter  2  43 
1999).  Animal  studies  have  also  noted  that  the  increased  TR  activity  is  not  permanent  as 
prolonged  exposure  to  high  selenium  levels  result  in  a  decline  to  basal  levels  (Berggren  et 
al.,  1999).  Recent  evidence  suggests  that  TR  activity  is  not  affected  in  rats  fed  with 
chernopreventive  doses  of  SMC  and  methylselenic  acid  (Ganther  and  lp,  2001). 
Trx  is  also  overexpressed  in  many  cancers,  is  secreted  by  tumour  cells  and  stimulates 
proliferation  while  inhibiting  apoptosis  in  cells  in  culture  (Powis  and  Montfort,  2001). 
Cells  transfected  with  Trx  cDNA  show  increased  turnour  growth  and  decreased  apoptosis 
in  vivo  and  it  appears  that  it  is  the  reduced  form  that  mediates  these  effects  (Powis  et  al., 
1998).  A  continuously  high  dietary  level  of  selenium  results  in  a  reduction  in  TR  activity, 
postulated  to  be  due  to  formation  of  an  irreversible  diselenide  'trap'  at  the  selenocysteine 
in  its  active  site  (Ganther,  1999):  this  would  also  result  in  a  reduction  in  the  level  of 
reduced  Trx  .  Of  particular  interest  in  this  context  is  the  fact  that  ASKI,  a  mediator  of  pro- 
apoptotic  signalling,  is  inhibited  by  binding  of  reduced  Trx  to  its  N-terminal  region  (Ichijo 
et  al.,  1997;  Saitoh  et  al.,  1998):  thus  depletion  of  reduced  Trx  by  selenium  compounds  via 
this  mechanism  or  by  direct  oxidation  of  reduced  Trx  might  be  expected  to  activate  ASK1 
and  induce  apoptosis. 
Z6.6  Activities  of  other  selenoproteins  and  other  new  functions 
In  the  NPC  trial  showing  inhibition  of  human  cancer  incidence  on  selenium 
supplementation,  very  few,  if  any,  patients  had  nutritionally  limiting  selenium  intakes  as 
judged  by  their  baseline  plasma  selenium  level  (see  Section  2.5.3).  Tbus  it  appears  to  be 
highly  probable  that  anti-cancer  activities  of  selenium  at  supranutritional  doses  involve 
mechanisms  unrelated  to  the  activities  of  known  selenoproteins.  However,  a  role  for 
selenoenzymes  in  nutritionally  deficient  situations  may  be  possible.  If  any  as  yet 
unidentified  and/or  uncharacterised  selenoproteins  are  involved  in  mediating  anti-cancer 
actions,  selenium  levels  at  which  their  activities  are  saturated  is  likely  to  be  much  higher 
than  the  known  selenoenzymes. 
Newly  identified  selenoprotein  with  unknown  functions,  like  the  15kDa  selenoprotein 
whose  expression  is  reduced  dramatically  in  some  cancers  is  potentially  interesting  and 
may  reveal  clues  to  novel  cancer-inhibitory  mechanisms  employed  by  selenium 
(Gladyshev  et  al.,  2000). 
Selenoenzymes  like  iodothyronine  5-deiodinases  (DI)  may  also  affect  cancer  cell  growth 
by  regulating  thyroid  hormone  metabolism.  Thyroid  hormones  have  been  shown  to  oppose Chapter  2  44 
oestrogen-induced  proliferation  of  breast  cancer  cells  (Vorheff,  1987).  This  may  be 
relevant  as  breast  cancer  patients  have  low  selenium  levels  and  lower  plasma  thyroxine 
levels  (Combs  Jr  and  Lu,  2000).  Breast  cancer  incidence  is  also  significantly  higher  in 
areas  of  endemic  iodine  deficiency  compared  to  non-endemic  areas  (Combs  Jr  and  Lu, 
2000). 
In  several  cancers,  tumour  suppressor  genes  may  be  inactivated  by  methylation  of  specific 
cytosine  residues.  Inhibition  of  methyltransferesae  (MTase)  activity  has  also  been 
suggested  as  an  important  mechanism  of  chernoprevention  by  selenium  compounds  and 
recent  work  has  demonstrated  that  selenite,  BSC  and  pXSC  can  efficiently  inhibit  Wase 
activity  (Fiala  et  al.,  1998),  presumably  via  reactions  with  the  critical  thiol  residues  on  the 
Wase  protein. 
In  contrast  to  increased  methylation  of  key  turnour  suppressor  genes,  overall  genomic 
hypomethylation  of  DNA  has  been  recognised  as  a  very  consistent  early  event  in  human 
colorectal  carcinogenesis  (Feinberg  and  Vogelstein,  1983).  Recently,  in  vitro  and  in  vivo 
studies  using  selenite  and  selenomethionine  have  shown  that  selenium  may  prevent 
occurrence  of  hypomethylated  DNA  in  the  colon  and  liver,  suggesting  that  this  may  also  be 
a  potential  anti-cancer  activity  (Davis  et  al.,  2000). 
Z6.7  Growth  inhibition  by  suppressing  proliferation  andlor  apoptosis 
From  a  cellular  point  of  view,  deregulation  of  tissue  size  homeostasis  is  the  basis  for 
cancer,  thus  the  disease  can  occur  in  a  tissue  when  the  rate  of  proliferation  exceeds  the  rate 
of  cell  death.  Selenium  compounds  can  have  a  negative  influence  on  carcinogenesis  by 
decreasing  the  rate  of  cellular  proliferation  and/or  increasing  the  rate  of  apoptosis.  A  large 
corpus  of  data  has  accumulated  indicating  that  selenium  compounds  can  inhibit  cellular 
proliferation  and/or  induce  apoptosis.  A  strong  correlation  has  been  observed  between  the 
effectiveness  of  selenium  compounds  as  chernopreventive  agents  in  vivo  and  their  ability  to 
induce  growth  arrest  and  apoptosis  in  vitro  (Lanfear  et  al.,  1994;  Ronai  et  al.,  1995; 
Thompson  et  al.,  1994;  Wilson  et  al.,  1992).  Animal  studies  have  also  confirmed  the 
growth  inhibitory  effects  of  selenium  at  chernopreventive  conditions  in  vivo  (Ip  and  Dong, 
2001;  Ip  et  al.,  2000c;  Ip  et  al.,  2000d). Chapter  2 
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Although  neoplasia  involves  many  other  processes,  in  almost  all  instances,  the  underlying 
platform  for  neoplastic  growth  is  deregulated  cell  proliferation  and  suppressed  cell  death.  It 
is  understandable  therefore,  that  evolution  has  forged  very  tight  and  complex  regulatory 
mechanisms  to  maintain  cellular  homeostasis.  Thus,  conversely,  intervention  at  the  level  of 
these  fundamental  biological  underpinnings  of  tumour  cells  can  form  the  basis  of  anti- 
cancer  therapeutic  strategies. 
A  cell  normally  undergoes  a  growth  (or  'gap')  phase  (Gl)  prior  to  replicating  its  DNA  in 
the  synthesis  phase  (S).  Following  a  further  'gap'  phase  (G2)  the  cell  finally  enters  the 
mitotic  phase  (M)  and  divides  (Murray  and  Hunt,  1993)  (see  Fig  2.6.1).  The  timing  and 
order  of  cell  cycle  events  are  monitored  during  cell  cycle  checkpoints  that  occur  at  the 
Gl/S  phase  boundary,  in  S  phase,  and  during  G2/M  phases  (reviewed  in  (Murray,  1994)). 
These  checkpoints  ensure  that  critical  events  in  a  particular  phase  are  completed  prior  to 
the  initiation  of  the  next  phase,  thereby  precluding  the  generation  of  genetically  abnormal 
cells.  Cell  cycle  progression  can  be  blocked  at  these  checkpoints  in  response  to  the  status 
of  both  the  intra-  and  extracellular  environments.  For  example,  growth  arrest  is  induced  on 
detection  of  incomplete  DNA  replication,  DNA  damage  or  chromosomal  misalignment  on 
the  mitotic  spindle  (Murray,  1994).  Also,  the  expression  of  some  genes  necessary  for  DNA 
replication  occurs  only  in  the  presence  of  mitogens  (Murray  and  Hunt,  1993).  Upon 
rectification  of  the  error,  progression  through  the  cell  cycle  resumes.  However  if  the 
aberration  is  too  severe  or  the  cell  is  incapable  of  repairing  the  damage:  apoptosis  is 
invoked  to  eliminate  damaged  cells  (Murray  and  Hunt,  1993).  The  choice  of  progression  or 
delay  while  the  error  is  rectified  or apoptotic  cell  death  is  decided  at  the  checkpoints. 
The  regulation  of  the  cell  cycle  is  achieved  primarily  by  the  activities  of  two  protein 
families:  the  cyclins  and  the  cyclin-dependent  protein  kinases  (cdk's)  (Hunter  and  Pines, 
1994;  Murray,  1994).  The  kinase  activity  of  cdk's  is  dependent  on  their  interaction  with 
activating  cyclins  and  subsequent  phosphorylation  of  specific  substrates  allows  progression 
through  the  cell  cycle  (Fig  2.6.1).  The  abundance  of  specific  cyclins  increases  during  the 
phase  of  the  cell  cycle  where  they  are  required  and  decline  in  phases  when  they  are  not 
needed  (Murray  and  Hunt,  1993).  For  example,  usually  cyclin  D  associates  with  cdk4  and 
cdk6  during  early  G1,  whereas  cyclin  E  activates  cdk2  during  the  G1  to  S  transition. 
Cyclin  A  binds  to  cdk2  or  cdc2  during  S  phase  and  the  G2  to  M  transition  (Fig  2.6.1).  Thus 
specific  cyclin/cdk  complexes  are  activated,  and  their  phosphorylation  of  -particular 
proteins  permit  the  cell  cycle  to  progress.  The  transcription  of  genes  necessary  for  S  phase, 46 
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Fig  2.6.1  Regulation  of  cell  cycle  progression. 
The  principal  regulatory  components  of  the  mammalian  mitotic  cell  cycle  are  represented.  The 
major  cdk's  (red)  and  cyclins  (blue)  and  their  cell  cycle  phase-specific  regulation  is  shown  (see 
text  for  discussion).  Some  other  regulatory  components  are  also  indicated.  G  I,  'Gap'  phase  1;  S, 
synthesis  (DNA)  phase;  G2,  'gap'  phase  2;  M,  mitosis. Chapter  2  47 
for  example,  is  regulated  by  cyclin  D/cdk4-dependent  phosphorylation  of  the 
retinoblastoma  (Rb)  protein  (Fisher,  1997;  Morgan,  1995). 
Cyclin/cdk  complexes  can  also  be  bound  by  cdk  inhibitor  proteins  which  inhibit  kinase 
activity  and  prevent  cell  cycle  progression.  Two  major  ?  amilies  of  cdk  inhibitor  proteins 
have  been  identified:  the  CIP/KIP  family,  including  p2l,  p27  and  p57,  predominantly 
inhibit  G1  to  S  transition  and  the  INK4  family,  including  p15,  p16,  p18  and  p19,  which  are 
often  mutated  in  certain  cancers  and  specifically  interact  with  cdk4  and  cdk6  (Fig  2.6.1) 
(Harper  and  Elledge,  1996;  Xiong,  1996). 
Several  other  genes  are  known  to  modulate  cell  proliferation  by  affecting  the  formation  or 
activity  of  cdk  complexes.  For  example,  the  proto-oncogene  c-myc  is  a  transcription  factor 
which  with  other  factors,  like  Max,  to  promote  mitogenesis  (Amati  et  al.,  1993).  The 
expression  of  c-myc,  which  is  modulated  bý  growth  factors,  is  required  for  quiescent  cells 
to  enter  the  cell  cycle.  This  activity  is dependent  on  c-myc  induced  transcription  of  Cdc25, 
a  phosphatase  that  activates  cdk's  (Galaktionov  et  al.,  1996). 
Apoptosis  is  an  evolutionary  conserved,  genetically  regulated  form  of  cell  death  necessary 
in  many  processes,  ranging  from  embryonic  development  and  tissue  homeostasis.  It  is 
distinguished  from  necrosis  by  characteristic  chromatin  condensation,  nuclear 
fragmentation,  cell  shrinkage  and  plasma  membrane  blebbing,  whereby  cells  break  into 
small,  membrane-suffounded  fragments  (apoptotic  bodies)  that  are  phagocytosed  without 
inciting  an  inflammatory  response  (Wyllie,  1997). 
Survival  of  all  somatic  cells  requires  the  continuous  input  of  survival  and  trophic  signals  to 
suppress  apoptosis  (Evan  and  Vousden,  2001).  The  central  engines  of  apoptosis  are  the 
caspases,  cascades  of  cysteine  aspartyl  proteases  that  implement  cell  death  by  cleaving  a 
variety  of  intracellular  substrates  triggering  cell  dissolution  (Earnshaw  et  al.,  1999;  Wolf 
and  Green,  1999).  Caspases  exist  as  latent  zymogens  and  their  activation  comprises  an 
activation  cascade  involving  multiple  caspases  which,  according  to  their  sequence  of 
activation,  are  organised  into  apoptotic  initiator  caspases  (caspase  2,8,9  and  10)  and 
apoptotic  executor  caspases  (caspase  3,6  and  7)  (Earnshaw  et  al.,  1999;  Wolf  and  Green, 
1999)  (Fig  2.6.2).  One  such  apical  cascade  pathway  is  mediated  by  the  transmembrane 
death  receptors  of  the  Fas/'IRAII,  /tumour-necrosis  factor  (TNF)  receptor  1  family,  whose 
ligation  triggers  recruitment  of  adaptor  proteins  like  Fas-associated  death  (FADD)  domain 
protein  and  assembly  of  a  multiprotein  receptor-bound  death-inducing  signalling  complex 
(DISC)  that  recruits  and  activates  the  initiator  caspase  8  (Fig  2.6.2) 48 
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Fig  2.6.2  Molecular  mechanisms  of  apoptosis  induction  (adapted  from  Reed,  2001). 
The  molecular  machinery  responsible  for  the  induction  of  apoptosis  is  summarised  in  this  figure. 
The  mitochondria-dependent  and  the  death  receptor  pathway  and  their  major  regulatory 
components  are  delineated.  Functions  of  the  components  have  been  discussed  in  the  text.  DD 
indicates  proteins  with  'death  domain'  motifs;  DED,  proteins  containing  'death  effector  domain' 
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(Walczak  and  Krammer,  2000).  The  other  major  death-signalling  pathway  involves  the 
mitochondrion,  which  acts  as  an  integrating  sensor  of  death  insults  by  releasing 
cytochrome  c  into  the  cytosol  where  it  triggers  caspase  activation  (Hengartner,  2000).  The 
mitochondrial  pathway  is  thought  to  be  the  principal  target  of  survival  signalling,  which 
acts  by  stabilising  mitochondrial  function  and  integrity  and  suppressing  cytochrome  c 
release.  Once  cytochrome  c  is  released  it  directs  the  formation  of  an  intracellular 
apoptosome  complex  that  recruits  the  initiator  caspase  9  via  the  adaptor  protein  Apaf-1 
(Fig  2.6.2)  (Hengartner,  2000).  Activation  of  both  these  initiator  caspase  cascades  lead  to 
the  activation  of  executor  caspases  like  caspase  3  (Reed,  2001). 
The  inhibitor  of  apoptosis  proteins  (IAP's)  are  a  family  of  evolutionary  conserved 
apoptosis  suppressors,  which  function  mainly  by  inhibiting  caspase  activity  (Reed,  2001). 
Consistent  with  their  role,  some  IAP's  like  survivin  are  commonly  overexpressed  in 
cancers.  Other  members  of  this  family  include  XIAP,  cIAP1  and  cIAP2.  IAP's  in  turn,  - 
have  been  shown  to  be  inhibited  by  the  mitochondria-released  protein  SMAC(DLABLO) 
(Fig  2.6.2).  Another  family  of  proteins,  the  anti-apoptotic  death  effector  domain  (ADED), 
which  include  members  like  Flip,  which  inhibits  FADD  and  caspase  8  activity  (Fig  2.6.2) 
(Reed,  2001). 
The  mitochondria-dependent  pathway  is  governed  by  the  Bcl2  family  of  proteins  which  are 
conserved  throughout  metazoan  evolution.  Both  pro-apoptotic  (like  Bax,  Bad,  Bak)  and 
anti-apoptotic  (like  B62,  BclxL)  Bcl2  family  proteins  exist,  which  often  form  complex 
networks  of  homo-  and  heterodimers  (Reed,  2001).  The  relative  amounts  of  active  pro-  and 
anti-apoptotic  proteins  determine  the  sensitivity  or  resistance  of  cells  to  a  variety  of 
impinging  apoptotic  stimuli  (Hengartner,  2000).  Alterations  in  the  expression  of  B62 
family  members  have  also  been  implicated  in  cancer  (Reed,  2001).  The  primary  function 
of  these  proteins  appear  to  be  the  regulation  of  the  release  of  cytochrome  c  and  other 
apoptogenic  proteins  from  mitochondria  (Fig  2.6.2)  (Reed,  2001). 
The  apoptotic  programme  is  optimised  to  ensure  that  signals  for  phagocytosis  are  displayed 
well  before  the  release  of  cellular  constituents.  A  major  phagocytosis  signal  is  the 
translocation  of  phosphatidylserine  to  the  outer  leaflet  of  the  plasma  membrane  (Henson  et 
al.,  2001). 
In  recent  years,  several  instances  of  caspase-independent  programmed  cell  death  have 
identified  (Lreist  and  Jaattela,  2001).  Non-caspase  proteases  like  cathepsins  and  calpain 
have  been  implicated  in  triggering  apoptosis  by  cleaving  death  substrates  that  lead  to  cell Chapter  2  50 
death.  Fas  receptor  has  been  also  described  to  induce  caspase-independent  cell  death, 
particularly  in  activated  primary  T-lymphocytes  presumably  via  the  induction  of  ROS 
(Leist  and  Jaattela,  2001).  Mitochondria  may  also  mediate  a  cell  death,  independent  of 
caspase  activation  by  the  release  of  mitochondria-derived  ROS  or  by  the  release  of 
apoptosis-inducing  factor  (AIF)  from  the  intermembrane  space.  This  flavoprotein  can 
directly  induce  nuclear  changes  and  death  induction  (Leist  and  Jaattela,  2001). 
Selenium  treatment  has  been  shown  to  modulate  a  number  of  key  regulators  of  cell  cycle 
progression  and  apoptosis  (surnmarised  in  Table  2.6.1)  and  are  discussed  next. 
2.6.7.2  Cell  cycle  progression  and  selenium 
Post-initiation  anti-cancer  effects  of  selenium  are  likely  to  involve  perturbation  of  tumour 
cell  behaviour.  Exposure  of  cells  to  selenium  compounds  like  selenite  has  been  shown  to 
reduce  DNA,  RNA  and  protein  synthesis  and  inhibit  cellular  proliferation  and  is 
accompanied  by  a  block  in  the  cell  cycle  at  the  S/G2-M  phase  ((Lu  et  al.,  1995a;  Sinha  et 
al.,  1996)  and  reviewed  in  (Combs  Jr  and  Lu,  2000;  Ip,  1998)).  In  contrast,  SMC  induces  a 
much  moderate  growth  inhibition  that  was  accompanied  by  a  block  at  the  G1  phase  of  the 
cell  cycle  (Sinha  et  al.,  1996).  pXSC  is  known  to  inhibit  the  activity  of  thymidine  kinase 
(TK)  (Tillotson  et  al.,  1994)  which  may  directly  affect  the  rate  of  DNA  synthesis  and 
subsequently  cell  cycle  progression,  though  inhibition  of  cell  cycle  progression  has  not 
been  reported  for  pXSC.  As  the  first  step  in  thymidine  incorporation  involves  its 
phosphorylation  by  TK  (Broet  et  al.,  2001),  the  close  correlation  between  TK  inhibition 
and  suppression  of  thymidine  incorporation  suggests  a  functional  interaction. 
SMC  and  its  derivative,  methylselenic  acid,  was  found  to  inhibit  cdk2  activity  and  reduce 
the  cdk2-cyclin  E  content,  which  is  compatible  with  the  observed  G1  arrest  (Sinha  et  al., 
1996;  Sinha  et  al.,  2001).  However,  selenite  also  decreased  cdk2  activity  but  did  not 
significantly  affect  its  association  with  cyclins  D1,  A  or  E  (Sinha  et  al.,  1996).  This 
observation  is  inconsistent  with  the  observed  S/G2-M  arrest  seen  on  treatment  of  cells  with 
selenite  (see  Fig  2.6.1).  A  later  study,  using  synchronised  cells  treated  with  SMC,  revealed 
a  significant  delay  in  progression  through  the  S  phase  rather  than  a  block  at  G1  and  this 
was  associated  with  a  reduction  in  cdk2  activity  but  only  a  transient  inhibition  of  cdk2- 
cyclin  E  association  (Sinha  and  Medina,  1997).  While  this  would  allow  entry  into  the  S 
phase,  progression  through  S  would  be  severely  delayed.  It  should  be  noted  that  while 
these  studies  offer  a  plausible  explanation  for  observed  cell  cycle  perturbations  upon  SMC 
treatment,  functional  evidence  (for  example,  whether  constitutively  active  cdk2  could 51 
Form  Parameter  Outcome 
Selenite  ROS  E 
DNA  SSBs  E 
elF2  I 
p53  E 
AP-1 
NF-KB 
C-myc 
C-fos  E 
PKC  I 
PKA  I 
DNA  cytosine  methyltransferase  I 
cdk2  I 
cyclins  A,  DI,  E  NE 
caspase  3  EME 
PARP  cleavage  ONE 
JNK  E 
p38  E 
GADD  family  E 
Bcl2,  Bax  NE 
SDG  ROS  E 
p53  E 
AP-1 
PKC 
PKA 
SIVIC  ROS  E 
DNA  SSBs  NE 
PKC  I 
PARP  cleavage  E 
Caspase  3,8,9  E 
JNK  NE 
p38  NE 
cdk2  I 
cyclin  E  I  (transient) 
GADD  family  E 
PCNA,  p2l  (in  vivo)  NE 
cyclins  A,  D1  (in  vivo)  I 
p27  (in  vivo)  E 
Bcl2  (in  vivo)  I 
PXSC  PKC  I 
DGK  E 
PKA  I 
TK  I 
JNK  E 
DNA  cytosine  methyltransferase 
PKC  (in  vivo) 
Table  2.6.1  Molecular  targets  of  selenium  compounds. 
The  current  knowledge  of  candidate molecular  targets  of  some  major  chemopreventive 
selenium  compounds,  that  may  mediate  their  proliferation-inhibitory  and  apoptosis-inducing 
abilities,  is  summarised  in  this  table.  I:  inhibition,  E:  enhancement  and  NE:  no  effect.  Other 
abbreviations  have  been  discussed  in  the  text. Chapter  2  52 
override  cell  cycle  defects)  is  not  currently  available.  Selenomethionine,  on  the  other  hand, 
has  been  shown  to  induce  a  transient  block  in  the  G2/M  stage  accompanied  by  a 
concomitant  decrease  in  cyclin  B  levels  and  cdc2  activity  (Chigbrow  and  Nelson,  2001; 
Menter  et  al.,  2000).  Thus  different,  selenium  compounds  appear  to  block  cell  cycle 
progression  at  different  stages,  possibly  involving  modulation  of  different  regulatory 
molecules. 
Selenium  compounds  like  pXSC,  BSC,  selenite,  SDG  and  SMC  have  been  shown  to 
inhibit  activity  of  PKCs  (Foiles  et  al.,  1995;  Gopalakrishna  et  al.,  1997;  Rao  et  al.,  2000; 
Sinha  et  al.,  1999).  This  may  explain  the  some  of  the  cell  cycle  effects  noted  above,  as 
cdk2  has  been  proposed  to  be  a  distal  target  for  PKCs  (Hamada  et  al.,  1996).  Several 
selenium  compounds,  including  SDG  and  Se-allylselenocysteine  (SAC)  have  been  shown 
to  induce  accumulation  of  p53  which  could  also  lead  to  cell  cycle  arrest  (Jiang  et  al., 
2001b;  Lanfear  et  al.,  1994).  Consistent  with  this,  SAC  treatment  can  elevate  p2l  protein 
levels  and  inhibit  Rb  phosphorylation  (Jiang  et  al.,  2001b),  which  may  influence  cell  cycle 
progression.  Rb  phosphorylation  is  initiated  predominantly  by  cyclin  D  complex  formation 
with  cdk4  and  is  sustained  by  cyclin  E-cdk2  complex  formation  (see  Section  2.6.7.1). 
Interestingly,  SAC  treatment,  in  vitro,  reduces  the  protein  levels  of  cdks  2  and  4,  and 
cyclins  E  and  D  (Jiang  et  al.,  2001b;  Zhu  et  al.,  2000a).  Inhibitors  of  cdk  activities,  p2l  and 
p27  are  also  induced  on  exposure  to  SAC  (Jiang  et  al.,  2001b;  Zhu  et  al.,  2000a).  Members 
of  the  growth  arrest  and  DNA-damage  inducible  (GADD)  family  are  induced  by  selenium 
compounds  like  selenite,  methylselenocyanate  and  SMC  (Kaeck  et  al.,  1997;  Sinha  et  al., 
1999)  and  may  represent  functional  pathways  leading  to  cell  cycle  modulation,  though  this 
is  not  reproducible  in  vivo  (Lu,  2001). 
Selenite  and  SDG  have  been  shown  to  inhibit  overall  protein  synthesis,  possibly  via 
phosphorylation  (and  subsequent  inactivation)  of  eukaryotic  initiation  factor  2  (eIF-2) 
(Safer  et  al.,  1980;  Vernie,  1987).  Such  an  inhibition  has  been  shown  to  associate  with 
inhibition  of  tumour  growth  (Combs  Jr  and  Lu,  2000). 
Whether  cell  cycle  arrest  and  apoptosis  induction  are  mutually  exclusive  events  (perhaps 
dependent  on  form  of  selenium  and  cell  type)  or  whether  these  events  are  interrelated  is  not 
known.  However,  evidence  from  other  contexts  suggests  that  these  cellular  responses  are 
intimately  related,  often  sharing  major  regulatory  components.  For  example,  SAC  induces 
both  cell  cycle  arrest  and  apoptosis  and  both  appear  to  be  associated  with  p53  expression 
(Jiang  et  al.,  2001b).  There  is  precedent,  for  example  on  UV  exposure,  that  a  delay  in  cell 
cycle  progression  may  initiate  apoptosis-induction  (Bulavin  et  al.;  2001),  and  a  similar Chapter  2  53 
observation  has  been  made  in  colon  cancer  cells  treated  with  selenomethionine  (Chigbrow 
and  Nelson,  2001). 
In  terms  of  chernopreventive  effects,  growth  inhibition  not  accompanied  by  apoptosis  will 
only  be  effective  as  long  as  the  agent  is  present  continuously,  because  elimination  of 
transformed  cells  is  not  possible.  This  is  the  response  observed  in  studies  with  TPS,  which 
inhibits  DNA  synthesis  but  does  not  induce  apoptosis  (Lu  et  al.,  1995a).  When 
administered  continuously  during  the  entire  phase  of  tumour  promotion  and  progression  it 
very  efficiently  suppresses  turnour  growth,  presumably  by  cytostasis.  However,  when  the 
treatment  period  is  shortened,  its  efficacy  decreases  dramatically  Qp  et  al.,  1998b). 
Selenium  compounds  that  are  potent  inducers  of  apoptosis,  a  shortening  of  selenium 
treatment  does  not  affect  chernopreventive  efficacy  (Baldwin  and  Parker,  1987;  el- 
Bayoumy  et  al.,  1992;  Ip  et  al.,  1995). 
A  recent  report,  using  SMC,  in  a  much  used  model  for  selenium-mediated 
chernoprevention  of  mammary  gland  lesions,  found  no  alteration  in  BrDU  labelling  or  the 
expression  of  cell  cycle  biomarkers  PCNA  and  cyclin  D1  in  either  normal  epithelia  or  in 
premalignant  lesions  -  while  the  progression  of  the  latter  to  carcinoma  was  inhibited  (lp  et 
al.,  2000c).  This  suggests  that  inhibition  of  cell  growth  is  not  a  primary  response  to  SMC. 
In  contrast,  TPS,  consistent  with  its  activity  described  in  the  last  paragraph,  decreased 
BrDU  incorporation  and  expression  of  PCNA  and  cyclin  Dl,  and  while  the  total  number  of 
lesion  were  not  reduced,  there  were  significantly  less  larger  lesions  (lp  et  al.,  2000c). 
Further  interesting  observations  were  reported  in  a  follow-up  of  the  study  discussed  above 
Detailed  analysis  revealed  that  SMC  significantly  inhibited  BrDU  incorporation  and  levels 
of  cyclins  A  and  D1,  and  elevated  p27  expression  only  in  physically  smaller  lesions  Qp  and 
Dong,  2001).  In  larger  lesions  no  effect  on  cellular  proliferation  (assessed  by  the  same 
criteria)  was  detectable  and  considering  all  lesions  together  (prior  to  size-dependent 
grouping)  no  overall  inhibition  of  proliferation  rates  was  observed  (Ip  and  Dong,  2001). 
Apoptosis  induction,  however,  was  evident  irrespective  of  size.  These  observations  imply 
that  selenium-mediated  inhibition  of  cellular  proliferation  may  be  sensitive  to  the 
pathological  stage  of  the  lesions.  A  'rheostat'  mechanism  could  be  invoked  to  explain  this 
phenomenon  where  either  early  lesions  are  more  responsive  to  SMC-induced  inhibition  of 
proliferation  than  pathologically  advanced  ones  or  transformed  cells  become  more  resistant 
to  SMC-induced  antiproliferative  effects  as  they  acquire  a  certain  number  of  mutations.  As 
apoptosis  is  induced,  irrespective  of  lesion  size  (equivalent  to  pathological  stage?  ),  this 
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short-term  treatment  of  SMC  offers  comparable  chernopreventive  efficacies  as  continuous 
treatment  (Ip  et  al.,  1991).  Since  the  number  of  the  premalignant  lesions  in  the  mammary 
gland  far  exceeds  the  number  eventually  progressing  to  carcinomas,  further  studies  need  to 
be  performed  to  address  which  subset  of  lesions  ultimately  progress.  Perhaps  only  those 
pre-disposed  to  progress  (due  to  accumulation  of  a  certain  number  of  mutational  events?  ) 
are  targeted  by  the  primary  response,  i.  e.  apoptosis,  induced  by  selenium.  Others,  likely  to 
be  smaller  if  pathological  stage  correlates  with  physical  size,  may  be  subject  to  secondary 
effects  like  inhibition  of  proliferation.  I-- 
2.6.7.3  Apoptosis  and  selenium 
Induction  of  apoptosis  is  a  plausible  mechanism  for  selenium-mediated  chemoprevention, 
as  it  can  delete  carcinogen-initiated  cells  and  suppress  clonal  expansion  of  a  transformed 
cell  population.  Our  laboratory,  and  others  described  apoptosis-induction  by  selenium 
compounds  in  vitro  in  the  early  1990s  (Lanfear  et  al.,  1994;  Thompson  et  al.,  1994;  Wilson 
et  al.,  1992).  Since  then  a  substantial  proportion  of  the  literature  has  focused  on  this 
phenomenon  and  strong  evidence  for  apoptosis  at  chernopreventive  levels  have  been 
shown  to  occur  both  in  vitro  and  in  vivo  (el-Bayoumy  et  al.,  1995;  lp  et  al.,  2000c;  Ip  et  al., 
2000d;  Ronai  et  al.,  1995).  While  p53  appears  to  be  induced  by  several  selenium 
compounds,  our  group,  using  a  mouse  erythroleukemia  cell  line,  was  able  to  show  that 
induction  of  apoptosis  by  SDG  did  not  necessarily  require  functional  p53  activity  (Lanfear 
et  al.,  1994).  This  has  since  been  confirmed  for  methylselenocyanate  in  a  mouse  mammary 
cell  line  with  a  p53  null  phenotype  (Kaeck  et  al.,  1997)  and  for  selenomethionine  in  a 
colon  cell  lines  expressing  a  mutated  p53  (Redman  et  al.,  1997).  As  p53  mutations  are 
present  in  a  majority  of  human  cancers,  the  fact  that  selenium-induced  apoptosis  does  not 
require  functional  p53  is  of  potential  usefulness. 
A  major  issue  in  the  field  has  been  the  involvement  of  non-specific  genotoxicity.  Selenite 
has  been  shown  to  induce  DNA  single  strand  breaks  (SSB)  in  a  murine  leukaemia  cell  line 
possibly  induced  by  the  generation  of  ROS  (Lu  et  al.,  1994).  DNA  SSBs  have  also  been 
shown  to  precede  cell  death  and  apoptotic  DNA  fragmentation  induced  by  selenite 
treatment  (Lu,  2001).  Specific  inhibition  of  endonucleases  responsible  for  apoptotic  DNA 
fragmentations  prevented  loss  of  viability  but  not  the  generation  of  SSBs  (Lu,  2001). 
Similar  genotoxicity  via  the  induction  of  ROS  has  been  reported  for  selenite  and  SDG  in 
other  in  vitro  systems,  though  this  remains  to  be  verified  in  vivo.  In  appears  that  the 
generation  of  H2Se  by  the  inorganic  pool  of  selenium  is  critical  for  induction  of  ROS  and 
subsequent  genotoxicity,  since  inhibition  of  H2Se  formation  attenuates  selenium-induced Chapter  2  55 
loss  of  cellular  viability  (Garberg  et  al.,  1988).  Moreover,  methylated  compounds  that 
bypass  the  H2Se  stage  induce  apoptosis  without  accompanied  genotoxicity  (i.  e.  SSBs) 
(Wilson  et  al.,  1992).  Our  group  has  recently  demonstrated  that  free  radical  scavengers  like 
mannitol  and  pyrollidine  dithiocarbarnate  (PDTC)  do  not  inhibit  SDG-induced  loss  of 
cellular  viability  while  they  attenuate  pXSC-induced  loss  of  viability  suggesting  different 
molecular  targets  of  these  two  compounds  (Fleming  et  al.,  2001).  N-acetylcysteine  (NAC), 
another  antioxidant,  however,  inhibits  anti-proliferatory  effects  of  pXSC,  selenite  and  SDG 
(Fleming  et  al.,  2001).  Similar  results  have  been  reported  elsewhere  for  selenite-induced 
apoptosis,  where  mannitol  also  failed  to  inhibit  DNA  SSBs  (Lu,  2001).  These  results 
would  suggest  that  free  radicals  do  not  mediate  the  generation  of  SSBs  and  loss  of 
viability.  Inhibition  of  cellular  viability  by  inorganic  selenium  compounds  but  not 
methylated  compounds  has  been  assumed  to  involve  ROS  as  established  by  ROS 
generation  assays  and  protective  effects  of  NAC  supplementation.  However,  the  situation 
is  not  entirely  clear  since  a  recent  report  has  shown  that  apoptosis  induced  by  SMC,  which 
is  believed  to  enter  the  metabolic  pathway  by-passing  selenide  formation,  also  involves 
generation  of  ROS  and  is  inhibited  on  NAC  treatment  (Jung  et  al.,  2001). 
The  vast  majority  of  animal  chemoprevention  studies  have  used  selenite,  which  is  effective 
in  the  absence  of  any  evidence  for  non-specific  toxicity  in  vivo  or  adverse  effects  on 
animal  health;  thus,  it  appears  that  at  physiological  doses,  non-specific  genotoxicity  may 
not  be  relevant.  In  vitro  results  could  be  an  artefact  of  cell  culture  settings  or even  a  result 
of  excessive  selenium  dosage.  One  potential  problem  is  that,  for  practical  reasons, 
detection  of  a  significant  amount  of  apoptosis  and  associated  biochemical  changes  in  vitro 
requires  much  higher  doses  than  those  tolerated  in  vivo,  whereas  a  difference  of  as  small  as 
1%  in  apoptotic  rates  may  have  a  significant  contribution  in  attenuating  growth  of  pre- 
malignant  lesions.  A  further  technical  issue  is  that  a  large  proportion  of  the  in  vitro  studies 
have  used  leukaemia  cell  lines  which  are  exceptionally  sensitive  to  genotoxic  damage.  As 
the  evidence  for  selenium-mediated  chernoprevention  has  been  obtained  primarily  using 
epithelial  systems,  choice  of  leukaemia  cell  lines  for  in  vitro  studies  may  have  been 
unfortunate  and  misleading.  In  human  context,  the  NPC  study  also  failed  to  detect  any 
protective  effect  of  selenium  supplementation  on  incidence  of  leukaemias  and  lymphomas. 
Molecular  targets  of  selenium,  functionally  associated  with  induction  of  apoptosis,  have 
not  been  clearly  defined.  There  are  conflicting  reports  as  to  whether  selenite  induces 
caspase  3  activation  and  it  appears  that  this  may  be  cell  type  specific.  Induction  of  caspase 
3  activity  (assayed  by  a  fluoregenic  peptide  cleavage)  by  selenite  is  reported  in  HepG2 
hepatoma  cells  (Shen  et  al.,  2001)  but  not  in  HLAO  leukaemic  cells  (Kim  et  al.,  2001)  and Chapter  2  56 
DU-145  prostate  cancer  cells  (Jiang  et  al.,  2001a).  However,  cleavage  of  poly(ADP- 
ribose)polymerase,  PARP  (a  physiological  substrate  of  caspase  3),  is  observed  in  HepG2 
(Shen  et  al.,  2001),  DU-145  (Menter  et  al.,  2000),  two  other  prostate  cancer  cell  lines 
(Menter  et  al.,  2000),  suggesting  activation  of  caspase  3  by  selenite.  However,  functional 
intervention  using  caspase  3  inhibitors  were  not  performed  in  the  studies  reporting 
activation.  In  contrast,  SMC  and  methylselenic  acid  have  been  shown  to  induce  caspase  3 
activity  in  HL,  60  (Kim  et  al.,  2001)  and  DU-145  cell  lines  (Jiang  et  al.,  2001a), 
respectively.  In  these  cases,  inhibitors  of  caspase  3  activation  attenuated  the  induction  of 
apoptosis  suggesting  caspase  3  to  be  a  functional  component  of  the  apoptotic  pathway. 
Activation  of  caspase  9  and  release  of  cytochrome  c  from  the  mitochondria  has  been 
documented  for  SMC  treatment  (Jiang  et  al.,  2001a)  but  intervention  experiments  on  these 
have  not  been  performed.  Cytochrome  c  release  has  also  been  reported  for  selenite  in 
hepatic  cells  (Shen  et  al.,  2001)  but  not  in  DU-145  prostate  cells  (Jiang  et  al.,  2001a). 
Activation  of  caspase  8  (comparable  to  the  extent  of  caspase  9  activation)  by  methylselenic 
acid  but  not  sodium  selenite  has  also  been  reported  recently  (Jiang  et  al.,  2001a).  Thus  in 
the  case  of  SMC,  mitochondria  dependent  apoptosis  could  be  involved;  however,  the 
observation  that  caspase  8  is  activated  may  suggest  a  role  for  death  receptors. 
Apart  from  the  evidence  for  involvement  of  caspases  described  above,  little  is  known  about 
other  components  of  the  signalling  pathway  mediating  selenium-induced  apoptosis.  While 
components  involved  in  selenium-mediated  cell  cycle  regulation  may  contribute  to  the 
induction  of  apoptosis  (as  described  in  Section  2.6.7.2),  it  is  very  likely  that  apoptosis 
specific  signalling  would  also  be  involved.  Inhibition  of  polyamines  has  been  suggested  as 
one  mechanism  for  selenomethionine-induced  apoptosis  and  exogenous  administration  of 
spermine  has  been  shown  to  prevent  apoptosis  on  selenomethionine  exposure  (Redman  et 
al.,  1997). 
p53  is  a  known  mediator  of  apoptosis  and  while  it  has  shown  that  p53  may  not  be 
necessary  for  apoptosis  induction  by  selenium  in  cancers  (discussed  earlier  in  this  section), 
it  may  still  be  an  important  player  in  p53  wild  type  cells.  It  has  been  demonstrated  that  p53 
levels  are  increased  on  treatment  with  apoptosis-inducing  doses  of  SDG,  selenide  and  SAC 
(Jiang  et  al.,  2001b;  Lanfear  et  al.,  1994).  Comparing  apoptosis  induction  by  SAC  and 
methylselenic  acid  in  a  cell  line  with  non-functional  p53  and  its  parental  line  with  wild 
type  p53  revealed  that  the  presence  of  functional  p53  considerably  enhanced  apoptosis  (Ip 
et  al.,  2000d;  Zhu  et  al.,  2000b).  Inhibition  of  Rb  phosphorylation  and  induction  of  the Chapter  2  57 
GADD  family  proteins  may  also  contribute  to  apoptosis  induction  (discussed  in  Section 
2.6.7.2). 
In  vitro,  selenide  has  been  shown  to  downregulate  the  expression  of  the  anti-apoptotic 
protein  Bc12  (Wei  et  al.,  2001),  while  selenite  and  methylselenocyanate  had  no  effect 
(Kaeck  et  al.,  1997).  Expression  of  the  pro-apoptotic  protein,  Bax,  was  also  unaffected  by 
selenite  and  methylselenocyanate  treatment  (Kaeck  et  al.,  1997).  Recent  in  vivo  studies 
using  SMC  have  revealed  a  downregulation  of  Bcl2  expression  (Ip  and  Dong,  2001).  It 
remains  to  be  seen  whether  in  situations  where  Bc12  is  downregulated,  overexpression  of 
exogenous  Bc12  confers  protection  from  apoptosis.  Previous  studies  in  our  laboratory  have 
indicated  this  may  not  be  the  case,  at  least  for  SDG  (Blower,  1998). 
There  is  also  strong  evidence  that  selenium  can  modulate  the  activities  of  key  transcription 
factors,  thereby  altering  gene  expression  patterns  which  may  subsequently  influence 
induction  of  apoptosis  and  cellular  proliferation  rates.  Covalent  modifications  of  thiol 
groups  on  critical  residues  have  been  postulated  to  mediate  the  inhibition  of  NF-KB  seen 
on  treatment  with  selenite  and  ebselen  (Kim  and  Stadtman,  1997;  Makropoulos  et  al., 
1996;  Shimohashi  et  al.,  2000).  NF-KB  has  been  implicated  to  be  intimately  involved  in 
regulation  of  apoptosis  and  cellular  proliferation  (Abraham,  2000;  Bours  et  al.,  2000; 
Gilmore,  1999)  and  this  inhibition  may  form  the  basis  for  growth  inhibition  by  selenium. 
Similar  inhibition  has  been  reported  for  other  transcription  factors  like  AP-1  (Handel  et  al., 
1995;  Spyrou  et  al.,  1995)  and  c-myc  (Nelson  et  al.,  1996a;  Yu  et  al.,  1990)  with  known 
functions  influencing  cellular  growth.  A  caveat  to  these  studies  is  that  the  responses  were 
measured  at  non-apoptosis-inducing  conditions  and  may  not  necessarily  be  the  same  at 
higher  doses  of  selenium.  Such  studies  need  to  be  performed  at  chemopreventive  doses  of 
selenium  and  further  supplemented  by  functional  intervention  approaches  in  order  to 
establish  their  contribution  to  apoptosis. 
2.6.7.4  Signal  transduction  and  cellular  growth:  a  target  for  selenium? 
The  survival  of  an  organism  depends  on  its  ability  to  respond  to  environmental  changes.  In 
metazoans,  this  dynamic  relationship  extends  to  every  individual  cell,  which  may 
proliferate,  differentiate,  exhibit  motility  or  undergo  apoptosis  in  response  to  physical  or 
chemical  cues.  For  a  cell  to  elicit  a  response,  appropriate  to  the  environmental  cues,  three 
critical  criteria  need  to  be  fulfilled.  A  cell  should  have  a)  sensory  mechanisms  to  detect 
environmental  alterations;  b)  molecular  systems  to  interpret  and  integrate  this  information, 
and  finally  c)  'effector'  machinery  to  carry  out  appropriate  cellular  responses.  In  the  case Chapter  2  58 
of  selenium  mediated  growth  inhibition  some  clues  exist  as  what  the  first  and  third  criteria 
may  comprise  of.  It  is  likely  that  accumulation  of  selenium  compounds  and/or 
selenoprotein  activities  above  a  threshold  acts  as  a  sensory  mechanism.  The  inhibition  of 
proliferation  and  induction  of  apoptosis,  perhaps  mediated  by  the  candidate  molecular 
targets  discussed  in  Sections  2.6.7.2  and  2.6.7.3  (summarised  in  Table  2.6.1),  comprise  the 
cellular  response  and  the  immediate  'effector'  machinery.  What  remains  obscure  and  until 
very  recently  completely  uninvestigated,  is  the  machinery  that  interprets  and  integrates  the 
sensory  information  following  selenium  exposure  to  ensure  an  appropriate  response,  in  this 
case  of  tumour  growth  inhibition. 
Many  signal  transduction  pathways  co-operate  and  participate  in  this  decision-making 
process  (reviewed  in  (Chang  and  Karin,  2001;  Dhanasekaran,  1998)).  Regulation  of  cell 
growth  is  mediated  by  a  complex  array  of  signalling  pathways  precisely  co-ordinated  by 
different  families  of  cell  surface  receptors.  The  vast  majority  of  signal  transduction  occurs 
via  phosphorylation  cascades  mediated  by  the  activities  of  kinases  and  phosphatases 
(Dhanasekaran,  1998).  In  the  last  decade,  several  signalling  paradigms  modulating  cellular 
proliferation  and  apoptosis  have  emerged  and  selenium  biologists  are  poised  to  extend  this 
knowledge  to  their  subject  of  study  (reviewed  in  (Ghose  et  al.,  2001b)).  Also,  we  have 
recently  reported  that  selenium  compounds  like  pXSC  and  SDG  induce  widespread 
tyrosine  phosphorylation  (Fleming  et  al.,  2001). 
In  the  literature,  there  are  indications  that  some  signalling  components  that  may  have  a  role 
in  growth  inhibition  are  influenced  by  selenium  (summarised  in  Table  2.6.1).  The  best 
described  is  the  inhibition  of  several  PKC  isoforms  by  selenium  compounds  like  selenite, 
SDG,  pXSC  (also  in  vivo),  BSC  and  SMC,  in  manner  dependent  on  the  number  of 
conserved  cysteine  residues  at  the  catalytic  domain  (Foiles  et  al.,  1995;  Gopalakrishna  et 
al.,  1997;  Rao  et  al.,  2000;  Sinha  et  al.,  1999).  PKC  is  a  major  signal  transduction  molecule 
regulating  several  key  cellular  processes  including  mitogenesis,  apoptosis,  cell  migration, 
angiogenesis,  cell  adhesion  and  invasion  (Gopalakrishna  and  Jaken,  2000).  Also  PKC 
mediates  cellular  transformation  by  phorbol  esters,  an  event  selenium  can  inhibit  both  in 
vitro  and  in  vivo  (Jaken,  1990;  Perchellet  et  al.,  1987).  However,  while  selenite  was  shown 
to  decrease  phorbol  ester  binding  to  PKC,  selenecysteine  and  SDG  did  not  affect  binding 
but  were  able  to  inactivate  the  kinase  activity  (Gopalakrishna  et  al.,  1997).  In  principle, 
inhibition  of  PKC  may  also  lead  to  inhibition  of  AP-1  and  NF-KB  activity  as  observed  on 
selenium  treatment  (Gopalakrishna  and  Jaken,  2000).  However  such  a  signalling  event  is 
unlikely  as  mutagenesis  studies  have  shown  that  a  direct  modification  of  cysteine  residues 
in  these  proteins  is  involved,  suggesting  a  direct  interaction  (Kim  and  Stadtman,  1997; Chapter  2  59 
Spyrou  et  al.,  1995).  cdk2,  whose  activity  is  inhibited  by  SMC  and  is  correlated  to  SMC 
induced  cell  cycle  deregulation  has  also  been  suggested  to  be  a  distal  target  for  PKCs 
(Hamada  et  al.,  1996):  this  therefore  warrants  investigation.  Finally,  while  inhibition  of 
PKC  may  play  a  critical  role  in  chemopreventive  activities  of  selenium  compounds,  it  is 
unlikely  that  its  inhibition  is  sufficient.  Evidence  for  this  comes  from  studies  on  the 
synthetic  selenium  compound,  ebselen,  which  can  very  efficiently  inhibit  PKC  activity  but 
has  been  shown  to  lack  anti-cancer  activity  (lp  and  Ganther,  1990;  Wakamura  et  al.,  1990). 
pXSC  has  been  reported  to  increase  the  activity  of  diacylglycerol  kinase  (DGK)  which 
suggests  an  enhanced  conversion  of  diacylglycerol  (DAG)  to  phosphatidic  acid  (Rao  et  al., 
2000).  DAG  is  a  well  characterised  allosteric  activator  of  PKC:  suggesting  the  enhanced 
DGK  activity  could  be  functionally  upstream  of  PKC  inhibition  (Gopalakrishna  and  Jaken, 
2000).  DGK  may  have  other  signalling  functions,  apart  from  inhibiting  PKC:  it  has  been 
shown  to  influence  ras  activity  which  may  subsequently  alter  mitogen  activated  protein 
kinase  (MAPK)  pathways  (Topham  and  Prescott,  2001). 
Studies  have  also  revealed  SDG  and  selenocysteine,  but  not  selenite,  can  inhibit  protein 
kinase  A  (PKA)  but  at  higher  concentration  than  those  required  to  inhibit  PKC  activity 
(Gopalakrishna  et  al.,  1997).  The  aromatic  selenium  compounds,  pXSC  and  BSC,  have 
also  been  shown  to  efficiently  inhibit  PKA  activity  (Foiles  et  al.,  1995).  PKA  may 
influence  both  proliferation  and  apoptosis  (Cross  et  al.,  2000).  It  has  been  shown  to  have 
enhanced  expression  in  many  cancers  and  its  inhibition  results  in  a  suppression  of 
proliferation  (Alper  et  al.,  1999).  Activation  of  PKA  has  been  reported  to  inhibit  apoptosis 
induction  by  several  apoptotic  stimuli,  perhaps  via  modulation  of  activities  of  the  Bc12 
family  of  proteins  (Cross  et  al.,  2000). 
The  mitogen  activated  protein  kinases  (MAPK)  are  an  evolutionary  conserved  family  of 
enzymes  that  regulate  several  critical  cellular  processes  including  proliferation  and 
apoptosis  (Chang  and  Karin,  2001;  Ichijo,  1999).  MAPK  activity  is  regulated  through  a 
three-tiered  kinase  cascade  composed  of  a  MAPK,  MAPK  kinase  (MAPKK  or  MEK)  and 
a  MAPKK  kinase  (MAPKKK  or  MEKK).  MAPK's  affect  a  number  of  cellular  targets 
including  transcription  factors  and  other  effector  kinases  (Fig  2.6.3).  In  mammals,  four 
distinctly  regulated  groups  of  MAPK's  have  been  identified:  the  extracellular  signal- 
regulated  kinases  (ERK1/2),  c-jun-N-terminal  kinases  (JNK1/2/3),  p38  kinases 
(p38a/p/y/8)  and  ERK5  (Fig  2.6.3)  (Chang  and  Karin,  2001). 60 
Growth  Growth  factors  Protein  inhilAtors,  inflammatory 
factors  and  oxidants  cytokines,  UV,  heat  or  osmotic  shock, 
oxidants 
MAPKKK  Raf,  7  MEKK1-3  ASK  I,  PAK  etc. 
MAPKK  MKKI/2  MEK5  MK  K4/7  MKK3/6 
MAP  kinase  MAPKI2,  ERK5  JNKI-3  p38  OAIS 
Substrides  Elk-I  MEF-2C  c-jun,  Elkl,  ATF2  ATF2,  Elkl,  MAPKAP-2 
Fig  2.63  Mammalian  mitogen  activated  protein  kinase  (MAPK-)  pathways. 
The  three-tiered  cascade  modules  of  the  mammalian  MAPK  pathways  are  schematically 
represented.  MAPK's  have  a  diverse  range  of  substrates  including  transcription  factors,  other 
kinases  and  a  variety  of  cellular  regulators,  some  of  which  are  indicated.  Principal  inductive 
stimuli  for  the  four  major  groups  of  MAPK's  are  shown  above  each  group. Chapter  2  61 
At  the  time  of  commencement  of  this  project,  there  was  only  one  study  addressing  the  role 
of  these  signalling  proteins  in  cancer  chernoprevention  by  selenium.  This  study 
demonstrated  that  pXSC  at  chernopreventive  doses  was  capable  of  inducing  JNK 
activation  and  also  potentiating  JNK  activation  by  UV  (Adler  et  al.,  1996).  JNK  is 
activated  by  several  cellular  stresses,  like  oxidative  stress,  DNA  damage,  chemotherapeutic 
drugs,  and  has  been  shown  to  functionally  mediate  apoptosis  (Davis,  2000).  The  paper 
however  provided  no  functional  evidence  nor  was  any  correlation  made  with  inhibition  of 
proliferation  and  induction  of  apoptosis  by  selenium. 
Another  set  of  studies  has,  somewhat  serendipitously,  indicated  modulation  of  MAPK 
pathways  by  selenium.  These  authors,  while  investigating  the  insulin-mimetic  properties  of 
selenium,  have  observed  that  selenate  induces  phosphorylation  of  the  epidermal  growth 
factor  receptor  (EGF  receptor)  and  the  insulin  receptor  (Stapleton,  2000;  Stapleton  et  al., 
1997).  They  also  showed,  in  accordance  with  the  activation  of  EGF  receptor,  activation  of 
the  ERK  1  and  2  kinase  activities  which  are  strongly  implicated  in  growth  regulation  and 
apoptosis  (Stapleton,  2000;  Stapleton  et  al.,  1997).  Selenate  has  also  been  reported  to 
activate  p70  S6  kinase  via  a  pathway  that  is  sensitive  to  rapamycin  (Hei  et  al.,  1998),  this 
may  be  of  some  relevance  as  p70  S6  kinase  is  known  to  regulate  cell  size,  growth  and 
proliferation  (Proud,  1996). 
Finally,  an  interesting  body  of  information  has  been  generated  from  studies  on  the  fruit  fly, 
Drosophila.  Mutation  of  the  Drosophila  homologue  of  the  selenophosphate  synthetase 
gene  completely  inhibits  selenoprotein  synthesis  and  cells  harbouring  this  mutation 
exhibited  lower  levels  of  proliferation  and  accumulation  in  the  G2  phase,  coincident  with 
enhanced  levels  of  cyclin  B  (Alsina  et  al.,  1999).  This  suggests  an  important  role  for 
selenoproteins  in  regulating  proliferation.  The  same  authors  have  noted  that  the  effects 
observed  in  these  mutants  were  similar  to  those  described  for  mutants  in  the  EGF  receptor 
pathway  and  have  subsequently  detected  genetic  interactions  with  components  of  the 
ras/MAPK  pathway  (Morey  et  al.,  2001).  This  would  suggest  that  selenoprotein  function 
may  modulate  activity  of  some  components  of  the  EGF  signalling  pathway,  presumably 
via  altering  the  redox  state  of  the  cell. 
2.7  Project  rationale  and  alms 
Evidence  for  selenium  compounds  as  cancer-risk  modifiers  is  considerable;  therefore  it  is 
pertinent  to  investigate  candidate  mechanisms  that  may  be  mediating  this  effect.  As 
discussed  earlier  (Section  2.6)  selenium-mediated  anti-cancer  activity  may  be  plausibly Chapter  2  62 
mediated  by  a  number  of  candidate  mechanisms.  The  aim  of  chemoprevention  by  dietary 
supplementation,  ideally,  is  to  eliminate  the  incidence  and  progression  of  pre-neoplastic 
lesions:  therefore  mechanisms  that  affect  initiation  stages  of  cancer  are  of  great 
importance.  Rodent  studies  indicate  selenium-mediated  chernoprevention  is  evident  at  the 
initiation  stages  of  cancer  inhibiting  incidence  of  pre-neoplastic  lesions,  thus  candidate 
mechanisms  like  inhibition  of  neoangiogenesis  and  invasion  and  perhaps  even  enhanced 
immune  surveillance  are  irrelevant  in  these  situations.  However,  these  mechanisms  may 
significantly  affect  established  cancers  and  are  well  worth  investigating  as  they  may 
provide  novel  opportunities  for  intervention.  As  suggested  by  the  two-stage  model  (Fig 
2.5.1),  supranutritional.  doses  of  selenium  are  likely  to  induce  anti-cancer  activities  that  are 
different  from  those  induced  by  nutritional  repletion  of  selenium  in  deficient  individuals. 
In  the  latter  situation  selenoprotein  mediated  activities  like  protection  from  oxidative  stress 
are  likely  to  be  key  mediators.  Whilst,  in  the  case  of  selenium  supplementation  at 
supranutritional  levels,  where  selenoprotein  activity  is  saturated,  the  action  of  selenium 
metabolites  is  likely  to  mediate  anti-cancer  activities  predominantly.  It  appears  from 
animal  experiments  that  at  chernopreventive  levels  of  intake,  several  selenium  compounds 
confer  a  lasting  protection  from  cancer  incidence  even  when  provided  for  a  short  period 
during  the  early  promotion  stages  of  carcinogenesis  (1p,  1998).  This  suggests  that  selenium 
treatment  is  capable  of  eliminating  transformed  cells  in  vivo.  As  tissue  homeostasis  is 
maintained  by  a  balance  of  proliferation  and  cell  death,  it  is  conceivable  that  selenium 
exerts  its  anti-tumour  activity  by  modifying  the  rates  of  these  events.  While  inhibition  of 
cellular  proliferation  at  chemopreventive  doses  is  a  possibility,  recent  studies  have  failed  to 
demonstrate  this  for  some  very  potently  anti-carcinogenic  selenium  compounds  (see 
Section  2.6.7.1).  Apoptosis-induction  however,  is  readily  detectable  at  these  conditions, 
suggesting  cell  death  to  be  a  key  player  in  selenium-mediated  cancer  chernoprevention. 
While  apoptosis-inducing  abilities  of  selenium  compounds  are  well  documented,  the 
molecular/cellular  mechanisms  that  mediate  this  activity  is  unknown.  Elucidation  of  these 
molecular  mediators  is  absolutely  critical  in  the  evaluation  of  selenium  compounds  as 
potential  anti-cancer  agents  in  humans.  Delineating  apoptosis-inducing  pathways  would  be 
invaluable  in  assessing  the  efficacy  and  toxic  consequences  of  selenium  compounds  and 
could  serve  as  candidate  surrogate  biomarkers  of  selenium-mediated  chernopreventive 
activity.  Detailed  knowledge  of  apoptosis  mediators  also  presents  the  opportunity  to 
enhance  the  efficacy  and/or  reduce  toxicity  of  existing  compounds  via  chemical 
manipulations.  This  is  particularly  relevant  to  the  synthetic  organoselenium  compounds 
discussed  in  Section  2.5.2  because  of  their  amenability  to  structural  manipulations. Chapter  2  63 
The  explosion  of  interest  in  apoptosis  in  the  last  two  decades  has  led  to  the  identification  of 
several  apoptotic  signalling  pathways,  particularly  those  mediated  by  the  MAPKs.  As 
discussed  in  Section  2.6.8,  there  is  some  evidence  that  such  phosphorylation  dependent 
signalling  cascades  may  be  significantly  altered  upon  exposure  to  selenium.  The  primary 
aim  of  this  study  was  therefore  to  identify  the  molecular  mediators  of  selenium-induced 
apoptosis,  to  investigate  systematically  the  role  of  cellular  signalling  in  initiating  such  a 
response,  and  finally,  using  molecular  genetic  and  pharmacologic  tools,  to  address  the 
functional  significance  of  the  putative  mediators. 
As  apparent  from  the  literature,  different  selenium  compounds  have  disparate  abilities  to 
induce  apoptosis,  possibly  utilising  different  signalling  pathways  and  mediators.  This  study 
investigated  apoptosis-induction  by  a  natural,  inorganic  selenium  compound, 
selenodiglutathione  (SDG),  and  a  synthetic  organoselenium  compound,  1,4-phenylene-bis- 
(methylene)selenocyanate  (pXSQ.  SDG  is  the  primary  metabolite  of  selenite,  the  most 
commonly  used  selenium  compound  in  animal  chernoprevention  studies  and  pXSC  is  a 
synthetic,  aromatic  compound  which  has  the  highest  chernopreventive  index  (the  ratio  of 
the  maximum  tolerated  dose  to  the  dose  required  to  give  a  50%  inhibition  of  total  tumour 
yield)  of  all  currently  tested  selenium  compounds.  The  rationale  for  choosing  these 
compounds  is  based  on  the  fact  that  these  have  been  demonstrated  to  potently  inhibit 
cancerous  lesions  in  several  different  animal  models  of  cancer,  although  their  significance 
to  human  cancers  remains  unaddressed.  Also,  the  fact  that  one  is  a  natural,  inorganic 
compound  and  the  other  an  organic  synthetic  compound  may  reveal  potential  difference  in 
the  mechanisms  underlying  apoptosis-induction  by  these  compounds.  This  argument  is 
borne  out  by  the  fact  that  some  cancer  types  are  sensitive  to  one  and  not  the  other  (see 
Section  2.5.2).  SDG  was  preferred  over  selenite  as  it  has  been  shown  to  be  a  more  potent 
inducer  of  apoptosis  than  selenite  and  there  are  indications  that  growth  inhibitory  effects  of 
selenium  are  dependent  on  its  conversion  to  SDG  (Fleming  et  al.,  2001). 64 
3  Materials  and  Methods 
3.1  Materials 
3.1.1  Selenium  compounds 
Selenodiglutathione  (SDG)  was  prepared  by  J.  Fleming  (Beatson  Institute,  UK)  as 
described  previously  (Ganther,  1971).  1,4-phenylene-bis-(methylene)selenocyanate 
(pXSC)  was  provided  as  a  part  of  an  ongoing  collaboration  with  Dr  K.  El-Bayoumy 
(American  Health  Foundation,  USA). 
3.1.2  Cell  lines  and  primary  cultures 
Human  cervical  carcinoma  cell  line,  HeLa  was  obtained  from  S.  Boldt,  Beatson  Institute, 
UY-  A431  cells,  a  human  vulvar  epidermoid  cancer  cell  line,  stably  transfected  with 
TAM67  or  the  corresponding  'empty'  vector  was  obtained  from  Dr  G.  Stapleton.  Primary 
cultures  of  oral  keratinocytes,  derived  from  biopsy  material  was  obtained  from  Dr  F. 
McGregor,  Beatson  Institute,  UY- 
3.1.3  Tissue  culture 
3.1.3.1  Beatson  Institute  Central  Services 
Sterile  distilled  water;  sterile  glycerol;  sterile  phosphate  buffered  saline  (PBS);  phosphate 
buffered  saline  +  EDTA  (PE);  sterile  glass  pipettes;  sterile  Pasteur  pipettes. 
3.1.3.2  Becton  Dickinson,  UK 
60mm,  90mm  tissue  culture  dishes;  10ml,  25ml,  50ml  plastic  pipettes;  Falcon  1059 
polypropylene  tubes;  Falcon  2059  polypropylene  tubes;  Falcon  2098  polypropylene  tubes; 
sterile  Plastic  pack  syringes;  18,25  gauge  sterile  syringe  needles;  40[tm  nylon  cell 
strainers. 
3.1.3.3  Bibby  Sterilin  Ltd,  UK 
Sterile  plastic  7ml  bijoux  and  20ml  universal  containers. Chapter  3 
3.1.3.4  Costar  Corporation,  UK 
6,12  and  96  well  tissue  culture  plates;  disposable  Cell  scrapers. 
3.1.3.5  Gibco  BRL  Europe  Life  Technologies  Ltd.,  UK 
65 
Dulbecco's  medium  (Beatson  formulation);  10x  Dulbecco's  Modified  Eagles  medium; 
Ham's  F12  medium;  2.5%  trypsin;  200mM  L-glutamine;  7.5%  sodium  bicarbonate; 
100mM  sodium  pyruvate;  Geneticin  (G418);  EGF. 
3.1.3.6  Gelman  Sciences,  UK 
Sterile  0.2  [um  acrodisc  filters. 
3.1.3.7  Harlan  Sera-Lab  Ltd 
Foetal  calf  serum. 
3.1.3.8  Nunc,  Denmark 
T25,80,  and  175  cm2  tissue  culture  flasks;  cryotubes. 
3.1.3.9  Oiagen,  UK 
Effectene"  Transfection  Reagent 
3.1.3.10  Sigma,  UK 
Bufferall;  transferrin;  adenine;  cholera  toxin;  hydrcotisone. 
3.1.4  Antibodies 
3.1.4.1  Becton  Dickinson,  UK 
Fas  ligand,  anti-human  Fas  ligand  monoclonal  antibody;  B62  monoclonal  antibody;  Bax 
monoclonal  antibody;  BClXL  monoclonal  antibody. Chapter  3 
3.1.4.2  Calbiochem,  USA 
c-jun  (Ab-3)  monoclonal  antibody  -  to  detect  TAM67  expression. 
3.1.4.3  New  England  Biolabs,  UK 
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Phosphospecific  (Ser63/73)  c-Jun  polyclonal  antibody  kit;  PhosphoPlus  Tm  p3S  kinase 
(tyr182)  polyclonal  antibody  kit;  PhosphoPluJm  Akt  (ser  473)  polyclonal  antibody  kit; 
cleaved  caspase  3  ployclonal  antibody;  cleaved  PARP  monoclonal  antibody. 
3.1.4.4  Promega,  UK 
Activated  ERKsl/2  polyclonal  antibody. 
3.1.4.5  Roche,  Germany 
Anti-HA  High  Affinity  rat  monoclonal  antibody  (clone  MO). 
3.1.4.6  Santa  Cruz  Biotechnology,  USA 
Activated  JNK  monoclonal  antibody  p-JNK(G-7);  total  ERK1(C-16)-G  polyclonal 
antibody;  ERKS(C-20)  antibody. 
3.1.4.7  Sigma,  UK 
FLAG  tag  monoclonal  antibody. 
3.1.4.8  Upstate  Biotechnology,  USA 
MAPKAP-2  kinase  monoclonal  antibody. 
3.1.5  Plasmids 
3.1.5.1  dnFADD-GFP 
Dominant  negative  Fas  associated  death  domain  (FADD)  protein  fused  to  green 
fluorescent  protein  (GFP)  was  a  gift  from  Dr  H.  Wajant,  University  of  Stuttgart,  Germany. Chapter  3  67 
The  construct  was  prepared  by  replacing  the  amino  terminal  death  effector  domain  of 
FADD  by  full  length  GFP. 
3.1.5.2  pEGFP-Cl 
pEGFP-C1  is  a  commercially  available  eukaryotic  expression  plasmid  that  encodes  the 
enhanced  green  fluorescence  protein  (EGFP)  (a  red-shifted  variant  of  GFP  which  contains 
the  double  amino-acid  substitution  of  Phe64  to  Leu  and  Ser65  to  Thr).  In  the  following 
text,  this  plasmid  is  refeffed  to  as  'GFP'. 
3.1.5.3  TAM67 
TAM67  is  a  dominant  negative  c-jun  construct  lacking  amino  acids  3-122.  The  plasmid 
was  a  kind  gift  from  Dr  D.  Gillespie  (Beatson  Institute,  UK). 
3.1.5.4  c-jun  SOMA 
c-jun  S63/73A  is  a  c-jun  construct  with  the  two  JNK  phosphorylation  sites,  Ser63  and 
Ser73  mutated  to  Ala.  This  was  a  kind  gift  from  Dr  M.  Karin  (University  of  California,  San 
Diego,  USA). 
3.1.5.5  MEK5(D) 
MEK5(D)  is  a  HA-tagged  constitutively  activated  mutant  of  the  MAPKKK  MEK5  where 
Ser313  and  Thr317  has  been  replaced  aspartic  acid  residues.  This  construct  was  a  kind  gift 
from  Dr J-D.  Lee  (Scripps  Research  Institute,  USA). 
3.1.5.6  ERK5  and  ERK(AEF) 
Both  construct  are  gifts  from  Dr  J-D.  Lee  (Scripps  Research  Institute,  USA).  ERK5  is  the 
wild  type  MAPK  ERK5  in  a  mammalian  expression  vector  and  is  FLAG  tagged. 
ERK5(AEF)  is  a  FLAG  tagged  ERK5  mutant  with  Thr218  and  Tyr220  replaced  with  Ala 
and  Phe,  respectively. Chapter  3 
3.1.6  Bacteriology 
3.1.6.1  Beatson  Institute  Central  Services 
L-Broth  (Luria  Bertani)  liquid  medium. 
3.1.6.2  Becton  Dickinson,  UK 
Falcon  1059,2059,2501  polypropylene  tubes. 
3.1.6.3  Bibby  Sterilin  Ltd.,  UK 
90mm  bacteriological  petri  dishes. 
3.1.6.4  Difco  Laboratories,  UK 
Bacto-Agar 
3.1.6.5  Gibco  BRL,  UK 
Exo1i  DH5a  competent  cells. 
3.1.6.6  Sigma,  UK 
Ampicillin 
3.1.7  Chemicals,  radlochemicals,  reagents  and  kits 
3.1.7.1  Sigma,  UK 
All  chemicals  unless  otherwise  mentioned. 
3.1.7.2  Amersham,  UK 
[y  32]  dATp;  [3  H]-thymidine. 
3.1.7.3  Calbiochem,  UK 
Ac-DEVD-CHO;  SB203580;  PD98059;  LY294002;  SB202190. 
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3.1.7.4  Clontech,  UK 
Annexin  V-FrrC  apoptosis  detection  kit. 
3.1.7.5  Fischer  Chemicals,  UK 
Histoclear 
3.1.7.6  Fisons  Scientific  Equipment,  Uk 
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Ammonium  acetate;  Butan-2-ol;  Chloroform;  Dimethyl  sulfoxide  (DMSO);  Ethylene 
diamine  tetra  acetate  (EDTA)  disodiurn  salt;  Ethylene  Glycol-bis(b-aminoethyl 
Ether)N,  N,  N',  N'-tetraacetic  acid  (EGTA);  Methanol;  Propan-2-ol;  Sodium  acetate; 
Sodium  dodecyl  sulphate  (SDS). 
3.1.7.7  Gibco  BRL,  UK 
Agarose  (ultrapure  electrophoresis  grade);  Tris  base. 
3.1.7.8  Hughes  and  Hughes,  UK 
HistoMountTm 
3.1-7.9  Intergen,  USA 
ApoTag@  fluorescein  direct  in  situ  apoptosis  detection  kit. 
3.1.7.10  James  Burrough  Ltd.,  UK. 
Ethanol 
3.1.7.11  Premier  Brands,  UK 
Marvel  dried  skimmed  milk. 
3.1.7.12  Qlagen  Ltd,  UK 
QIAGEN  Plasmid  Maxi  Kit. Chapter  3 
3.1.7.13  R&D  Systems,  UK 
Fas/Fc  chimera 
3.1.7.14  Severn  Biotech  Ltd. 
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30%  (w/v)  acrylamide:  0.8%  (w/v)  bis-acrylamide;  40%  (w/v)  acrylamide:  2.1%  (w/v)  bis- 
acrylamide. 
3.1.7.15  Surgipath,  UK 
Eosin;  haemotoxilin. 
3.1.7.16  Transgenomic,  UK 
RNase  A 
3.1.7.17  Upstate  Biotechnology,  USA 
Human  soluble  FasL  and  accompanying  potentiator  antibody. 
3.1.7.18  Vector  Laboratories,  USA 
Vectastain  ABC  kit;  Peroxidase  substrate  DAB  kit;  Vectashield  mounting  medium. 
3.1.8  Miscellaneous 
3.1.8.1  Amersham,  UK 
Hybond  ECI:  rm  nitrocellulose  membrane;  ECL  Tm  enhanced  chemoluminiscence  reagent 
3.1.8.2  Elkay  laboratory  products  Ltd.,  UK 
1.5ml  microcentrifuge  tubes;  1.5ml  screw-cap  microcentrifuge  tubes. 
3.1.8.3  Fuji  Ltd.,  Japan 
Fujifilm  SuperRX  X-ray  film. Chapter  3 
3.1.8.4  GibcoBRL,  UK 
BenchMarlim  pre-stained  protein  ladder 
3.1.8.5  Kodak  Ltd,  UK 
X-OMAT  AR  X-Ray  film;  X-OMAT  RA  X-ray  film  processor. 
3.1.8.6  Whatman  international  Ltd 
Whatman  3mm  filter  paper 
3.1.9  Water 
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Distilled  water  for  the  preparation  of  buffer  stocks  was  obtained  from  a  MilliRO  15  system 
(Millipore,  UK),  and  for  protein,  enzyme,  RNA  or  recombinant  DNA  procedures  was 
further  purified  on  a  Millipore  MilliQ  System  (Millipore,  UK),  to  18  MQ/cm.  Sterile 
distilled  water  for  making  up  tissue  culture  media  was  supplied  by  the  Beatson  Institute 
Central  services. 
3.1.1OXenograft  studies 
Charles  River  Ltd.,  UK 
CD-1  nu/nu  mice 
3.1.10.2  Harlan  Tekland,  UK 
Selenium  supplemented  and  depleted  mouse  diets. 
3.1.10.3  Stratech,  UK 
Matrigel Chapter  3 
3.2  Methods 
3.  Z  I  Cell  culture 
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All  cell  culture  work  was  performed  using  strict  aseptic  techniques  inside  a  laminar  flow 
hood  (Class  II  Microbiological  Safety  Cabinets,  Medical  Air  technology  Ltd.,  Manchester, 
UK).  Cells  were  incubated  at  37"C  in  a  dry  atmosphere  containing  5%  (V/V)  C02  (Heraeus, 
Essex,  UK)  and  were  routinely  screened  for  mycoplasma  infection  using  a  fluorescent  dye 
technique.  All  media  used  contained  Bufferall  to  maintain  the  pH  at  7.0. 
HeLa  cells  were  maintained  in  modified  Dulbecco's  medium  (Beatson  formulation) 
supplemented  with  10%  foetal  calf  serum  and  1mM  glutamine.  Cells  were  maintained  in 
culture  for  a  maximum  of  6-8  w  before  being  replaced  with  cells  from  frozen  stocks. 
A431  cells  stably  transfected  with  TAM67  or  the  corresponding  empty  vector  were 
obtained  from  Dr  G.  Stapleton  (Beatson  Institute,  UK):  their  generation  has  been  described 
previously.  Both  lines  were  maintained  in  Dulbecco's  MEM  (Beatson  formulation) 
supplemented  with  10%  foetal  calf  serum,  1mM  glutarnine  and  under  G418  selection. 
The  derivation  and  characterisation  of  the  primary  cultures  of  biopsies  of  normal  human 
oral  mucosa  or  carcinomas  has  been  described  previously  (Edington  et  al.,  1995; 
McGregor  et  al.,  1997).  All  cells  were  maintained  on  irradiated  (60Gy  from  a  C060 
radiation  source)  Swiss  3T3  feeders,  either  in  FAD+  medium  (1:  3  Ham's  F12/Dulbecco's 
MEM  with  10%  foetal  calf  serum  and  insulin,  EGF,  transferrin,  cholera  toxin, 
hydrocortisone  and  adenine)  in  the  case  of  normal  cells  or  10H  medium  (Dulbecco's  MEM 
plus  10%  foetal  calf  serum  without  added  growth  factors  except  hydrocortisone)  in  the 
case  of  carcinomas  (Edington  et  al.,  1995;  McGregor  et  al.,  1997).  Normal  cultures  were 
used  within  the  first  2-3  passages  from  frozen  stocks,  before  their  growth  rate  deteriorated 
significantly.  Oral  cultures  were  used  for  experimentation  whilst  rapidly  growing  at  not 
more  than  70%  confluence  after  which  the  irradiated  3T3  feeders  were  carefully  removed 
by  treatment  with  phosphate  buffered  saline  (PBS)/0.02%EDTA  and  the  cultures  re-fed 
with  normal  medium.  Swiss  3713  cells  were  maintained  in  10C  medium  (Dulbecco's  MEM 
plus  10%  donor  calf  serum).  Immediately  prior  to  all  experimentation  both  carcinomas  and 
normals  were  grown  on  10H  medium  to  avoid  complications  arising  from  growth  in 
different  media. Chapter  3  73 
To  freeze  cell  stocks  for  storage,  semi-confluent  cultures  were  trypsinised,  pelleted  and  the 
pellet  resuspended  at  a  concentration  of  approximately  106  cells/ml  in  chilled  medium 
containing  50%  serum  and  10%(v/v)  DMSO.  Suspensions  were  aliquoted  into  1mI  Nunc 
cryotubes  and  placed  in  a  polystyrene  box  and  frozen,  well  insulated,  at  -70'C  overnight  to 
ensure  a  slow  rate  of  cooling.  The  ampoules  were  then  transferred  to  a  liquid  nitrogen  tank 
until  required. 
Frozen  stocks  were  recovered  by  removing  the  ampoules  from  liquid  nitrogen  and  placed 
into  a  small,  covered  bucket  of  water  at  37C.  Once  thawed,  the  cells  were  added  to  10  ml 
of  the  appropriate  pre-warmed  growth  medium,  centrifuged,  resuspended  in  fresh  growth 
medium  and  transferred  to  T125  flasks. 
3.2.1.1  Transient  transfection  of  HeLa  cells 
106  cells/100mm  plate  were  seeded  the  night  before  transfection  and  incubated  o/n.  The 
next  day  2[tg  of  DNA  were  transfected  into  cells  using  Effectene  TM  transfection  reagent 
following  manufacturer's  instructions.  All  plasmids  used  were  verified  by  diagnostic 
restriction  digest  analysis  and  sequencing.  18  hours  later  cells  were  washed  once  in  PBS, 
re-fed  with  complete  medium,  and  incubated  o/n.  Cells  were  treated  and/or  harvested  16h 
later. 
GFP-transfected  cells  were  sorted  in  sterile  conditions  for  further  analysis  (like 
immunoblotting)  using  the  CellQuest  software  (Becton  Dickinson,  UK)  and  FACSVantage 
SE  (Becton  Dickinson,  UK)  flow  cytometry. 
3.2.2  DNA  synthesisIthymidine  incorporation  assay 
104  HeLa  cells  were  plated  in  20OVI  of  medium  per  microtitre  well.  After  18h,  the  medium 
was  replaced  with  medium  containing  SDG  or  pXSC  and  incubated  overnight.  Each  well 
was  then  given  0.5[tCi  of  tritiated  thymidine  for  6h,  the  medium  removed  and  the  cells 
trypsinised  and  transferred  onto  a  filter  paper  mat  (printed  filtermat  A,  Pharmacia)  using  a 
microtitre  plate  harvester  (Skatron  Combi  Harvester,  model  11900  (Skatron,  Norway, 
distributed  by  LKB).  After  adding  scintillator,  the  mat  was  scanned  and  counted  using  a 
plate  counter  (model  1205  BetaplateTm,  Pharmacia).  Four  replicate  wells  were  used  for 
each  condition.  The  radioactivity  incorporated  into  DNA  was  calculated  as  a  percentage  of 
untreated  cultures. Chapter  3  74 
3.  Z3  Trypan  blue  assessment  of  cellular  viability 
1.5  x  106  HeIa  cells/100mm  plate  were  seeded  18h  prior  to  treatment  with  selenium 
compounds.  After  treatment  cells  were  trypsinised  and  harvested.  Trypan  Blue  was  added 
for  2min  before  cells  were  counted  using  an  haernocytometer.  Cells  not  staining  with 
trypan  blue  were  considered  viable. 
3.  Z4  Apoptosis  assays 
3.2.4.1  TUNEL  assay 
5x  105  cells/60mm  plate  (or  5x  103  cells  on  mm  glass  cover  slips)  were  seeded  18h  prior 
to  treatment  with  selenium.  Apoptosis  in  was  measured  by  the  Terminal  deoxynucleotidyl 
transferase-mediated.  dUTP  nick  end-labelling  (TUNEL)  assay  using  the  ApoTag@  kit 
according  to  the  manufacturer's  protocol.  For  oral  cells,  after  plating  the  cells  for  2d, 
irradiated  373  feeders  were  carefully  removed  from  the  cultures  prior  to  experimentation 
by  washing  the  cultures  vigorously  three  times  with  PBS/0.02%  EDTA.  Selenium  was 
added  18h  after  the  removal  of  feeders.  Assays  were  performed  with  3  replicate  plates  of 
cells  and  at  least  5  randomly  selected  fields  totalling  a  minimum of  300  cells  per  plate  were 
counted  for  TUNEL-positive  cells. 
3.2.4.2  Accumulation  of  hypodiplold  DNA  of  transfected  cells 
Assessment  of  apoptosis  among  the  HeLa  cells  transiently  co-transfected  with  a  green 
fluorescent  protein  (GFP)-encoding  vector  was  performed  by  measuring  the  sub-GO/Gi 
DNA  content  of  the  GFP-positive  poýulation.  Cells  were  harvested  after  treatment,  washed 
in  cold  PBS,  fixed  in  1%  paraformaldehyde  for  1h  on  ice  and  permeabilized  with  70% 
ethanol  for  1h  on  ice.  Cells  were  then  resuspended  in  1  ml  of  PBS  to  which  0.5  ml  of 
Phosphate-citric  acid  buffer  (0.2M  NaH2PO4,4mM  citric  acid)  was  added  and  incubated  at 
room  temperature  for  5  min.  After  RNase  treatment  (250[tg/ml),  the  DNA  was  stained  with 
propidium  iodide  (PI;  10  gglml)  and  the  cell  cycle  distribution  determined  by  analysing 
104  GFP  positive  cells  with  the  CellQuest  software  using  a  FACScan  flow  cytometer 
(Becton  Dickinson,  UK).  Similar  protocol  was  used  to  assess  sub-GO/G1  DNA  content  of 
untransfected  cells  excluding  the  selecting  of  GFP  positive  cells.  All  treatments  were  in 
triplicate. Chapter  3  75 
3.2.4.3  Annexin  assay 
For  the  annexin  V  assays  the  cells  were  plated  on  60mm  plates  or  coverslips  as  described 
earlier  (Section  3.2.4.1).  Annexin  V  staining  was  carried  out  using  the  Annexin  V-FrrC 
apoptosis  detection  kit  according  to  the  manufacturer's  protocol.  The  percentage  of 
Annexin  V-staining  cells  was  then  determined  microscopically.  Cells  positive  for  Annexin 
V  and  negative  for  PI  staining  were  scored  as  apoptotic. 
3.  Z5  Detection  of  proteins  by  SDS-PAGE  and  Western  blotting 
To  prepare  whole  cell  protein  extracts  for  immunoblotting,  the  cells  were  washed  twice 
with  ice-cold  PBS  and  then  scraped  off  in  0.2ml  of  lysis  buffer  (2OmM  Hepes,  pH  6.8, 
5mM  EDTA,  10mM  EGTA,  5mM  NaF,  0.1[tg/ml  okadaic  acid,  1mM  DTIP,  OAM  KCI, 
0.4%  Triton  X-100,10%  glycerol,  5[tg/ml  leupeptin,  50[tg/ml  PMSF,  1mM  benzamidine, 
5[tg/ml  aprotinin,  1mM  sodium  orthovanadate),  incubated  on  ice  for  20  min,  followed  by 
centrifugation  at  13,000  rpm  in  a  microfuge  for  20  min  and  the  lysate  (supernatant) 
recovered.  The  supernatant  was  stored  at  -700C.  Up  to  50[tg  of  protein  sample  (quantitated 
using  the  bicinchonic  acid-copper(losulphate  method)  was  mixed  with  an  equal  volume  of 
2x  loading  buffer  (187.5  mM  Tris-HCI,  pH  6.8,30%  glycerol,  6.9%  SDS,  2.1M  P- 
mercaptoethanol,  0.1%  bromophenol  blue),  boiled  for  10  min  before  electrophoresis  on  a 
SDS-polyacrylamide  gel  electorphoresis  (SDS-PAGE)  gel. 
Gels  containing  different  concentration  of  polyacrylamide  (i.  e.  6%,  8%,  10%)  were  used  to 
resolve  proteins  according  to  their  molecular  weight.  The  resolving  gel  was  made  by 
adding  the  appropriate  volume  of  30%  (w/v)  acrylamide:  0.8%  (w/v)  bis-acrylamide  to  a 
solution  of  0.45M  Tris,  0.1%  SDS,  0.08%  TEMED  and  0.1%  (w/v)  APS.  The  stacking  gel 
comprised  of  0.125M  Tris,  pH6.8,0.1%  SDS,  1.7ml  30%  (w/v)  acrylamide:  0.8%  (w/v) 
bys-acrylamide,  0.2%  APS  and  0.3%  TEMED.  Protein  were  loaded  along  with 
BenchMarIP  pre-stained  protein  ladder  and  electrophoresis  was  performed  o/n  prior  to 
transfer  onto  nitrocellulose  using  a  Camlab  semi-dry  blotter  (Camlab,  UK),  following  the 
manufacturer's  protocol.. 
Western  blots  were  blocked  in  the  presence  of  TBST  (5OmM  Tris  pH  7.5,50mM  NaCl, 
1mM  EDTA,  0.1%  Tween-20)  containing  5%  non-fat  dried  milk  for  lh  at  room 
temperature;  washed  3x  10min  with  TBST  and  then  incubated  with  antibodies  diluted  in 
TBST  containing  0.1-1%  bovine  serum  albumin  (according  to  antibody  manufacturer's 
instruction)  and  0.1%  sodium  azide.  The  antibody  dilutions  and  the  length  of  incubation Chapter  3  76 
were  according  to  manufacturer's  instructions.  Following  incubation  with  the  primary 
antibody  the  membrane  was  washed  3x  10  min  with  TBST.  This  was  followed  by 
incubation  in  20ml  of  a  1:  3000  dilution  of  the  appropriate  IgG  HRP-linked  antibody  in 
blocking  buffer  for  1.5h.  The  secondary  antibody  solution  was  removed  and  the  membrane 
was  washed  3x  10  minutes  with  TBST.  After  removal  of  excess  surface  liquid,  bound 
primary  antibody  was  detected  using  ECL  chemiluminescent  methodology  according  to 
manufacturer's  instructions. 
For  loading  controls,  blots  were  stripped  by  incubation  for  30min  with  1x  Stripping  buffer 
(100mM  2-mercaptoethanol,  2%  SDS,  62.5mM  Tris-HCI  pH6.7)  at  500C.  The  membrane 
was  washed  with  2x  TBST  prior  to  proceeding  to  blocking  and  subsequent  manipulations 
as  described  in  the  last  paragraph. 
3.2.5.1  Detection  of  ERK5  mobility  shift 
Phosphorylation  of  ERK5  results  in  a  shift  in  its  electrophoretic  mobility  detectable  by 
western  blotting,  and  a  consistent  correlation  between  the  shifted  fraction  of 
phosphorylated  ERK5  and  the  activity  of  ERK5  as  measured  by  protein  kinase  assay  has 
been  observed  (Kato  et  al.,  1998).  This  electrophoretic  mobility  shift  was  thus  used  as  an 
assay  for  ERK5  activity.  Essentially  a  6%SDS-PAGE  was  used  as  described  in  Section 
3.2.5,  with  exception  of  30%  (w/v)  acrylamide:  0.2%  (w/v)  bis-acrylamide  stock  solution 
to  resolve  the  band  shift. 
3.  Z6  Immunecomplex  kinase  assays 
Cells  were  washed  in  ice  cold  PBS  and  then  scraped  off  in  0.15ml  of  lysis  buffer  (25mM 
Hepes  pH  6.8,75mM  NaCl,  2.5mM  M902,  O.  1mM  EDTA,  25mM  NaF,  0.5mM  DTT,  1% 
NP-40,10[tg/ml  leupeptin,  1mM  PMSF,  3mM  benzamidine,  20mM  P-glycerophosphate 
and  O.  1mM  sodium  orthovanadate),  incubated  on  ice  for  20min,  followed  by  centrifugation 
at  13,000  rpm  in  a  microfuge  for  20min  and  the  lysate  (supernatant)  recovered.  After 
protein  quantitation,  100-200[tg  of  protein  in  10OVI  was  incubated  o/n  on  a  roller  at  40C 
with  2[tg  of  either  MAPKAP-2,  JNK  or  ERK5  antibody  and  50VI  of  -50%  protein  A 
sepharose  slurry.  Following  immunecomplex  formation  the  beads  were  washed  4x  in  1ml 
of  wash  buffer  (2OmM  Hepes  pH  6.8,50mM  NaCl,  2.5mM  MgCl2,  O.  1mM  EDTA  and 
0.05%  Triton  X-100)  and  incubated  for  30min  with  30pl  of  kinase  reaction  mix  at  300C. 
300  kinase  reaction  mix  comprised  of  15[d  2x  kinase  buffer  (20mM  HEPES,  20mM 
MgC12,0.1[tg/ml  okadaic  acid,  20mM  P-glycerophosphate,  O.  1mM  sodium  orthovanadate Chapter  3  77 
and  2mM  DTI'),  1OmM  ATP,  5[tCi  y  32  ATP  and  5[tg  of  appropriate  substrate  (hsp25  for 
MAPKAP-2;  GST-c-jun  for  JNK;  MBP  for  ERK5).  The  reaction  was  stopped  by  adding 
30[d  of  2x  loading  buffer  (Section  3.2.5),  boiled  for  10min  and  electrophoresed  on  a 
10%SDS-PAGE  prior  to  Western  Blotting  (Section  3.2.5).  Radioactivity  was  detected  by 
exposing  membranes  to  X-ray  films. 
3.2.7  Transformation  of  Competent  Bacterial  Cells 
Exo1i  DH5a  competent  cells  were  used  for  the  propagation  of  plasmid  DNA.  A  20[d 
aliquot  of  the  competent  cells  were  thawed  on  ice  and  then  transferred  to  a  chilled 
polypropylene  tube  (Falcon  2059).  The  appropriate  amount  of  DNA  was  added  to  each 
tube  and  left  to  incubate  on  ice  for  30  minutes.  Cells  were  then  heat  shocked  for  45 
seconds  in  a  water  bath  at  42C.  80[d  of  L-broth  was  added  to  each  sample  and  each  tube 
was  incubated  at  37C  for  1  hour  with  vigorous  shaking.  The  whole  of  the  transformation 
reaction  was  then  plated  on  to  L-agar  plates  containing  50[tg/ml  of  ampicillin.  Plates  were 
inverted  and  incubated  o/n  at  37*C  to  allow  colony  formation. 
Single  bacterial  colonies  were  picked  and  used  to  inoculate  a  sterile  universal  tube 
containing  5  ml  of  L-broth  medium  containing  ampicillin.  After  incubation  for  6  hr  at  370C 
accompanied  by  vigorous  shaking,  the  culture  was  added  to  500  ml  of  L-broth  with 
ampicillin  and  incubated  o/n  under  the  same  conditions. 
Plasmid  preparation  of  was  carried  using  the  Qiagen  maxiprep  kit  following  the 
manufacturer's  recommendations.  The  concentration  of  nucleic  acid  was  determined 
spectrophotometrically  using  a  Beckman  DU  650  spectrophotometer.  Optical  density  (OD) 
readings  were  obtained  at  260  nrn  and  280  nm;  concentration  was  calculated  by  assuming 
an  OD  reading  of  1  at  260  nm  (A260  ý-  1)  to  approximately  correspond  to  a  concentration  of 
50  [tg/ml  of  double  stranded  DNA.  The  ratio  between  readings  at  260  nrn  and  280  nm 
(Aj6o:  A28o)  provided  an  estimate  of  the  sample  purity;  a  ratio  of  -1.8  indicated  that 
preparations  were  sufficiently  pure.  The  DNA  concentration  was  determined  as  described 
below  and  the  plasmid  DNA  was  aliquoted  and  stored  at  minus  20'C. 
3.  Z8  Production  and  purification  of  GST-c-jun  protein 
GST-c-jun  (1-79)  fusion  vector  was  used  to  transform  E.  coli  DH5a  as  described  in  Section 
3.2.7.  The  follow  day  individual  colonies  were  picked  and  grown  in  culture  o/n.  2ml  of  o/n 
culture  was  diluted  to  100ml  of  L-broth  containing  ampicillin  and  incubated  at  culture Chapter  3  78 
growth  conditions  till  the  OD  at  600nm  reached  0.3-0.5.  At  this  stage  isopropylthio-P-D- 
galactoside  (IPTG)  was  added  to  a  final  concentration  of  1mM  and  the  culture  incubated 
for  4h  in  order  to  induce  fusion  protein  expression.  Bacterial  cell  were  centrifuged  at 
3,000rpm  for  5min  and  resuspended  pellet  added  to  the  NETN  buffer  (2OmM  Tris  pH8.0, 
1OOmM  NaCl,  1mM  EDTA  and  0.5%  NP-40)  prior  to  sonication  on  ice  for  3x  15sec.  The 
suspension  was  pelleted  by  a  microfuge  and  the  supernatant  (crude  bacterial  extract) 
recovered.  3ml  of  crude  extract  was  mixed  with  150pl  of  -50%  glutathione  sepharose 
slurry  (prepared  in  NETN  buffer)  and  allowed  to  mix  for  30min  at  room  temperature  on  a 
roller.  The  beads  were  pelleted  by  a  microfuge  and  supernatant  discarded,  washed  R  with 
NETN  buffer  and  finally  resuspended  in  an  equal  volume  of  NETN  buffer.  GST-fusion 
protein  bound  sepharose  was  either  prepared  fresh  or  used  within  a  week  of  preparation. 
For  kinase  assays  (described  in  Section  3.2.6),  20W  of  the  GST-fusion  protein  bound  to 
sepharose  was  washed  thrice  in  wash  buffer  (see  Section  3.2.6),  resuspended  in  30PI  of 
kinase  buffer  (see  Section  3.2.6)  and  kinase  assay  performed  as  described  in  Section  3.2.6. 
3.  Z9  Pharmacological  inhibitors  and  Fas-Fc  chimera  experiments 
Pharmacological  inhibitors  Ac-DEVD-CHO  (50[tM),  SB203580  (10RM),  PD98059 
(50gM),  LY294002  (50[tM)  and  SB202190  (10[tM  and  30[tM)  were  used  at  the  indicated 
concentrations  and  added  30min  prior  to  adding  SDG  and  pXSC. 
For  the  Fas/Fc  chimeric  protein  experiments  cells  were  grown  on  3T3  feeders  on  glass 
coverslips.  Cells  were  grown  to  the  appropriate  density,  the  feeder  layer  removed  and  then 
incubated  for  a  further  16h.  Cells  were  then  treated  with  the  Fas/Fc  chimeric  protein 
(250ng/ml)  for  1h  prior  td  treatment  with  either  selenium  compound  or  recombinant 
soluble  human  Fas  ligand  (150ng/ml)  and  the  potentiator  antibody  (2[tg/ml).  After  16h 
incubation,  the  TUNEL  assay  was  performed  as  described  in  Section  3.2.4.1. 
3.  Z  1OXenograft  studies 
Immunosuppressed  'nude'  mice  of  CD-1  nu/nu  background  were  bred  and  supplied  by 
Charles  River  Ltd.,  UK  The  animals  were  maintained  in  a  protected  and  controlled 
environment.  Animal  handling  and  procedures  were  carried  out  in  a  laminar  air  flow  hood 
and  in  accordance  with  the  permit  and  guidelines  issued  by  the  Home  Office,  UK- 
18  mice  were  divided  into  2  groups,  on  high  (2ppm)  and  low  selenium  (<O.  lppm)  diets.  3d 
after  switching  to  the  experimental  diets  the  mice  were  injected  with  human  squarnous  cell Chapter  3  79 
carcinoma  (SCC)  cells.  SCC  primary  culture  BICR31  was  harvested  and  107  cells  in  200ý1 
was  mixed  with  an  equal  volume  of  matrigel.  All  treatments  were  performed  on  ice  using 
chilled  reagents  and  plasticware.  Nude  mice  were  injected  subcutaneously  with  0.4ml  of 
the  cell  suspension/Matrigel  mixture  using  a  chilled  25  gauge  needle. 
Engraftment  was  determined  by  direct  visualisation  of  tumour  growth  and  caliper  aided 
measurement.  Day  to  day  maintenance  was  carried  out  by  Technological  (Animal  House) 
Services,  Beatson  Institute,  UK  and  tumour-size  measured  every  week. 
3.2.11  Paraffin-embedded  sections  and  immunohistochemistry 
The  xenograft  tissue  was  Rxed  in  neutral  buffered  formalin  o/n  and  processed  in  a  Shandon 
Citade12000  processor.  The  tumours  were  dehydrated  through  a  series  of  graded  alcohols, 
embedded  in  paraffin  wax,  sectioned  at  5gm,  and  stained  with  haernatoxylin  and  eosin  for 
pathological  analysis  (processed  by  Technological  Services,  Beatson  Institute,  UK). 
For  immunohistochemistry,  the  sections  were  deparaffinized  for  30min  using  Histoclear 
followed  by  xylene  for  10min.  Rehydration  was  carried  out  sequentially  in  100%  and  20% 
ethyl  alcohols  (5min  in  each  step)  and  finally  water.  Sections  were  incubated  in  0.3%H202 
for  15min  followed  by  a  5min  wash  in  distilled  water.  Following  treatment  with  0.05% 
Saponin  for  15min  and  washing  with  PBS,  immunohistochernistry  was  carried  out  using 
the  Vectastain  ABC  (avidin-biotin-peroxidase)  kit  for  rabbit  IgG  according  to 
manufacturer's  instructions.  Caspase  3  antibody  was  used  at  1:  100  dilution  (or  Rabbit  IgG 
at  0.5[tg/ml  as  negative  control)  for  1.5h  at  room  temperature  in  a  moist  chamber. 
Peroxidase  substrate  DAB  (3,3'-diaminobenzidine)  kit  was  used  to  visualise  the  primary 
antibody  according  to  manufacturer's  instructions.  Counterstaining  was  carried  out  using 
eosin  and  the  section  dehydrated  with  sequential  treatment  with  water,  70%  and  100% 
ethanol,  and  xylene.  Finally  the  section  was  mounted  in  Histomount  and  covered  with  a 
cover  slip. 
3.  Z  12  Microscopy 
Immunohistochemistry,  Annexin  V  staining  and  TUNEL  staining  were  visualised  using  a 
Zeiss  Axioskop  20  microscope  (Zeiss,  Germany)  with  an  appropriate  light  source  and 
photornicrographs  recorded  using  the  AxioVision  ver.  3.0.6  software  (Zeiss,  Germany). 
For  some  high  resolution  images/scoring  the  Leica  TCS  SP2  spectral  confocal  multiphoton 
system  (I-eica,  Germany)  using  a  Leica  DMI  RBE  microscope  (Leica,  Germany)  and  Leica Chapter  3  80 
Confocal  Software  (Leica,  Germany)  was  used.  For  visualising  growing  cultures  an 
inverted  Zeiss  Axiovert  25  microscope  (Zeiss,  Germany)  was  used. 
3.  Z  13  Statistical  analysis 
Differences  between  experimental  groups  were  compared  using  the  equal  variance,  two- 
sided  Student  Mest.  A  p<0.05  was  considered  significant. 81 
4  Induction  of  Apoptosis  by  Chernopreventive 
Selenium  Compounds 
4.1  Background 
Ever  since  the  Clark  et  al.,  1996  study  there  has  been  a  rejuvenated  interest  in  elucidating 
the  molecular  mechanisms  underlying  selenium-mediated  chernoprevention.  A  survey  of 
published  data  reveals  that  the  chernopreventive  activities  of  selenium  compounds  in  vivo 
closely  parallel  their  growth  inhibitory  properties  exhibited  in  vitro.  This  is  an  attractive 
hypothesis  as  it  could  potentially  check  the  expansion  of  transformed  cells  to  limit  turnour 
development. 
Several  laboratories,  including  ours,  have  demonstrated  the  induction  of  apoptosis  by  a 
variety  of  chernopreventive  selenium  compounds  (see  Section  2.6.7.3).  Perturbations  in 
cycle  progression  have  also  been  shown  in  some  systems;  however,  the  significance  of  this 
to  the  mode  of  action  to  the  most  potent  selenium  compounds  remains  unclear.  However 
the  evidence  for  apoptosis  induction  is  overwhelming  but  it  remains  to  be  seen  if  cell  cycle 
defects  and  apoptosis-induction  are  functionally  interlinked. 
Though  the  induction  of  apoptosis  is  generally  accepted  to  have  a  major  contribution  to  the 
anti-cancer  activities  of  selenium  compounds,  at  the  commencement  of  this  study  little  was 
known  about  the  molecular  mechanisms  involved  in  this  process. 
The  objective  of  this  part  of  the  study  was  therefore  primarily  to  characterize  the  nature  of 
the  growth  inhibitory  mechanisms  employed  by  two  compounds  showing  very  strong  anti- 
turnour  activity  in  vivo;  SDG  and  pXSC.  The  experiments  were  carried  out  in  a  human 
cervical  carcinoma  cell  line,  HeLa,  which  has  dysfunctional  p53. 
4.2  Inhibition  of  cellular  proliferation  by  selenium 
In  order  to  test  whether  SDG  and/or  pXSC  resulted  in  some  form  of  growth  inhibition  in 
Hela  cells,  incorporation  of  tritiated  thymidine  into  DNA  was  measured.  HeLa  cells 
treated  overnight  with  either  compound  showed  a  dose  dependent  decrease  in  DNA 
synthesis  (Fig  4.2.1A).  This  is  in  keeping  with  previous  assays  for  cellular  viability 
(assessed  by  tetrazolium.  salt  reduction)  which  had  shown  a  similar  response  in  different 
cell  lines  (data  not  shown).  Higher  concentrations  of  pXSC  were  required  to  achieve 82 
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Fig  4.2.1  Growth  inhibition  of  HeLa  cells  by  treatment  with  SDG  or  pXSC. 
(A)  HeL-a  cells  were  treated  overnight  with  the  indicated  concentrations  of  SDG  or  pXSC  and 
incorporation  of  tritiated  thymidine  measured  to  assess  inhibition  of  DNA  synthesis.  (B)  SDG 
(5ýN)  and  pXSC  (50ýtNo  were  added  to  HeLa  cells  for  the  indicated  times  and  cellular  viability 
assessed  by  the  Trypan  blue  dye  exclusion  method. 
5  10  15  20 
PXSC  (ýtm) 
246 
SDG  (pM) Chapter  4  83 
inhibition  of  DNA  synthesis  than  SDG,  which  reflects  the  previously  published 
observation  that  a  higher  dose  of  pXSC,  compared  to  selenite,  is  required  to  show 
chernopreventive  activity  in  vivo  (see  Section  2.5.2). 
Exposure  of  HeLa  cells  to  higher  doses  of  selenium  showed  a  decrease  in  the  actual 
number  of  viable  cells,  over  time,  as  assessed  by  Trypan  blue  exclusion  (Fig  4.2.1B).  This 
suggested  that  a  mechanism  involving  loss  of  cellular  viability  and  not  a  cell  cycle  arrest 
was  the  key  event  mediating  the  observed  inhibition  of  growth. 
4.3  Apoptosis  induction  by  SDG  and  pXSC 
Morphological  analysis  of  HeLa  cells  exposed  to  selenium  displayed  apoptotic 
characteristics  like  increased  reffactile  nature,  cell  shrinkage  and  rounding  up,  chromatin 
condensation  and  suggestions  of  membrane  blebbing  (Fig  4.3.1A). 
HeU  cells  treated  with  SDG  or  pXSC,  at  doses  that  had  a  marked  effect  on  cellular 
viability,  were  analysed  by  several  different  apoptosis  assays.  One  of  the  reasons  for 
performing  a  variety  of  assays  was  to  prove  conclusively  that  the  cell  death  observed  was 
not  due  to  non-specific  necrosis.  In  retrospect,  a  major  indirect  benefit  of  standardising 
several  different  assays  was  the  flexibility  of  adapting  one  or  the  other  to  suit  specific 
needs  of  later  experiments. 
Apart  from  establishing  concordance  by  3  differpt  assays,  cell  death  evaluation  was  by 
two  independent  criterion.  TUNEL  (Fig  4.3.1B)  and  the  sub-GO/Gl  DNA  content 
quantification  (Fig  4.3.1C)  addressed  the  characteristic  DNA  fragmentation  in  apoptosis 
whereas  AnnexinV  staining  measured  specific  alteration  in  membrane  composition.  Use  of 
AnnexinV  allowed  a  robust  discrimination  between  apoptotic  and  necrotic  cells  as  the 
assay  is  dependent  on  the  exposure  of  phosphotidylserine  to  the  outer  surface  of  the  plasma 
membrane  while  maintaining  membrane  integrity  -a  characteristic  of  early  apoptosis. 
Necrotic  cell  are  also  AnnexinV  positive  as  'membrane  disruption  allows  staining. 
Therefore  propidium  iodide  (PI)  is  used  to  discriminate  between  early  apoptosis  and 
necrosis:  it  enters  and  stains  the  DNA  of  necrotic  cells  but  not  early  apoptotic  cells  (since 
the  plasma  membrane  is  still  intact).  Only  AnnexinV  positive  and  PI  negative  cells  were 
scored  as  apoptotic.  The  extent  of  apoptosis  measured  by  this  assay  was  comparable  to 
those  evaluated  by  measuring  the  accumulation  of  hypodiploid  DNA  or  TUNEL  (Fig 
4.3.2)  suggesting  limited  non-specific  toxicity  by  SDG  and  pXSC,  at  least  at  the  doses 
used. 84 
A 
pXSC  50[tM 
B 
Control 
C 
IA 
0 
el) 
CD 
FL2-H  FL2-4i 
SDG  5ýN 
990802  cc.  001 
0 ki) 
pXSC  50pM 
Control  SDG  3.5pM 
C) 
FL2-H 
pXSC  35ýM 
Fig  43.1  Analysis  of  apoptosis  induction  in  HeLa  cells  by  SDG  and  pXSC. 
HeLa  cells  were  treated  with  the  indicated  concentrations  of  selenium  compounds  for  l6h  before 
assessing  apoptosis  induction  by  (A)  morphology,  (B)  TUNEL  assay  and  (C)  accumulation  of 
hypodiploid  DNA  content.  (A)  light  microscope  photomicrographs  of  morphological  changes 
associated  with  SDG  and  pXSC  treatment.  (B)  represents  merged  photornicrographs  of  TUNEL 
assay  showing  FITC  (green)  and  PI  (red)  fluorescence.  FITC  fluorescence  indicates  apoptotic 
cells  while  PI  is  a  general  DNA  stain.  (C)  FACS  generated  profiles  of  cellular  DNA  content  in 
all  stages  of  the  cell  cycle  showing  accumulation  of  sub-GO/GI  DNA  framents  on  SDG  and 
pXSC  treatment.  Control  in  all  cases  is  DMSO. 
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Fig  43.2  Induction  of  apoptosis  by  SDG  and  pXSC  in  HeLa  cells. 
HeL-a  cells  treated  for  16h  (10h  for  Annexin  V  staining)  with  indicated  concentrations  of 
selenium  compounds  were  subjected  to  apoptotic  assays  -  TUNEL,  sub-GO/Gl  DNA 
accumulation  and  Annexin  V  staining.  C,  represents  treatment  with  solvent  vehicle,  DMSO. 
Error  bars  indicate  standard  errors.  Each  treatment  was  performed  in  triplicate.  Data  presented 
are  representative  of  3  independent  experiments. 
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TUNEL  (Terminal  deoxynucleotidyl  transferase-mediated  dUTP  nick  end  labelling)  assay 
(Fig  4.3.1B),  AnnexinV  staining  and  appearance  of  hypo-diploid  DNA  content  (Fig 
4.3.1C)  conclusively  proved  the  induction  of  apoptosis  in  HeLa  cells  by  SDG  and  pXSC. 
Cell  death  was  dose-dependent  (Fig  4.3.2)  and  corroborated  well  with  loss  viability  seen  in 
Section  4.2. 
4.4  Involvement  of  Caspase  3 
The  major  downstream  effectors  of  the  apoptotic  cascade  are  the  caspases.  Caspase 
activation  cascades  converge  on  caspase  3  which,  on  activation,  proteolytically  cleaves 
(thereby  activating)  several  key  proteins  including  PARP  (poly(ADP-ribose)  polymerase) 
which  bring  about  DNA  fragmentation  and  cell  death  (see  Section  2.6.7.1). 
Treatment  of  HeLa  cells  with  SDG  or  pXSC  resulted  in  the  activation  of  caspase  3 
assessed  by  using  an  antibody  specifically  recognising  the  cleaved  fragment  of  caspase  3 
(Fig  4.4.1A).  At  concentrations  that  induce  significant  apoptosis,  SDG  induced  caspase  3 
only  slightly  whereas  this  induction  was  greater  with  pXSC. 
Treatment  of  cells  with  a  specific  pharmacologic  inhibitor  of  caspase  3,  Ac-DEVD-CHO, 
resulted  in  a  decrease  in  apoptosis  in  response  to  both  SDG  and  pXSC  (Fig 4.4.1A).  This 
inhibition  was  more  marked  (55%,  p=0.04)  with  pXSC  than  SDG  (27%,  p=0.032)  perhaps 
reflecting  the  disparate  abilities  of  the  two  compounds  to  induce  caspase  3.  The  efficacy  of 
the  inhibitor  was  tested  by  assessing  cleavage  of  PARP  -a  downstream  proteolytic  target 
of  caspase  3.  Use  of  a  cleaved  PARP  fragment  specific  antibody  revealed  that  the  inhibitor 
did  reduce  cleavage  of  PARP,  again  more  efficiently  for  pXSC  (53%  compared  to  27%) 
than  for  SDG. 
It  is  clear  from  the  extent  of  inhibition  of  PARP  cleavage  that  50ým  of  the  caspase  3 
inhibitor  has  a  partial  effect,  perhaps  explaining  the  partial  protection  from  apoptosis 
induction.  Higher  concentrations  of  the  inhibitor  proved  to  be  toxic  to  HeLa  cells 
precluding  the  possibility  of  inhibiting  caspase  3  activity  completely.  It  is  possible  that 
there  may  be  a  caspase  independent  apoptotic  mechanism,  as  has  been  previously 
documented  in  other  contexts  (see  Section  2.6.7.1),  but  this  investigation  does  not  provide 
any  conclusive  evidence  for  such  a  route. 87 
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Fig  4.4.1  Caspase  3  activity  in  SDG-  and  pXSC-induced  apoptosis. 
HeLa  cells  treated  with  indicated  concentrations  of  selenium  compounds  for  l6h  were  assayed 
for  the  involvement  of  caspase  3.  (A)  Cell  lysates  were  prepared  and  Western  blotted  with  either 
an  antibody  against  the  cleaved  fragment  of  caspase  3  or  a  total  p38  kinase  antibody  as  a  loading 
control.  UV,  HeLa  cells  exposed  to  20OJm72  UV  irradiation  6h  prior  to  the  preparation  of  cell 
lysates.  (B)  TUNEL  assay  measuring  the  extent  of  apoptosis  induction  by  selenium  compounds 
in  the  presence  or  absence  of  specific  caspase  3  inhibitor,  Ac-DEVD-CHO  (at  50gM,  added 
30min  prior  to  selenium  treatment).  Error  bars  indicate  standard  effors.  Each  treatment  was 
performed  in  triplicate.  Data  presented  is  representative  of  2  independent  experiments.  (C)  HeLa 
cells  were  treated  with  the  indicated  concentrations  of  SDG  and  pXSC  for  l6h  in  the  presence  or 
absence  of  Ac-DEVD-CHO.  Cell  lysates  were  western  blotted  using  antibodies  against  the 
cleaved  fragment  of  PARP  or  total  p38  kinase  as  loading  control.  The  figures  below  the  blots 
indicate  the  fold  increase  in  cleaved  PARP  above  untreated  level,  normalized  to  the  loading 
control.  C,  in  all  cases,  represents  treatment  with  solvent  vehicle,  DMSO. 
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4.5  Molecular  mediators  of  SDG  and  pXSC  induced  apoptosis 
Programmed  cell  death  can  be  broadly  classified  into  two  major  groups;  receptor  mediated 
and  mitochondria  dependent  (See  Section  2.6.7.1).  In  recent  years,  however,  the  boundary 
between  these  two  classes  is  getting  increasingly  bluffed  with  evidence  mounting  for  cross- 
talk  and  synergistic  activation  of  both  modes  leading  to  amplification  of  the  response. 
These  mechanisms  are  not  mutually  exclusive  and,  while  they  may  function  separately  in 
some  situations,  they  may  co-operate  in  other  scenarios. 
4.5.1  Role  of  the  BcI2  family  members 
The  Bcl2  family  members  (see  Section  2.6.7.1)  critically  regulate  mitochondrial 
cytochrome  c  release  (and  therefore  apoptosis)  and  have  been  implicated  in  several 
apoptotic  responses  induced  by  oxidants,  chemotherapeutic  drugs  etc  (Reed,  2001).  These 
proteins  are  often  regulated  at  the  transcriptional  level  and  fall  into  pro-  and  anti-  apoptotic 
classes.  Bcl2  and  BClXL  are  anti-apoptotic  and  are  often  downregulated  in  response  to 
several  apoptotic  stimuli  while  their  overexpression  alleviates  the  apoptotic  response.  Bax  , 
on  the  other  hand,  is  acutely  pro-apoptotic  and  recent  evidence  suggests  that  it  is  perhaps 
indispensable  in  mediating  most  forms  of  mitochondria  mediated  cell  death  (Zhang  et  al., 
2000b). 
To  test  whether  Bcl2  family  members  were  involved  in  the  apoptosis  induction  by 
selenium  compounds,  SDG  and  pXSC  were  added  at  apoptosis-inducing  concentrations  for 
various  times  to  assess  any  alterations  in  the  levels  of  Bcl2,  BclXL  and  Bax  proteins. 
However,  Western  blotting  revealed  that  none  of  the  protein  levels  were  altered  on 
treatment  with  pXSC  or  SDG  (Fig.  4.5.1). 
This  corroborates  with  an  earlier  study  that  found  no  induction  of  Bcl2  family  members  on 
treatment  with  selenite  (Kaeck  et  al.,  1997).  However,  other  selenium  compounds  like 
SMC  have  been  shown  to  decrease  levels  of  Bcl2  in  vivo  (Ip  and  Dong,  2001).  There  is  no 
information  regarding  pXSC  in  other  systems.  Overexpression  of  Bcl2  protein  in  mouse 
C57  cells  have  been  shown  to  have  no  added  protection  from  SDG  treatment  (Blower, 
1998).  However,  the  relevance  of  this  data  is  confounded  by  the  fact  that  in  this  system  no 
protection  from  H202  treatment  was  observed. 
However,  the  lack  of  change  in  protein  levels  of  the  B62  family  members  does  not 
necessarily  exclude  the  possibility  of  mitochondrial  involvement  in  SDG/pXSC  mediated 89 
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Fig  4.5.1  Protein  levels  of  Bcl2  family  members  on  exposure  to  selenium. 
HeLa  cells  were  treated  as  indicated  with  SDG  and  pXSC  and  the  cell  lysates  western  blotted 
using  antibodies  against  Bc12,  BclxL,  Bax  and  total  p38  kinase  as  loading  control.  C,  represents 
treatment  with  solvent  vehicle,  DMSO. Chapter  4  90 
cell  death.  Bcl2  family  members  not  included  in  our  study,  like  Bad  and  Bak,  may  be 
involved.  There  is  also  the  possibility  of  post-translational  modification  of  Bcl2  family 
members.  For  example,  phosphorylation-mediated  inactivation  of  Bcl2  and  BClXL  by  JNK 
(Deng  et  al.,  2001;  Fan  et  al.,  2000)  and  p38  (Torcia  et  al.,  2001)  has  been  documented,  as 
well  as  the  phosphorylation  of  BAD  by  the  Akt  kinase  (del  Peso  et  al.,  1997).  These 
remain  very  real  possibilities  particularly  because  other  experiments  reported  elsewhere  in 
the  thesis  have  shown  that  both  the  selenium  compounds  under  investigation  can  induce 
JNV,  p38  and  Akt  activities.  Identification  of  such  post-translational  modifications  of  Bcl2 
family  members  is  difficult  since  phosphorylation  site-specific  antibodies  for  these 
modifications  are  not  generally  available.  Alternative  strategies,  for  example  assaying 
alterations  in  migration  patterns  due  to  phosphorylation  and  overexpressing  of  putative 
phosphorylation  site/s  mutants  need  to  be  considered. 
The  involvement  of  the  mitochondrial  pathway  could  also  perhaps  be  addressed  by 
examining  cytochrome  c  release  or changes  in  mitochondrial  membrane  potential.  Caspase 
8  is  activated  by  the  receptor  mediated  pathway  while  the  mitochondrial  route  utilises 
caspase  9  (see  Section  2.6.7.1).  Therefore  assays  for  individual  activities  of  these  caspases 
followed  by  assessment  of  functional  contribution  using  of  specific  inhibitors  could 
indicate  the  relative  contibution  of  the  two  apoptotic  modes.  However,  the  emerging 
evidence  for  overlap  between  the  pathways  might  make  such  simplistic  experiments 
difficult  to  interpret. 
4.5.2  Involvement  of  Fas  ligand  (Fasi)  in  selenium  mediated  cell  death 
Apoptosis-related  receptors  are  activated  by  cognate  apoptosis-inducing  ligands  and 
thereby  trigger  programmed  cell  death  by  several  diverse  stimuli.  This  often  involves 
transcriptional  upregulation  of  the  ligand  which  is  secreted  into  the  extracellular  space 
thereby  inducing  autocrine  or  paracrine  apoptosis  in  cells  bearing  the  complementary 
receptors.  Fasl  is  one  such  cell  death  mediating  ligand  which  has  been  shown  to  be 
upregulated,  both  in  vitro  and  in  vivo,  in  response  to  various  cellular  stresses  and 
chemotherapeutic  agents  (Debatin,  1999). 
Treatment  of  HeLa  cells  with  SDG  and  pXSC  led  to  the  rapid  induction  of  Fasl  protein  in  a 
dose  dependent  manner  (Fig.  4.5.2A,  B).  Only  the  soluble  form  of  Fasl  was  detectable, 
which  fits  well  with  the  idea  of  autocrine/paracrine  apoptosis.  The  expression  of  the  Fas 
receptor  in  HeLa  cells  has  been  previously  described  (Wajant  et  al.,  1998)  making  the 91 
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Fig  4.51  Induction  of  Fas  ligand  mediates  SDG-  and  pXSC-induced  apoptosis. 
HeLa  cells  were  treated  as  indicated  with  SDG  (A)  and  pXSC  (B).  Cell  lysates  were  Western 
blotted  using  antibodies  against  Fas  ligand  or  total  p38  kinase  as  loading  control.  (C)  Levels  of 
apoptosis  of  HeLa  cells  transiently  transfected  with  dnFADD-GFP  or  an  empty  vector  (GFP  co- 
transfected)  were  assessed  after  selenium  treatment  for  16h  by  measuring  the  accumulation  of 
hypodiploid  DNA  within  the  GFP  positive  fraction  of  cells.  M  represents  a  positive  control 
treatment  with  400pM  MMS  for  8h.  Error  bars  indicate  standard  errors.  Each  treatment  was 
performed  in  triplicate.  Data  presented  is  representative  of  3  independent  experiments.  C,  in  all 
cases,  represents  treatment  with  solvent  vehicle,  DMSO. 
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involvement  of  the  Fas  mediated  cell  death  pathway  a  putative  candidate  mechanism  in 
selenium-induced  apoptosis  in  these  cells. 
The  levels  of  Fasl  induction  correlated  well  with  the  cell  death  observed,  therefore  we 
tested  if  this  was  functionally  required.  Stimulation  of  Fas  leads  to  the  formation  of  a 
receptor-bound  death-inducing  signaling  complex  (DISC),  consisting  of  FADD  and  two 
different  forms  of  caspase-8  (see  Section  2.6.7.1).  It  has  been  shown  that  disruption  of 
FADD  protects  cells  from  Fas  mediated  apoptosis  (Wajant  et  al.,  1998):  providing  us  with 
a  tool  to  assess  functional  requirement  of  the  Fas  pathway  in  SDG/pXSC-induced 
programmed  cell  death. 
Dr  H  Wajant  (University  of  Stuttgart,  Germany)  very  kindly  provided  us  with  a  dominant 
negative  FADD  (dnFADD)  expression  construct  where  the  amino-terminal  death  effector 
domain  of  FADD  is  replaced  by  GFP.  HeLa  cells  were  transiently  transfected  with  the 
dnFADD  or  empty  vector  for  24h  followed  by  treatment  with  selenium  compounds.  Using 
fluorescence  activated  cell  sorting  (FACS)  the  sub-GO/G1  DNA  content  of  the  cells 
expressing  GFP  was  assessed  (Fig  4.5.2A).  Exogenous  expression  of  dnFADD  resulted  in 
a  reduction  in  of  SDG-induced  (43%  and  34%  for  5  and  7  [tM,  respectively;  p=0.014  and 
0.002)  and  to  a  lesser  extent  for  pXSC-induced  apoptosis  (28%  and  29%  for  35  and  50 
[LM,  respectively;  p=0.02  and  0.034). 
These  studies  have  therefore  shown  for  the  first  time  induction  of  Fasl  by  selenium 
compounds  and  have  also  confirmed  its  functional  involvement  apoptosis  induction.  One 
consideration,  prior  to  the  transfection  studies,  was  as  HeLa  cells  expressed  relatively  low 
levels  of  Fas  receptor  (Wajant  et  al.,  1998),  the  induction  of  the  ligand  observed  could  be 
non-specific  and  may  not  contribute  to  cell  death.  However,  use  of  dnFADD  successfully 
demonstrated  the  functional  relevance  of  this  pathway  suggesting  that  the  low  levels  of  Fas 
receptor  expression  was  sufficient.  No  evidence  for  the  induction  of  the  Fas  receptor  itself 
was  found  (work  of  J.  Fleming). 
Expression  of  exogenous  dnFADD  results  in  partial  protection  from  apoptosis  suggesting 
either  only  partial  protection  is  attained  by  transfecting  dnFADD  or  Fas-independent 
pathways  also  contribute  to  the  induction  of  apoptosis.  It  is  a  possibility  that  other 
cytotoxic  ligands  (like  TRAIL  -  TNF-related  apoptosis  inducing  factor)  may  be  involved 
or  perhaps  there  may  be  some  contribution  of  mitochondrial  dysfunction.  Experiments 
suggested  in  Section  4.5.1  may  be  of  some  importance  in  order  to  dissect  the  relative 
importance  of  the  mitochondria-mediated  pathway. Chapter  4  93 
Finally,  given  that  both  pXSC  and  SDG  induce  JNK  activation  (Section  4.3.1)  the 
involvement  of  Fasl  described  here  opens  up  the  possibility  of  an  apoptosis  signalling 
pathway  from  JNK  activation  to  Fasl  induction  via  transcriptional  activation  of  c-jun  as  has 
been  shown  in  other  systems  (Kolbus  et  al.,  2000;  Sharma  et  al.,  2000). 
4.6  Conclusions 
This  chapter  describes  apoptosis  induction  by  chernopreventive  selenium  compounds,  SDG 
and  pXSC,  in  HeLa  cells.  Several  different  assays  have  been  used  to  assess  cell  death 
which  appears  to  be,  at  least  partially,  dependent  on  caspase  3  induction  as  judged  by  the 
caspase  inhibitor  experiments.  Bc12,  BCIXL  and  Bax  protein  levels  do  not  change  when 
cells  are  treated  with  cytotoxic  doses  of  selenium  compounds.  This  however  does  not 
exclude  the  possibility  of  post-translational  regulation  of  these  key  mediators  of  cell  death. 
Selenium  compounds  were  also  shown  to  induce  Fasl  which  appears  to  have  a  functional 
contribution  to  the  induction  of  cell  death.  This  is  of  particular  importance,  since  it  is  the 
first  functional  mediator  of  selenium-induced  apoptosis  to  be  identified. 
4.7  Chapter  summary 
Chernopreventive  selenium  compounds,  pXSC  and  SDG,  reduce  proliferation  of 
HeLa  cells  accompanied  by  a  loss  of  cellular  viability. 
The  loss  of  cellular  viability  is  primarily  due  to  the  induction  of  apoptosis. 
e  Caspase  3  is  activated  by  selenium  and  inhibition  of  its  activity  partially  protects 
from  selenium-induced  apoptosis. 
e  The  levels  of  Bc12,  BClXL  and  Bax  proteins  do  not  change  during  the  course  of 
selenium  exposure. 
0  FasL  is  induced  by  pXSC  and  SDG  and  disruption  of  Fas  signalling  by 
overexpressing  a  dominant  negative  FADD  protects  from  apoptosis  induction. 94 
5  Signalling  Mechanisms  Mediating 
induced  Cell  Death 
5.1  Background 
Selenium- 
As  established  in  the  previous  chapter  and  described  extensively  in  the  literature,  several 
chemopreventive  selenium  compounds  induce  programmed  cell  death  (see  Section 
2.6.7.3).  A  major  issue  remaining  unresolved  is  what  integrates  the  cellular  sensing  of 
chemopreventive  levels  of  selenium  to  an  appropriate  response  -  in  this  case  that  of  cell 
death  (including  an  involvement  of  the  Fas  mediated  pathway  in  the  context  of  this  thesis). 
The  evolutionary  conserved,  Mitogen  activated  protein  kinase  (MAPK)  signal  transduction 
pathways  have  been  shown  to  critically  regulate  cell  growth,  survival  and  apoptosis  by 
accurately  interpreting  the  sensory  cues  (see  Section  2.6.7.4).  The  MAPK  pathways  are 
extremely  context  dependent  and  it  is  believed  that  a  balance  of  pro-  and  anti-apoptotic 
signals  regulate  the  ultimate  cellular  response.  The  context-specificity  and  the  intimacy  of 
the  cross-talk  between  different  pathways  result  in  a  highly  sophisticated  signal 
transduction  system  sensitive  to  even  small  alterations  of  its  environment.  Given  the 
central  role  of  MAPK  signalling  and  the  fact  that  several  known  apoptotic  stimuli  involve 
functional  alterations  in  MAPK  signal  transduction,  this  study  investigated  whether  any  of 
the  major  MAPKs  are  involved  in  selenium  induced  cell  death.  Precedent  for  the 
involvement  of  MAPKs  has  been  discussed  in  Section  2.6.7.4.  Our  lab  has  also  found 
evidence  for  the  induction  of  haernoxygenase  (HO-1)  by  selenium  compounds  (Fleming  et 
al.,  2001)  which  is  a  typical  marker  for  a  cellular  stress  response,  often  involving  the 
activation  of  the  stress  induced  MAPKs  like  JNK  and  p38,  thus  strengthening  the  case  for 
investigation  into  these  pathways. 
5.2  Involvement  of  p38  kinase 
The  induction  of  p38  stress  kinases  have  been  documented  for  a  number  of  apoptotic 
stimuli  including  those  mediated  by  the  activation  of  the  Fas  pathway  (Zhang  et  al., 
2000a).  Depending  on  the  context,  p38  can  be  both  pro-  or  anti-  apoptotic  (Martin-Blanco, 
2000).  It  is  believed  that  p38  kinase  activation  is  involved  in  DNA  damage-induced 
apoptosis,  but  recent  evidence  suggests  that  its  primary  role  may  be  in  initiating  a  block  in 
the  G2/M  phase  of  the  cell  cycle  which  may,  in  turn,  potentiate  apoptosis  (Bulavin  et  al., 
2001).  'ne  'pro-proliferatory'  function  of  p38  kinase  is  less  well  elucidated,  but  the  current Chapter  5  95 
evidence  suggests  it  may  be  involved  in  fibroblast  growth  factor  2-induced  proliferation  of 
Swiss  373  and  granulocyte  colony-stimulating  factor-induced  proliferation  of 
haernatopoetic  cells  (Nebreda  and  Porras,  2000).  p38  has  also  been  shown  to  mediate 
survival  in  cardiornyocytes  from  anisomycin-induced  apoptosis  and  in  neuronal.  survival, 
probably  via  the  activation  of  the  MEF2  transcription  factor  (Nebreda  and  Porras,  2000). 
5.  Zl  Activation  of  p38  kinase  by  SDG  and  pXSC 
Fig  5.2.1A  shows  the  dose  dependent  activation  of  p38  kinase  on  treatment  with  both  SDG 
and  p-XSC  using  phosphorylation  state  specific  antibodies  against  the  Thr180/Tyr182 
residues.  While  the  phosphorylated  fraction  (activated)  of  p38  gets  induced,  there  is  no 
change  in  the  levels  of  the  total  protein.  The  activation  is  fairly  rapid  -  within  10  min  for 
pXSC  and  30  min  for  SDG. 
As  the  duration  of  p38  activity  may  influence  its  downstream  response,  HeLa  cells  were 
treated  with  chemopreventive  doses  of  selenium  for  longer  time  periods  (Fig  5.2.1B).  This 
revealed  that  p38  activation  was  sustained  throughout  the  period  of  the  treatment  and  when 
substantial  apoptosis  was  detectable. 
The  antibodies  used  recognise  the  phosphorylated  fraction  of  the  p38  isoforms  a  and  P. 
p38  has  two  other  major  isoforms,  8  and  y,  which  have  been  implicated  in  certain 
physiological  responses.  However,  the  unavailability  of  phospho-specific  or  total 
antibodies  against  these  isoforms  precludes  the  analysis  of  the  endogenous  activities  of 
these  forms. 
5.  Z2  Specific  inhibition  of  p38  activity  does  not  reveal  a  functional  role  in 
apoptotic  signalling 
A  very  highly  specific  pharmacological  inhibitor  for  p38a  and  0  activities  have  been 
developed  and  extensively  characterised.  This  inhibitor,  SB203580,  was  used  to  assess  the 
contribution  of  p38  activation  to  cell  death  induction  by  SDG  and  pXSC.  HeLa  cells  were 
pretreated  with  10[tM  SB203580  prior  to  addition  of  selenium.  At  these  conditions  the 
inhibitor  completely  abolished  p38  activity,  determined  by  assaying  the  kinase  activity  of 
MAPKAP-2  (MAPK  activated  protein  kinase  2;  see  Fig  2.6.3)  -  an  immediate  downstream 
p38  target  (Fig  5.2.2A).  The  specificity  of  the  inhibition  was  reflected  in  its  failure  to  affect 
JNK  activity,  assessed  by  the  specific  phosphorylation  of  c-jun  by  JNK  at  serine  63,  at 
conditions  that  completely  attenuated  p38  activity  (Fig  5.2.213). 96 
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Fig  51.1  Activation  of  p38  kinase  by  SDG  and  pXSC. 
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HeLa  cells  were  treated  as  indicated  with  SDG  or  pXSC,  cell  lysates  prepared,  and  analysed  by 
SDS/PAGE  and  western  blotting  with  antibodies  against  the  activated  form  of  p38  (p38*).  As 
loading  controls,  the  blots  were  then  stripped  and  western  blotted  with  antibodies  against  total 
p38.  (A)  Shows  activation  of  p38  kinase  after  a  short  exposure  to  selenium  compounds,  while 
(B)  shows  the  same  after  longer  treatments.  H,  represents  a  positive  of  2mM  H202  treatment  for 
30min.  C,  in  all  cases  represents  treatment  with  solvent  vehicle,  DMSO. 97 
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Fig  511  Effect  of  inhibition  of  p38  activity  on  apoptosis  induction  by  SDG  and  pXSC. 
(A)  HeLa  cells  were  treated  with  indicated  concentrations  of  selenium  compounds  for  16h  in  the 
presence  or  absence  of  specific  p38  inhibitor,  SB203580  (at  lOpM,  added  30min  prior  to 
selenium  treatment).  Cell  lysates  were  analysed  for  p38  kinase  activity  by  an  immunecomplex 
kinase  assay  for  endogenous;  MAPKAP-2  (direct  substrate  of  p38  kinase)  activity  using  hsp25  as 
a  substrate.  (B)  JNK  activity  in  cell  lysates  prepared  after  30min  of  selenium  treatment  in  the 
presence  or  absence  of  SB203580  (at  lOpM,  added  30min  prior  to  selenium  treatment)  were 
measured  by  western  blot  analysis  using  antibodies  against  phosphorylated  Serine  63  of  c-jun 
(c-jun*(Ser  63)).  (C)  Levels  of  apoptosis  induction  by  selenium  compounds,  with  or  without 
pre-treatment  with  SB203580  (at  10ýM,  added  30min  prior  to  selenium  treatment),  was 
measured  by  TUNEL  assay.  UV,  HeLa  cells  exposed  to  20OJnr2  UV  irradiation  l2h  prior  to  the 
preparation  of  cell  lysates.  Error  bars  indicate  standard  effors.  Each  treatment  was  performed  in 
triplicate.  Data  presented  is  representative  of  4  independent  experiments.  C,  in  all  cases, 
represents  treatnient  with  solvent  vehicle,  DMSO. 
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On  measuring  the  extent  of  cell  death  induced  by  either  selenium  compound  in  HeLa  cells 
treated  with  or  without  SB203580,  no  difference  in  the  number  of  cells  undergoing 
apoptosis  was  found  (Fig  5.2.2C).  A  control  experiment  exposing  cells  to  UV  showed 
marked  reduction  of  apoptotic  cells  when  p38  activity  was  inhibited  (Fig  5.2.2C).  These 
experiments  suggest  that  apoptosis  induction  by  selenium  does  not  require  p38  activation. 
Though  no  obvious  role  for  p38  could  be  demonstrated  by  these  experiments,  it  is  quite 
possible  that  p38  contributes  to  selenium-mediated  cyto-toxicity  by  more  subtle  means.  For 
example,  p38  may  promote  some  deregulation  of  cell  cycle  progression  that  may  potentiate 
apoptosis.  This  view  is  supported  by  the  evidence  that  treatment  with  some  selenium 
compounds  induces  several  members  of  the  GADD  (Growth  arrest  and  DNA  damage) 
family  of  proteins  that  regulate  cell  cycle  progression  and  are  known  to  be  influenced  by 
p38  activity  (Sheikh  et  al.,  2000).  Selenomethionine  induces  a  cell  cycle  block  associated 
with  the  inhibition  of  cdc2  activity.  Evidence  from  other  studies  suggest  that  cdc2  activity 
may  be  inhibited  by  p38,  possibly  via  inactivation  of  phosphatases  (Pearce  and  Humphrey, 
2001).  Our  experiments  perhaps  employed  an  apoptotic  impetus  that  was  too  acute  to 
detect  these  differences.  A  detailed  study  of  cell  cycle  patterns  in  synchronous  cultures 
treated  with  or  without  SB203580  would  perhaps  be  more  appropriate  to  investigate 
whether  p38  induced  by  SDG  and  pXSC  has  a  role  in  altering  the  cell  cycle.  One  cannot, 
however,  expect  a  dominant  effect  arising  from  possibilities  mentioned  above  as  no  effect 
on  apoptosis  induction  was  revealed  in  the  inhibitor  studies. 
p38  activity  may  also  be  downstream  of  the  induction  of  apoptosis,  perhaps  in  some  form 
of  a  postive  feedback  loop  to  strengthen  an  acute  cytotoxic  response.  There  is  evidence  that 
casapase  3  may  activate  MEKK1  which,  in  turn,  may activate  p38  (Cardone  et  al.,  1997; 
Nakagami  et  al.,  2001).  Having  cells  treated  with  or without  a  caspase  3  inhibitor  prior  to 
selenium  treatment  and  following  the  kinetics  of  p38  activation  could  verify  this  particular 
phenomenon.  Again  such  a  response  enhancement  mechanism  appears  to  be  unlikely  given 
the  very rapid  activation  of  p38,  low  caspase  3  activity  (particularly  for  SDG)  and  the  fact 
that  if  it  had  a  major  contribution  then  it  would  have  been  revealed  in  the  inhibitor 
experiment. 
Due  to  the  fact  that  available  reagents  (phospho-specific  antibodies  and  inhibitors)  only 
recognise/affect  the  p38a  and  P  isoforms,  the  role  of  p388  and  y  could  not  be  investigated. 
It  is  possible  that  one  or  both  of  these  are  activated  concomitantly  with  a  and  0  and  share  a 
redundant  (or  even  perhaps  independent)  role  in  apoptosis  induction  with  the  latter. 
Whether  SDG/pXSC  activates  the  8  and  y  isoforms  could  be  assessed  by  activation  of  an Chapter  5  99 
overexpressed  tagged  construct  by  'pull-down'  kinase  assays.  If  found  activated,  specific 
dominant  negative  constructs  could  then  be  utilised,  individually  or  in  combination  with 
SB203580,  to  investigate  their  possible  functional  involvement. 
A  final  relevant  fact  is  that  in  HeLa  cells,  in  response  to  certain  stimuli,  p38CE  appears  to 
promote  apoptosis  whereas  p38P  enhances  survival  (Nemoto  et  al.,  1998).  A  detailed 
investigation  into  this  isoform  specificity  would  again  entail  overexpression  studies  with 
wild  type  and  dominant  negative  constructs. 
Thus,  though  SDG  and  pXSC  rapidly  induced  sustained  p38  activity,  its  association  with 
cell  death  in  this  particular  context  remains  unclear. 
5.3  Involvement  of  c-jun  N-terminal  kinase  (JNK) 
The  JNK  pathway  is  activated  by  the  exposure  of  cells  to  several  types  of  stress,  though  its 
role  in  the  stress  response  is  unclear  (Davis,  2000;  Dong  et  al.,  2001a).  It  is  possible  that  it 
may  mediate  some  of  the  effects  of  stress  on  the  cells,  like  induce  apoptosis,  or, 
alternatively  be  a  survival  response.  Thus  the  specific  role  depends  on  the  cellular  context 
and  both  apoptotic  and  survival  signaling  by  JNK  has  been  documented  (Leppa  and 
Bohmann,  1999).  Phosphorylation  of  c-jun  on  the  sites  that  are  phosphorylated  by  JNK 
(Ser-36  and  Ser-73)  causes  increased  transcriptional  activity  (Derijard  et  al.,  1994; 
Kyriakis  et  al.,  1994).  Apoptosis  mediated  by  c-jun-regulated  effector  proteins  like  Fasl  are 
often  preceded  by  enhanced  JNK  activity  and  this  altered  gene  expression  mediated  cell 
death  is  well  documented  (Kolbus  et  al.,  2000;  Sharma  et  al.,  2000). 
5.3.1  SDG  and  pXSC  activate  JNK 
Phospho-specific  antibodies  against  Thr183/Tyr185  of  JNK1  and  2,  the  major  isoforms  in 
non-neuronal  cells,  are  excellent  markers  of  JNK  activity  (Derijard  et  al.,  1994;  Kyriakis  et 
al.,  1994).  Treatment  with  SDG  and  pXSC  revealed  a  rapid,  dose  dependent  increase  in 
JNK  activity  within  10-30  min(Fig  5.3.1A). 
As  with  p38,  the  duration  of  the  JNK  induction  appears  to  determine  the  specific  response, 
for  example  proliferation  or  apoptosis  (Davis,  2000).  HeLa  cells  were  therefore  treated 
with  the  selenium  compounds  over  longer  time  periods:  this  revealed  that  JNK  activity  was 
sustained  over  the  course  of  the  treatment  (Fig  5.3.1B).  This  fits  well  with  the  current 100 
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Fig  5.3.1  Activation  of  the  stress  kinase,  JNK  by  SDG  and  pXSC. 
h 
JNK  1/2* 
JNK  1/2 
HeLa  cells  were  treated  as  indicated  with  SDG  or  pXSC,  cell  lysates  prepared,  and  analysed  by 
SDS/PAGE  and  western  blotting  with  antibodies  against  the  activated  forms  of  JNKI/2  (JNK 
1/2*).  As  loading  controls,  the  blots  were  then  stripped  and  western  blotted  with  antibodies 
against  total  JNKI/2.  (A)  Shows  activation  of  JNK  kinase  after  a  short  exposure  to  selenium 
compounds,  while  (B)  shows  the  same  after  longer  treatments.  H,  represents  a  positive  of  2MM 
H202  treatment  for  30min.  C,  in  all  cases,  represents  treatment  with  solvent  vehicle,  DMSO. Chapter  5  101 
model  for  pro-apoptotic  JNK  signalling  where  sustained  JNK  activation  is  thought  to 
induce  apoptosis  (Davis,  2000;  Dong  et  al.,  2001a). 
5.3.2  JNK  activation  leads  to  the  phosphotylation,  of  c-jun 
To  ensure  the  JNK  activity  observed  resulted  in  the  phosphorylation  of  its  major 
downstream  target,  c-jun,  a  GST-fusion  of  the  N-terminal  half  of  c-jun  was  used  as  a  JNK 
substrate  in  a  'pull-down'  kinase  assay  (Fig  5.3.2A).  An  increased  in  GST-c-jun 
phosphorylation  was  observed  confirming  the  results  from  the  phospho-specific  antibody 
experiments. 
To  confirm  that  JNK  was  indeed  phosphorylating  c-jun  at  the  appropriate  sites  (Ser-63  and 
Ser-73),  phospho-specific  antibodies  recognizing  these  particular  sites  were  used.  Fig 
5.3.2B  shows  the  increased  phosphorlyation  of  c-jun  at  residues  Ser-63  and  Ser-73  on 
treatment  with  both  SDG  and  pXSC. 
5.3.3  JNK  mediates  selenium-induced  apoptotic  signalling  via  c-jun  activity 
As  specific  pharmacologic  inhibitors  of  the  JNK  pathway  are  not  very  well  characterised 
and  there  is  considerable  signalling  redundancy  amongst  the  known  upstream  JNK 
activators,  c-jun  was  chosen  as  an  appropriate  level  for  disruption  of  the  JNK  pathway. 
JNK1  and  2  kinase  dead  constructs  have  been  previously  described  but  were  not  used  as 
they  are  not  very  efficient  (Dr  S.  Gutkind,  personal  communication). 
A  dominant  negative  c-jun  construct,  TAM67  (a  kind  gift  from  Dr  D.  Gillespie,  Beatson 
Institute,  UK),  has  been  used  extensively  in  the  literature  (Brown  et  al.,  1994;  Fan  et  al., 
2001;  Freemerman  et  al.,  1996).  This  construct  was  used  to  transiently  transfect  Heu  cells 
prior  to  selenium  treatment.  To  monitor  changes  in  the  population  of  transfected  cells,  the 
plasmid  of  interest  was  co-transfected  with  a  GFP  construct  and  FACSCAN  used  to 
evaluate  accumulation  of  hypodiploid  DNA  content  only  in  the  fraction  positive  for  GFP 
fluorescence.  TAM67  expression  in  the  GFP  sorted  population  was  at  least  as  high  as 
endogenous  c-jun  (Fig  5.33A).  The  level  of  induction  of  apoptosis  SDG  in  TAM67- 
expressing  cells  was  reduced  by  about  40%  (p=0.003  and  0.006  for  5[LM  and  7[LM  SDG, 
respectively)  compared  to  cells  transfected  with  vector  alone  (Fig  5.3.313).  The  protection 
from  pXSC,  however,  was  only  about  20%  though  this  was  statistically  significant 
(p=0.003  for  both  35[tM  and  50[tM). 102 
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Fig  5.3.2  Activation  of  c-jun  by  SDG  and  pXSC. 
(A)  Immnunecomplex  kinase  assay  of  JNK  activity  was  performed  on  HeLa  cell  lysates  that 
were  treated  for  30min  with  indicated  concentrations  of  selenium  compounds,  using  a  GST 
fused  N-terminal  fragment  of  c-jun  as  substrate.  H,  represents  a  positive  control  of  2mM  H202 
treatment  for  30min  (B)  Activation  of  c-jun  by  selenium  treatment  was  assessed  by  western  blot 
analysis  of  cell  lysates  derived  from  HeLa  cells  treated  with  SDG  and  pXSC  as  indicated. 
Antibodies  against  phosphorylated  forms  of  c-jun  at  serines  63  (c-jun*(Ser63))  and  73  (c- 
jun*(Ser73))  were  used  to  measure  c-jun  activation.  As  loading  controls,  the  blots  were  then 
stripped  and  western  blotted  with  antibodies  against  total  c-jun.  C,  in  all  cases,  represents 
treatment  with  solvent  vehicle,  DMSO. 103 
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Fig  533  Effect  of  overexpression  of  a  c-jun  dominant  negative,  TAM67,  on  SDG-  and 
pXSC-induced  apoptosis. 
(A)  HeLa  cells  transiently  co-transfected  with  GFP  and  TAM67  or  an  empty  vector  were  sorted 
using  FACS  to  enrich  the  GFP  positive  cells.  Western  blotting  using  a  total  c-jun  antibody  was 
carried  out  to  analyse  TAM67  expression  between  empty  vector  transfected  (V)  and  TAM67 
transfected  cells.  (B)  Levels  of  apoptosis  of  HeLa  cells  transiently  co-transfected  with  GFP  and 
TAM67  or  an  empty  vector  were  assessed  after  selenium  treatment  for  16h  by  measuring  the 
accumulation  of  hypodiploid  DNA  within  the  GFP  positive  fraction  of  cells.  K  represents  a 
positive  control  treatment  with  2mM  H202.  Each  treatment  was  performed  in  triplicate.  Data 
presented  is  representative  of  3  independent  experiments.  (C)  A431  cells  stably  transfected  with 
TAM67  or  the  'empty'  expression  vector  were  treated  with  SDG  and  pXSC  as  indicated,  for 
16h,  and  levels  of  apoptosis  measured  by  TUNEL  assay.  Error  bars,  in  all  cases,  indicate 
standard  errors.  C,  in  all  cases,  represents  treatment  with  solvent  vehicle,  DMSO. 
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To  confirm  these  findings  from  transient  transfection  studies  described  above,  we  tested 
cell  death  induction  in  A431  cells  stably  expressing  TAM67  or  an  empty  vector  (kindly 
provided  by  Dr  G.  Stapleton,  Beatson  Institute,  UK).  The  expression  of  TAM67  and  its 
functional  attenuation  of  c-jun  activity  in  these  cells  have  been  previously  described 
(Malliri  et  al.,  1998)  and  was  confirmed  by  Dr  G.  Stapleton  (Beatson  Institute,  UK)  for  the 
particular  batch  of  cells  used  in  our  study.  Studies  with  A431  cells  stably  expressing 
TAM67  confirmed  the  conclusions  from  the  transient  transfection  studies:  compared  to 
empty  vector  transfected  cells,  stable  expression  of  TAM67  showed  an  attenuated  response 
to  SDG  and  pXSC  induced  apoptosis,  (Fig  5.3.3C).  Again  the  protection  from  pXSC  (25% 
reduction,  p=0.04)  was  less  than  that  from  SDG-induced  cell  death  (41%  reduction, 
P=0.001). 
Disruption  of  c-jun  function  results  in  cells  cycling  considerably  more  slowly  (Schreiber  et 
al.,  1999).  It  is  conceivable  that  the  reduction  in  apoptosis  observed  could  be  due  to  this 
non-specific  effect  in  TAM67  expressing  cells.  However,  other  experiments  showed  that 
this  was  not  the  case  for  transient  overexpression  of  TAM67  in  HeLa  cells,  since  the 
incorporation  of  tritiated  thymidine,  prior  to  selenium  treatment,  was  comparable  for  both 
TAM67  and  empty  vector  transfected  cells  (data  not  shown). 
As  TAM67  completely  disrupts  c-jun  function,  it  is  possible  that  use  of  this  strategy  might 
disrupt  other  non-JNK  mediated  activities  of  c-jun  and  therefore  the  protection  against 
selenium-induced  apoptosis  observed  might  not  be  specific  to  the  disruption  of  JNK 
activity.  To  address  this  issue  similar  transient  overexpression  experiments  were  performed 
using  a  HA-tagged  c-jun  construct  whose  serine  residues  at  positions  63  and  73  (sites  on  c- 
jun  specifically  phosphorylated  by  JNK)  had  been  altered  to  alanine,  c-jun  S63/73A  (a  kind 
gift  from  Dr  M.  Karin,  University  of  California,  San  Diego,  USA).  The  expression  of  the 
mutant  protein  was  confirmed  using  antibodies  against  the  HA  epitope  tag  (Fig  5.3.4A). 
Comparing  levels  of  apoptosis,  between  cells  expressing  c-jun  S63/73A  and  empty  vector, 
attenuation  of  cell  death  mediated  by  SDG  (45%  reduction,  p=0.0001)  and  pXSC  (18% 
reduction,  p=0.04)  was  found  due  to  c-jun  SOMA  overexpression  (Fig  5.3.4B). 
To  test  if  there  was  any  co-operative  effect  between  JNK  and  p38  activation,  HeLa  cells 
transiently  transfected  with  TAM67  were  treated  with  the  p38  inhibitor  SB203580  (Fig 
5.3.5).  This  study  revealed  no  enhanced  protection  by  p38  and  JNK  inhibition  from  cell 
death  induction  compared  to  TAM67  expression  on  its  own. 105 
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Fig  53.4  Effect  of  overexpressing  a  phosphorylation  defective  mutant,  c-jun  SOMA,  on 
SDG-  and  pXSC-  induced  apoptosis. 
(A)  HeLa  cells  transiently  co-transfected  with  GFP  and  HA-tagged  c-jun  S63n3A  or  an  empty 
vector  were  sorted  using  FACS  to  enrich  the  GFP  positive  cells.  Western  blotting  using  an  anti- 
HA  tag  antibody  was  carried  out  to  compare  c-jun  S63n3A  expression  between  empty  vector 
transfected  (V)  and  c-jun  S63n3A  transfected  cells.  JI  and  J2  are  two  pools  of  c-jun  S63/73A 
transfected  cells  prior  to  FACS  sorting.  JS,  is  c-jun  S63/73A  transfected  cells  after  FACS 
enrichment.  (B)  Levels  of  apoptosis  of  HeLa  cells  transiently  co-transfected  with  GFP  and  c-jun 
S63/73A  or  an  empty  vector  were  assessed  after  selenium  treatment  for  16h  by  measuring  the 
accumulation  of  hypodiploid  DNA  within  the  GFP  positive  fraction  of  cells.  IL  represents  a 
positive  control  treatment  with  2mM  H.  02.  Each  treatment  was  performed  in  triplicate.  Data 
presented  is  representative  of  2  independent  experiments.  Error  bars  indicate  standard  errors.  C, 
represents  treatment  with  solvent  vehicle,  DMSO. 
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Fig  53.5  Effect  of  simultaneous  abrogation  of  p38  kinase  and  c-jun  activity  on  cell  death 
induced  by  selenium  compounds. 
HeLa  cells  transiently  co-transfected  with  GFP  and  TAM67  or  an  empty  vector  were  treated 
with  SDG  and  pXSC  in  the  presence  or  absence  of  SB203  5  80  (at  I  OpM,  added  3  Omin  prior  to 
selenium  treatment  -  see  Fig  5.2.2A).  Extent  of  apoptosis  of  all  combinations  of  transfections 
and  inhibitor  was  assessed  by  measuring  the  accumulation  of  hypodiploid  DNA  within  the  GFP 
positive  fraction  of  cells.  Each  treatment  was  performed  in  triplicate.  Data  presented  is 
representative  of  2  independent  experiments.  Error  bars  indicate  standard  erTors.  C,  represents 
treatment  with  solvent  vehicle,  DMSO. 
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This  data  indicates  that  activation  of  JNK  by  the  selenium  compounds  is  a  functionally- 
required  pro-apoptotic  signalling  pathway  acting  through  c-jun.  This  in  turn  implies  that,  at 
least  partially,  selenium  induced  apoptosis  requires  new  gene  expression.  One  candidate  is 
clearly  Fasl  in  view  of  the  data  already  noted  in  Section  4.5.2:  this  hypothesis  is  explored 
in  the  next  section.  However,  the  relative  contribution  of  the  JNK  pathway  to  SDG  and 
pXSC  induced  apoptosis  appears  to  be  different.  It  is  clear  from  these  experiments  that 
mechanisms  apart  from  the  JNK/c-jun  pathway  are  involved  particularly  in  the  case  of 
pXSC.  Whether  these  are  entirely  JNK  independent  mechanisms  or  they  involve  other  JNK 
functions  remain  unclear.  The  use  of  the  recently  developed  JNK1-/-,  JNK2  -/-  double 
knockout  cells  might  reveal  the  complete  spectrum  of  JNK  functions  in  selenium-induced 
apoptosis. 
The  most  plausible  role  of  JNK  in  mediating  apoptosis,  apart  from  the  c-jun  mediated 
pathway,  is  to  influence  mitochondrial  cytochrome  c  release.  Evidence  for  JNK 
phosphorylating  and  inactivating  antiapoptotic  functions  of  Bc12  and  BCIxL  in  certain 
contexts  have  already  been  described  (Deng  et  al.,  2001;  Fan  et  al.,  2000).  It  would  be  very 
illuminating  to  study  JNK  mediated  post-translational  modifications  of  the  Bcl2  family  of 
proteins  in  response  to  selenium  -  but  with  currently  available  reagents  the  endogenous 
activities  of  these  proteins  cannot  be  studied. 
5.4  JNK  regulates  the  induction  of  Fas  ligand 
The  induction  of  Fasl  in  response  to  various  stresses  and  alkylating  agents  has  been  shown 
to  be  dependent  on  c-jun  transcriptional  activity.  Given  that  phosphorylation  of  c-jun  at 
serines  63  and  73  by  JNK  increases  its  transcriptional  activity,  it  is  possible  that  JNK 
activity  is  required  for  Fasl  induction.  As  Fasl  is  strongly  induced  by  SDG  and  pXSC  and 
attenuation  of  Fas  signalling  resulted  in  partial  protection  from  apoptosis  (about  the  same 
extent  as  that  obtained  by  disrupting  JNK  mediated  c-jun  activation;  Fig  4.5.2),  this 
hypothesis  was  tested  directly  by  evaluating  whether  disruption  of  c-jun  activity  affected 
selenium  induced  FasL  expression. 
Cells  transfected  with  either  TAM67  or  an  empty  vector  were  treated  with  selenium  and 
the  levels  of  Fasl  induction  examined  (Fig  5-4.1A).  The  transfection  efficiency  of  vector 
only  and  TAM67  expressing  cells  were  comparable  (85%  and  83%,  respectively)  as  judged 
by  GFP  co-transfection.  TAM67  expression  was  found  to  reduce  the  induction  of  FasL  by 
SDG  (by  -5  fold),  but  not  that  by  pXSC.  This  perhaps  reflects  the  lower  extent  of 108 
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Fig  5.4.1  Effect  of  c-jun  and  p38  activation  on  Fasl  induction  by  SDG  and  pXSC. 
(A)  Vector  (V)-  or  TAM67  (T)-transfected  HeLa  cells,  co-transfected  with  a  GFP-expression 
vector,  were  treated  with  the  indicated  concentrations  of  SDG  or  pXSC  for  18h  and  then 
analysed  for  Fasl  expression  using  western  blotting.  The  loading  control  is  total  p38  kinase.  The 
percentages  of  transfected  cells,  determined  from  the  percentage  of  GFP-expressing  cells,  were 
85%  and  83%  for  vector  and  TAM67  transfections,  respectively.  (B)  HeLa  cells  were  treated 
with  the  indicated  concentrations  of  SDG  and  pXSC  in  the  presence  or  absence  of  SB203580  (at 
I  OpM,  added  30min  prior  to  selenium  treatment),  ccil  lysatcs  prepared  and  subjected  to  western 
blotting  using  anti-Fasl  and  total  p38  kinase  (for  loading)  antibodies.  C,  represents  treatment 
with  solvent  vehicle,  DMSO.  The  figures  below  the  lanes  indicate  the  fold  increase  in  Fasl 
expression  above  control  level  after  selenium  treatment,  normaliscd  to  the  loading. Chapter  5  109 
protection  from  pXSC-induced  apoptosis  by  TAM67  and  dnFADD  (see  Sections  5.3.3  and 
4.5.2)  overexpression  compared  to  SDG-induced  apoptosis. 
The  role  of  p38  kinase  activation  in  the  induction  of  Fasl  was  tested  by  pre-treating  cells 
with  SB203580  prior  to  addition  of  the  selenium  compounds.  No  differences  in  the  levels 
of  Fasl  induction  resulted  from  inhibiting  p38  kinase  activity  (Fig  5.4.1B). 
This  set  of  data  therefore  implicate  the  JNK  pathway  to  be  responsible  for  the  induction  of 
Fasl  (via  c-jun  transcriptional  activity)  which,  at  least  partially,  contributes  to  the  induction 
of  apoptosis  by  chemopreventive  selenium  compounds. 
5.5  ERKs  1/2  in  selenium-induced  programmed  cell  death 
Historically,  ERKs  1  and  2  have  been  considered  to  be  the  major  mediators  of  cellular 
proliferation  (Cross  et  al.,  2000;  English  et  al.,  1999).  However,  in  the  recent  years  ERKs 
have  also  been  found  to  be  actively  involved  in  apoptosis  inhibition  (Cross  et  al.,  2000; 
Dhanasekaran,  1998).  This  view  is  rapidly  gaining  momentum  particularly  with  the  recent 
Raf  (the  upstream  activator  of  ERKs)  knockout  studies  where  greatly  enhanced  apoptotic 
sensitivity  has  been  noted  (Huser  et  al.,  2001;  Mikula  et  al.,  2001;  Wojnowski  et  al.,  1997). 
ERK  activity  has  often  been  found  to  be  inhibited  in  cells  undergoing  apoptosis  on 
exposure  to  a  range  of  cytotoxic  stimuli  (Cross  et  al.,  2000).  Conversely,  forced  activation 
of  ERK  inhibits  apoptosis  in  response  to  a  wide  range  of  stimuli  including  oxidative  stress 
and  chemotherapeutic  drugs  (Cross  et  al.,  2000). 
5.5.1  ERKs  112  activities  are  altered  on  selenium  exposure 
In  order  to  determine  whether  ERK  1/2  activities  were  altered  on  selenium  treatment,  HeLa 
cells  were  serum  starved  overnight  (to  reduce  basal  levels  of  ERK  activity)  and  then 
treated  with  SDG  and  pXSC  at  concentrations  that  induce  apoptosis.  Both  the  compounds 
resulted  in  the  activation  ERKs  1  and  2  after  treatment  for  2h  as  measured  by  Western 
blotting  using  phospho-specific  antibodies  (Fig  5.5.1A).  The  activation  by  SDG  was 
stronger  than  that  by  pXSC  under  these  conditions. 
In  order  to  see  if  these  compounds  prevented  the  activation  of  ERKs  1  and  2  by  mitogenic 
stimuli,  as  would  be  the  case  in  the  tumour  environment,  serum-starved  cells  were  pre- 
treated  with  selenium  prior  to  the  addition  of  epidermal  growth  factor  (EGF).  Compared  to 110 
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Fig  5.5.1  Effect  of  selenium  compounds  on  ERKI/2  activity. 
(A)  HeLa  cells  were  serum-starved  for  16h  and  then  treated  with  the  indicated  concentrations  of 
SDG  or  pXSC  for  2h,  in  some  cases  followed  by  I  Ong/ml  EGF  treatment  for  20min.  Cell  lysates 
were  prepared  and  run  on  SDS/PAGE  gels  and  Western  blotted  using  antibodies  that  recognise 
total  ERKI/2  or  only  the  activated  form  (ERKI/2*).  (B)  HeLa  cells  were  serum-starved  for  16h 
and  then  treated  as  indicated.  ERKI/2  activities  were  measured  as  in  (A). Chapter  5  ill 
EGF  only  control,  treatment  with  SDG  and  pXSC  showed  a  dose  dependent  inhibition  of 
ERK  activation  by  EGF  (Fig  5.5.1A). 
Treatment  of  HeLa  cells  by  SDG  and  pXSC  for  longer  time  periods  showed  a  substantial 
degree  of  ERK  1/2  activity  which  is  maintained  over  the  entire  period  of  the  treatment  (Fig 
5.5.1B).  Again  SDG  seemed  to  be  a  more  potent  inducer  of  ERK  activity  than  pXSC 
though  not  to  the  extent  as  seen  during  treatments  for  shorter  times. 
Thus  a  complex  scenario  of  ERKs  1/2  activity  modulation  by  selenium  compounds  is 
emerging.  On  one  hand  apoptosis-inducing  doses  induce  activation  but,  on  the  other, 
selenium  compounds  retard  activation  by  mitogens  like  EGF.  Changes  in  ERK  activity  in 
the  continuous  presence  of  mitogens,  over  a  time  period  that  induces  substantial  apoptosis, 
could  not  be  resolved  as  prolonged  exposure  to  mitogens  (like  measuring  ERK  activity  in 
cells  growing  in  the  presence  of  serum)  led  to  an  overwhelming  activation  that  did  not 
allow  quantitative  discrimination  between  the  activity  levels  to  be  made. 
5.5.2  Complete  inhibition  of  ERKs  112  has  only  a  small  effect  on  selenium- 
induced  apoptosis 
In  order  to  investigate  the  functional  relevance  of  modulation  of  ERK  1/2  activity  to 
selenium-induced  apoptosis  the  effect  of  complete  inhibition  of  ERK  activity  on  apoptotic 
signalling  was  investigated.  If  complete  inhibition  resulted  in  decreased  apoptosis  then  this 
would  indicate  that  ERK  activation  was  pro-apoptotic,  whilst  increased  apoptosis  would 
implicate  a  protective  function. 
The  well  characterised  MEK  inhibitor,  PD98059,  when  added  prior  to  selenium  treament 
completely  abolished  ERK  1/2  activation  by  both  SDG  and  pXSC  (Fig  5.5.2A).  This  was 
associated  with  slight  sensitisation  (-  20%)  of  HeLa  cells  to  selenium-induced  apoptosis 
(Fig  5.5.2B).  This  difference  was  only  statistically  significant  for  some  of  the 
concentrations  of  the  selenium  compounds  used  (p=0.039  and  0.041  for  SDG  5[tM  and 
pXSC  35[tM,  respectively).  The  other  doses,  though  showing  the  same  trend,  were  not 
significant  (p=0.054  and  0.05  for  SDG  3.5[LM  and  pXSC  SOVM,  respectively).  This 
suggests  the  ERK  activation  may  be  a  survival  response,  albeit  an  ineffective  one.  Given 
the  small  difference  in  sensitivity,  further  complicated  by  statistical  variation  over 
concentration  ranges,  the  biological  significance  of  the  phenomenon  remains  unclear. 112 
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Fig  5.5.2  Effect  of  inhibition  of  ERK1/2  activity  on  apoptosis  induction  by  SDG  and  pXSC. 
(A)  Serum-starved  HeLa  cells  were  pre-treated  with  50ýLM  PD98059  for  30min  and  then  treated 
with  indicated  concentrations  of  SDG  and  pXSC  for  16h.  The  effect  on  activation  of  ERKI/2 
was  determined  by  western  blotting  using  antibodies  that  recognise  phospho-specific  (ERKI/2*) 
or  total  ERK.  (B)  Induction  of  apoptosis  following  treatment  with  indicated  concentrations  of 
selenium  compounds  for  16h,  in  the  presence  or  absence  of  the  ERK  inhibitor,  was  measured  by 
TUNEL  assay.  Each  treatment  was  performed  in  triplicate.  Data  presented  is  representative  of  3 
independent  experiments.  Error  bars  indicate  standard  errors.  H,  represents  a  positive  control 
treatment  with  200mM  H202  for  16h.  C,  in  all  cases,  represents  treatment  with  solvent  vehicle, 
DMSO. 
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Thus,  while  ERK  1/2  activation  may  be  involved  in  anti-apoptotic  survival  signalling  in 
response  to  selenium  compounds  -  its  contribution  is  relatively  small.  It  is  possible  that  the 
overall  effect  of  selenium  is  inhibition  of  ERK  activity  which  could  not  be  directly 
assessed  in  our  earlier  experiments.  Therefore,  forcible  activation  of  the  ERK  pathway, 
using  constitutively  activated  constructs  of  upstream  activators,  may  reveal  a  functional 
role.  However,  the  overall  inhibition,  if  any,  can  only  be  partial  as  no  differences  in  ERK 
activity  can  be  seen  on  treating  cells  growing  in  serum  with  selenium.  If  inhibition  of  ERK 
activity  by  selenium  compounds  were  functionally  significant,  the  complete  abolition  of 
ERK  activity  by  PD98059  would  have  been  expected  to  reveal  a  strong  sensitisation,  to 
apoptosis  unlike  the  small  trend  observed.  Thus  it  is  likely  that  the  overall  effect  of 
selenium  treatment,  in  the  presence  of  continued  mitogenic  stimulation,  is  not  a 
functionally  relevant  inhibition  of  ERK  activity. 
The  mechanisms  mediating  the  anti-apoptotic  function  of  ERK  activity  is  unclear.  There  is 
evidence  that  caspase  3  activation  may  cleave  and  inactivate  Raf-1,  and  hence  block  ERK 
activation  (Widmann  et  al.,  1998).  ERK  has  also  been  shown  to  inhibit  caspase  activation 
following  cytochrome  c  release  possibly  by  a  phosphorylation  dependent  mechanism 
(Erhardt  et  al.,  1999).  All  these  possibilities  could  be  addressed  by  standard  caspase  assays 
used  in  conjunction  with  specific  caspase  inhibitors.  The  activities  of  the  B62  family 
members  may  also  be  regulated  post-translationally  by  the  ERK  pathway  (Scheid  and 
Duronio,  1998).  However,  in  view  of  the  small  functional  contribution  of  ERK  1/2 
activation  on  apoptosis  induction  by  chernopreventive  selenium  compounds  such  studies 
were  considered  to  be  of  lower  priority. 
5.6  Big  Mitogen  Kinase  1  (or  ERK5)  in  SDG  and  pXSC  mediated 
cell  death 
Recently,  a  new  member  of  the  MAPK  family,  named  the  Big  Mitogen  Kinase  1  (BMK1) 
or  ERK5,  has  been  described  (Han  et  al.,  1996;  Lee  et  al.,  1995).  Apart  from  being 
activated  by  mitogens,  like  EGF  (Kato  et  al.,  1997;  Kato  et  al.,  1998),  it  is  also  redox 
sensitive  and  induced  by  oxidants  (Abe  et  al.,  1996).  The  role  of  ERK5  in  cellular 
proliferation  has  been  particularly  well  characterised  in  HeLa  cells  where  it  appears  to  be 
the  major  pathway  mediating  EGF  induced  proliferation  (Kato  et  al.,  1998).  Though  no 
direct  role  of  ERK5  in  anti-apoptotic  signalling  has  been  elucidated  and  its  downstream 
targets  remain  elusive,  it  could  potentially  be  an  important  regulator  of  apoptosis. Chapter  5  114 
5.6.1  Selenium  compounds  inhibit  BMK1  (or  ERK5)  activity 
Phosphorylation  (and  thereby  activation)  of  ERK5  results  in  a  shift  in  electrophoretic 
mobility  detectable  by  western  blotting.  This  shifted  fraction  of  phosphorylated  ERK5  is 
consistently  correlated  to  its  activity  as  measured  by  kinase  assays  (Kato  et  al.,  1998). 
However,  by  this  assay,  serum-starved  cells  treated  with  SDG  and  pXSC  showed  no 
increase  in  ERK5  (Fig  5.6.1A).  An  EGF  treated  control  showed  a  reproducible  shift  in 
ERK5  mobility  indicating  activation  (Fig  5.6.1A). 
To  investigate  if  selenium  compounds  affected  mitogen  mediated  activation  of  ERK5, 
serum-starved  cells  were  pre-treated  with  SDG  and  pXSC  prior  to  stimulation  with  EGF. 
Compared  to  the  EGF  control,  selenium-treatment  caused  an  acute  dose-dependent 
inhibition  of  ERK5  activation  by  EGF  (Fig  5.6.1A).  This  inhibition  of  EGF  stimulation 
was  confirmed  by  an  endogenous  ERK5  'pull  down'  kinase  assay  using  myelin  basic 
protein  (MBP)  as  a  substrate  (Fig  5.6.1B). 
Similar  experiments  also  tested  whether  the  selenium  compounds  could  inhibit  ERK5 
activity  in  the  continued  presence  of  mitogens.  HeLa  cells  grown  in  10%  foetal.  bovine 
serum  (FBS)  were  treated  with  apoptosis-inducing  doses  of  SDG  and  pXSC.  This  revealed 
that,  even  with  persistent  mitogenic  stimulation,  selenium  compounds  still  attenuated 
ERK5  activity  (Fig  5.6.1C). 
These  studies  therefore  demonstrated  that  both  pXSC  and  SDG  potently  inhibit  ERK5 
activity  at  doses  that  induce  substantial  apoptosis.  This  raises  the  intriguing  possibility  of 
ERK5  inhibition  being  a  functional  component  of  selenium  initiated  pro-apoptotic 
signalling. 
5.6.2  Constitutive  activation  of  ERK5  protects  from  selenium-induced 
apoptosis 
The  MAPK  kinase  MEK5  is  the  immediately  upstream  activator  of  ERK5.  A  constitutively 
activated  mutant  of  MEK5,  MEK5(D),  has  been  generated  by  substituting  the  conserved 
phosphorylation  sites,  serine  313  and  threonine  317,  with  aspartate  residues  (Kato  et  al., 
1997).  A  mutant  ERK5,  ERK5(AEF),  with  its  tyrosine  and  threonine  phosphorylation  sites 
mutated  to  alanine  and  phenylalanine  has  also  been  developed.  These  were  made  available 
to  us  by  a  kind  gift  from  Dr  J-D.  Lee  (Scripps  Research  Institute,  USA).  We  used  the 
ERK5(AEF)  expression  construct  along  with  wild  type  ERK5  expression  constructs,  in 115 
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Fig  5.6.1  Inhibition  of  ERK5  activity  by  chemopreventive  selenium  compounds. 
(A)  HeLa  cells  were  serum  starved  for  16h  and  then  treated  with  the  indicated  concentrations  of 
SDG  or  pXSC  for  2h,  in  some  cases  followed  by  I  OngImI  EGF  treatment  for  20min.  Cell  lysates 
were  prepared  and  run  on  a  6%  SDS/PAGE  gel  (see  Section  3.2.5.1).  Activation  of  ERK5  was 
measured  by  its  change  in  migration  detected  by  Western  blotting  with  anti  ERK5  antibody.  (B) 
Serum  starved  cells  were  treated  as  in  (A)  and  an  immunecomplex  kinase  assay  using  MBP  as  a 
substrate  performed  to  measure  ERK5  kinase  activity.  (C)  HeLa  cells  growing  in  10%  FBS 
were  treated  with  indicated  concentrations  of  SDG  and  pXSC  for  16h  and  western  blot  analysis 
performed  as  before  to  compare  ERK5  activities.  Serum-starved  cells  were  also  analysed  as  a 
control.  The  level  of  total  p38  was  used  as  the  loading  control.  C,  in  all  cases,  represents 
treatment  with  solvent  vehicle,  DMSO. Chapter  5  116 
transient  transfection  studies  where  ERK5  activity  was  persistently  activated  by 
overexpressing  MEK5(D).  Co-expression  with  GFP  constructs,  as  described  earlier,  was 
used  to  identify  transfected  cells. 
The  expression  of  these  proteins  after  transfection  was  confirmed  by  western  blotting  using 
antibodies  against  their  specific  tags  (HA-tag  for  MEK5(D)  and  Flag-tag  for  the  two  ERK5 
constructs)  (Fig  5.6.2A).  The  specificity  of  persistent  ERK5  activation  by  the  constitutively 
activated  MEK5  construct  was  addressed  by  immunecomplex  kinase  assays  for  ERK5 
activity  (Fig  5.6.2B).  Only  the  combination  of  MEK5(D)  and  wild  type  ERK5  showed 
substantial  activity. 
FACS  analysis  of  accumulation  of  subGO/G1  DNA  content  within  the  GFP  positive 
population  revealed  that  constitutive  activation  of  ERK5  resulted  in  a  small  (-  20%)  but 
reproducible  protection  from  SDG  and  pXSC  induced  apoptosis  (Fig  5.6.2C).  This 
protection  was  consistent  over  different  doses  and  was  statistically  significant  (P=0.03  and 
0.04  for  SDG  5[tM  and  7VM,  respectively  and  p=0.04  for  both  35[tM  and  50[tM  pXSC). 
The  levels  of  apoptosis  in  the  ERK5(AEF)  mutant  expressing  cells  showed  no  consistent  or 
statistically  significant  differences. 
T11is  very  specific,  albeit  small,  protection  of  constitutive  activation  of  ERK5  suggests  that 
inactivation  of  ERK5  by  chernopreventive  selenium  compounds  may  be  of  biological 
relevance. 
It  is  possible  the  protection  observed  is  an  artefact  of  alterations  in  proliferation  potential 
as  thymidine  incorporation  levels  are  enhanced  on  constitutive  ERK5  activation.  However, 
the  rate  of  inhibition  of  DNA  synthesis  did  not  vary  between  empty  vector  and  MEK5(D) 
+  ERK5(AEF)  transfected  cells  (data  not  shown).  Furthermore,  in  general,  rapidly  cycling 
cells  show  enhanced  sensitivity  to  apoptosis  compared  to  slowly  cycling  cells,  whereas,  in 
these  experiments  the  converse  is  the  case. 
Given  the  dearth  of  knowledge  of  downstream  ERK5  targets,  how  ERK5  may  mediate 
anti-apoptotic  signalling  is  unclear.  However,  transcription  factors,  MEF2C  and  myc 
(English  et  al.,  1998;  Kato  et  al.,  2000),  are  known  downstream  targets  of  ERK5  and  have 
been  implicated  in  mediating  cell  survival/apoptosis.  Suppression  of  activities  of  these 
proteins  by  ERK5  inhibition  may  therefore  constitute  a  survival  signal  of  some  biological 
significance.  These  would  perhaps  therefore  be  reasonable  starting  points  to  further  dissect 
ERK5's  role  in  anti-apoptotic  signal  transduction. 117 
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Fig  5.6.2  Effect  of  constitutive  activation  of  ERK5  on  selenium-induced  apoptosis. 
(A)  HeLa  cells  were  transiently  co-transfected  with  GFP  and  HA-tagged  MEK5(D)  or  an  empty 
vector  together  with  either  Flag-tagged  ERKS  or  Flag-tagged  ERK5(AEF).  Transfected  cells 
were  sorted  using  FACS  to  enrich  the  GFP  positive  cells.  Western  blotting  using  anti-HA  tag  or 
anti-Flag  tag  antibody  was  carried  out  to  analyse  MEK5(D),  ERK5  and  ERK5(AEF)  expression 
between  empty  vector  transfected  (V)  and  cells  transfected  with  the  various  constructs.  U  is 
transfected  cells  prior  to  FACS  sorting.  S,  transfected  cells  after  FACS  enrichment.  MEK5(D)  is 
a  constitutively  activated  mutant,  ERK5  is  wild  type  and  ERK5(AEF)  is  a  phosphorylation 
defective  mutant.  (B)  ERK5  kinase  assay  using  MBP  as  a  substrate  was  carried  out  on  cells 
expressing  combinations  of  the  various  constructs.  (C)  Measurement  of  apoptosis  induction  was 
performed  by  analysing  the  subGO/GI  DNA  content  in  the  GFP  positive  fraction  of  cells.  Each 
treatment  was  performed  in  triplicate.  Data  presented  is  representative  of  2  independent 
experiments.  Error  bars  indicate  standard  errors.  *,  indicate  significance,  p<0.05.  C,  represents 
treatment  with  solvent  vehicle,  DMSO. 
c 
SDG  SDG  PXSC  PXSC 
5ýM  7pM  35[tM  5ogm Chapter  5  118 
5.7  Role  of  Akt  in  selenium  mediated  programmed  cell  death 
Protein  kinase  B  (PKB)/Akt  is  a  serine  threonine  kinase  (not  of  the  MAPK  family)  whose 
activity  is  very  closely  linked  to  enhanced  cell  survival  (Downward,  1998).  Akt  is 
activated  downstream  of  phosphoinositide  3-kinase  (P13K)  in  signalling  cascades  effected 
by  a  wide  range  of  receptors,  including  those  for  growth  and  survival  factors  (Alessi  and 
Cohen,  1998).  The  downstream  actions  of  PKB  appear  to  include  phosphorylation  of 
proteins  involved  in  the  apoptotic  cascade  (like  Bad)  (del  Peso  et  al.,  1997)  and  regulation 
of  expression  of  apoptotic  proteins  (by  inhibiting  transcription  factors  like  forkhead 
(Brunet  et  al.,  1999)  and/or  activating  others  like  NF-KB  (Romashkova  and  Makarov, 
1999)).  Thus  Akt  is  key  mediator  of  cell  survival  and  it  comes  as  no  surprise  that  it  can  be 
cleaved  and  inactivated  by  caspase  3  during  apoptosis  (Widmann  et  al.,  1998). 
Several  members  of  the  P13K-Akt  signalling  pathway  has  been  shown  to  upregulated  in  a 
variety  of  human  cancers,  and  this  is  correlated  to  enhanced  cellular  survival  (Cantley  and 
Neel,  1999;  Shayesteh  et  al.,  1999;  Staal,  1987).  Several  apoptotic  stimuli  inhibit  Akt 
activity,  whose  overexpression  leads  to  protection  (Cross  et  al.,  2000).  Other  apoptotic 
insults,  like  H202,  activate  Akt  as  a  survival  response  and  its  inhibition  leads  to  enhanced 
sensitivity  (Shaw  et  al.,  1998). 
5.7.1  Enhanced  Akt  activity  on  selenium  exposure 
To  investigate  the  role  of  Akt  in  selenium-induced  apoptosis  Hela  cells  were  serum- 
starved  overnight  to  reduce  Akt  activity  to  basal  levels,  followed  by  treatment  with 
chernopreventive  selenium  compounds.  Treatment  with  both  SDG  and  pXSC  increased  the 
phosphorylated  fraction  of  Akt  whereas  total  Akt  remained  constant  (Fig  5.7.1A,  B).  This 
implicated  a  dose-dependent  activation  of  Akt,  particularly  on  pXSC  exposure.  SDG  only 
weakly  activated  Akt. 
To  assess  if  Akt  activation  by  mitogens  was  reduced  by  the  selenium  compounds,  serum- 
starved  cells  were  pre-treated  with  SDG  and  pXSC  prior  to  stimulation  with  10%  FBS. 
Phospho-specific  antibodies  revealed  no  change  in  the  levels  of  Akt  activations  between 
EGF  only  control  and  those  pre-treated  with  selenium  (Fig  5.7.1A,  B). 
These  experiments  concluded  that  selenium  compounds,  especially  pXSC,  rapidly 
activated  Akt  but  do  not  inhibit  Akt  activation  by  mitogenic  stimulation. 119 
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Fig  5.7.1  Activation  of  Akt  by  SDG  and  pXSC  treatment. 
HeLa  cells  were  serum  starved  for  16h  and  then  treated  as  indicated  with  SDG  (A)  or  pXSC  (B), 
in  some  cases  followed  by  10%  FBS  treatment  for  3  Omin.  Cell  lysates  were  prepared  and  run  on 
SDS/PAGE  gels  and  Western  blotted  using  antibodies  that  recognise  total  Akt  or  only  the 
activated  form  (Akt*). Chapter  5 
5.7.2  Pharmacologic  inhibition  of  Akt  activation 
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LY294002  is  a  well  characterised,  specific  inhibitor  of  P13K  activity,  which  is  necessary 
for  Akt  activation  (Vlahos  et  al.,  1994).  Pre-treating  HeLa  cells  with  50[tM  of  LY294002 
completely  abolished  Akt  activation  by  either  selenium  compound  (Fig  5.7.2A). 
Quantifying  apoptosis  in  HeLa  cells  treated  with  cytotoxic  doses  of  SDG  and  pXSC,  the 
inhibition  of  Akt  activity  was  found  to  have  no  significant  effect  on  the  levels  of  cell  death 
observed  (Fig  5.7.213).  In  contrast,  a  H202  positive  control  in  the  same  experiment  showed 
a  40%  increase  in  cell  death  by  LY294002  treatment  (Fig  5.7.213). 
This  suggests  that,  although  Akt  activity  is  associated  with  selenium  exposure,  it  is 
unlikely  that  this  has  any  substantial  contribution  to  apoptosis  induction.  Perhaps  activation 
of  Akt,  is  a  failed  survival  response  that  is  overwhelmed  by  the  acute  apoptotic  stimuli. 
It  is  possible  that  Akt  activation  is  an  artefact  of  general  P13K  activity  which  regulates 
other  aspects  of  cellular  physiology  not  detected  in  the  cell  death  assays  used  in  these 
experiments.  Akt,  acting  through  GSK3,  has  been  implicated  in  inhibiting  DNA  binding 
activity  of  c-jun  (Nikolakaki  et  al.,  1993).  This  attenuation  of  AP-1  transactivation,  taken 
together  with  the  increased,  pro-apoptotic  c-jun  activity  seen  on  exposure  to  selenium 
compounds,  underscores  the  suggestion  that  the  Akt  activation  observed  in  our  study  may 
be  a  failed  survival  response. 
5.8  Conclusion 
This  chapter  describes  an  investigation  of  the  major  signalling  pathways  that  may  mediate 
selenium-induced  apoptosis.  Chernopreventive  selenium  compounds,  SDG  and  pXSC, 
induced  global  changes  in  several  of  major  signalling  pathways  and  functional  evidence 
suggests  that  at  least  some  of  these  modulations  directly  mediate  selenium-induced 
programmed  cell  death. 
The  stress  activated  protein  kinase  (SAPK),  JNIC,  was  shown  to  be  a  major  player  acting 
and  through  Fasl  induction  via  c-jun  transactivation.  However,  compared  to  SDG,  the 
importance  of  this  pathway  for  pXSC-induced  cell  death  is  considerably  less.  Although 
p38  activity  was  induced  by  both  the  compounds,  experiments  using  a  p38  specific 
inhibitor  did  not  reveal  any  functional  role  for  this  kinase.  Inhibition  of  ERK  1/2  activity 
showed  a  possible  sensitisation  whereas  the  forced  activation  of  ERK5  resulted  in  a  small, 121 
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Fig  5.71  Effect  of  inhibition  of  Akt  activity  on  apoptosis  induction  by  SDG  and  pXSC. 
(A)  Serum-starved  HeLa  cells  were  pre-treated  with  50pM  LY294002  for  30min  and  then 
treated  with  indicated  concentrations  of  SDG  and  pXSC  for  16h.  The  effect  on  activation  of  Akt 
was  determined  by  Western  blotting  using  antibodies  that  recognise  phospho-specific  (Akt*)  or 
total  Akt.  (B)  Induction  of  apoptosis  following  treatment  with  indicated  concentrations  of 
selenium  compounds  for  16h,  in  the  presence  or  absence  of  the  Akt  inhibitor,  was  measured  by 
TUNEL  assay.  Each  treatment  was  performed  in  triplicate.  Data  presented  is  representative  of  2 
independent  experiments.  Error  bars  indicate  standard  errors.  C,  represents  treatment  with 
solvent  vehicle,  DMSO. 
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but  consistent,  protection.  Akt,  though  activated  by  both  compounds,  does  not  seem  to  be 
adequate  to  affect  apoptosis  as  revealed  by  inhibiting  its  activation. 
It  is  believed  that  an  intimate  interaction  between  pro-  and  anti-  apoptotic  signals 
determines  the  cell  fate  and  probably  reflects  the  importance  of  the  evolutionary  conserved 
genetic  programme  leading  to  apoptosis.  Thus,  it  is  only  to  be  expected  that  several 
signalling  modules  will  orchestrate  signal  transduction  in  a  concerted  manner,  thereby 
increasing  the  complexity.  The  complexity  itself  enforces  a  tight  control  over  the  entire 
process  which,  if  disregulated,  would  be  of  disastrous  consequence  to  the  organism.  When 
seen  from  this  perspective,  it  is  quite  possible  that  the  small  functional  trends  described  for 
some  of  the  kinases  may  have  a  physiological  role  which  a  reductionist  approach  of 
studying  individual  kinases  in  isolation  may  fail  to  resolve. 
Several  other  pathways  have  also  been  implicated  in  apoptotic  signalling  and  it  will  be 
interesting  to  look  at  the  relative  contributions  of  these  pathways.  For  example,  as 
described  in  Sections  2.6.7.2,2.6.7.3  and  2.6.7.4,  other  studies  have  shown  selenium 
mediated  inhibition  of  protein  kinase  A,  C2'  dependent  and  independent  protein  kinase 
C's  (PKC),  cyclin-dependent  kinase2  (cdk2)  and  thymidine  kinase  (TK).  However,  the 
significance  of  these  to  apoptosis  remains  to  be  clarified.  Another  major  modulator  of 
apoptotic  signalling  in  response  to  various  stimuli,  like  oxidative  stress,  is  the  NF-ICB 
pathway.  Selenium  compounds  (at  sub-micromolar  doses)  have  been  shown  to  inhibit  NF- 
icB  activity  (Kim  and  Stadtman,  1997),  but  the  implications  of  this  to  apoptosis  is  yet  to  be 
addressed.  Tyrosine  kinases  like  c-Abl  may  also  be  involved  as  certain  selenium 
compounds  have  been  shown  to  induce  DNA  damage. 
5.9  Chapter  Summary 
e  Chemopreventive  selenium  compounds  induce  sustained  p38  kinase  activity  but 
pharmacologic  inhibition  did  not  affect  cell  death  induction. 
The  stress  kinase,  JNK,  is  rapidly  activated  by  SDG  and  pXSC  and  leads  to  the 
phosphorylation  of  c-jun.  Dominant  negative  and  phosphorylation  defective 
mutants  of  c-jun  suppress  SDG  induced  apoptosis;  the  inhibition  is  much  smaller 
for  pXSC  treatment. 
The  induction  of  Fasl  by  SDG  is  attenuated  by  overexpression  of  a  dominant 
negative  c-jun  construct.  Fasl  induction  by  pXSC  remains  unaffected. Chapter  5  123 
'Pro-pToliferation  signalling  kinases  ERKs  1  and  2  are  induced  by  both  compounds 
but  their  activation  by  exogenous  mitogenic  stimulation  is  reduced.  Complete 
inhibition  of  ERK1/2  activities  slightly  sensitises  cells  to  apoptosis. 
ERK5  activity  is  strongly  inhibited  by  SDG  and  pXSC,  and  forced  activation  of 
ERK5  results  in  a  small,  but  consistent,  protection  from  apoptosis. 
Anti-apoptotic  signalling  mediated  by  Akt  is  induced  by  selenium  compounds 
(particularly  pXSC)  but  functional  significance  of  this  is  unclear  since  inhibition  of 
P13K  activity  does  not  influence  selenium  mediated  cell  death. 124 
6  Mechanisms  of  Selenium-induced  Apoptosis  in 
Primary  Cultures  of  Oral  Keratinocytes 
6.1  Background 
In  Chapters  4  and  5,  molecular  mechanisms  mediating  apoptosis  induction  by 
chernopreventive  selenium  compounds  were  investigated  in  the  established  human  cervical 
carcinoma  cell  line,  HeLa,  primarily  due  to  the  exploratory  nature  of  the  work  and  the  ease 
of  manipulation  of  these  cells.  These  investigations  identified  several  functional 
mechanisms  underlying  the  induction  of  apoptosis  by  these  compounds.  However,  the 
significance  of  these  studies  to  the  in  vivo  situation  remains  unclear.  This  is  because  firstly, 
epidemiological  evidence  suggests  that  selenium  mediated  anti-cancer  activity  is  restricted 
to  particular  cancer  types  (see  Section  2.2)  and  secondly,  since  established  cell  lines 
accumulate  genetic  changes  as  a  result  of  prolonged  culture,  their  relevance  to  'real'  cancer 
cells  in  vivo  is  questionable. 
In  this  study,  the  premises  adopted  was  that  induction  of  apoptosis  may  be  a  major 
mechanism  underlying  the  chernopreventive  actions  of  selenium.  The  data  presented  in 
previous  chapters  has  established  that  apoptosis-induction  by  selenium  is  functionally 
regulated  by  signal  transduction  pathways.  Thus,  one  may  argue  that  a  detailed 
investigation  into  the  regulatory  signalling  pathways  mediating  programmed  cell  death 
may reveal  how  selenium  compounds  discriminate  between  normal  and  tumours.  It  is  to 
these  ends  that  our  group  has  attempted  to  develop  an  in  vitro  primary  culture  system 
relevant  to  human  cancers  where  differences  in  sensitivity  between  normal  and  tumour 
cells  may  be  investigated. 
In  view  of  the  fact  that  lung,  upper  respiratory  tract  and  oesophageal.  cancers  are  three  of 
the  cancer  types  in  which  the  epidemiological  evidence  for  a  cancer  protective  effect  of 
selenium  is  strongest  (see  Section  2.2),  we  have  focused  on  human  oral  cancers  as  they 
share  similar  risk  factors  to  lung  and  other  head  and  neck  cancers.  It  is  also  relevant  to  note 
that  one  of  the  handful  of  intervention  trial  using  selenium  found  a  significant  inverse 
correlation  between  selenium  supplementation  and  incidence  of  oral  lesions  (see  Section 
2.2.2).  To  obtain  data  as  relevant  as  possible  to  human  squamous  cell  carcinomas  (SCC),  a 
panel  of  primary  cultures  of  biopsies  of  oral  squamous  cancers  and  normal  oral  mucosa 
cells  (NOMC)  which  have  been  characterised  previously  at  the  Beatson  Institute  were  used 
(Edington  et  al.,  1995;  McGregor  et  al.,  1997).  Putative  functional  pathways  defined  earlier Chapter  6  125 
in  HeLa  cells  (Chapters  4  and  5)  were  tested  in  this  oral  cell  model  to  establish  their 
relevance  to  chemoprevention  in  humans. 
The  panel  of  primary  cultures  of  biopsies  of  NOMCs  and  SCCs  were  maintained  using  the 
373  feeder  layer  system  (see  Section  3.2.1).  The  irradiated  373  feeder  layer  was  carefully 
removed  by  EDTA  treatment  prior  to  experiments  commencing  with  the  remaining  oral 
cells,  typically  at  60-70%  confluence.  The  NOMCs  were  used  within  2-3  passages  from 
frozen  stocks,  while  they  were  still  proliferating  rapidly,  prior  to  senescence  occurring. 
6.2  Enhanced  sensitivity  of  human  oral  carcinomas  to  induction 
of  apoptosis  by  selenium  compounds 
Two  independently-derived  primary  cultures  of  SCCs  (BICR31  and  BICR56)  and  NOMCs 
(FNB5  and  FNB6)  were  treated  with  SDG  and  pXSC  and  the  extent  of  apoptosis  measured 
by  AnnexinV  staining.  While  both  the  compounds  induced  cell  death  in  oral  keratinocytes, 
SCCs  were  markedly  more  sensitive  to  SDG  than  NOMCs  (p<<0.001,  for  pooled  SCC  and 
NOMC  data)  whereas  any  differences  in  sensitivity  to  pXSC  were  marginal  and  not 
statistically  significant  (p=0.5  1,  for  pooled  SCC  and  NOMC  data  )(Fig  6.2.1). 
This  result  has  since  been  confirmed  by  TUNEL  assay  using  these  and  other 
independently-derived  SCCs  and  NOMCs  (Ghose  et  al.,  2001a).  We  have  also  observed 
that  increased  sensitivity  of  SCCs  to  SDG  treatment  can  be  reproduced  at  the  level  of 
growth  inhibition,  as  measured  by  tritiated  thymidine  uptake.  Again,  as  with  apoptosis,  no 
consistent  differences  in  sensitivity  was  seen  between  SCCs  and  NOMCs  on  pXSC 
treatment. 
It  might  be  argued  that  the  NOMCs  may  be  progressing  through  the  cell  cycle  more  slowly 
and  were  thereby  more  resistant  to  apoptosis.  However,  this  is  unlikely  as  pXSC  did  not 
show  any  tumour  selectivity  and,  more  importantly,  thymidine  uptake  levels  of  the  SCCs 
and  NOMCs  are  comparable  at  the  conditions  they  were  used  to  measure  apoptosis  (data 
not  shown). 
Thus  we  have  developed  an  in  vitro  system,  relevant  to  selenium  mediated 
chernoprevention  in  humans  which  can  be  used  to  dissect  molecular  mechanisms 
responsible  for  selective  apoptosis  induction.  Recently,  since  this  work  was  completed,  an 
independent  study  has  shown  similar  turnour  selectivity  of  apoptosis  induction  by  selenite 
and  selenomethionine  comparing  primary  cultures  of  normal  prostate  cells  to  prostate 126 
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Fig  61.1  Sensitivity  of  NOMCs,  and  SCCs  to  selenium  induced  apoptosis. 
The  degree  of  apoptosis  after  treatment  of  NOMCs  or  SCCs  with  solvent  control  (C),  SDG  or 
pXSC  for  16h  was  quantitated  by  the  AnnexinV  staining  protocol.  Error  bars  indicate  standard 
errors.  Each  treatment  was  performed  in  triplicate.  Data  presented  is  representative  of  2 
independent  experiments.  C,  represents  treatment  with  solvent  vehicle,  DMSO. 
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cancer  cell  lines  (Menter  et  al.,  2000).  As  SDG  is  the  primary  physiological  metabolite  of 
selenite  this  evidence  corroborates  our  conclusions.  It  remains  unclear  why  pXSC,  though 
potently  chemopreventive  in  animal  studies,  does  not  show  such  a  selectivity.  This  could 
be  a  reflection  of  differing  tumour-type  specificity  between  SDG  and  pXSC. 
6.3  Fasl  mediates  selenium-induced  programmed  cell  death  in 
oral  keratinocytes 
Fasl  was  induced  readily  on  selenium  treatment  and  was  shown  to  be  a  functional  mediator 
of  cell  death  in  HeLa  cells,  therefore,  this  was  tested  in  the  primary  cultures.  Both  SDG 
and  pXSC  induced  Fasl  in  SCCs  and  NOMCs  (Fig  6.3.1A,  B)  at  apoptosis  inducing  doses. 
Strikingly,  the  induction  of  Fasl  by  SDG  in  SCCs  was  considerably  greater  than  that  in 
NOMCs  (3  and  6.3  times  more  at  SDG  concentrations  5[tM  and  8[tM,  respectively)(Fig 
6.3.1A).  No  such  differences  between  SCCs  and  NOMCs  were  seen  with  pXSC  treatment 
(Fig  6.3.1B).  Tbus  the  degree  of  Fasl  induction  appears  to  correlate  closely  with  the  extent 
of  apoptosis  induced  by  selenium  compounds. 
As  transfection  efficiencies  of  these  primary  keratinocytes  is  extremely  poor,  a  Fas/Fc 
chimeric peptide  was  used  to  block  the  engagement  of  Fas  receptor  by  Fasl  (Itoh  et  al., 
1991).  Apotosis  mediated  by  addition  of  recombinant  soluble  Fasl,  as  a  control,  was 
attenuated  on  pretreating  oral  cells  with  Fas/Fc.  The  extent  of  apoptosis  induced  by  SDG 
(43%  inhibition;  p=0.021)  and  pXSC  (39%  inhibition;  p=0.044)  was  significantly  reduced 
by  blocking  receptor  engagement  by  Fasl  (Fig  6.3.1Q.  This  confirmed  that  selenium- 
induced  apoptosis  was  mediated  by  Fasl  in  oral  cells.  However,  the  protection  confered  by 
blocking  Fas  activation  on  selenium-induced  apoptosis  was  less  than  that  achieved  for 
exogenous  sFast  treatment  (Fig  6.3.1C):  this  suggests  that  Fas-independent  pathways  may 
also  contribute  to  selenium-mediated  apoptosis. 
In  keeping  with  the  mechanistic  role  of  Fasl  in  inducing  apoptosis  in  oral  cells  it  appears 
that  the  relative  levels  of  Fasl  induction  determines  the  extent  of  apoptosis.  This  may  well 
explain  why  SDG,  and  not  pXSC,  exhibits  turnour  selectivity.  A  point  of  interest  is  that  in 
the  oral  cells  the  importance  of  the  Fas  pathway  is  comparable  between  SDG  and  pXSC, 
whereas  in  HeLa  cells  it  appeared  to  be  more  important  to  SDG-induced  apoptosis  than 
pXSC  (Fig  4.5.2Q. 128 
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Fig  63.1  Induction  of  Fas  ligand  by  SDG  and  pXSC  in  oral  keratinocytes. 
NOMCs  and  SCCs  were  treated  with  the  stated  concentrations  of  SDG  (A)  or  pXSC  (B)  for 
16h,  cell  lysates  prepared  and  Western  blotted  with  either  an  anti-Fasl  antibody  or  antibody 
against  total  p38  kinase  as  a  loading  control.  The  figures  below  the  blots  indicate  the  fold 
increase  in  Fasl  expression  above  untreated  level,  after  selenium  treatment,  normalised  to  the 
loading  control.  (C)  Protection  against  SDG-  and  pXSC-induced  apoptosis  (measured  by  the 
TUNEL  assay)  after  pre-treatment  of  SCCs  with  a  Fas/Fc  chimera  (250ng/ml)  for  lh  followed 
by  the  indicated  concentrations  of  SDG  or  pXSC  for  16h.  As  a  positive  control  cells  were  also 
treated  with  soluble  Fasl  (sFasL).  Each  treatment  was  performed  in  triplicate.  Data  presented  is 
representative  of  2  independent  experiments.  Error  bars  indicate  standard  errors.  C,  represents 
treatment  with  solvent  vehicle,  DMSO. 
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6.4  Stress  kinases  mediate  selenium-induced  programmed  cell 
death  in  oral  keratinocytes 
In  HeLa  cells,  the  activities  of  stress  kinases,  JNK  and  p3S,  were  induced  on  treatment 
with  selenium  compounds.  While  no  functional  role  for  p38  activation  could  be 
determined,  inhibition  of  the  JNK  pathway  at  the  level  of  c-jun  led  to  an  attenuated 
apoptotic  response  involving  inhibition  of  Fasl  induction. 
6.4.1  Induction  of  JNK  and  p38  activity  by  SDG  and  pXSC 
Using  phosphospecific  antibodies,  the  activation  of  p38  and  JNK  after  selenium  exposure 
was  tested  in  the  primary  cultures  of  the  oral  cells.  Both  SDG  and  pXSC  caused  activation 
of  JNK  and  p38  in  both  normal  and  carcinoma  cells  under  conditions  in  which  apoptosis 
was  induced  (Fig  6.4.1A,  B).  There  was  no  significant  differences  between  NOMCs  and 
SCCs  in  the  extent  of  induction  of  JNK  and  p38  kinase  by  pXSC  (Fig  6AAA,  B). 
However,  SDG  was  reproducibly  more  efficient  at  activating  JNK  and  p38  in  SCCs  than 
NOMCs  (Fig  6.4.1B),  thus  mirroring  the  greater  sensitivity  of  SCCs  to  induction  of 
apoptosis  by  SDG  (Fig.  6.2.1). 
6.4.2  JNK,  but  not  p38,  mediates  selenium-induced  cell  death  In  oral 
keratinocytes 
All  further  functional  experiments  were  mainly  performed  using  SCCs  in  view  of  their 
increased  sensitivity  to  apoptosis  induction,  particularly  by  SDG.  As  transfection 
strategies,  such  as  those  used  in  the  HeLa  cell  experiments  described  in  Section  5.3.2, 
could  not  be  utilised  due  to  low  transfection  efficiencies  a  pharmacologic  approach  was 
adopted.  The  well  documented  differential  sensitivities  of  p38  kinase,  JNK  and  ERKs  1/2 
to  the  SB202190  chemical  inhibitor  of  the  MAPK  family  was  exploited:  low 
concentrations  (up  to  about  10[LM)  have  been  shown  to  selectively  inhibit  p38  kinase,  at 
30[tM  both  p38  and  JNK  are  inhibited,  whereas  ERKs  1&2  are  not  affected  until  even 
higher  concentrations  (Jacinto  et  al.,  1998;  Le-Niculescu  et  al.,  1999;  Whitmarsh  et  al., 
1997). 
Control  experiments  confirmed  that  10[tM  SB202190  prevented  SDG  or  p-XSC  induced 
activation  of  p38  kinase  (measured  by  activation  of  its  downstream  target  MAPKAPK-2  in 
an  immunecomplex  kinase  assay),  but  not  activation  of  JNK  (measured  by  phosphorylation 
of  c-Jun  at  Ser63)  or  ERKs  1&2  (measured  using  phosphospecific  antibodies);  whereas 130 
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Fig  6.4.1  Activation  of  JNK  and  p38  kinase  by  SDG  and  pXSC  in  oral  keratinocytes. 
NOMCs  or  SCCs  were  left  untreated  (C)  or  treated  with  the  indicated  concentrations  of  SDG  or 
p-XSC  for  lh  or  30min,  respectively,  cell  lysates  prepared,  and  analysed  by  SDS/PAGE  and 
western  blotting  with  antibodies  against  the  activated  forms  of  (A)  p38  (p38*)  or  (B)  JNK 
(JNK*).  As  loading  controls,  the  blots  were  then  stripped  and  western  blotted  with  antibodies 
against  total  p38  or  JNK.  The  figures  below  the  blots  indicate  the  relative  levels  of  p38,  JNK 
activation  after  normalisation  to  the  loading  control  levels.  C,  represents  treatment  with  solvent 
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30[tM  SB202190  prevented  activation  of  both  p38  kinase  and  JNK,  but  did  not  affect 
activation  of  ERKs  1&2  (Fig  6.4.2A). 
Measurement  of  apoptosis  indicated  while  10[tM  SB202190  had  no  effect,  30[tM 
SB202190  prevented  SDG-  (36%  inhibition;  p=0.033)  and  p-XSC-induced  (33% 
inhibition;  p=0.041)  apoptosis  (Fig  6.4.2B).  This  suggests  that  the  activation  of  JNK  is (at 
least  partially)  mechanistically  linked  to  apoptosis  induction  while  p38  activation  has  no 
functional  significance.  These  results  closely  miffor  the  earlier  work  on  HeLa  cells  in 
Chapter  5. 
6.5  JNK  activity  regulates  Fasl  induction  by  selenium  In  oral 
carcinomas 
The  observations  described  in  Sections  6.3  and  6.4  are  particularly  interesting  as 
differential  induction  of  Fasl  appears  to  be  a  key  regulator  of  enhanced  sensitivity  of  SCCs 
and,  in  HeLa  cells,  JNK  activity  has  been  shown  to  regulate  Fasl  induction  (at  least  for 
SDG)  (Section  5.4). 
Whether  stress  kinase  activities  influenced  the  induction  of  Fasl  in  oral  cells  was 
investigated  using  the  same  pharamacologic  approach  described  in  Section  6.4.2. 
Inhibition  of  p38  only  did  not  affect  Fasl  induction,  while  inhibition  of  both  JNK  and  p38 
resulted  in  reduced  Fasl  production  in  response  to  both  pXSC  and  SDG  by  about  50%  (Fig 
6.5.1).  This  strongly  suggests  that  activation  of  the  JNK  pathway  is  necessary  for  the 
induction  of  Fasl  and  apoptosis  by  SDG  and  pXSC,  whereas  activation  of  the  p38  pathway 
is  not. 
A  point  of  interest  is  that  the  pharmacologic  approach  in  the  oral  cells  revealed  the  role  of 
JNK  in  inducing  Fasl  in  response  to  both  pXSC  and  SDG.  In  HeLa  cells  however, 
transfection  of  TAM67  reduced  Fasl  induction  by  SDG  only.  This  may  suggest  that  pXSC 
can  induce  Fasl  via  JNK  activation  but  independent  of  c-jun  activation.  The  pharmacologic 
strategy  applied  to  HeU  cells  could  resolve  this  issue  but  the  increased  toxicity  to  HeLa 
cells  of  high  doses  of  inhibitor  precludes  this  analysis. 132 
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Fig  6.41  Effect  of  inhibition  of  p38  and  JNK  activation  on  induction  of  apoptosis  by  SDG 
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(A)  Effect  of  varying  concentrations  of  SB202190  on  the  activation  of  p38  kinase,  JNK  and 
ERKsI/2  by  8ýM  SDG  (S)  or  30pM  pXSC  (P)  was  analysed.  p38  kinase  activity  was  measured 
by  activation  of  its  direct  substrate  MAPKAPK-2  in  an  immunoprccipitation  kinase  assay  using 
hsp25  as  MAPKAPK-2  substrate.  Activation  of  JNK  and  ERKI/2  was  assayed  by 
phosphorylation  using  a  phospho-specific  anti-c-jun  serine  63  (c-jun*(Ser63))  or  ERKI/2 
(ERKI/2*)  antibodies.  (B)  SCCs  were  pre-treated  for  30  min  with  the  indicated  concentrations 
of  SB202190  followed  by  8pM  SDG  or  30pM  pXSC  for  16h.  Apoptosis  was  measured  by 
TUNEL  staining.  Each  treatment  was  performed  in  triplicate.  Data  presented  is  representative  of 
2  independent  experiments.  Error  bars  indicate  standard  errors.  C,  represents  treatment  with 
solvent  vehicle,  DMSO. 133 
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Fig  6.5.1  Effect  of  inhibition  of  p38  and  JNK  activation  on  induction  of  Fasl  by  SDG  and 
PXSC  in  SCCs- 
SCCs  were  pre-treated  for  30  min  with  the  indicated  concentrations  of  SB202190  followed  by 
8pM  SDG  or  30pM  pXSC  for  16h.  Fasl  levels  were  measured  by  Western  blotting  using  an  anti- 
Fasl  antibody.  Total  p38  levels  were  used  as  loading  controls.  The  figures  below  the  blots 
indicate  the  fold  increase  in  Fasl  expression  above  control  level,  after  selenium  treatment, 
normalised  to  the  loading  control  level. Chapter  6  134 
6.6  Inhibition  of  ERK  1/2  and  Akt  activation  by  chernopreventive 
selenium  compounds 
As  with  HeLa  cells  (Sections  5.5.1  and  5.7.1),  both  ERKs  1/2  and  Akt  were  activated  by 
both  selenium  compounds  (work  of  J.  Fleming).  However,  in  contrast  to  HeLa  cells,  there 
was  no  reduction  of  mitogen-induced  ERK  1/2  stimulation  on  selenium  pre-treatment. 
ERK5  does  not  appear  to  be  a  prominent  signalling  pathway  in  these  cells  as  it  cannot  be 
activated  by  known  stimulants  like  EGF  (work  of  J.  O'Prey). 
To  test  the  functional  role  of  ERK1/2  and  Akt  activation,  specific  inhibitors  were 
employed  as  described  in  Sections  5.5.2  and  5.7.2.  Control  experiments  in  oral  cells 
showed  that  under  conditions  of  use  PD98059  and  LY294002  completely  inhibited 
selenium  induced  activation  of  ERK  1/2  and  Akt,  respectively  (Ghose  et  al.,  2001a). 
Parallel  experiments  measuring  the  extent  of  apoptosis  revealed  no  difference  in  pXSC- 
induced  cell  death  on  inhibition  of  ERK1/2  or  Akt  activity  (Fig  6.6.1).  However,  while 
inhibition  of  ERK1/2  activity  had  no  effect  on  SDG-induced  apoptosis,  treatment  with 
LY294002  resulted  in  a  significant  increase  (59%)  in  apoptosis  (Fig  6.6.1).  This  would 
suggest  that  the  activation  of  Akt  by  SDG  is  a  potent  survival  response  whose  inhibition 
sensitises  the  cells.  ERK  1/2  activation  by  both  selenium  compounds  and  activation  of  Akt 
by  pXSC  appear  to  have  no  functional  role  and  may  be  unsuccessful  survival  responses. 
Thus  we  have  for  the  first  time  identified  a  definite  survival response  which  acts  to  check 
the  extent  of  apoptosis  (in  HeLa  there  was  a  small  trend  with  ERK1/2  and  a  small  effect 
via  ERK5  -  Sections  5.5.2  and  5.6.2).  Once  this  inhibition  is  removed  by  the  LY294002 
inhibitor,  the  extent  of  apoptosis  increase  considerably.  Further  experiments  aimed  towards 
identifying  downstream  targets  of  Akt  activation  may  reveal  its  underlying  function. 
Intriguingly,  Akt  can  inhibit  the  forkhead  transcription  factor  which  may  regulate  Fasl 
transcription  (Brunet  et  al.,  1999).  Inhibition  of  Akt  could  presumably  lift  this  repression 
leading  to  increased  induction  of  Fasl  and  thereby  enhanced  rate  of  apoptosis.  Obviously 
other  downstream  survival  related  activities  of  Akt,  including  phosphorylation  and 
inactivation  of  caspase  9  (Cardone  et  al.,  1998)  and  Bad  phosphorylation  (del  Peso  et  al., 
1997),  may  complicate  such  a  simplistic  analysis.  However,  given  the  importance  of  Fas  in 
SDG  mediated  apoptosis,  analysing  levels  of  Fasl  induced  by  SDG,  with  or  without 
inhibition  of  Akt  activity  should  address  this  issue.  Very  recently  a  report  has  described 
that  inhibition  of  PI3K  activity  sensitises  of  HL60  leukaemia  cells  to  both 
chemotherapeutic  drug-  and  Fas-induced  apoptosis  (OGorman  et  al.,  2001).  It  also  showed 135 
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Fig  6.6.1  Inhibition  of  selenium-induced  ERK1/2  and  Akt  activities  in  SCCs. 
SCCs  were  pre-treated  with  50gM  LY294002  or  50ýM  PD98059  and  then  treated  with  8pM 
SDG  or  30pM  pXSC  for  18h.  Induction  of  apoptosis  was  measured  by  TUNEL  staining.  Each 
treatment  was  performed  in  triplicate.  Data  presented  is  representative  of  2  independent 
experiments.  Error  bars  indicate  standard  errors.  C,  represents  treatment  with  solvent  vehicle, 
DMSO. 
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that  P13K  inhibition  significantly  increases  chemotherapeutic  drug-induced  JNK  activation 
but  whether  this  was  of  functional  relevance  remains  unclear. 
6.7  Conclusions 
The  main  purpose  of  this  work  was  to  identify  the  signal  transduction  mechanisms 
responsible  for  apoptosis  induced  by  cancer-protective  selenium  compounds  using  a 
relevant  human  model  and  to  test  whether  selenium-induced  apoptosis  had  a  tumour 
selective  component.  The  major  novel  finding  is  that  human  SCCs  are  more  sensitive  to 
induction  of  apoptosis  by  the  SDG  than  NOMCs.  This  is  clearly  of  considerable  relevance 
to  understanding  the  cancer-protective  effect  of  selenium  compounds,  particularly  selenite. 
It  is  not  clear  why  pXSC  does  not  show  the  turnour-selectivity  exhibited  by  SDG  but  it 
may  reflect  the  relative  importance  of  the  JNK/Fasl  pathway  in  mediating  the  effects  of  the 
two  compounds  which  is  strongly  correlated  to  the  extent  of  apoptosis  induced. 
For  the  most  part,  molecular  mechanisms  of  selenium-induced  apoptosis  identified  in  HeLa 
cells  are  quite  similar  to  those  seen  in  the  primary  cultures.  Thus,  we  have  successfully 
extended  our  work  on  established  cell  lines  to  a  model  more  akin  to  the  in  vivo  conditions. 
Taken  together,  the  two  sets  of  studies  in  different  cellular  models,  very  strongly 
implicates  the  critical  involvement  of  the  JNK/c-jun/Fasl  pathway.  Selenium  is  known  to 
influence  a  myriad  of  biological  processes  and  it  is  possible  that  other  major  mediators  are 
involved  which  the  current  set  of  experiments  have  not  addressed.  This  is  particularly 
relevant  as  most  of  our  functional  studies  have  always  demonstrated  partial  inhibition.  An 
outstanding  issue,  given  that  the  JNK/c-jun/Fasl  pathway  may  form  the  basis  of  tumour 
selectivity,  is  the  differential  induction  of  upstream  components  of  this  pathway.  To  this 
end,  there  is  an  urgent  need  to  analyse  the  relative  activities  of  the  known  upstream  JNK 
activators  in  SCCs  and  NOMCs. 
Apart  from  defining  this  particular  mechanistic  pathway,  these  experiments  may  also  have 
broader  implications.  The  differential  induction  of  JNK  and  Fasl,  if  reproduced  in  vivo,  can 
be  used  as  surrogate  biomarkers  of  selenium  activity  as  an  anti-cancer  agent.  It  is  true  that 
primary  cultures,  at  best,  provide  only  a  close  approximation  of  the  in  vivo  situation.  This 
and  the  fact  that  we  have  already  identified  possible  major  regulators  of  selenium-mediated 
apoptosis  makes  the  case  for  venturing  into  in  vivo  experimentation  very  strong. Chapter  6 
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A  novel  primary  culture  model,  relevant  to  selenium  mediated  chernoprevention  in 
humans  developed  from  biopsies  of  SCCs  and  NOMCs,  has  been  used  to  analyse 
the  mechanism  of  action  of  SDG  and  pXSC. 
SCC's  showed  enhanced  sensitivity  to  SDG-,  but  not  pXSC-,  induced  apoptosis. 
This  correlated  strongly  with  the  level  of  Fasl  induction  which  (at  least  partially) 
mediates  apoptosis  induction  by  both  compounds. 
SCCs  were  more  efficient  in  activating  JNK  than  NOMCs  and  this  correlated  well 
with  their  enhanced  sensitivity  and  levels  of  Fasl  induction. 
JNKý  but  not  p38,  activation  mediated  cell  death  and  Fasl  induction  by  SDG  and 
PXSC. 
Inhibition  of  Akt  activation  by  SDG,  and  not  pXSC,  increased  the  apoptotic  rate. 
No  difference  in  apoptosis  levels  was  seen  on  inhibition  of  ERK  1/2  activation. 138 
7  Molecular  Mechanisms  Mediating  Anti-cancer 
Activities  of  Selenite  in  vivo 
7.1  Background 
The  previous  chapter  has  identified  that  treatment  of  oral  keratinocytes  with 
chernopreventive  selenium  compounds  results  in  the  induction  of  apoptosis,  in  vitro.  Some 
of  the  dominant  pathways  that  are  likely  to  regulate  selenium-induced  programmed  cell 
death  in  these  cells  have  been  identified  and  it  appears  that  a  signalling  route  leading  from 
the  induction  of  JNK  activity  to  the  induction  of  Fasl,  via  activation  of  c-jun,  is  of 
particular  significance. 
Active  discrimination  between  tumour  and  normal  cells  form  the  basis  of  any  anti-cancer 
agent  and  identification  of  its  underlying  mechanisms  are  of  great  importance.  Chapter  6 
also  implicated  the  differential  utilisation  of  this  JNK-mediated  signalling  module  to  be  the 
putative  mechanism  underlying  turnour  selectivity,  at  least  for  SDG. 
These  findings  are  generally  similar  in  established  cell  lines  and  primary  cultures  relevant 
to  humans,  but  if  any  real  biological  relevance  is  to  be  attached  to  these  findings,  it  is 
necessary  to  reproduce  them  in  vivo.  To  this  end,  in  collaboration  with  J.  Fleming  (Beatson 
Institute,  UK),  the  chernopreventive  activities  of  selenium  have  been  investigated  in  mouse 
models. 
Human  SCCs  growing  in  primary  cultures  were  used  in  xenograft  studies  in  immuno- 
supressed  'nude'  mice.  The  fact  that  SDG,  the  primary  metabolite  of  selenite,  showed 
significant  turnour  selectivity  and  activation  of  the  JNK/c-jun/Fasl  pathway,  together  with 
the  historically  strong  chemopreventive  activity  of  selenite  in  several  mouse  models  of 
cancer,  prompted  us  to  choose  selenite  as  the  compound  of  choice  in  these  animal 
experiments. 
It  needs  to  be  stressed  that  the  study  described  here  is  still  ongoing  and  is  designed  as  an 
pilot  for  a  possible  larger  study.  The  results  described  here  are  preliminary  and 
considerable  caution  is  therefore  necessary  in  interpreting  the  data. Chapter  7 
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A  human  oral  SCC  (BICR31)  was  chosen  for  xenograft  studies  in  nude  mice  because  of  its 
previous  characterisation  in  xenograft  studies  by  Dr  J.  Brown  (Beatson  Institue,  UK4 
unpublished  data)  which  demonstrated  its  aggressive  growth  upon  transplantation. 
Immuno-suppressed  'nude'  mice  were  divided  into  two  groups  of  nine  and  placed  on  either 
high  (2ppm)  or  depleted  selenium  (<<  O.  1ppm)  diets,  in  the  form  of  sodium  selenite.  The 
concentration  of  selenium  in  a  standard  mouse  diet  is  -  0.16  ppm,  we  chose  to  compare  a 
higher  and  a  depleted  dose  on  the  simplistic  assumption  that  possible  biological  differences 
may  be  enhanced. 
BICR31  cells  in  a  matrigel  matrix  were  subcutaneously  injected  into  nude  mice  and 
turnour  growth  followed  over  time.  As  per  the  relevant  Home  Office  project  grant 
regulations,  mice  bearing  a  tumour  load  of  1cm  2,  as  measured  in  any  two  dimensions,  were 
killed  and  the  tumour  removed  for  analysis.  At  the  time  of  writing  this  report  the  mice 
were  on  the  15th  week  after  the  injection. 
Preliminary  analysis  of  week  12  turnours  revealed  the  growth  of  the  SCC's  in  tumour  nests 
surrounded  by  mouse  tissue  (Fig  7.2.1A,  B).  The  invading  mass  of  tumour  cells  were 
obvious  and  other  indicators  of  malignancy  like  vacuolar  and  clear  cells  were  sometimes 
present.  No  immediate  differences  were  observed  at  this  level  between  turnours  from  mice 
on  high  or  low  selenium  diets  (Fig  7.2.1A,  B).  Detailed  pathological  analysis  of  these 
sections  will  be  carried  out  when  the  experimental  endpoint  is  reached. 
7.3  Effect  of  high  selenium  diet  on  xenograft  growth 
Weekly  measurement  of  tumour  size  was  carried  out  to  establish  whether  this  dose  of 
selenite  in  the  diet  affected  the  growth  of  xenografts.  As  the  study  is  currently  ongoing  it  is 
difficult  to  statistically  represent  differences  in  growth  characteristic. 
There  is  however,  an  indication  that  high  selenium  in  the  diet  inhibits  or  at  least  delays 
xenograft  outgrowth.  Fig  7.3.1  plots  the  number  of  live  mice,  an  inverse  indicator  of 
tumour  burden  (in  view  of  the  requirement  that  mice  are  killed  when  a  tumour  size  Of  1CM2 
is  reached),  as  a  function  of  time.  It  is  clear  that  at  the  later  stages  of  the  experiment,  a 
lower  number  of  mice  in  the  low  selenium  cohort  are  alive.  This  suggests  that  high 
selenium  in  the  diet  may  delay  the  growth  of  xenografts. 140 
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Fig  7.2.1  Histology  sections  of  human  SCC  xenografts  in  nude  mice. 
5j.  iM  paraffin  embedded  histology  sections  from  human  SCC  xenografts  growing  on  nude  mice 
were  stained  with  haematoxylin/eosin  to  visualise  histological  characteristics.  (A)  is  a  histology 
section  of  a  tumour  growing  on  a  mouse  fed  with  a  depleted  selenium  diet  while  (B)  is  from  a 
mouse  on  high  selenium  diet.  White  arrowheads  show  'tumour  nests'  of  human  SCC  surrounded 
by  mouse  tissue. 141 
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Fig  7.3.1  Sensitivity  of  SCC  xenograft  growth  to  dietary  selenium  levels. 
Sensitivity  of  xenograft  growth  to  dietary  selenium  levels  was  assayed  by  plotting  the  number  of 
mice  with  turnours  less  than  lcm2  (after  which  they  are  killed)  as  a  function  of  time  after 
xenograft  initiation. 
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Comparison  of  the  actual  tumour  sizes  also  reveal  a  trend  towards  smaller  turnours  in  the 
high  selenium  cohort  (data  not  shown).  It  is  clear  from  this  that  the  tumour  sizes  in  both  the 
groups  remain  fairly  constant  till  the  11'h  week  after  which  they  start  to  proliferate  and 
establish  themselves.  It  is  after  this  stage  that  the  trend  towards  smaller  tumour  sizes  in 
mice  on  high  selenium  diet  begin  to  emerge.  Our  study  has  so  far  reached  a  few  weeks 
after  the  xenografts  have  started  to  expand,  therefore  later  timepoints  may  yield 
biologically  meaningful  results.  However,  going  by  the  observed  trend  it  is  a  possibility 
that  we  may  be  looking  at  early  stages  of  selenite  mediated  inhibition  of  human  SCC 
xenograft  outgrowth. 
7.4  High  dietary  levels  of  selenium  correlates  with  apoptosis 
induction  in  vivo 
The  major  objective  of  this  study  was  to  validate  apoptotic  mechanisms  elucidated  in  cell 
lines  in  an  in  vivo  situation.  In  view  of  the  slight  inhibition  of  tumour  outgrowth  by  high 
selenium  diet  observed  at  these  early  stages  of  analysis,  the  contribution  of  apoptosis 
induction  to  this  phenomenon  was  investigated. 
Tissue  sections  from  turnours  were  immunostained  with  an  antibody  against  the  cleaved 
fragment  of  caspase  3,  accumulation  of  which  is  a  strong  marker  for  apoptosis  induction 
(Riss,  2001).  Three,  week  12  turnours,  1  from  high  and  2  from  low  selenium  cohorts  (one 
showing  signs  of  ulceration)  were  assessed.  A  significantly  large  induction  of  apoptosis 
was  seen  in  the  high  selenium  tumour  compared  to  the  two  others  on  low  selenium  (Fig 
7.4.1).  The  extent  of  apoptosis  was  more  widespread  and  there  was  a  dramatic  increase  in 
the  intensity  of  staining.  The  apoptosis  appeared  to  be  mainly restricted  to  the  tumour  nests 
suggesting  specificity. 
its  is  clear  from  this  particular  experiment  that  increased  apoptosis  appears  to  occur  in 
turnours  in  mice  on  the  high  selenium  diet.  However,  quantification  of  the  extent  of 
apoptosis  and  analysis  of  more  turnours  (from  later  timepoints)  is  necessary  to  confirm  that 
this  conclusion  is  statistically  valid.  There  is  also  the  need  to  confirm  the  same  using  a 
different  assay,  like  TUNEL  To  judge  if  high  selenium  in  diet  induces  targeted  cell  death 
in  turnours  or  enhances  the  rates  of  apoptosis  generally,  unrelated  mouse  tissue  matched 
with  the  tumours  needs  to  be  analysed. 
The  induction  of  caspase  3  indicates  a  difference  from  in  vitro  cell  culture  data  where, 
according  to  the  available  literature,  its  induction  by  selenite  is  contentious  (see  Section 143 
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Fig  7.4.1  Enhanced  induction  of  in  vivo  apoptosis  in  SCC  xenografts  in  response  to  a 
supplemented  selenium  diet. 
Paraffin  embedded  xenograft  sections  from  3  mice  killed  12  weeks  after  xenograft  initiation 
were  subjected  to  immunohistochernistry  using  a  antibody  against  cleaved  caspase  3  (activated). 
Background  staining  was  with  eosin.  2  mice  were  from  the  depleted  selenium  cohort  (A,  B)  while 
the  third  was  from  the  supplemented  selenium  cohort  (Q.  Caspase  3  staining  is  indicated  with 
white  arrowheads.  Tissue  section  in  (A)  was  from  a  tumour  sample  that  showed  signs  of 
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2.6.7.3).  Our  in  vitro  studies  have,  however,  found  induction  of  caspase  3  by  both  pXSC 
and  SDG  (Section  4.4).  Also,  as  its  induction  appears  to  be  restricted  to  the  tumour  nests,  it 
suggests  some  form  of  specificity  and  not  a  general  toxic  effect.  One  has  to  bear  in  mind 
that,  even  in  tissue  culture,  the  low  doses  of  selenite  exposure  does  not  have  the  non- 
specific  genotoxic  effects  described  for  higher  concentrations.  This  would  imply,  that  a 
small  increase  in  selenium  exposure,  in  vivo,  results  in  a  considerable  turnour-selective 
effect. 
One  final  issue  is  regarding  the  extent  of  apoptosis,  in  vivo.  Even  a  1%  increase  in 
apoptosis  will  considerably  effect  the  tumour  size,  in  vivo  but  this  will  not  be  relevant  in 
vitro.  Thus  a  very  careful  apoptotic  quantitation  for  turnours  from  a  individual  mouse 
needs  to  be  performed  and  correlated  to  its  particular  tumour  growth  characteristics. 
7.5  Conclusions 
This  ongoing  study  is  addressing  the  need  to  elucidate  molecular  mechanisms  mediating 
the  anti-cancer  activities  of  chernopreventive  selenium  compounds  in  vivo.  As  our  in  vitro 
work  has  already  identified  several  putative  candidates,  we  now  have  defined  targets  to 
investigate  in  vivo. 
The  data  discussed  in  this  section,  though  preliminary,  suggests  possibilities  that  fit  our 
current  model  for  selenium  mediated  chemoprevention  very  well.  It  appears  that  the 
induction  of  apoptosis  may  be  a  major  player  in  selenium  mediated  chernoprevention  in 
vivo  and  significantly  bolsters  our  in  vitro  data. 
However,  a  lot  of  work  remains  to  be  done  to  confirm  the  tentative  conclusions  presented 
in  this  chapter.  Apart  from  taking  the  study  to  completion  (ideally  to  a  stage  where  all  the 
mice  in  the  low  selenium  diet  have  been  killed  due  to  their  increased  tumour  burden) 
several  other  aspects  need  to  be  addressed.  Firstly,  the  level  of  selenium  in  the  blood 
plasma  of  individual  animals  has  to  determined.  Secondly,  activation  of  JNK  (and  possibly 
c-jun)  and  Fasl  needs  to  be  investigated  using  immunostaining.  Thirdly,  detailed 
pathological  analysis  should  be  performed  to  identify  histological  features  of  selenium- 
mediated  inhibition  of  xenograft  outgrowth.  Immunohistochernical  studies  directed  at 
markers  of  cellular  proliferation  will  also  be  carried  out  to  assess  if  cytostatic  activity 
correlate  with  the  inhibitory  effect  on  xenograft  growth. Chapter  7 
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An  in  vivo  model,  of  human  SCC  xenograft  in  nude  mice  has  been  developed  and 
tumour  outgrowth  in  response  to  high  or  low  selenium  containing  diet  is  under 
investigation 
Preliminary  data  suggests  that  inhibition  of  xenograft  growth  is  correlated  with 
selenium  enhanced  diet. 
*  This  inhibition  is  reflected  in  the  increased  levels  of  apoptosis  observed  in  turnours 
growing  on  mice  fed  with  selenium  supplemented  diet. 146 
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8.1  Summary  of  results 
The  large  corpus  of  data  from  epidemiological,  ecological  and  clinical  prospective  trials 
suggesting  a  strong  inverse  correlation  between  dietary  selenium  intake  and  incidence  of 
several  human  cancers  has  led  to  an  explosion  of  interest  in  elucidating  cellular  and 
molecular  mechanisms  that  mediate  anti-cancer  activities  of  selenium  compounds.  This 
study  investigated  the  molecular  mechanisms  mediating  anti-cancer  activities  of  two 
chernopreventive  selenium  compounds.  Both  pXSC  and  SDG  (and  its  metabolic  precursor 
selenite)  have  been  extensively  characterised  in  different  models  of  animal  cancers  and 
found  to  have  strong  chernopreventive  activity  against  the  incidence  of  neoplastic  growth. 
The  approach  undertaken  in  this  study  was  to  define  molecular  pathways  responsible  for 
chernopreventive  actions  of  these  compounds,  in  vitro,  in  established  cell  lines.  The 
knowledge  generated  here  was  then  translated  into  a  primary  culture  system  more  relevant 
to  human  cancers.  Finally,  in  vivo  validation  of  in  vitro  data  is  being  undertaken  using 
xenograft  analysis  of  mice  on  selenium  depleted  or  supplemented  diets. 
The  study  found  that  both  compounds,  pXSC  and  SDG,  induce  apoptosis  in  cell  lines 
which  is,  at  least  partially,  dependent  on  caspase  3  activation.  While  protein  levels  of  the 
major  Bcl2  family  members  do  not  change  on  selenium  treatment,  induction  of  Fasl 
appears  to  be  necessary.  Activities  of  several  members  of  the  MAPK  family  were 
modulated  by  both  the  compounds,  and  activation  of  JNK  appear  to  be  particularly 
important.  JNK  activation  was  required  for  induction  of  Fasl  (particularly  with  SDG)  and 
appeared  to  be  working  via  the  activation  of  c-jun.  Thus  a  signalling  pathway  from  JNK 
activity  leading  c-jun  activation  and  finally  Fasl  induction  appeared  to  be  functionally 
mediating  induction  of  apoptosis  by  SDG  and  pXSC. 
Use  of  a  panel  of  primary  cultures  of  SCCs  and  NOMCs  underlined  the  importance  of  this 
pathway  as  its  relative  usage  strongly  correlated  to  the  extent  of  apoptosis  induction.  SCCS 
showed  enhanced  sensitivity  to  SDG  induced  apoptosis  compared  to  NOMCs  and  this  was 
reflected  in  the  levels  of  induction  of  Fasl  and  JNK  activity.  Activation  of  Akt  by  SDG  was 
shown  to  have  a  putative  role  in  cell  survival  by  inhibiting  the  level  of  apoptosis. 
Immunosuppressed  mice  harbouring  xenografts  derived  from  human  SCCs  are  being 
currently  used  as  an  in  vivo  model.  Preliminary  data  suggests  that  a  high  dietary Chapter  8  147 
concentration  of  selenium  retards  tumour  growth,  possibly  due  to  turnour-selective 
induction  of  apoptosis. 
8.2  Selenium  concentration  ranges  in  vivo  and  its  relevance  to  in 
vitro  studies 
The  relative  efficacies  of  selenium  derivatives  as  chernopreventive  agents  in  vivo  parallel 
their  growth  inhibitory  effects  in  vitro  and  their  ability  to  induce  apoptosis  (Lanfear  et  al., 
1994;  Ronai  et  al.,  1995;  Thompson  et  al.,  1994;  Wilson  et  al.,  1992).  Though  evidence  for 
growth  inhibitory  activities  is  forthcoming  from  several  in  vivo  studies,  the  vast  majority  of 
the  current  knowledge  (including  all  the  evidence  in  human  systems)  is  from  in  vitro 
studies  in  tissue  culture  settings.  Thus  a  logical  concern  regarding  translation  of  in  vitro 
knowledge  to  human  conditions  is  the  dose  of  selenium  used.  While  it  is  true  that  in  vivo, 
factors  like  selective  tissue  selenium  uptake,  immune  reactions  and  detoxification  may 
complicate  analysis,  it  is  of  paramount  importance  to  maintain  some  sort  of  relationship 
with  physiologically  relevant  doses  and  in  vitro  experimentation. 
It  appears  from  human  studies  that  the  plasma  selenium  levels  have  the  strongest 
correlation  with  the  effectiveness  of  selenium  to  inhibit  cancer  incidence.  An  analysis  of 
data  from  people  living  in  seleniferous  areas  reveal  plasma  selenium  concentrations  of  upto 
5[tM,  although  higher  than  the  average  level,  can  be  found  in  humans  (Fig  8.2.1)  with  no 
apparent  adverse  effects  (Fleming  et  al.,  2001;  Longnecker  et  al.,  1991).  In  vitro,  induction 
of  apoptosis  and  modulation  of  signalling  pathways  by  SDG,  as  described  in  this  study,  is 
readily  detectable  in  this  concentration  range  underscoring  the  potential  relevance  of  this 
data  to  in  vivo  conditions.  The  concentrations  of  the  synthetic  selenium  derivative,  pXSC, 
required  for  apoptosis  induction  are  higher  than  for  SDG  but  it  is  well  established  in 
animal  models  that  PXSC  has  a  higher  chernopreventive  index  than  selenite,  exerting  its 
maximum  cancer-protective  effect  at  high  dietary  levels  (about  30ppm  compared  to  1- 
2ppm  for  selenite)  presumably  due  to  its  lower  toxicity  (Tanaka  et  al.,  1985). 
8.3  Apoptosis  induction  by  selenium  compounds 
8.3.1  Non-specific  toxicity  and  selenium 
As  discussed  in  Sections  2.5.1  and  2.6.7.3,  selenium  compounds  can  induce  the  generation 
of  ROS,  which  may  contribute  to  non-specific  genotoxicity  leading  to  necrotic  tell  death. 
However,  at  least  at  doses  used  in  this  study,  this  does  not  seem  to  be  the  case  for  both  the 148 
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Fig  81.1  Range  of  selenium  levels  in  vivo  (compiled  from  data  in  Longnecker  et  al.,  1991). 
Plotting  the  selenium  intake  of  people  (pg/day)  living  in  seleniferous  areas  against  the  measured 
serum  selenium  levels  (pM)  revealed  that  serum  concentrations  of  3-5  ýLM  selenium  can  be 
achieved,  in  vivo,  by  people  taking  high  doses  of  selenium  without  any  apparent  adverse  effects. 
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SDG  and  pXSC  as  evident  from  AnnexinV  experiments  discussed  in  Section  4.3. 
Furthermore,  most  of  the  functional  intervention  experiments  described  in  Chapter  5  were 
also  reproducible  using  AnnexinV  staining  as  an  assay  (data  not  shown),  suggesting  that 
the  involvement  of  signalling  pathways  investigated  pertain  to  apoptosis  and  not  non- 
specific  necrosis. 
Stoichiometry  of  the  biochemical  reactions  leading  to  generation  of  ROS  by  selenium 
indicates  an  equimolar  ratio  between  selenium  and  H202  generated  (Fig  8.3.1).  However, 
concentration  of  H202  required  for  similar  levels  of  growth  inhibition  is  about  100  times 
higher  than  the  selenium  level  required  (Wu  et  al.,  1995a).  It  is  also  pertinent  to  note  that 
despite  the  interest  in  pXSC  as  a  chernopreventive  agent,  it  has  not  been  shown  to  induce 
any  form  of  non-specific  toxicity.  Yet,  interestingly,  our  earlier  work  has  revealed  that  free 
radical  scavengers  like  mannitol  can  prevent  pXSC-,  but  not  SDG-,  induced  loss  of 
viability  and  that  tyrosine  phosphorylation  patterns  of  pXSC  (but  not  of  SDG)  were 
somewhat  comparable  to  those  induced  by  H202  (Fleming  et  al.,  2001).  Curiously,  a  recent 
study  has  reported  that  overexpression  of  the  same  phosphorylation  defective  c-jun  mutant 
that  protects  against  selenium-induced  apoptosis  in  our  study  (Section  5.3.3),  sensitises 
apoptosis  induced  by  a  range  of  DNA  damaging  agents  but  not  by  other  apoptosis  inducers 
which  do  not  cause  DNA  damage  (Potapova  et  al.,  2001). 
ROS,  for  years,  have  been  regarded  as  unwanted  toxic  by-products  -a  price  paid  for  living 
in  an  aerobic  environment.  The  large  body  of  knowledge  about  cellular  defences  against 
ROS  and  their  damaging  nature  has  bolstered  this  prejudice.  However,  recent  research 
suggests  that  ROS,  in  appropriate  amounts,  may  serve  as  specific  intracellular  second 
messengers  in  signal  transduction  and  are  indispensable  to  normal  physiology  (reviewed  in 
(Finkel,  1998;  Finkel,  2000)).  In  cultured  cells,  stimulation  by  EGF,  PDGF,  angiostensin  11 
and  a  host  of  cytokines  trigger  rapid  production  of  ROS  that  may  mediate  tyrosine 
phosphorylation  cascades.  While  it  is  true  that  accumulation  of  large  quantities  of  ROS 
cause  severe  cellular  damage,  a  careful  investigation  into  the  physiological  role  of  ROS  is 
also  warranted. 
Most  studies  of  ROS  induction  by  selenium  have  used  chemical  scavengers  or 
overexpression  of  antioxidant  proteins  to  investigate  functional  significance.  The  doses 
used  in  most  studies  are  greatly  higher  than  antioxidant  levels  achieved  in  vivo  and  are  thus 
difficult  to  interpret.  It  might  may  well  be  that  some  selenium  compounds,  at  certain  doses 
(say  in  in  vitro  conditions),  generate  excessive  amounts  of  ROS  that  cause  non-specific 
toxicity,  however  in  other  situations  (such  as  in  vivo  or  in  low  concentrations)  may  be 150 
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Fig  8.3.1  Generation  of  ROS  and  hydrogen  peroxide  from  oxidation  of  hydrogen  selenide 
(adapted  from  Harrison  et  al.,  1997). 
Schematic  representation  of  generation  of  hydrogen  peroxide,  superoxide  and  free  radicals  from 
oxidation  of  selenium  compounds.  Selenide  can  release  reactive  oxygen  species  (ROS)  which  is 
converted  to  H20,  by  the  action  of  SOD.  H202  can  either  by  removed  by  the  action  of  GPXs  or 
lead  to  the  further  formation  superoxides  via  catalase  activity  or  ferrous/ferric  oxido-reductive 
reactions  (Haber-Weiss  reaction).  ROS  and  H202  are  shown  in  red.  GSH/GSSH, 
reduced/oxidised  glutathione;  GPXs,  glutathione  peroxidases;  SOD,  superoxide  dismutase. Chapter  8  151 
generating  just  enough  to  mediate  intracellular  signalling  and  perhaps  a  regulated 
enhancement  of  ROS,  may  directly  contribute  to  the  anti-cancer  activities  of  selenium. 
8.3.2  Growth  arrestor  programmed  ceH  death? 
A  large  body  of  data  implicate  growth  arrest  and  apoptosis  to  be  important  mediators  of 
selenium-induced  anti-cancer  activity  (Section  2.6.7.3).  The  cell  cycle  is  very  closely 
associated  with  apoptosis  and  several  proteins,  like  p53  and  Rb,  regulate  both  these  events 
and  are  also  influenced  by  selenium  treatment  (see  Section  2.6.7.1).  This  makes  the 
scenario  of  these  two  events  being  part  of  the  same,  perhaps  mutually  enhancing,  chain  of 
events  very  plausible.  However,  certain  selenium  compounds  may  either  induce  a  cell 
cycle  arrest  or  apoptosis. 
For  most  selenium  compounds  with  strong  chemopreventive  efficacies,  it  is  likely  that 
apoptosis  would  be  relatively  more  important  a  mechanism  than  growth  arrest:  this  is 
because  growth  arrest  not  accompanied  by  apoptosis  will  result  in  cytostasis  and  not 
deletion  of  transformed  cells  and  therefore  a  chemopreventive  effect  would  require 
continued  presence  of  the  inhibitory  agent.  This  is  the  response  seen  with  TPS,  which 
inhibits  DNA  synthesis  but  does  not  induce  apoptosis  (discussed  in  Section  2.6.7.2). 
Selenium  compounds  that  are  potent  inducers  of  apoptosis,  like  monomethylated 
compounds,  a  shortening  of  selenium  treatment  does  not  affect  chernopreventive  efficacy. 
The  compounds  used  in  this  particular  study  are  of  the  latter  class  so  while  deregulation  of 
the  cell  cycle  may  be  concomitant  and  may  even  potentiate  apoptosis,  it  is  unlikely  to  be 
the  dominant  component  of  their  chemopreventive  actions.  It  is  relevant  to  note  in  this 
context  that  previous  attempts  at  measuring  cell  cycle  alterations  induced  by  pXSC  have 
been  uninformative  (Ronai  et  al.,  1995),  presumably  because  of  an  overwhelming 
apoptotic  response.  Our  work  with  SDG  also  indicates  a  similar  observation  (data  not 
shown),  suggesting  that  the  selenium  compounds  used  in  our  study  predominantly  induce 
apoptosis. 
Also,  a  recent  study  using  one  of  the  animal  models  for  breast  cancer  (methylnitrosourea- 
induced  lesions)  in  which  a  large  amount  of  chernoprevention  work  has  been  conducted, 
has  reported  that  SMC  does  not  alter  the  cellular  proliferation  rates  in  premalignant  lesions, 
thus  disputing  the  fact  that  selenium  inhibits  progression  to  malignancy  via  inhibition  of 
proliferation  (discussed  in  Section  2.6.7.2).  Apoptosis,  on  the  other  hand,  was  easily 
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to  investigate  detailed  mechanisms  of  apoptosis-induction  by  chernopreventive  selenium 
compounds,  particularly  in  vivo. 
8.3.3  SDG-  and  pXSC-induced  programmed  ceH  death 
The  only  functional  evidence  in  the  literature  describing  mechanisms  involved  in 
selenium-induced  apoptosis  is  for  activation  of  caspase  3.  Our  data  also  implicates, 
particularly  for  pXSC,  the  involvement  of  caspase  activity  in  apoptosis  induction  (Section 
4.4).  Caspase  3  is  a  distal  effector  cysteine  protease  that  executes  the  apoptotic  process  (see 
Section  2.6.7.1).  Once  the  caspase  activation  cascade  is  initiated  leading  to  the  activation 
of  caspase  3,  the  apoptotic  process  is  essentially  irreversible.  Thus,  while  detailed 
investigation  into  caspase  3  activity  reveal  the  execution  patterns  of  selenium-induced 
apoptosis,  it  does  not  address  the  critical  issue  of  what  initiates  this  process  or  what  confers 
the  specificity  towards  tumour  cells  as  evidenced  from  the  absence  of  non-specific  toxicity 
in  animal  studies  and  restriction  of  apoptosis  to  tumour  nests  as  shown  in  Section  7.4. 
Instead,  studies  of  upstream  caspases  like  caspases  8  and  9  may  be  valuable  to  dissect  the 
relative  contributions  of  the  death  receptor  and  the  mitochondria  mediated  cell  death 
pathways  (see  Fig  2.6.2).  Induction  of  caspase  3,  particularly  by  SDG,  was  very  weak 
(Section  4.4).  Also,  the  specific  caspase  3  inhibitor  reduced  apoptosis  only  partially:  this 
may  be  indicative  of  caspase  independent  mechanisms.  Interestingly,  it  has  been  reported 
that  in  certain  contexts  the  Fas  pathway  may  induce  caspase-independent  cell  death  via 
RIP  protein  dependent  induction  of  ROS  (Vercammen  et  al.,  1998):  this  may  explain  the 
relatively  small  induction  of  caspase  3,  particularly  by  SDG  which  may  predominantly  use 
this  alternative  route.  Caspase-independent  cell  death  by  SDG  is  also  supported  by  the 
reported  formation  of  50kb  DNA  fragments  with  SDG  (Lanfear  et  al.,  1994)  which  is 
typical  of  AIF-induced  apoptosis  that  does  not  require  caspase  activity  (see  Section 
2.6.7.1). 
A  novel  finding  is  that  human  SCCs  are  more  sensitive  to  induction  of  apoptosis  by  the 
SDG  than  NOMCs.  This  is  clearly  of  considerable  relevance  to  understanding  the  cancer- 
protective  effect  of  selenium  compounds,  particularly  selenite.  It  is  not  clear  why  pXSC 
does  not  show  the  tumor-selectivity  exhibited  by  SDG  but  it  may  reflect  the  relative 
importance  of  JNK/c-Jun  pathway  in  mediating  the  effects  of  the  two  selenium  compounds 
(see  Sections  6.3  and  6.4.1).  Selenite  (SDG)-  and  pXSC-mediated  chernoprevention  studies 
on  animal  models  have  shown  that  their  efficacies  against  various  cancer  types  are 
different  (for  example,  pXSC,  but  not  selenite,  protects  from  NNK-induced  lung  cancers). 
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while  SDG  (or  selenite)  will.  However,  in  murine  model,  pXSC  does  show 
chernopreventive  activity  against  the  incidence  of  certain  oral  cancers  (Tanaka  et  al., 
1997). 
As  evident  from  selenium-mediated  chemoprevention  studies  on  animal  models  of  cancer, 
while  the  inhibition  of  neoplastic  growth  is  considerable  there  is  no  evidence  of  general 
animal  health  to  be  affected  adversely.  This  very  strongly  suggests  some  form  of  tumour 
selectivity  to  be  operational.  This  study  and  another  reported  recently  (Menter  et  al.,  2000) 
have  for  the  first  time  demonstrated  this  in  vitro  and,  significantly,  in  cancer  types  for 
which  the  evidence  for  selenium-mediated  chernoprevention  is  the  strongest  (i.  e.  in  oral 
and  prostate  cancers).  The  major  advantage  of  our  system  over  the  prostate  model  is  that  it 
is  a  direct  comparison  between  corresponding  primary  cultures  of  SCCs  and  NOMCs  and 
not  primary  normal  cells  and  cancer  cell  lines.  We  also  provide  functional  evidence  in  our 
study  which  is  lacking  in  the  other. 
Given  the  widespread  occurrence  of  p53  mutations  in  several  human  cancers,  it  is 
interesting  to  note  that  selenium-induced  apoptosis  does  not  necessarily  require  functional 
p53  (discussed  in  Section  2.6.7.3).  Both  the  SCCs  used  in  our  study  have  been  shown  to 
have  dysfunctional  p53.  The  p53  status  of  the  NOMCs  is  wild  type  as  evident  from 
ongoing  sequencing  by  Dr  A.  Muntoni  and  J.  Fleming. 
In  vitro  models,  like  the  one  described  in  this  study,  are  invaluable  tools  to  assess 
chernopreventive  activity  of  selenium  compounds.  They  provide  an  opportunity  to  evaluate 
the  molecular  mechanisms  underlying  tumour-selectivity,  the  very  basis  of  the  mode  of 
action,  of  any  promising  chernopreventive  agent.  Apart  from  testing  currently  available 
selenium  compounds,  such  a  system  could  form  the  basis  for  a  primary  screen  to  select  for 
novel  compounds  that  may  have  potential  chernopreventive  activity.  Again,  due 
consideration  has  to  be  given  to  the  cancer  type-specificity  of  particular  selenium 
compounds. 
8.3.4  Fasl  and  selenium-induced  apoptosis 
A  novel  finding  from  this  study  is  the  induction  and  functional  requirement  of  Fasl  in 
SDG-  and  pXSC-induced  apoptosis  (Sections  4.5.2  and  6-3).  The  size  of  the  Fasl  produced 
corresponded  to  the  soluble  form  of  the  protein  which  could  therefore  be  secreted  and  act 
intercellularly.  The  option  of  a  secreted  death-inducing  protein  is  particulary  relevant  as  it Chapter  8  154 
may  contribute  to  enhance  apoptosis  induction  by  initiating  cycles  of  autocrine  and 
paracrine  apoptosis. 
Fasl  expression  in  biopsies  of  squamous  carcinomas  of  the  head  and  neck  has  also  been 
demonstrated  in  a  recent  report  and  shown  to  be  biologically  active  in  inducing  apoptosis 
in  co-cultivated  activated  T  lymphocytes  (Gastman  et  al.,  1999).  This  is  of  considerable 
interest  since  the  Fasl/Fas  receptor  interaction  is  one  of  the  major  pathways  initiating 
apoptosis  by  a  variety  of  agents,  including  alkylating  agents  (Kolbus  et  al.,  2000)  and 
drugs  used  in  chemotherapy  (Debatin,  1999).  Since  both  NOMCS  and  SCCs  express  the 
Fas  receptor  constitutively  (work  of  J.  Fleming),  induction  of  Fasl  may  explain  why 
selenium  compounds  induce  apoptosis  in  human  oral  cells. 
Fasl  was  induced  considerably  more  strongly  by  SDG  in  SCCs  than  in  NOMCs,  whereas 
pXSC  seemed  to  be  equally  effective  in  both  normal  cells  and  carcinomas.  Thus,  the  extent 
of  Fasl  induction  by  the  selenium  compounds  correlated  closely  with  the  level  of  apoptosis 
induced  in  normal  mucosa  or  carcinomas  and  inhibition  of  the  Fas  pathway  in  SCCs  by  a 
Fas/Fc  chimera  attenuated  the  induction  of  apoptosis  by  SDG  and  p-XSC.  Activation  of  the 
Fas  pathway  results  in  the  activation  of  caspase  8  (see  Section  2.6.7.1).  Interestingly,  a 
recent  paper  has  reported  the  induction  of  caspase  8  by  methylselenic  acid  but  not  selenite, 
the  parent  compound  of  SDG  (Jiang  et  al.,  2001a). 
A  recent  study  has  reported  the  cleavage  of  G1/S  checkpoint  regulator  proteins  Rb  and 
murine-double-minute-2  (mdm2)  by  caspase  activity  induced  by  Fas  activation  (Bi  et  al., 
2001).  This  results  in  the  accumulation  of  p53  and  the  E2F-1  transcription  factor.  As  E2F-1 
overexpression  induces  apoptosis  and  E2F-1-deficient  cells  are  resistant  to  Fas  induced 
apoptosis,  it  is  possible  that  E2F-1  may  be  a  mediator  of  selenium-induced  cell  death. 
In  vivo,  the  augmented  levels  of  soluble  Fasl  produced  by  carcinoma  cells  could  also 
enhance  immunological  responses  that  could  target  the  carcinoma  cells  (Krammer,  2000). 
Tumours  expressing  Fasl  are  rapidly  destroyed,  with  these  sites  regressing  into  abscesses 
(Restifo,  2000b)  and  this  activity  is  thought  to  be  mediated  by  the  activation  of  caspase  1 
(interleukin(IL)-l  P  -converting  enzyme  -  ICE).  In  mouse  models  Fas  activation  has  been 
linked  to  the  production  of  IL-1P  and  IL,  18  (Miwa  et  al.,  1998;  Puren  et  al.,  1998)  which 
in  turn  leads  to  the  induction  of  the  inflammatory  cytokine  IL-8.  IL-1P  is  known  to  trigger 
a  variety  of  immune  activating  chemokines  and  cytokines  possibly  via  NF-KB 
transactivation  (reviewed  in  (Restifo,  2000a)).  Activation  of  the  Fas  pathway  by  selenium Chapter  8  155 
compounds  could  therefore  be  a  factor  explaining  their  effects  in  enhancing  anti-tumor 
immune  responsiveness. 
IL,  2  is  known  to  actively  induce  turnour  regression  and  is  widely  touted  as  a  major  anti- 
turnour,  immunotherapeutic  agent  (reviewed  in  (Rosenberg,  2001)).  Selenium  treatment 
can  induce  IL-2  mediated  activities  by  upregulating  IL-2  receptor  subunits  (Roy  et  al., 
1992;  Roy  et  al.,  1994).  It  is  therefore  interesting  to  note  that  IL-2  treatment  has  been 
shown  to  induce  Fasl  expression  and  apoptosis  resulting  in  the  complete  regression  of 
mammary  carcinomas  and  inhibition  of  neoplastic  transition  in  mice  (Wigginton  et  al., 
2001). 
In  this  context  it  is  particularly  interesting  to  note  that  a  recent  study  has  reported  that 
supplementation  of  200Vg/day  of  sodium  selenite  in  head  and  neck  SCC  patients  resulted 
in  a  significantly  enhanced  cell-mediated  immune-responsiveness,  as  reflected  in  the 
ability  of  the  patients  lymphocytes  to  respond  to  mitogenic  stimulation,  to  generate 
cytotoxic  lymphocytes,  and  to  destroy  tumour  cells  (Kiremidjian-Schumacher  et  al.,  1994; 
Kiremidjian-Schumacher  et  al.,  1996). 
Our  data  show  that  Fasl  induction  by  the  selenium  metabolite,  SDG,  is  readily  detectable  at 
a  selenium  concentration  within  the  range  of  plasma  concentrations  found  in  humans, 
although  higher  than  the  average  level  (Section  8.2).  The  concentration  necessary  for  Fasl 
induction  by  pXSC  is  higher  and  correlates  with  the  dose  required  to  induce  apoptosis  by 
this  compound. 
8.4  Signalling  pathways  in  selenium-mediated  apoptosis 
This  study  has  demonstrated  for  the  first  time  global  modification  of  signal  transduction 
pathways  upon  selenium  treatment  (summarised  in  Fig  8.4.1).  Some  of  the  modulations  in 
MAPK  activities  have  been  shown  to  be  functionally  required  for  apoptosis  induction. 
While  alterations  in  ERK5  and  possibly  ERK1/2  may  have  a  small  effect  on  selenium- 
induced  apoptosis,  the  dominant  functional  effect  by  far  (and  reproduced  in  a  variety  of 
tissue  culture  models)  is  the  induction  of  JNK  activity  in  response  to  SDG  and  pXSC  (see 
Chapters  5  and  6). 
JNK  activity  leads  to  the  phosphorylation  of  c-jun  at  serines  63  and  73  and  its  subsequent 
transactivation  (Derijard  et  al.,  1994;  Kyriakis  et  al.,  1994)  (Fig  8.4.1).  Unlike  other 
stimuli,  like  UV  (Shaulian  et  al.,  2000),  that  induce  persistent  JNK  activation  selenium 156 
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Fig  8.4.1  Schematic  representation  of  major  signalling  pathways  mediating  selenium- 
induced  apoptosis. 
The  major  signalling  pathways  investigated  in  this  study  and  found  likely  to  be  functionally 
involved  in  selenium-  induced  apoptosis  are  represented  in  this  diagram.  The  molecules  directly 
investigated  in  this  study  are  in  red.  The  thick  arrows  mark  the  signal  transduction  route  as 
revealed  in  this  study.  Candidates  of  outstanding  importance  that  are  likely  to  contribute  directly 
to  the  regulation  of  the  identified  apoptotic  signalling  route  are  represented  in  blue.  Molecules 
whose  function  may  also  influence  our  model  are  in  purple.  Several  other  major  signalling 
components  which  might  influence  apoptosis  induction  profoundly  are  not  shown  as  these  were 
not  investigated,  thus  this  scheme  is,  at  best,  a  partial  representation. 
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compounds  tested  did  not  induce  c-jun  protein  expression  (Section  5.3.2).  However,  c-jun 
transactivation  is  enhanced  as  reflected  in  the  induction  of  Fasl  (Section  4.5.2  and  6.3) 
which  is  attenuated  by  inhibition  of  JNK  activity  (Section  6.4)  or  expression  of  a  dominant 
negative  c-jun  mutant  (Section  5.4).  c-jun  homodimers  and  heterodimers  (with  other 
members  of  the  jun  and  fos  family  of  proteins)  form  the  AM  transcription  complex 
(Shaulian  and  Karin,  2001).  AM  DNA-binding  activity  has  been  previously  shown  to 
inhibited  by  sub-micromolar  concentrations  of  SDG,  but  these  concentrations  are  not 
relevant  to  induction  of  apoptosis  (see  section  2.6.7.3). 
The  Fasl  promoter  can  be  directly  activated  by  c-jun,  through  a  single  AP-1  binding  site 
(Eichhorst  et  al.,  2000).  Also,  c-jun-1-  fibroblasts  that  are  relatively  resistant  to  UV  and 
alkylating  agent  induced  apoptosis  are  also  impaired  in  Fasl  induction  (Debatin,  1999; 
Kolbus  et  al.,  2000).  There  is  abundant  evidence  in  the  literature  indicating  that  the  JNK/c- 
Jun  pathway  is  mechanistically  upstream  of  Fasl  (Debatin,  1999;  Eichhorst  et  al.,  2000). 
However,  this  is  not  necessarily  the  case  (reviewed  in  (Davis,  2000)):  for  example,  there  is 
evidence  that  the  Fas/Fasl  interaction  induces  JNK  activation,  rather  than  the  reverse 
(Goillot  et  al.,  1997;  Villunger  et  al.,  2000),  and  that  activation  of  JNK  by  Fas  is  not 
necessarily  required  for  induction  of  apoptosis  (Chang  et  al.,  1999;  Lenczowski  et  al., 
1997;  Low  et  al.,  1999).  Recent  studies  on  JNK1  -/-  JNK2  -/'  cells  have  shown  that  these 
cells  are  not  resistant  to  Fas  induced  apoptosis  (but  resistant  to  UV  and  methyl 
methanesulphonate)  suggesting  that  the  JNK  activation  is  not  downstream  of  Fas  activation 
(Fournier  et  al.,  2000).  Fas  activation  has  also  been  shown  to  activate  both  JNK  and  p38 
activation  in  Jurkat  cells:  however,  in  this  case,  activation  of  the  MKK3/p38  pathway 
appeared  to  be  important  as  a  downstream  target  for  Fas  induced  caspases  (Juo  et  al., 
1997).  Moreover,  targeted  disruption  of  FADD,  the  adaptor  protein  required  for  Fas- 
induced  apoptosis,  does  not  eliminate  adriamycin-induced  apoptosis  (Yeh  et  al.,  1998). 
This  may  be  because  the  Fas  death  domain  of  Fas  binds  independently  to  two  effector 
molecules:  FADD,  which  couples  Fas  to  pro-caspase-8;  and  Daxx,  which  couples  Fas  to 
the  JNK  pathway,  ýossibly  activating  an  independent  apoptotic  programme  (Goillot  et  al., 
1997)  (Fig  8.4.1). 
One  possibility  is  that  the  complexity  in  JNK/p38  signalling  and  its  role  in  Fas  mediated 
apoptosis  is  the  formation  of  self-enhancing  feedback  signals.  This  would  suggest  dual 
functions  for  JNK  (and  possibly  p38)  function;  first,  in  the  activation  of  c-jun  and  Fasl 
induction;  and  second,  following  Fas  receptor  activation,  to  amplify  the  apoptotic  response 
by  activating  further  cell  death  cascades  by  augmenting  Fasl  transcription  and  perhaps 
other  pathways.  If  this  were  the  case,  it  may  explain  the  partial  protection  obtained  in  the Chapter  8  158 
intervention  experiments  on  the  JNK/c-jun/Fasl  pathway.  The  role  of  p38  may  be  post-Fas 
activation,  though  the  rapid  induction  of  p38  activity  and  the  lack  of  effect  of  p38 
inhibitors  on  apoptosis  induction  suggests  otherwise. 
As  far  as  other  signalling  pathways  are  concerned,  activation  of  p38  and  ERK  1/2  and 
inhibiton  of  ERK5  activity  (though  only  in  HeLa  cells  reflecting  its  particular  importance 
in  this  cell  type)  did  not  seem  to  affect  apoptosis  induction  greatly.  However,  these  may 
either  have  a  role  in  'priming'  the  cell  for  apoptosis  or  have  secondary  functions  not 
resolved  in  this  study.  An  interesting  observation  in  this  context  is  that  inhibition  of  ERKs 
1/2  activities  in  HeLa  cells  by  the  specific  inhibitor  PD98059  enhanced  selenium-mediated 
apoptosis  slightly  (Section  5.5.2).  This  may  reflect  the  observation  that  selenium 
compounds  inhibit  activation  of  ERKs  1/2  by  EGF  (Sections  5.5.1).  Forced  activation  of 
ERK5  conferred  a  small  but  consistent  inhibition  of  selenium-mediated  apoptosis  (Section 
5.6.2)  suggesting  a  functional  role  for  the  observed  downregulation  of  ERK5  activity 
(Section  5.6.1).  In  the  oral  cells  activation  of  Akt  by  SDG,  but  not  pXSC,  appeared  to 
constitute  a  potent  survival  signal  (Section  6.6)  though  molecular  targets  of  this  remain 
obscure. 
Modulation  of  a  MAPK  in  isolation  is  not  very  meaningful,  as  its  qualitative  value  is 
absolutely  dependent  on  its  context,  duration  of  activity  and  to  the  activation  status  of  other 
signalling  pathways.  Extensive  crosstalk  and  redundancy  underscore  the  tight  control  of 
the  specificity  of  these  pathways.  From  this  perspective,  it  is  likely  that  the  other 
alterations  observed  in  this  study  with  apparently  non-functional  roles  could  be 
components  of  a  specificity-generating  process  for  apoptosis. 
Exactly  how  selenium  compounds  induce  the  stress  kinase  pathways  is  not  yet  clear.  One 
possibility  is  that  selenium  inhibits  phosphatase  action  that  leads  to  activation  of  kinases 
(usually  mediated  by  phosphorylation).  However,  this  is  unlikely  to  be  the  case  for  the 
activation  of  JNK  as  the  expression  of  MAPK  phosphatase  1  (MKP-1),  which  specifically 
dephosphorylates  and  inactivates  JNK  (Liu  et  al.,  1995),  did  not  protect  from  growth 
inhibition  by  SDG  and  pXSC  (data  not  shown).  Another  hypothesis  to  explain  induction  of 
apoptosis  by  SDG  is  that  it  may  alter  the  redox  status  of  the  cells  by  manipulating  level  of 
a  cellular  reducing  agent,  such  as  Trx,  which  has  been  implicated  in  growth  control  in 
various  contexts  and  is  over-expressed  in  many  tumors.  This  may  be  a  plausible  idea  since 
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Of  particular  interest  in  this  context  is  the  fact  that  ASK1,  one  of  the  upstream  activators  of 
both  JNK  and  p38  (Ichijo  et  al.,  1997)  (see  Fig  8.4.1),  is  inhibited  by  binding  of  reduced 
thioredoxin  to  its  N-terminal  region  (Saitoh  et  al.,  1998):  thus  depletion  of  reduced 
thioredoxin  by  selenium  compounds  by  one  of  the  mechanisms  described  above  might  be 
expected  to  activate  ASK1  and  induce  apoptosis.  Studies  on  Askl  --  cells  have  suggested 
that  it  is  critically  required  for  persistent  JNK  and  p38  activation  (Tobiume  et  al.,  2001),  as 
seen  with  pXSC  and  SDG.  Thus,  studies  of  ASK1  activation  by  selenium  compounds  are 
clearly  of  some  importance. 
While  this  project  was  ongoing  three  papers  appeared  that  had  investigated  the  role  of 
MAPKs  in  the  context  of  selenium.  The  first  two  used  non-growth  inhibitory  doses  of 
selenite  (nM  range),  therefore  their  relevance  to  cancer-chemopreventive  mechanisms  is 
debatable.  One  showed  that  selenite  inhibited  peroxynitrite-induced  activation  of  p38  but 
not  JNK  (Schieke  et  al.,  1999).  The  second  study  reported  selenite-mediated  inhibition  of 
UV-induced  JNK  and  p38  activity  (Park  et  al.,  2000b).  Similar  data  was  reported  for 
selenite  mediated  inhibition  of  caspase  3  activity  (Park  et  al.,  2000a).  However,  the  use  of 
non-growth  inhibitory  doses  make  these  studies  irrelevant  to  the  present  discussion  and 
presumably  reflect  the  ability  of  low  doses  of  selenite  to  stimulate  antioxidant  activities  in 
the  cells.  The  third  report  addressed  the  issue  of  apoptosis  induction  by  selenium 
compounds  directly  and  reported  the  activation  of  p38  and  JNK  kinase  activities  by 
selenite  (the  metabolic  precursor  of  SDG)  but  not  methylselenic  acid  (Jiang  et  al.,  2001a), 
however  no  functional  evidence  was  forthcoming. 
8.4.1  A  two-stage  cellular  response  to  selenium  treatment 
The  activation  of  p38,  JNK,  c-jun  (and  thereby,  indirectly,  AP-1)  and  caspase  3  found  in 
our  study  is  in  apparent  contrast  to  data  obtained  by  non-apoptosis  inducing,  sub- 
micromolar  doses  of  selenium  (selenite  and  SDG)  discussed  above  and  in  Section  2.6.7.3. 
Cellular  responses  to  selenium  treatment  appear  to  reflect  the  two-step  cancer  prevention 
model  described  in  Section  2.5.3.  At  low  concentrations,  selenoprotein  activities  are 
induced  resulting  in  alterations  in  redox  potential  which  quench  the  redox-dependent 
activation  of  the  mentioned  entities  QNE,  AP-1,  caspase  3  etc.  )  (Fig  8.4.2).  At  higher 
concentrations,  more  akin  to  those  showing  chemopreventive  activities,  selenoprotein 
activity  is  already  saturated  and  selenium  metabolites  induce  growth  inhibitory  pathways 
reflected  in  the  activation  of  these  molecules  (Fig  8.4.2).  As  discussed  in  Section  2.6.7.3 
inhibition  of  NF-KB  DNA  binding  activity  has  also  been  shown  for  selenite  treatment, 
again  the  doses  used  were  far  lower  than  those  inducing  apoptosis. 160 
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Fig  8.4.2  Two-stage  model  for  selenium-induced  in  vitro  cellular  responses. 
This  model  shows  that  selenoprotein  activities  increase  in  response  to  low  doses  of  selenium 
treatment  which  can  explain  the  inhibition  of  apoptosis,  stress  kinases,  AP-I  and  caspase  3.  At 
higher  concentrations,  selenoprotein  activities  are  saturated  and  apoptosis/ccll  cycle  arrest  is 
induced  with  concomitant  increase  in  JNK/p38,  ANI  and  caspase  3  activity.  Even  higher 
concentration  result  in  non-specific  toxicity.  The  role  of  signalling  components  in  the  toxic  dose 
ranges  have  not  been  investigated.  The  words  in  parentheses  refer  to  equivalent  response  in  vivo. Chapter  8  161 
In  terms  of  cancer  prevention,  both  these  responses  could  result  in  a  positive  synergy. 
Selenium  supplementation  and  the  resultant  saturation  of  selenoprotein  activities  could 
conceivably  protect  against  damaging  oxidative  stress  in  selenium  deficient  individuals 
while  the  activities  of  the  selenium  metabolites  may  actively  inhibit  neoplastic  growth  in 
selenium  replete  individuals. 
8.5  Turnour  selectivity  of  selenium  compounds:  a  molecular 
hypothesis 
Chemopreventive  selenium  compounds  appear  to  specifically  target  transformed  cells,  as 
normal  cells  and  tissues  appear  to  be  generally  unaffected.  This  study  and  another  on 
prostate  cells  (Menter  et  al.,  2000)  referred  to  earlier  have  recapitulated  this  in  vitro.  It 
remains  a  critical  issue  to  elucidate  the  underlying  mechanisms  of  the  selectivity.  Our 
study  implicates  the  relative  use  of  the  JNK/c-jun/Fasl  signalling  pathway  to  be  critical, 
however  the  molecular  basis  of  this  differential  activation  remains  unresolved. 
Neoplastic  transformation  occurs  as  a  result  of  mutations  which  lead  to  the  changes  in  the 
structure  and  function  of  the  proteins  they  encode.  Cellular  transformation,  clonal 
expansion  and  progression  result  from  accumulation  of  abnormal  protein/s  in  cell.  This 
genotypic,  and  the  resultant  phenotypic,  alteration  distinguishes  normal  cells  from  mutated 
cells  in  the  same  tissue.  As  selenium  compounds  cannot,  conceivably,  detect  alterations  at 
the  genetic  level,  abnormal  proteins  are  its  most  likely  targets. 
As  discussed  in  Section  1.6,  low  molecular  weight  selenium  compounds  can  undergo  a 
number  of  characteristic  biochemical  reactions.  It  can  therefore  be  hypothesised  that 
chemopreventive  selenium  compounds  may  selectively  counteract  the  activities  of 
oncoproteins  by  direct  interactions  while  leaving  the  wild-type  protein  unaffected.  Such  an 
alteration  could  not  only  abrogate  oncoprotein  activity,  it  may  potentially  confer  novel 
chemical  functionality,  perhaps  with  respect  to  redox  regulation.  Such  a  model  could 
therefore  form  the  basis  for  turnour-selective  activity  of  selenium  compounds. 
Given  the  versatility  of  selenium  mediated  biochemical  reactions,  there  are  a  number  of 
conceivable  ways  such  an  activity  could  be  achieved.  There  is  considerable  evidence  that 
activating  mutations  in  proto-oncogenes  often  manifest  in  the  substitution  of  glycine, 
arginine  or  serine  by  cysteine  (see  the  following  paragraphs  for  evidence).  It  is  feasible  that 
selenium  compounds  can  bind  to  the  sulphur  of  the  thiol  group  (of  the  substituted  cysteine) 
as  an  adduct  and  alter  the  oncogenic  property/s  of  the  protein  in  question  (e.  g.  type  2 Chapter  8  162 
reaction  in  Section  1.6).  Other  selenium  mediated  biochemical  modifications  like 
formation  of  selenotrisulphide  bond  (S-Se-S)  and  formation/disruption  of  disulphide  bonds 
are  candidate  mechanisms  that  could  potentially  alter  the  acquired  functionality  of 
oncoproteins  which  have  gained  thiol  containing  aminoacids  (like  cysteine)  by  mutational 
events.  In  this  way  selenium  could  selectively  alter  the  properties  of  transformed  cells  but 
not  of  untransformed,  normal  cells. 
Signal  transduction  proteins  with  altered  activities  are  often  oncogenic  and  frequently 
acquire  cysteine  substitutions.  This,  according  to  our  hypothesis,  could  allow  selenium 
compounds  to  differentially  influence  signalling  pathways  between  transformed  and 
untransformed  cells.  For  example,  cysteine  substitutions  are  quite  common  in  K-ras  which 
lead  to  its  acquisition  of  transforming  activity.  Glycine  to  cysteine  activating  mutations  in 
K-ras  have  been  seen  in  sporadic  hepatic  angiosarcomas  (Przygodzki  et  al.,  1997),  oral 
squamous  cell  carcinoma  (Kuo  et  al.,  1994)  and  in  non-small  cell  lung  carcinomas  (where 
it  is  an  indicator  of  poor  prognosis)  (Noda  et  al.,  2001;  Slebos  and  Rodenhuis,  1992). 
Constitutively-activating  mutations  of  signalling  molecules  are  frequently  oncogenic. 
Often  activation  of  signalling  proteins  are  dependent  on  dimerisation  and  cysteine 
substitutions  could  aid  this  process  by  forming  covalent  links  via  disulphide  bonds.  Stat-3, 
when  constitutively  activated,  is  a  putative  oncogene  and  is  frequently  mutated  in  several 
turnours,  particularly  in  head  and  neck  cancers  (Garcia  and  Jove,  1998;  Grandis  et  al., 
1998).  It  is  thought  cysteine  substitutions  in  Stat-3  results  in  dimerisation  (via  disulphide 
bridges)  leading  to  constitutive  activity  (Bromberg  et  al.,  1999).  Mutation  in  GTPases 
constitutively  activate  a  subunits  of  signal-transducing  guanine  nucleotide-binding 
proteins  (G-proteins)  and  arginine  to  cysteine  mutations  have  been  documented  in  the 
activation  of  several  G  proteins,  like  the  oncogene  gip2  (Pace  et  al.,  1991). 
Apart  from  direct  modifications  of  signal  transduction  components,  similar  alterations  in 
growth  factor  receptors  could  be  affected  by  selenium  and  thereby  influence  cellular 
signalling.  Activating  cysteine  substitutions  in  growth  factor  receptors,  like  fibroblast 
growth  factor  receptor  3  (FGFR3),  have  been  have  been  reported  to  be  associated  with  a 
number  of  cancers  (Wu  et  al.,  2000). 
Alternatively,  mutations  in  genes  whose  products  protect  against  cancer  initiation  may  act 
as  oncogenes.  Increased  risk  of  oesophagal  SCC  incidence  has  been  related  to  serine  to 
cysteine  mutations  in  the  hOGG1  gene  (Xing  et  al.,  2001).  The  hOGG1  gene  product  is 
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this  mutation  (Kohno  et  al.,  1998).  Curiously,  the  study  which  found  this  association  was 
carried  out  on  the  same  population  which  showed  decreased  mortality  of  oesophagal  and 
gastric  cancer  in  an  intervention  trial  with  supplementation  with  antioxidants,  including 
selenium  (Blot  et  al.,  1993).  A  recent  follow-up  study  has  shown  that  participants  in  this 
trial  who  had  enhanced  plasma'seleniurn  levels,  as  a  result  of  supplementation,  had 
significantly  reduced  risk  of  developing  these  cancers  (Mark  et  al.,  2000). 
The  suggested  hypothesis  would  predict  that  the  efficacy  of  selenium  as  a  chernopreventive 
agent  will  be  depend  on  the  relative  amount  of  the  activated  turnour-promoting  proteins 
(levels  of  one  particular  protein  or  different  ones)  and  available  selenium  for  biochemical 
activity  (eg.  adduct  formation).  This  fits  in  rather  well  with  the  evidence  from  animal 
studies  where  selenium  appears  to  have  a  more  profound  effect  at  initiation  stages 
(presumably  lower  number  of  mutational  events)  than  on  later  ones  (el-Bayoumy  et  al., 
1992;  Ip  et  al.,  1995;  Thompson  et  al.,  1982).  Also  chernopreventive  action  of  selenium 
compounds  is  generally  dose-dependent  Qp  et  al.,  1991;  lp  et  al.,  1995;  Reddy  et  al.,  1997). 
Several  studies  have  shown  that  higher  doses  of  the  initiating  carcinogen  tend  to  shift  the 
anti-tumorigenic  effects  of  selenium  to  the  post-initiation  phase  (Ip  and  Daniel,  1985;  Ip  et 
al.,  1981).  This  again  could  be  explained  by  a  temporal  delay  before  selenium  compounds 
have  altered  the  activities  of  the  oncoproteins  in  sufficient  levels  to  display  an  effect  at  the 
organismal  level. 
It  should  be  cautioned  that  early  effects  of  selenium  in  chemical-induced  cancer  models 
can  be  attributed,  at  least  partially,  to  carcinogen  detoxification,  reduction  of  oxidative 
stress  and/or  inhibition  of  carcinogen-DNA  adduct  formation  (see  Section  2.6).  These 
phenomena  suggest  a  possible  role  for  selenoprotein  induction  and  the  hypothesis 
presented  above  need  not  be  invoked. 
To  test  this  hypothesis,  the  following  preliminary  information/experiments  would  be 
useful:  a  literature  trawl  should  reveal  the  key  gene  products  with  known  oncogenic 
potential  for  those  cancer  types  most  effectively  protected  against  by  selenium 
supplementation.  Elucidation  of  differentially  activated  pathways  between  turnours  and 
corresponding  normals,  resulting  from  in  vitro  studies  such  as  those  described  in  Chapter 
6,  could  also  suggest  potential  candidates  meriting  such  investigations.  Data  from  pre- 
existing  polymorphism  studies  could  be  screened  to  identify  cysteine  substitutions  with 
putative  contribution  to  activity.  Overexpression  of  wild-type  and  cysteine  substituted 
tagged  candidate  proteins  in  cells  treated  with  or  without  radiolabelled  selenium  followed 
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mobility  shift  should  indicate  selenium-adduct  formation.  This  approach  is  obviously  not 
applicable  to  selenoproteins  and  other  proteins  that  may  physically  bind  selenium.  More 
precise  characterisation  of  candidate  proteins  is  possible  by  exploiting  recent  advances  in 
mass  spectroscopy.  Potential  candidates  would  then  have  to  be  investigated  further  to  see  if 
their  normal  and  oncogenic  activities  are  altered  in  response  to  adduct  formation. 
Finally,  selective  uptake  of  selenium  by  tumour  cells  could  also  be  a  component  of 
selectivity.  However,  no  evidence  for  a  mechanistic  pathway  that  may  facilitate  such  an 
activity  is  currently  available.  Also,  the  relatively  broad  spectrum  of  cancers  affected  by 
selenium  treatment  makes  this  possibility  unlikely  as  one  would  expect  either  a  global  or 
very  tissue  specific  enrichment  of  selenium. 
8.6  Translational  considerations  and  chemoprevention  strategies 
A  candidate  chemopreventive  agent  ideally  has  to  satisfy  several  criterion  before  it  can  be 
can  recommended  for  general  use.  These  would  include  supporting  evidence  from 
epidemiological  and  animal  studies;  detailed  knowledge  of  metabolism  and  identification 
of  active  metabolites;  knowledge  of  most  likely  mechanisms  at  the  molecular  and  cellular 
level;  low  incidence  of  adverse  effects  that  are  easily  reversible;  knowledge  of  endpoint 
biomarkers  and  the  ease  of  administration.  Finally,  the  possibility  of  developing  'fine- 
tuned',  second  generation  chemopreventive  agents  based  on  the  features  of  the  original 
should  also  be  an  important  criteria  as  this  may  allow  greater  flexibility,  increased 
accessibility  and  also  enhanced  specificity. 
While  evidence  in  support  of  anti-tumorigenic  activities  of  selenium  has  been 
accumulating  from  both  epidemiological  studies  and  those  on  animal  models,  much  less  is 
known  about  the  mechanisms  involved.  Similarly,  selenium  metabolism  is  reasonably  well 
characterised  but  there  is  a  vigorous  debate  regarding  the  identity  of  the  active  metabolites. 
Surrogate  end-point  biomarkers  are  usually  derived  from  the  underlying  mechanism/s  of 
action.  As  these  molecular  and  cellular  dynamics  have  remained  elusive,  direct  end  point 
markers  for  selenium  mediated  anti-turnour  activity  have  been  largely  unavailable. 
This  study  has,  for  the  first  time,  identified  signalling  pathways  that  form  the  underlying 
molecular/cellular  basis  for  selenium-induced  apoptosis  -  considered  to  be  a  major 
candidate  mechanism  of  anti-tumorigenic  activity.  Also,  by  demonstrating  the  induction  of 
Fasl  that  can  be  secreted  into  the  extracellular  space,  a  putative  candidate  that  may 
influence  the  anti-tumour  immune  functions  of  selenium  has  been  recognised.  These Chapter  8  165 
findings  have  implications  on  addressing  some  of  the  major  issues  relevant  to  the  use  of 
selenium  compounds  as  chernopreventive  agents. 
Assessment  of  effects  of  selenium  on  cancer  incidence  without  using  cancer  as  an  endpoint 
is  an  almost  insurmountable  problem.  Surrogate  endpoint  biomarkers  offer  the  potential  of 
evaluating  the  efficacy  of  chernopreventive  agents  without  the  high  costs,  and  time 
commitments  of  large-scale  intervention  trials.  Therefore  it  is  crucial  to  identify  and 
develop  candidate  surrogate  markers  of  selenium  efficacy  and  safety.  Apoptosis  appears  to 
be  a  plausible  component  of  anti-tumourigenic  activities  of  selenium.  Therefore  it  can  be 
considered  as  a  putative  surrogate  biomarker  to  directly  assess  efficacy  of  selenium 
compounds.  Selenium  has  been  shown  to  induce  apoptosis  in  xenografts  under  conditions 
where  xenograft  growth  is  reduced  (Chapter  7).  Correlating  chernopreventive  activities 
with  the  ability  to  induce  apoptosis,  in  vivo,  could  therefore  provide  a  measure  of  the 
potential  of  apoptosis  as  a  biomarker  assessing  efficacy  of  selenium  compounds.  Similar 
approaches  could  also  be  used  to  assess  JNK  activity  (using  phospho-specific  antibodies) 
and  Fasl  induction  as  candidate  biomarkers. 
In  humans,  procedures  to  detect  apoptosis  and  JNK  activation  are  likely  to  be  complicated 
and  of  an  invasive  nature.  It  is  unlikely  enough  biornaterial  could  be  obtained  from  non- 
invasive  procedures,  such  as  sputum  or  urine  collection,  to  evaluate  these  markers 
convincingly.  Instead,  the  use  sensitive  ELISA  based  assays  that  can  detect  small  increases 
of  circulating  Fasl  in  plasma  may  be  of  more  practical  use  since  induction  of  Fasl  appears 
to  correlate  with  the  extent  of  apoptosis  induction  (Sections  4.5.2  and  6.3).  It  should  be 
cautioned  that  some  cancers  result  in  higher  levels  of  circulating  Fasl  which  may  mask  any 
selenium-induced  increase  (Anastassiou  et  al.,  2001;  Bennett  et  al.,  2001):  confounding 
issues  such  as  this  needs  to  be  investigated  thoroughly.  The  issue  of  circulating  Fasl  will  be 
addressed,  in  vivo,  in  the  course  of  our  ongoing  xenograft  analysis. 
The  Clark,  1996  study  reported  a  significant  reduction  in  the  incidence  of  mortality  due  to 
cancer  of  the  lung,  prostate  and  colon.  This  was  achieved  by  supplementation  of  the  diet 
with  200[tg  of  selenium  per  day.  While  this  report  has  generated  a  lot  of  interest  in  using 
selenium  as  a  chemopreventive  agent,  little  has  been  achieved  in  the  form  of  comparative 
analysis  of  these  clinical  findings  with  what  is  known  from  in  vitro  and  animal  studies.  In 
this  trial  selenium  was  administered  in  the  form  of  selenised  yeast,  which  is  a  complex 
source  of  selenium  compounds  like  SM,  SMC,  selenocysteine  and  selenothionine  (Bird  et 
al.,  1997;  Ip  et  al.,  2000b)  -  thus  the  form  of  selenium  responsible  for  cancer  prevention 
remains  undefined.  It  is  thus  of  paramount  interest  to  identify  the  active  form.  Detailed Chapter  8  166 
knowledge  of  molecular/cellular  mechanisms  mediating  the  induction  of  cell  death  by 
selenium  compounds  could  also  be  a  tool  in  the  identification  of  active  metabolites  of 
selenium.  This  would  particularly  be  the  case  for  pathways,  like  the  JNK/c-jun/Fasl, 
relative  use  of  which  is  tightly  linked  to  the  extent  of  apoptosis.  If  such  a  pathway  was 
critical  to  the  anti-cancer  activities  of  selenium,  then  one  might  expect  that  the  active 
metabolites  would  induce  this  pathway  more  efficiently  than  other  compounds.  Obviously 
such  an  approach  could  be  confounded  by  stability  and  specific  biochemical 
transformations  of  the  particular  metabolite,  but  when  interpreted  together  with  data  from 
in  vivo  chernoprevention  studies  may  yield  valuable  insights. 
Molecular  mechanisms  of  action  could  also  provide  ample  evidence  for  specificity, 
efficacy  and  for  possible  adverse  side-effects.  The  other  aspect  where  such  knowledge  will 
prove  invaluable  is  in  the  field  of  novel  drug  development.  Based  on  identified 
molecular/cellular  mechanisms  new  drugs  can  be  specifically  tailored  for  enhancement  of 
efficacy  and  minimisation  of  toxicity.  This  is  particularly  a  possibility  for  organic  selenium 
compounds.  However,  such  an  approach  primarily  needs  the  establishment  of  detailed 
structure-function  relationships.  Therefore,  how  alteration  in  the  structure  may  affect 
induction  of  JNK,  say,  might  provide  useful  data  for  design  of  novel  anti-tumourigenic 
selenium  based  compounds.  On  the  other  hand  if  activities  of  selenoproteins  are  involved 
in  cancer-protective  effects,  then  gene  therapy  approaches  ectopically  modifying 
expression/activity  of  critical  selenoproteins  need  to  be  considered. 
Laboratory  animals  and  in  vitro  studies  have  greatly  aided  the  understanding  of 
mechanisms  responsible  for  the  protective  role  of  selenium  against  cancer.  How  far  this 
knowledge  is  applicable  to  humans  remains  unclear.  Therefore  there  is  a  need  to  initiate 
pilot  studies  to  determine  the  role  of  various  forms  of  selenium  (particularly  those 
approved  for  human  use)  on  cellular  and  molecular  targets  that  are  critical  to  the  process  of 
carcinogenesis.  These  studies  are  necessary  to  learn  whether  data  obtained  in  laboratory 
animals  and  in  vitro  are  applicable,  if  so  how  far,  to  humans.  Again  it  is in  the  selection  of 
these  candidate  molecular/cellular  targets,  whose  investigation  is  proposed,  that  knowledge 
obtained  from  this  and  similar  studies  will  be  invaluable. 
8.7  Future  work 
This  section  discusses  some  of  the  issues  that  need  to  be  addressed  in  order  to  obtain  a 
clearer  picture  of  selenium-induced  programmed  cell  death.  Some  deal  with  mechanistic Chapter  8  167 
considerations  resulting  directly  from  this  particular  study  (see  Fig  8.4.1)  while  others  are 
peripheral  issues  of  considerable  importance. 
8.7.1  Mechanistic  considerations  of  SDG-  and  pXSC-induced  apoptosis. 
In  order  to  characterise  the  molecular  mechanisms  underlying  apoptosis  induction  by  SDG 
and  pXSC,  the  expertise  developed  during  the  course  of  this  study  needs  to  be  extended 
and  appropriately  exploited.  Work  presented  here,  taken  together  with  a  survey  of  the 
current  literature,  suggests  that  there  are  several  mechanistic  pathways,  working  at 
different  levels  that  may  mediate  cancer  protective  effects  of  selenium;  thus  the  picture  is 
far  from  complete.  It  is  obvious  from  the  intervention  studies  that  though  the  JNK/c- 
jun/Fasl  pathway  is  important,  it  does  not  completely  account  for  the  level  of  apoptosis 
induction.  All  interventions  produced  only  partial  abrogation  of  apoptosis  suggesting  other 
mechanisms  are  also  involved.  A  simplistic,  linear  route  has  been  characterised  (see  Fig 
8.4.1),  whereas,  current  knowledge  of  other  signalling  mechanisms  suggests  that  pathways 
rarely  represent  a  simple,  linear  chain  of  events.  Tbus,  functions  of  other  contributing 
factors  need  to  be  addressed. 
Within  our  specific  model  of  proapoptotic  signalling  several  issues  need  to  be  addressed 
(see  Fig  8.4.1  and  discussion  in  Section  2.6.7.1).  Mitochondria  mediated  cell  death  plays  a 
pivotal  role  in  apoptosis  and  is  regulated  by  the  Bcl2  family  of  proteins.  However,  at  the 
protein  level,  no  alterations  in  the  Bc12  family  members  were  detectable.  Given  their 
critical  role  in  regulating  apoptosis  and  evidence  in  the  literature  about  post-translational 
modifications,  particularly  inhibitory  modifications  mediated  by  JNE'  investigation  into 
such  phenomenon  is  warranted.  Release  of  cytochorome  c  from  the  mitochondria  is  an 
early  event  in  apoptosis  induction  via  these  organelles.  Therefore,  an  initial  investigation 
assessing  cytochrome  c  release  should  indicate  the  involvement  of  mitochondria.  If  this 
were  so,  detailed  analysis  of  whether  post-translational  modifications  alter  Bcl2  activities 
could  be  considered.  Relative  contributions  of  receptor  mediated  and  mitochondria- 
dependent  apoptosis  can  be  assessed  by  the  relative  activations  of  caspases  8  and  9, 
respectively.  However,  there  is  indication  that  selenium  compounds  activate  both  capsase  8 
and  9,  suggesting  both  these  pathways  may  be  acting  concomitantly. 
The  role  of  p38  induction  remains  intriguingly  unresolved.  Its  activation  kinetics  suggests 
a  putative  role  but  this  was  not  confirmed  in  the  functional  intervention  studies  in  the 
context  of  apoptosis  induction  by  SDG  and  pXSC.  However,  p38  can  induce  cell  cycle 
arrest  and  potentiate  apoptosis  indirectly  in  other  contexts  (Bulavin  et  al.,  2001).  If  this Chapter  8  168 
were  the  case,  initiating  an  acute  apoptotic  response  could  obscure  its  early  activity.  To 
investigate  this  possibility,  synchronously  growing  cells  will  need  to  be  treated  with  a 
broad  dose  range  of  selenium  compounds  and  their  progression  through  the  cell  cycle 
observed. 
The  functional  role  of  Akt  as  a  survival  signal  (in  SDG  treated  SCCs)  is  also  very 
intriguing.  Akt  can  directly  block  transcription  of  Fasl  by  inhibiting  transactivation  of  the 
Forkhead  transcription  factor  (see  Fig  8.4.1)  (Brunet  et  al.,  1999).  As  overexpression  of  c- 
jun  dominant  negative  and  JNK  inhibition  only  reduces  Fasl  induction  partially,  it  remains 
a  possibility  that  other  transcription  factor  regulate  its  transcription.  Initially,  the  effect  of 
inhibition  of  Akt  activation  on  the  induction  of  Fasl  could  be  measured.  Akt  can  also 
directly  inhibit  capspase  9  activity  (Bulavin  et  al.,  2001),  as  selenite  has  been  shown  to 
process  pro-caspase  9  but  not  enhance  its  activity  (Jiang  et  al.,  2001a),  it  is  possible  that 
Akt  activation  functions  to  inhibit  casapase  9  activation.  Initially  this  could  be  tested  by 
simply  assessing  caspase  9  activity  in  response  to  selenium  in  the  presence  or absence  of  a 
specific  PI3K  inhibitor.  Similar  inhibitor-mediated  experiments  could  be  performed  to 
assess  whether  Akt  activation  retards  c-jun  activity  as  has  been  previously  reported 
(Nikolakaki  et  al.,  1993). 
As  discussed  in  Section  8.4,  ASK1  is  a  potential  upstream  target  for  induction  of  apoptosis 
and  stress  kinase  activation.  It  is  suggested  that  its  redox  regulation  via  thioredoxin  may 
make  it  a  suitable  target  for  modulation  by  selenium  compounds.  This  hypothesis  can  be 
tested  by  primarily  looking  for  activation  of  ASK1  by  selenium  compounds  at  apoptosis- 
inducing  doses.  Our  initial  studies  failed  to  detect  any  substantial  activation,  however  these 
are  inconclusive  as  known  inducers  of  ASK1  also  failed  to  show  any  effect  on  its 
activation.  Optimisation  of  the  technique  is  currently  ongoing.  If  ASK1  activation  is 
implicated,  dominant  negative  mutants  of  ASK1  will  be  used  to  resolve  its  contribution  to 
apoptosis  induction.  Modulation  of  ASK1  activity  by  thioredoxin  can  be  initially  tested  by 
immunoprecipitation  to  analyse  changes  in  ASK1-thioredoxin  binding  in  response  to 
selenium  treatment.  If  necessary,  further  characterisation  including  assays  for  alterations  in 
subcellular  localisation  can  be  performed  using  immunocytochemistry. 
Three  major  signalling  entities  known  to  influence  apoptosis  significantly  and  whose 
modulation  by  selenium  is  already  recorded  are  PKC,  PKA  (see  Section  2.6.7.4). 
Investigation  of  the  activities  of  these  molecular  entities  at  apoptosis-inducing  doses 
followed  by  functional  intervention  using  overexpression  and  pharmacologic  strategies  are 
necessary  to  dissect  their  role/s.  It  is  interesting  to  note  that  Fas  mediated  apoptosis  may  be Chapter  8  169 
inhibited  by  PKC  activation  (Gomez-Angelats  et  al.,  2000;  Gomez-Angelats  and 
Cidlowski,  2001),  this  may  suggest  that  the  inhibition  of  PKC  observed  on  selenium 
treatment  may  have  a  functional  role.  The  transcription  factor  NF-icB  induces  the 
expression  of  several  apoptosis  suppressing  proteins  of  the  Bcl2  and  IAP  families  (Reed, 
2001).  Therefore  it  is  intriguing  to  note  that  selenite  can  inhibit  NF-KB  activity  (Kim  and 
Stadtman,  1997),  though  at  non-apoptosis  inducing  doses.  This  therefore  warrants 
investigation  of  NF-KB  status  at  growth  inhibitory  condition  and  whether  any  such 
modulation  is  functionally  significant  to  apoptosis-induction. 
The  relevance  of  signalling  pathways  needs  to  be  investigated  in  vivo.  With  the  advent  of 
phosphorylation  state  specific  antibodies,  descriptive  studies  should  be  relatively  less 
complicated.  However,  intervention  approaches  are  still  technically  limiting  and  require 
complicated  genetic  procedures.  A  sensible  approach  to  in  vivo  signalling  studies,  given 
the  limited  amount  of  biological  material  and  complicated  procedures  involved,  is  a 
translational  approach  of  tissue  culture  knowledge  to  look  for  targets  that  are  likely  to  be 
involved.  It  is  from  this  consideration  that  the  xenograft  approach  described  in  Chapter  7 
was  initiated  and  should  be  instrumental  in  validating  several  mechanistic  issues  in  vivo. 
&7.2  Broader  perspectives  on  selenium  mediated  chemoprevention 
As  discussed  in  the  Chapter  2,  the  biological  activities  of  selenium  are  properties  of  its 
various  covalent  compounds  rather  than  intrinsic  properties  of  the  element  per  se.  Keeping 
this  in  mind  and  the  vigorous  debate  on  the  identity/s  of  active  compounds,  there  is  a  need 
to  investigate  whether  a  molecular  mechanism  identified  for  a  particular  compound  is 
relevant  to  other  compounds.  In  vitro  assays,  as  described  in  this  study,  can  be  used  to  test 
different  selenium  compounds  for  candidate  mechanisms.  While  this  study  shows  the 
natural  metabolite,  SDG  and  the  synthetic  organoselenium  compound,  pXSC  to  share 
similar  mechanisms,  it  may not  necessarily  be  so  for  other  compounds.  Monomethylated 
selenium  compounds  are  reported  to  mediate  enhanced  chernopreventive  activities 
accompanied  with  reduced  non-specific  DNA  damage  in  comparison  to  inorganic 
compounds  (see  Section  2.5.1).  It  has  been  recently  reported  that  methylselenic  acid  did 
not  activate  JNK  at  apoptosis  inducing  doses,  however  p38  activity  is  induced  (Jiang  et  al., 
2001a).  In  contrast,  recent  work  by  J.  Fleming  has  shown  that  SMC  (a  methylselenic  acid 
precursor)  induces  JNK  activation  at  apoptosis-inducing  doses.  While  there  is  some 
evidence  that  the  modulation  of  the  MAPKs  may  be  a  common  feature  of  several 
chemopreventive  selenium  compounds,  no  overarching  conclusions  can  be  made  until  all 
the  major  compounds  are  uniformly  tested  and  relative  contributions  assessed. Chapter  8  170 
A  major  step  in  understanding  tumour-specific  effects  of  selenium  treatment  would  be  the 
qualitative  and  quantitative  analysis  molecular  mechanisms  underlying  anti-cancer 
activities  of  selenium  compounds.  The  use  of  sensitive  cDNA  microarray  technology  can 
provide  a  global  perspective  of  selenium-induced  differential  gene  expression  profiles  in 
normal  and  tumour  tissues.  Apart  from  implicating  differential  gene  expression  (for  e.  g., 
Fasl),  our  study  also  suggests  that  differential  modulation  of  activities  of  signalling  entities 
(for  e.  g.,  JNK)  may  form  the  basis  of  tumour-selectivity.  To  resolve  such  issues  proteomic 
approaches  need  to  be  considered. 
All  mechanistic  phenomenon  underlying  anti-tumour  activities,  particularly  programmed 
cell  death,  of  selenium  compounds  in  tissue  culture  settings  need  to  be  validated  in  vivo. 
This  is  also  the  route  for  identification  of  novel  biomarkers  of  selenium  activity  as  a 
chernopreventive  agent.  As  seen  with  Fasl  and  immune  enhancement  by  selenium,  a  study 
of  underlying  mechanisms  of  a  particular  process  may  often  reveal  interesting  clues  to 
possible  molecular/cellular  basis  of  other,  perhaps  not  directly  overlapping,  phenomenon. 
Validations  of  these  processes  in  vivo  will  not  only  address  the  primary  activity  under 
scrutiny  but  may  also  reveal  mechanistic  foundations  of  other  related  activities. 
Chernoprevention  of  cancer  is  likely  to  have  a  significant  impact  on  the  health  of  the 
world's  population.  One  of  the  candidates  likely  to  be  considered  (perhaps  in  combination 
with  other  agents)  is  selenium.  While  evidence  from  laboratory  animals  and  clinical 
intervention  trials  consistently  report  a  reduction  in  cancer  incidence  on  selenium 
supplementation,  the  molecular  mechanisms  underlying  this  anti-cancer  activity  remains 
unresolved.  Advances  in  the  recent  years  have  implicated  several  candidate  mechanisms, 
but  translation  of  this  body  of  data  (mainly  in  vitro)  to  clinical  situations  has  remained 
agonisingly  slow.  Its  is  recommended  that  a  network  of  clinicians,  chemists,  biologists, 
public  health  practitioners  and  epidemiologist  be  established,  as  in  the  chemotherapeutic 
field,  to  aid  the  translation  of  laboratory  findings  to  human  application.  In  the  same 
context,  a  comprehensive  database  of  pharmacologic  properties  of  selenium  compounds 
along  with  their  candidate  mechanisms  of  action  needs  to  be  developed  to  help  the  process 
of  translation. 9  Bibliography 
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Abstract 
Accumulated  evidence  from  prospective  studies,  intervention  trials  and  studies  on 
animal  models  of  cancer  have  suggested  a  strong  inverse  correlation  between  selenium 
intake  and  cancer  incidence.  Several  putative  mechanisms  have  been  suggested  to 
mediate  the  chernopreventive  activities  of  selenium:  of  these,  the  inhibition  of  cellular 
proliferation  and  the  induction  of  apoptosis  are  particularly  attractive. 
The  mitogen  activated  protein  kinase,  (MAPK)  pathways  are  known  to  be  important 
regulators  of  cell  death  and  our  recent  work  has  focused  on  the  involvement  of  these 
pathways  in  selenium-induced  apoptosis  in  primary  cultures  of  oral  cancers  and 
corresponding  normal  mucosa  derived  from  biopsy  material. 
Using  this  system,  the  oral  carcinoma  cells  were  found  to  have  enhanced  sensitivity  to 
apoptosis  when  treated  with  certain  selenium  compounds  compared  to  normal  oral 
mucosa.  Induction  of  Fas  ligand  was  associated  with  selenium-induced  apoptosis. 
Signal  transduction.  studies  suggests  that  selenium  induces  several  changes  in  the 
MAPK  signalling  pathways  but  functional  intervention/inhibitor  studies  indicate  that 
activation  of  the  JNK  pathway  seems  to  be  most  important. 
1.  Introduction 
Selenium  is  an  essential  trace  nutrient  of  fundamental  biological  importance.  Apart 
.I 
from  its  normal  physiological  role  in  maintaining  the  activities  of  a  number  of 
selenoproteins  with  important  antioxidant  or  detoxification  functions,  selenium  has 
also  been  implicated  in  several  disease  conditions.  Recent  research  suggests  that 
selenium-deprived  populations  are  at  risk  of  several  pathological  disorders  such  as 
exacerbated  viral  disease  progression  (e.  g.  111V  infection),  loss  of 3 
immunocompetence,  defects  in  reproduction,  cardiovascular  disease,  negative 
influence  on  mood  and  several  inflammitory  conditions  (for  a  recent  review  see  [24]). 
Several  prospective  studies  and  recent  intervention  trials  suggest  that  the  risk  of 
several  cancers  are  inversely  related  to  selenium  intake  at  plasma  levels  in  the  range  of 
0.5  -  2VM  [4]  (reviewed  in  [10]).  Work  with  animal  cancer  models  also  strongly 
supports  this  evidence:  the  maximum  chernopreventive  effect  occurs  at  supra- 
nutritional,  but  non-toxic,  dietary  levels  (for  review  see  [6,11]),  but  there  is  also  less 
consistent  evidence  that  selenium  deprivation  increases  cancer  incidence/growth  rates 
[5].  This  has  therefore  led  to  a  considerable  interest  in'the  mechanisms  that  may  be 
involved  in  the  cancer-protective  effect  of  selenium. 
Several  putative  mechanism  have  been  suggested  to  explain  the  cancer  protective  role 
of  selenium,  but  none  appear  to  account  for  the  observed  dose  response  relationship. 
As  selenium  is  known  to  be  essential  for  the  activities  of  several  antioxidant  and 
redox  regulatory  enzymes  in  the  form  of  selenocysteine  in  the  catalytic  site,  the 
resulting  increased  ROS  scavenging  activity  at  higher  selenium  levels  is  a  plausible 
mechanism  [27].  This  increased  antioxidant  activity  probably  accounts  for  the 
inhibition  of  UV-induced  apoptosis  after  pre-treatment  with  low  concentrations  (nM 
range)  of  selenium  [21,221.  "  Selenium  also  induces  Phase  R  detoxification  enýzymes 
and  influences  the  carcinogen  detoxification  process  [3].  However,  the  activities  of 
these  selenoenzymes  are  saturated  at  selenium  concentrations  considerably  less  than 
those  shown  to  have  maximum  chemopreventive  effect  in  animal  models  [35].  This 
implies  that  even  though  the  antioxidant  and  carcinogen  detoxification  processes  may 
contribute  significantly  to  the  chernopreventive  effect,  other  mechanisms  must  also  be 
involved. 4 
Selenium  appears  to  have  a  protective  effect  at  various  stages  of  carcinogenesis.  It  is 
thought  that  it  is  most  effective  in  the  early  stages  but  there  is  also  evidence  of  it 
influencing  later  stages  of  cancer  progression  [14].,  It  is  therefore  very  likely  that 
selenium  works  through  several  different  mechanisms  which  vary  in  importance  at 
different  stages  of  cancer  progression.  Thus,  the  carcinogen  detoxification  and  ROS 
scavenging  activity  induced  by  selenium  may  be  more  relevant  at  the  early  stages  of 
carcinogenesis,  whereas  others,  like  growth  inhibition  and  apoptosis  induction,  may 
be  critical  in  later  advanced  stages. 
A  strong  correlation  has  been  observed  between  the  effectiveness  of  selenium 
compounds  as  chernopreventive  agents  in  vivo  and  their  ability  to  induce  growth  arrest 
and  apoptosis  in  vitro  [18,26].  Extensive  animal  studies  have  also  confirmed  the 
inhibition  of  cellular  proliferation  and  apoptosis  induction  at  chemopreventive 
conditions  in  vivo  [7].  As  these  mechanisms  can  potenially  prevent  clonal  expansion 
of  transformed  cells  and  remove  carcinogen  initiated  cells  from  the  body,  their 
induction  by  selenium  could  be  of  some  importance. 
In  this  article  we  review  the  accumulating  evidence  for  selenium-induced  apoptosis,  as 
a  major  chemopreventive  mechanism  and  discuss  the  potential  molecular  mechanisms 
which  may  be  involved.  In  the  past  decade,  several  molecular  switches  regulating 
apoptosis  have  been  discovered  and  there  is  considerable  interest  in  exploiting  this 
knowledge  to  design  novel  anti-tumour  drugs.  As  chemopreventive  concentrations  of 
selenium  compounds  induce  apoptosis,  it  is  worthwhile  to  study  the  mechanisms 
involved  and  to  identify  the  actual  enzymes/proteins  that  are  the  targets  of  selenium 
action.  Since  known  selenoproteins  may  not  be  the  enzymes  mediating  the  cancer 5 
protective  effects  of  selenium,  such  studies  may,  identify  new  biomarkers  suitable  for 
evaluating  functionally  relevant  levels  of  selenium  in  vivo. 
Signal  transduction  processes  mediated  by  the  MAPK's  (Mitogen  activated  protein 
kinase)  regulate  cellular  responses,  like  proliferation  and  apoptosis,  in  response  to 
,.  extracellular  stimuli.  We  have  therefore  systematically  invesigated  whether  selenium- 
mediated  changes  in  the  MAPK  pathways  are  responsible  for  the  induction  of 
apoptosis  by  selenium  compounds. 
12.  Selenium  and  apoptosis  I 
The  first  evidence  for  selenium  induced  apoptosis  came  in  the  early  1990's  from  in 
vitro  studies  on  several  different  cell  lines  of  both  human  and  rodent  origin  [18,31]. 
This  was  soon  followed  by  in  vivo  experimental  evidence  in  animal  cancer  models 
clearly  establishing  the  involvement  of  -  apoptosis  in  selenium  mediated  anti-cancer 
activities  [7,13].  There  was  an  initial  controversy  that  selenium  compounds,  selenite 
in  particular,  induced  necrotic  cell  death  associated  with  single  strand  DNA  damage; 
however,  further  reports  using  methylated  forms  of  selenium  have  successfully 
dissociated  DNA  damage  induced  necrosis  from  the  apoptotic  response  observed  [33]. 
It  has  always  been  evident  that  the  chernopreventive  abilities  of  selenium  compounds 
vary  depending  on  their  chemical  structure.  Monomethylated  compounds  are 
especiaHy  effective  'as  chemopreventive  agents,  with  much  reduced  non-specific 
toxicity  compared  to  other  forms,  like  selenite  [33].  The'  fact  that  these 
monomethylated  derivatives  induce  apoptosis  rather  than  a  necrotic  cell  death 
underlines  the  importance  of  apoptosis  as  a  major  chernopreventive  mechanism. 
Another  illumminating  case'  is  that  of  triphenylselenonium  which  inhibits  DNA 
synthesis  and  consequently  induces  cytostasis  but  not  apoptosis  [12].  As  this  does  not 6 
destroy  transformed  cells  in  the'body,  thisý'compound  is  only  effective  when  present 
continuously  and  loses  its  efficacy  as  a  chemopreventive'agent  when  the  treatment  is 
withdrawn  [121. 
Our  group,  using  a  mouse  erythroleukemia  cell  line,  was  able  to  shbw  in  1994  that 
induction  of  apoptosis  by  selenodiglutathione  (SDG)'  the  primary'  metabolite"of 
selenite,  was  independent  of  wild-type  p53  activity.  [18).  This  has  since  been 
confirmed  for  methylselenocyanate  in  a  mouse  mammary  cell  line  with  a  p53  null 
phenotype  [15]  and  for  selenomethionine  in  a  colon  cell  lines  expressing  a  mutated 
p53  [25].  As  p53  mutations  are  present  in  a  majority  of  human  cancers,  the  fact  that 
selenium-induced  apoptosis  is  p53  independent  is  of  potential  usefulness. 
Alterations  in  cell  cycle  proteins  and  inhibition  of  DNA  synthesis  have  also  been 
observed  with  selenium  treatment.  A  detailed  study  using  synchronised  cells  revealed 
that  Se-methylselenocysteine  treatment  resulted  in  a  prolonged  delay  in  the  S-phase, 
rather  than  a  classical  cell  cycle  block  [30].  This  was  coincident  with  a  significant  loss 
of  cdk2  activity  and  was  preceded  by  an  early  transient  decrease  in  cyclin  E  levels 
allowing  the  cells  to  enters  S-phase  but  then  impeding  further  cell  cycle  progress  [301. 
Consistent  with  this,  inhibition  of  DNA  synthesis  activity  has  also  been  reported  and 
has  been  attributed  to  the  loss  of  thymidine  kinase  activity  [32].  Whether  this  delay 
I 
sensitises  cells  to  apoptosis  or  is  an  independent  effect  remains  to  be  investigated. 
Thus,  to  summarise,  the  current  consensus  is  firstly  that  selenium  induces  apoptosis 
both  in  vivo  and  in  vitro  at  physiologically  relevant  doses,  and  this  may  be  a  major 
mechanism  mediating  the  anti-turnour  activity  of  selenium.  Secondly,  this 
phenomenon,  at  least  for  the  selenium  compounds  tested,  is  independent  of  p53 7 
function  "and  this  is  of  enormous-  significance  in  terms  of  desiining  eff6ctive 
therapeutic  regimens. 
3.  Selenium  and  apoptotic  signal  transduction 
A  major  new  finding  to  arise  from  our  recent  studies  is  that  induction  of  apoptosis  by 
selenium  compounds  appears  to  be  due  to  the  induction  of  Fas  ligand  (data  submitted 
for  publication).  We  have  also  systematically  studied  the  involvement  of  the  MAPK 
pathways  in  apoptosis  induction  by  selenium  compounds,  such  as  selenodiglutathione 
(SDG)  and  1,4-phenylenebis(methylene)selenocyanate  (P-XSC).  SDG  is  the  primary 
metabolite  of  selenite,  the  most  commonly  used  form  of  selenium  used  in  animal 
studies,  while  p-XSC  is  a  synthetic,  organoseleniurn  compound  with  one  of  the 
highest  chempreventive  indices  known  for  any  form  of  selenium  [7]. 
We  have  performed  these  studies  on  human  oral  cancers  and  their  normal  mucosa 
counterparts,  using  a  panel  of  primary  cultures  derived  from  biopsy  material.  The 
rationale  for  this  being  the  fact  that  respiratory  tract  cancer  is  one  of  the  cancer  types 
for  which  the  epidemiological  evidence  for  a  cancer  protective  effect  of  selenium  is 
strongest.  Our  major  findings  are  also  reproducible  in  established  cell  lines  in  which 
signalling  pathways  have  been  well  characterised  and  appear  to  be  conserved  in 
different  cell  biology  systems. 
A  potentially  important  observation  is  that  in  this  oral  system  is  that  carcinomas  are 
significantly  more  sensitive  to  induction  of  apoptosis  SDG  than  normal  oral  mucosa 
(data  submitted  for  publication).  Detailed  investigation  into  the  differences  between 
the  selenium-mediated  apoptosis-inducing  mechanisms  in  normal  and  tumour  cells  in 
this  novel  in  vitro  culture  system,  may  provide  crucial  insight  into  the  tumour 
specificity  observed. 8 
Our  work  shows  that  the  activities  of  the  so  called  'pro-proliferative'  pathways  like 
ERKs  1,2  are  very  slightly  enhanced  whereas  the  so  called  'stress  activated  kinases', 
c-jun  N-terminal  kinase  (JNK)  and  p38  kinase  are  strongly  induced  (see  Fig.  1  for 
summary  of  the  signalling  pathways  involved)(data  submitted  for  publication).  This 
considerably  extends  the  earlier  evidence  for  induction  of  JNK  by  p-XSC  111.  Taken 
together  it  appears  that  these  alterations  in  the  MAPK  pathways  tip  the  balance  in 
favour  of  an  apoptotic  response. 
We  have  also  demonstrated  by  functional  studies  that  the  JNK  pathway  is  of  particular 
importance  since  blocking  this  pathway  by  cotransfection  of  a  dominant  negative  c- 
jun  mutant  significantly  decreased  the  induction  of  apoptosis,  whereas,  inhibiting  the 
p38  kinase  pathway  with  a  specific  chemical  inhibitor  (SB203580)  had  no  effect  (data 
submitted  for  publication).  Activation  of  JNK  by  selenium  is  probably  responsible  for 
the  induction  of  Fas  ligand  since  the  JNK  pathway  has  been  shown  to  be  involved  in 
Fas  ligand  regulation  (via  c-jun  transcriptional  activity)  in  other  contexts  [171. 
In  Hela  cells  the  situation  is  more  complex  since  SDG  and  p-XSC  also  inhibit  the 
activities  of  the  mitogenic  signalling  pathways  mediated  by  ERK's  1,2  and  5  and  this 
inhibition  is  of  some  functional  significance. 
Thus,  it  appears  that,  depending  on  the  tumour/cell  type,  the  modulation  of  the 
activities  of  the  various  MAP  kinases  is  functionally  significant  in  selenium-induced 
apoptosis.  Further  research  is  required  to  elucidate  both  the  upstream  modulators  and 
the  downstream  targets  of  these  pathways  and  their  contribution  to  the  induction  of 
apoptosis. 
4.  Upstream  changes  and  downstream  regulators 9 
Since  selenium  has  been  shown  to  influence  the  redox  state  of  the  cells,  a  redox- 
sensitive  mechanism  may  be,  at  least  partially,  involved  in  influencing  the,  stress 
kinase  pathways  or  even  apoptosis  directly.  For  example,  selenium  has  been  shown  to 
directly  affect  the  thioredoxin  system  which  may  drastically  influence,  the  cellular 
redox  state  [2,8].  Redox  changes  may  then  act  as,  potential  upstream  modulator  of 
various  signalling  pathways  or  even  as  regulators  of  trancriptional  activity  [16,20]. 
Interestingly,  there  is  evidence  for  thioredoxin  directly  inhibiting  ASKI,  a  MAP 
kinase  kinase  kinase  which  can  induce  JNK  and  p38  activity  (see  Fig.  1)  and  also 
apoptosis,  in  a.  redox-dependent  manner  [28].  Whether  selenium  compounds  affect 
ASK1  activity  is  cuffently  being  investigated. 
Selenium  compounds  are  also  known  to  inhibit  several  other  signalling  pathways  such 
as  protein  kinase  A,  C2+  dependent  and  independent  protein  kinase  C's  (PKC), 
Diacylglycerol  kinase  and  thymidine  kinase  [9,23,321.  Whether  these  pathways 
directly  influence  apoptosis  is  yet  to  be  established.  The  inhibition  of  the  PKC's, 
especially,  may  have  some  significance  as  there  are  precedents  of  such  inhibition 
influencing  the  induction  of  apoptosis  [19]. 
ROS  generation  by  selenium  compounds  at  concentrations  that  induce  apoptosis  have 
been  documented  and  inhibition  of  selenium-induced  loss  of  cellular  viability  on 
addition  of  ROS  scavengers  and  antioxidants  have  also  been  observed  [29].  However, 
ROS  generation  does  not  account  for  the  apoptotic  response  completely  as  there  are 
several  differences  observed  between  the  selenium  response  and  that  by  H202  [34]. 
The  Bcl-2  family  of  proteins  are  key  regulators  of  mitochondria  mediated  apoptosis 
and  selenium  is  known  to  influence  mitochondrial  activity  directly  [31],  however,  in  a 
previous  study  no  changes  is  expression  of  Bcl-2  family  members  was  found  [15]. 10 
Consitent  with  this,  we  have  found  that  overexpression  of  bcl-2  in  a  mouse  mammary 
cell  line  showed  no  effect  on  selenium  induced  loss  of  cellular  viability  (unpublished 
data). 
Caspases  are  thought  to  be  the  downstream  executors  of  the  apoptotic  programme  and 
though  there  are  some  documented  evidence  of  caspase-independent  apoptosis,  this 
appears  to  be  quite  infrequent.  It  has  been  suggested  that  selenium  compounds  like 
methylselenol  may  directly  activate  caspases,  thereby  inducing  apoptosis,  by  removing 
the  inhibitory  zinc  atom  from  the  catýlytic  site  of  these  cysteine  proteases  [8].  Our 
data  would  suggest  that  selenium  induced  apoptosis  is,  at  least  partially,  caspase- 
dependent  as  a  pan-caspase  inhibitor  reduces  the  number  of  cells  undergoing 
apoptosis,  (unpublished  data).  Cleavage  of  the  PARP  protein,  a  downstream  target  of 
caspase  3,  is  also  observed  in  s.  ome  situations  (unpublished  data). 
5.  Conclusion 
From  the  evidence  reviewed  here,  it  is  clear  that  the  apoptosis  induction  is  a  major 
mechanism  involved  in  the  anti-cancer  activities  of  selenium  compounds.  It  is  also 
evident  that  selenium  brings  about  global  alterations  in  the  MAPK  signalling 
pathways  and  the  induction  of  apoptosis  is  a  direct  consequence  of  these  changes. 
The  case  for  selenium  compounds  as  a  potentially  useful  class  of  chemopreventive 
agents  is  becoming  compelling.  However,  extensive  basic  research  into  the  molecular 
mechanisms  involved  is  necessary  before  selenium  compounds  can  be  tested 
effectively  in  chernopreventive  and  therapeutic  programmes. 11 
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Fig  1.  Schematic  representation  of  MAPK  cascades  in  mammalian  cells  depicting  the 
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ABSTRACr 
Prospective  studies  and  recent  intervention  trials  suggest  that  the  risk  of 
some  cancers,  including  respiratory  tract  cancers,  may  be  inversely  related  to 
selenium  (SE)  intake,  and  this  6  supported  by  strong  experimental  evidence 
with  chemical-induced  animal  cancer  models.  How  this  cancer-protective 
effect  is  mediated  Is  unclear,  but  Interference  with  the  balance  of  growth/ 
apoptosis  during  tumor  outgrowth  Is  one  plausible  hypothesis.  In  general, 
there  is  a  correlation  between  the  effectiveness  of  SE  compounds  as  chemo- 
preventive  agents  in  vivo  and  their  ability  to  inhibit  cell  growth  and  induce 
apoptosis  in  vitro.  This  study  has  investigated  the  signal  transduction  path- 
ways  affected  by  SE  compounds  in  biopsies  of  normal  human  oral  mucosa 
cells  and  human  oral  squamous  carcinoma  cells  (SCCs),  using  a  primary 
culture  system.  Two  SE  compounds  were  tested:  selenodiglutathione  (SDG), 
the  primary  metabolite  of  selenite  and  the  most  commonly  used  cancer- 
protective  SE  compound  in  animal  models,  and  the  synthetic  SE  compound, 
1,4-phenylenebis(metbylene)selenocyanate  (p-XSQ,  one  of  the  most  potent 
chemopreventive  pharmacological  SE  compounds.  Three  novel  findings  am 
reported:  (a)  SCCs  were  found  to  be  significantly  more  sensitive  to  induction 
of  apoptosis  by  SDG  than  normal  human  oral  mucosa  cells,  though  the 
differences  were  marginal  with  p-XSC;  (b)  both  SE  compounds  induced  the 
expression  of  Fas  ligand  (Fas-L)  in  oral  cells  to  a  degree  that  correlated  with 
the  extent  of  apoptosis  induction;  and  (c)  both  SDG  and  p-XSC  Induced  the 
stress  pathway  kinases,  Jun  NH2-terniinal  Idnase  (JNK)  and  p38  kinase,  at 
concentrations  causing  apoptosis;  p-XSC,  and  to  a  lesser  extent  SDG,  also 
activated  extracellular  regulated  kinases  M2  (ERKs  1&2)  and  protein  ki. 
nase-B  or  Akt.  To  test  their  functional  involvement,  the  effect  of  inhibiting 
each  of  these  pathways  on  induction  of  apoptosis  by  SDG  and  p-XSC  was 
determined  in  SCCs.  Inhibiting  the  ERKs  1&2  or  Ald  pathways  with  specific 
chemical  inhibitors  (PD98059  or  LY294002,  respectively)  did  not  affect  the 
extent  of  aPoPtOsis  induced  by  SDG  or  p-XSC  (with  the  exception  of 
LY294002,  which  actually  enhanced  the  level  of  induction  of  apoptosis  by 
SDG).  Ile  JNK  pathway  appeared  to  be  most  important  for  induction  of 
Fas-L  and  apoptosis  because  concentrations  of  SB202190  that  inhibited  acti- 
vation  of  both  the  JNK  and  P38  kinase  (but  not  ERKs  1&2)  in  SCC  reduced 
the  extent  of  induction  of  Fas-L  and  apoptosis  by  SDG  and  p-XSC,  whereas 
lower  concentrations  that  inhibited  activation  only  of  p38  kinase  did  not.  This 
was  confirmed  by  the  fact  that  exogenous  expression  of  a  dominant  negative 
deletion  mutant  of  c-Jun  (TAM67)  reduced  the  induction  of  both  apoptosis 
and  Fas-L  by  SDG. 
EVMODUMON 
There  is  currently  much  interest  in  the  potential  cancer-protective 
effects  of  SE.  '  Human  epidemiological  evidence  indicates  a  statistically 
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significant  inverse  relationship  between  SE  intake  (which  is  primarily  in 
the  form  of  selenomethione)  and  risk  of  cancer  overall,  particularly  in 
men  (1,2).  In  terms  of  individual  cancer  types,  the  evidence  from  the  - 
largest  studies  is  strongest  for  lung,  esophageal,  prostate,  and  gastric 
cancers,  but  there  is  little  evidence  of  any  link  with  breast  or  colon  cancer, 
although  the  length  of  follow-up  in  most  of  these  studies  was  quite  short. 
Three  intervention  trials  also  suggest  that  SE  supplementation  in  the  form 
of  selenized  yeas4  either  alone  or  with  other  antioxidant  vitamins,  re- 
duces  the  risk  of  cancer  (1).  The  most  recent  randomized  placebo- 
controlled  intervention  trial  with  men  with  a  prior  history  of  skin  basal  or 
squarnous  cell  carcinoma  found  no  evidence  for  a  reduction  in  risk  of 
recurrence  of  skin  cancer  with  200  ILg/d  SE,  but  total  cancer  rates  in  the 
treatment  arm  were  reduced  significantly  (by  37%),  as  were  the  rates  of 
lung,  colorectal,  and  prostate  cancers  (3,4).  The  strongest  treatment  effect 
was  observed  in  subjects  with  the  lowest  plasma  SE  levels  before  sup- 
plementation. 
This  evidence  for  a  cancer-protective  effect  of  dietary  SE  in  humans  is 
supported  by  very convincing  animal  evidence  indicating  that  a  high 
dietary  level  of  SF,  usually  in  the  form  of  sodium  selenite,  substantially 
reduces  the  incidence  of  a  wide  variety  of  animal  cancers  under  condi- 
tions  where  animal  growth  and  health  are  not  affected  (1,5,6).  Most 
studies  have  observed  the  maximum  cancer-protective  effect  at  nontoxic 
levels  considerably  higher  than  normal  nutritional  levels,  but  there  is  also 
more  limited  and  less  consistent  evidence  that  sub-nutritional  SE  depri- 
vation  increases  cancer  risk.  SDG,  the  primary  metabolite  of  selenite,  is 
potently  anticarcinogenic,  but  selenomethionine,  the  most  abundant  form 
of  SE  in  natural  foods,  has  generally  been  found  to  be  less  effective  than 
selenite  (reviewed  in  Ref.  1).  However,  plant  foods  also  contain  other  SE 
derivatives,  such  as  Se-methylselenocysteine,  which  is  an  effective  can- 
cer-protective  agent  in  animal  models  (5).  There  is  therefore  considerable 
interest  in  developing  novel  synthetic  SE  compounds  that  may  have 
greater  chemopreventive  properties  than  naturally  occurring  forms.  In 
animal  models,  the  most  effective  chemopreventive  agents  seem  to  be 
those  that  are  metabolized  directly  to  monomethylated  SE  metabolites 
(1,5,7),  including  aliphatic  or  benzyl  selenocyanates,  such  as  p-XSC 
(8-10),  used  in  this  study.  In  particular,  SE  derivatives  like  13-XSC  are 
effective  in  animal  carcinogenesis  models  in  which  selenite  is  not  so 
effective,  e-g-,  4-(methylniuxwamino)-I-(3-pyridyl)-l-butanone-induced 
lung  cancers  (10). 
Thus,  overall,  the  available  evidence  indicates  a  definite  cancer 
protective  effect  of  SE  in  animal  models  and  probably  also  in  humans. 
However,  as  noted  above,  the  human  intervention  trials  have  used  a 
complex  SE  source  (selenized  yeast)  rather  than  specific  SE  com- 
pounds,  and  so  it  cannot  be  assumed  that  the  mechanisms  responsible 
for  the  cancer-protective  effect  in  animals  is  necessarily  relevant  to 
the  human  studies  (reviewed  in  Refs.  1,2,11,  and  12).  Arguably,  the 
animal  studies  with  selenite  or synthetic  SE  derivatives  may  be  more 
nebis(methylene)scienocyanate;  GPY,  glutathione  peroxidase;  JNK,  Jun  NH2-terminal 
kinase;  EGF,  epidermal  growth  factor  TUNEJ,  terminal  deoxynucicoddyl  tramferaw- 
mediated  nick  end  labeling;  GFP,  green  fluorescent  protein;  MAPK,  mitogen-activated 
protein  kinase;  GSH,  glutathione;  MAPKAPK,  mitogen  activated  protein  kinase  activated 
protein  kinase;  FADD,  Fas-associated  death  domain;  Fas-1,  Fas  ligand. 
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relevant  to  devising  potential  future  chemoprevention  strategies  in 
high-risk  humans  than  to  the  putative  cancer  protective  effect  of  SE 
from  natural  human  diets. 
Several  possible  mechanisms  have  been  proposed  to  explain  the 
cancer-protective  effects  of  SE  compounds.  They  can  modulate 
immune  responses  (reviewed  in  Ref.  1),  but  the,  detailed  mecha- 
nisms  involved  require  to  be  elucidated,  and  it  remains  to'  be, 
established  that  this  effect  could  generate  a  sufficient  antitumor 
response  at  the  levels  of  SE  that  are  cancer-protective  in  vivo.  A 
second  hypothesis  proposed  that  the  chernopreventive  effect  of  SE 
might  be  mediated  by  selenoproteins,  such  as  the  GPXs,  eliminat- 
ing  tumor-promoting  reactive  oxygen  species;  however,  this  now 
seems  less  plausible  because  the  activities  of  known  selenoproteins 
seem  to  be  saturated  at  a  much  lower  dietary  SE  level  than  that 
required  for  the  maximum  chernopreventive  effect  of  SE  (13,14). 
There  is  additional  evidence  that  at  least  the  cytosolic  GPXI  is  not 
involved  because  GPX1-null  mice  do  not  show  any  abnormal  his- 
topathologies  up  to  15  months  of  age  (15,16),  although  they  are  more 
sensitive  to  exogenous  oxidative  stress  (17),  and  GPM-transgenic  mice 
are  actually  more sensitive  to  7,12-dimethylbenz[a]anthracene/12-0- 
tetradecanoylphorbol-13-acetate-induced  skin  cancer,  rather  than  the 
reverse,  hypothetically,  because  the  generation  of  tumor-promoting,, 
lipoxygenase-derived  peroxides  is  increased  (18).  However,  thioredoxin 
reductase  remains  a  possible  candidate  because  it  has  been  shown  to  be 
inhibited  by  protracted  high  SE  levels,  possibly  attributable  to  diselenide 
bond  formation  at  the  selenocysteine  in  the  active  site  (19).  Additionally,, 
new  selenoproteins  have  been  discovered  recently  (reviewed  in  ReL  6), 
but  it  is  not  yet  known  what  their  functions  are  or  the  SE  levels  at  which 
their  activities  are  saturated.  A  third  hypothesis  is  that  SE  compounds  act 
as  antipromotion  agents,  possibly  by  inducing  apoptosis  in  initiated 
premalignant  cells.  This  is  suggested  by  animal  evidence  that  selenite  and 
p-XSC  are  effective  if  given  after  carcinogen  in  the  early  phase  of  tumor 
progression,  although  they  may  also  reduce  DNA  damage  by  carcinogens 
(recently  reviewed  in  Refs.  1  and  5).  It  is  also  consistent  with  the  fact  tha4 
in  general,  the  relative  efficacies  of  SE  derivatives  as  chernopreventive 
agents  in  vivo  parallel  their  growth  inhibitory  effects  in  vitro  and  their 
ability  to  induce  apoptosis  (20-24);  moreover,  this  could  operate  in 
premalignant  cells  because  it  does  not  necessarily  require  a  functional 
p53  pathway  (10,21,25).  Recent  work  showing  that  both  inorganic  and 
organic  forms  of  SE  induce  gadd34,  gadd45,  and  gaddl53  (25,26),  and 
inhibit  cdk2  activity  (26)  suggests  that  interference  with  cell  cycle  check- 
point  controls  is  associated  with  growth  arrest/apoptosis  induced  by  SE 
compounds. 
Ile  work  reported  in  this  paper,  therefore,  tested  directly  whether  SE 
compounds  with  the  most  pronounced  cancer  protective  properties  affect 
any  of  the  signal  transduction  pathways  that  control  cell  growth,  survival, 
and  apoptosis.  In  view  of  the  fact  that  lung  and  esophageal  cancers  are 
two  of  the  cancer  types  in  which  the  epidemiological  evidence  for  a 
cancer-protective  effect  of  SE  is  strongest,  we  have  focused  on  human 
oral  cancers  because  they  share  similar  risk  factors  to  lung  and  other  head 
and  neck  cancers.  To  obtain  data  as  relevant  as  possible  to  human  SCCS, 
we  have  used  a  panel  of  primary  cultures  of  biopsies  of  oral  squamous 
cancers  and  NOMCý  which  we  have  characterized  previously  (27,28). 
We  have  investigated  primarily  two  of  the  most  potent  cancer-protective 
SE  compounds  in  animal  studies  (the  primary  metabolite  of  selenite, 
SDG,  and  p-XSC)  and  shown  that  they  act  by  a  similar  mechanism 
(induction  of  Fas-IJJNK-dependent  apoptosis). 
MATERIAIS  AND  METHODS 
Cells  and  Culture  Conditions.  '  The  derivation  and  characterization  of  the 
primary  cultures  of  biopsies  of  normal  human  oral  mucosa  or  carcinomas  has 
been  described  previously  (27,28).  All  cells  were  maintained  on  irradiated  3T3 
feeders,  either  in  FAD+  medium  (1:  3  Ham's  F-IZ(DMIEM  with  10%  FCS  and 
insulin,  EGF,  transferrin,  cholera  toxin,  hydrocortisone,  and  adenine)  in  the 
case  of  normal  cells  or  10H  medium  (DMEM  plus  10%  FCS  without  added 
growth  factors,  except  hydrocortisone)  in  the  case  of  carcinomas  (27,28). 
Normal  cultures  were  used  within  the  first  two  to  three  passages  from  frozen 
stocks,  before  their  growth  rate  deteriorated  significantly.  Oral  cultures  were 
used  for  experimentation  while  rapidly  growing  at  not  >70%  confluence,  after 
which  the  irradiated  3`13  feeders  were  carefully  removed  by  treatment  with 
PBS/0.02%  EDTA,  and  the  cultures  were  refed  with  normal  medium.  3`13  cells 
were  maintained  in  IOC  medium  (DMEM  plus  10%  donor  calf  serum).  HeI.  A 
cells  were  maintained  in  modified  DMEM  (Beatson  formulation;  Life  Tech- 
nologies,  Inc.,  Inchinnan,  United  Kingdom)  supplemented  with  10%  FCS  and 
I  mm  glutamine.  Cells  were  maintained  in  culture  for  a  maximum  of  6-8 
weeks  before  being  replaced  with  cells  from  frozen  stocks.  Ali  media  used 
contained  Bufferall  (Sigma  Chemical  Co.,  Gillingham,  United  Kingdom)  to 
maintain  the  pH  at  7.0. 
Chemicals.  SDG  was  prepared  as  described  previously  (29).  p-XSC  was 
purified  to  99.9%  homogeneity  as  described  by  E-Bayoumy  d  aL  (30). 
SB202190,  SB203580,  PD98059,  and  LY294002  were  obtained  from  Calbio- 
chem,  Nottingham,  United  Kingdom. 
DNA  Synthesis/Proliferation  Assay.  1W  irradiated  3T3  cells  were  plated 
in  200  pl  of  10C  medium  per  microtiter  well.  After  4d,  the  medium  was 
removed,  and  oral  epithelial  cells  were  added  (10'  in  the  case  of  normal  cells 
or  5X  103  carcinoma  cells)  in  100  pl  of  10H  medium.  After  48  h,  the  medium 
was  replaced  with  medium  containing  SDG  or  p-XSC  and  incubated  overnight. 
Each  Well  was  then  given  0.5  jkCi  of  tritiated  thymidine  for  6  h,  the  medium 
was  removed,  and  the  cells  were  trypsinized  and  transferred  onto  a  filter  paper 
mat  (printed  filtemat  A;  Pharmacia)  using  a  microtiter  plate  harvester  (Skatron 
Combi  Harvester,  model  11900;  LXB,  Skatron,  Norway).  After  adding  scin- 
tillator,  the  mat  was  scanned  and  counted  using  a  plate  counter  (model  1205 
Betaplate;  Pharmacia).  Four  replicate  wells  were  used  for  each  condition. 
Control  experiments  showed  that  the  irradiated  feeders  supported  growth  of  the 
oral  cells  for  the  duration  of  the  experiment  but  contributed  an  insignificant 
background  thymidine  incorporation  (<5%  of  that  of  the  oral  cells).  The 
radioactivity  incorporated  into  DNA  was  calculated  as  a  percentage  of  un- 
treated  cultures. 
Apoptosis  Assays.  Apoptosis  in  the  oral  cells  was  measured  by  TUNEL 
staining  using  the  Apotag  kit  (Intergen,  Purchase,  N'q  according  to  the  manu- 
facturer's  protoool.  The  irradiated  313  feeders  were  carefully  removed  from  the 
cultures  before  experimentation  by  washing  the  cultures  vigorously  three  times 
with  PBS/0.02%  EDTA.  Assays  were  performed  with  two  to  three  replicate  plates 
of  cells,  and  2'-10  randomly  selected  fields  per  plate  were  counted  for  TUNEL- 
positive  cells.  Assessment  of  apoptosis  among  the  HeLa  cells  transiently  cotrans- 
fected  with  a  GFP-encoding  vector  was  performed  by  measuring  the  sub-GO(GI 
DNA  content  of  the  GFP-positive  population.  Cells  were  harvested  after  treatment, 
washed  in  cold  PBS,  fixed  in  1%  paraformaldehyde  for  Ih  on  ice,  and  perme- 
abilized  with  70%  ethanol  for  Ih  on  ice.  Cells  were  then  resuspended  in  I  ml  of 
PBS  to  which  0.5  ml  of  Phosphate-citric  acid  buffer  was  added  and  incubated  at 
room  temperature  for  5  min.  After  RNase  treatment  (250  jug(mlý  the  DNA  was 
stained  with  propidium  iodide  (10  pglmlý  and  the  cell  cycle  distribution  was 
determined  by  analyzing  104  GFP-positive  cells  with  the  CellQuest  software  using 
a  FACScan  flow  cYtoroeter  (Becton  Dickinson,  Cowley,  United  Kingdom).  For 
the  annexin  V  assays,  the  cells  were  plated  on  coverslips  for  2  days,  and  then  the 
313  feeder  cells  were  removed  before  SE  treatment.  Annexin  V-FrM  staining  was 
carried  out  acoording  to  the  manufacturees  protocol  (CLON=i,  Basingstoke, 
United  Kingdom).  T"he  percentage  of  annexin  V-staining  cells  was  then  deter- 
mined  microscopically. 
In  some  experiments  (e.  g.,  using  the  Fas/Fc  chimeric  protein),  cells  were 
grown  on  313  feeders  on  glass  coverslips.  Cells  were  grown  to  the  appropriate 
density,  and  the  feeder  layer  was  removed  and  then  incubated  for  an  additional 
16  It.  Cells  were  then  treated  with  the  Fas/Fc  chimeric  protein  (250  ng/ml)  for 
1  It  before  treatment  with  either  SE  compound  or  recombinant  soluble  human 
Fas-L  (150  ng/ml)  and  the  potentiator  antibody  (2  Pg1ml).  After  16-h  incuba- 
tion,  the  TUNEL  assay  was  performed.  Soluble  recombinant  human  Fas-L  and 
mouse  monoclonal  IgG1  potentiator  antibody  were  obtained  from  Upstate 
Biotechnology,  Lake  Placid,  NY;  recombinant  human  Fas/Fc  chimera  protein 
was  obtained  from  R&D  Systems,  Abingdon,  United  Kingdom. 
Immunoblotting  and  MAPK  Assays.  To  prepare  whole  cell  protein  ex- 
tracts  for  immunoblotting,  the  cells  were  washed  twice  with  ice-cold  PBS  and 
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then  scraped  off  in  0.2  ml  of  buffer  [20  mm  HEPES  (pH  6.8ý  5  mm  EDTA,  10 
mm  EGTA,  5  mm  NaF,  0.1  jig/ml  okadaic  acid,  1  mm  DTT,  0.4  m  KCI,  0.4% 
Triton  X-100,10%  glycerol,  5  jLgIml  leupeptin,  50  ;  ig/ml  phenylmethylsul- 
fonyl  fluoride,  1  mm  benzamidine,  5  jLglml  aprotinin,  and  I  mm  sodium 
orthovanadatel  and  incubated  on  ice  for  20  min,  followed  by  centrifugation  at 
13,000  rpm  in  a  microfuge  for  10  min.  The  supernatant  was  stored  at  -70*C. 
Up  to  50  Ag  of  protein  sample  in  40  pl  of  buffer  was  mixed  with  20  pl  of 
loading  buffer  1187.5  mm  Tris-HCI  (pH  6.8ý  30%  glycerol,  6.9%  SDS,  2.1  m 
P-mercaptoethanol,  and  0.1%  bromphenol  blue]  before  electrophoresis  on  a 
SDS/8%PAGE  gel.  Ile  proteins  were  then  blotted  onto  nitrocellulose  (Am- 
ersham,  little  Chalfont,  United  Kingdom)  using  a  Camlab  semidry  blotter, 
following  the  manufacturer's  protocol.  Western  blots  were  preincubated  in  the 
presence  of  Tris-buffered  saline-T  [50  mm  Tris  (pH  7.5ý  50  mm  Nacl,  1  mm 
EDTA,  and  0.1%  Tween-20  containing  5%  dried  milk]  and  then  incubated 
with  antibodies  diluted  in  Tris-buffered  saline-T  containing  5%  BSA-  Acti- 
vated  or  total  amounts  of  specific  kinases  were  measured  using  the  following 
antibodies:  activated  INK  monoclonal  antibody  p-JNK  (G-7;  Santa  Cruz 
Biotechnology,  Santa  Cruz,  CA);  phospho-specific  (Ser63/73)  c-Jun  antibody 
kit  (New  England  Biolabs,  Hitchin,  United  Kingdom);  activated  and  total  p38 
kinase,  PhosphoPlus  p38  MAPK  (tyr182)  polyclonal  antibody  kit  (New  Eng- 
land  Biolabs);  activated  MAPKs  (ERKs  1&2),  polyclonal  antibody  (Promega, 
Southampton,  United  Kingdomý  and  total  MAPK,  ERK  l(C-16)-G  polyclonal 
antibody  (Santa  Cruz  Biotechnology);  ERK5  kinase,  ERK5(C-20)  polyclonal 
antibody  (Santa  Cruz  Biotechnology);  activated  Akt  and  total  Akt,  Phospho- 
plus  Akt  (set  473)  polyclonal  antibody  kit  (New  England  Biolabs);  and  Fas-I, 
antiburnan  Fas-L  monoclonal  antibody  (PharMingen/Becton  Dickinson,  Cow- 
ley,  United  Kingdom).  In  all  cases,  bound  primary  antibody  was  detected  using 
enhanced  chemiluminescence  methodology  (Amersham).  Phosphorylation  of 
ERK5  results  in  a  shift  in  its  electrophoretic  mobility  detectable  by  Western 
blotting  and  a  consistent  correlation  between  the  shifted  fraction  of  phospho- 
rylated  ERK5  and  the  activity  of  ERK5  as  measured  by  protein  kinase  assay 
has  been  observed  (data  not  shown  and  Ref.  31).  This  electrophoretic  mobility 
shift  was  thus  used  as  an  assay  for  ERK5  activity.  p38  kinase  activity  was 
measured  indirectly  by  a  protein  kinase  assay  for  the  p38  substrate,  MAPKAP 
kinase-2  (32). 
Transient  Transfection  of  Cells.  HeLa  cells  were  plated  at  a  density  of 
1.2  X  10'  cells  in  9G-mm  dishes.  Ile  next  day,  cells  were  cotransfected  with 
I  jig  each  of  a  GFP  construct,  pEGFP  (CLONETECII),  the  c-Jun  dominant 
negative  construct  (TAM67;  provided  by  Prot  B.  Ozanne,  Beatson  Institute, 
Glasgow,  United  Kingdomý  or  a  dominant  negative  FADD-GFP  construct 
(donated  by  Dr.  H.  Wajant,  University  of  Stuttgart)  using  the  Effectene 
(oiagen,  Crawley,  United  Kingdom)  transfection  reagent,  according  to  the 
manufacturees  protocol.  After  overnight  incubation,  fresh  medium  was  added 
and  incubated  for  another  6  b,  before  the  addition  of  SE  compounds  or 
chemical  inhibitors  for  the  appropriate  time.  Cells  were  then  harvested,  and 
apoptosis  assays  were  performed  to  assess  apoptosis  in  the  GFP-positive 
population  (see  above  for  details). 
RESULTS 
Sensitivity  of  NOMCs  and  SCCs  to  growth  inhibition  by  SE  com- 
pounds.  Our  panel  of  primary cultures  of  biopsies  of  NOMCs  and 
SCCs  were  derived  and  maintained  using  the  well-established  3T3 
feeder  layer  system  (27,28),  which  was  designed  to  permit  growth  of 
keratinocytes  at  all  stages  of  cancer  progression.  The  3T3  feeder  layer 
was  then  removed  before  experiments  commencing  with  the  remain- 
ing  oral  epithelial  6ells.  The  NOMCs  were  used  within  two  to  three 
passages  from  frozen  stocks,  while  they  were  still  proliferating  rap- 
idly,  before  senescence  occurring. 
We  have  tested  a  variety  of  SE  compounds.  Our  previous  studies 
found  that  the  most  effective  cancer-protective  SE  compounds  in 
animal  studies,  such  as  selenite,  Se-methylselenocysteine,  and  p-XSC, 
all  induced  growth  arrest  in  various  cell  types,  unlike  selenomethione, 
which  only  affected  cell  growth  at  very  high  concentrations  (21). 
However,  whereas  most  of  these  SE  compounds  only  inhibit  cell 
growth  after  a  lag  period  (21),  p-XSC  induces  growth  arrest/apoptosis 
much  more  quickly,  presumably  because  it  is  metabolized  more 
rapidly  to  the  directly  acting  SE  derivative.  The  fact  that  the  lag  period 
required  for  selenite  was  reduced  by  the  addition  of  GSH  (33)  sug- 
gested  that  the  active  inhibitor  might  be  SDG,  which  would  be  formed 
by  reaction  of  selenite  with  GSH  either  intra  or  extracellularly,  and 
this  was consistent  with  the  fact  that  purified  SDG  inhibited  cell 
growth  without  a  significant  lag  period  (33).  In  the  present  studies,  we 
therefore  focused  on  elucidating  the  signal  transduction  pathways 
affected  by  SDG  and  p-XSC,  because  their  effects  were  rapid  and 
arguably  most  likely  to  be  relevant  to  the  chemopreventive  effects  of 
the  most  effective  SE  compounds,  at  least  in  animal  models. 
Fig.  1  shows  the  dose-response  curves  for  growth  inhibition  of 
NOMCs  or  SCCs  by  SDG  or  p-XSC;  to  assess  whether  there  were  any 
consistent  differences  in  sensitivity  between  NOMCs  and  SCCs,  the 
results  for  three  independently  derived  NOMCs,  or  cultures  of  four 
carcinoma  biopsies,  have  been  pooled.  This  shows  that  NOMCs  may 
be  less  sensitive  to  SDG  than  carcinoma  cultures  in  the  range  4-5  ILm 
(P  <  0.001,  using  Student's  t  test),  whereas  with  p-XSC,  any  differ- 
ences  are  small  and  not  consistent  throughout  the  dose  range. 
Induction  of  Apoptosis  and  Fas-L  by  SE  Compounds.  We  (21, 
34)  et  aL  (20,22-24)  reported  previously  that  SE  compounds  induce 
apoptosis  in  rodent  mammary,  ovarian,  and  leukemia  established  cell 
lines.  We  found  that  both  SDG  and  p-XSC  induced  apoptosis  in  oral 
cell  cultures  as  judged  by  TUNEL  staining,  annexin  V  staining,  or 
measurement  of  sub-Go  cells  by  fluorescence-activated  cell  sorter 
analysis.  Care  was  taken  to  ensure  that  all  cultures  were  subconfluent 
and  growing  at  their  maximum  growth  rates.  Using  either  TUNEL 
staining  (Fig.  2,  A  and  C)  or  annexin  V  staining  (Fig.  2,  B  and  D)  as 
assays  of  apoptosis,  SCCs  were  significantly  more  sensitive  to  induc- 
tion  of  apoptosis  by  SDG  than  NOMCs  [Fig.  2,  C  and  D;  P=0.0003 
(TUNEL  data),  P=0.003  (Annexin  data),  using  the  Student's  t  test], 
whereas  any  differences  in  sensitivity  to  p-XSC  were  marginal  and 
not  statistically  significant  (Fig.  2,  C  and  D;  P=0.39,  P=0.5, 
respectively).  The  concentrations  of  SE  compounds  required  to  obtain 
a  significant  level  of  apoptosis  were  somewhat  higher  than  those 
required  to  detect  growth  arrest  by  inhibition  of  DNA  synthesis 
(compare  Figs.  1  and  2).  All  additional  molecular  studies  were  per- 
formed  at  SE  concentrations  found  to  induce  a  significant  level  of 
apoptosis  (usually  in  the  range  20-40%). 
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Fig.  1.  Sensitivity  of  NOMCs  and  carcinomas  to  growth  arrest/inhibition  of  DNA 
synthesis  by  SDG  and  p-XSC.  Cells  were  grown  in  the  indicated  concentration  of  SE 
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Fig.  2.  Sensitivity  of  NOWs  and  SCCs  to  SE  compounds.  The  degree  of  apoptosis 
after  treatment  of  NOMCs  or  SCCs  with  solvent  control,  SDG,  or  p-XSC  for  16  h  was 
quantitated  by  counting  the  percentage  of  TUNFI,  positive  cells  (A  and  ()  or  annexin 
V-positive  cells  (B  and  D).  The  results  are  the  averages  of  two  independent  NOMCs  or 
carcinoma  cultures  (--SEs). 
In  the  course  of  testing  whether  any  of  the  known  apoptotic  path- 
ways  were  induced  by  SE  compounds,  we  discovered  that  both  SDG 
and  p-XSC  induced  Fas-L  in  NOMCs  and  SCCs  under  conditions 
where  significant  apoptosis  was  induced  (Fig.  3A).  The  size  of  the 
Fas-L  produced  corresponded  to  the  secreted  form  of  the  protein  (35), 
Fas-L  was  induced  considerably  more  strongly  by  SDG  in  SCCs  than 
in  NOMCs,  whereas  p-XSC  seemed  to  be  equally  effective  in  both 
normal  cells  and  carcinomas  (Fig.  3A).  Thus,  the  degree  of  Fas-L 
induction  correlated  closely  with  the  extent  of  apoptosis  (compare  Fig. 
2).  Additional  experiments  showed  that  inhibition  of  the  Fas  pathway 
with  a  Fas/Fc  chimera  (36)  significantly  reduced  the  extent  of  induc- 
tion  of  apoptosis  by  both  SDG  and  p-XSC  (Fig.  3B;  11  =  0.021, 
P-0.044,  respectively).  Thus,  induction  of  Fas-L  is  functionally 
required  for  induction  of'  apoptosis  by  these  SE  compounds. 
Effects  of  SE  Compounds  on  ERKs  1/2,  ERK5,  and  Akt  Kinase 
Signal  Transduction  Pathways.  We  next  investigated  whether  SDG 
or  p-XSC  interfered  with  kinasc  signal  transduction  pathways  known 
to  control  growth  or  cell  survival.  ERKs  1&2  (37)  and  ERK5  (31) 
have  both  been  implicated  in  control  of  cell  proliferation  by  serum 
mitogens  or  EGF,  whereas  the  P-1-3  kinase/Akt  pathway  plays  an 
important  role  in  cell  survival  in  a  wide  variety  of  cell  types  (38). 
ERK5  has  also  been  reported  to  be  redox  sensitive  and  induced  by 
oxidants  (39).  In  view  of  their  increased  sensitivity  to  induction  of 
apoptosis,  particularly  by  SDG,  these  experiments  were  performed 
mainly  using  SCCs,  rather  than  NOMCs.  One  way  in  which  SE 
compounds  might  induce  apoptosis  is  by  interfering  with  the  activa- 
tion  of  mitogenic  or  survival  pathways  by  growth  factors.  To  test 
whether  SDG  or  p-XSC  interfered  with  activation  of  the  ERKs  1  &2  or 
Akt  pathways,  SCC  cultures  were  serum  starved  for  16  h,  then 
pretrcated  for  2h  with  SDG  or  p-XSC,  and  then  given  EGF  or  serum. 
Cell  extracts  were  prepared  and  then  analyzed  for  the  extent  of 
activation  of  ERKs  1&2  or  Akt  by  Western  blotting  with  antibodies 
that  recognize  either  the  total  amount  of  each  kinase  or  only  the 
activated  (phosphorylated)  forms.  These  experiments  revealed  no 
evidence  for  a  reduction  in  activation  of  ERKs  1  &2  or  Akt  by  SDG  or 
p-XSC  after  treatment  with  EGF  or  serum  (Fig.  4,  A  and  B).  Control 
experiments  showed  that  p-XSC  itself  induced  significant  activation 
of  ERKs  1&2,  though  this  was  much  less  marked  with  SDG  (Fig.  4A). 
Although  it  appears  paradoxical  that  an  agent  causing  growth  arrest 
should  activate  a  mitogenic  pathway,  this  has  been  shown  to  occur 
also  with  other  stress  factors,  such  as  oxidants  (40).  However,  neither 
p-XSC  nor  SDG  had  any  very  significant  effect  on  Akt  activation 
(Fig.  4B). 
To  investigate  more  thoroughly  by  functional  experiments  whether 
the  ERKs  1&2  and  Akt  pathways  were  involved  in  mediating  the 
induction  of  apoptosis  by  SE  compounds,  we  tested  whether 
the  apoptotic  effects  of  SDG  or  p-XSC  were  altered  by  inhibiting  the 
ERKs  l&2  or  Akt  pathways  with  the  specific  chemical  inhibitors, 
PD98059  (which  inhibits  activation  of  ERKs  l&2  by  inhibiting  MAP 
extracellular  signal  -regulated  kinase  activity)  and  LY294002  (which 
inhibits  P-1-3  kinase  and  therefore  activation  of  Akt;  Ref.  41).  Control 
experiments  showed  that  under  the  conditions  used,  PD98059  pre- 
vented  activation  of  ERKs  1&2,  and  LY294002  prevented  activation 
of  Akt  by  SDG  and  p-XSC  (Fig.  5A).  However,  neither  inhibitor 
protected  SCCs  from  induction  of  apoptosis  by  SDG  or  p-XSC  (Fig. 
5B);  in  fact,  inhibition  of  Akt  activation  by  treatment  with  LY294002 
significantly  increased  the  level  of  SIDG-induced  apoptosis  by  -55% 
(P  <  0.001;  Fig.  5B).  This  might  imply  that  the  induction  of  Akt 
activation  by  SDG  may  be  an  (inadequate)  attempt  to  protect  the  cells 
from  apoptosis.  These  experiments  therefore  confirm  that  the  ERKs 
l&2  and  Akt  pathways  are  not  of  major  importance  in  mediating  the 
induction  of  apoptosis  by  either  SDG  or  p-XSC  in  this  oral  cell 
system. 
ERK5  is  another  member  of  the  MAPK  family  that  has  also  been 
implicated  in  control  of  cell  proliferation  by  EGF  in  certain  cell  types 
(31).  We  therefore  determined  whether  activation  of  ERK5  could  be 
detected  in  our  oral  cultures  by  the  characteristic  change  in  its  migra- 
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Fig.  3.  Induction  of  Fas-L  by  SE  compounds.  In  A,  NOMCs  and  SCCs  were  treated 
with  the  stated  concentrations  of  SDG  or  p-XSC  for  16  h,  and  cell  lysates  were  prepared 
and  Western  blotted  with  either  an  anti-Fas-L  antibody  or  antibody  against  total  p38 
kinase  as  a  loading  control.  The  figures  below  the  blots  indicate  the  fold  increase  in  Fas-L 
expression  above  untreated  level  after  SE  treatment,  normalized  to  the  loading  control.  B, 
protection  against  SDG-  and  p-XS(7-induced  apoptosis  (measured  by  the  TUNEI.  assay) 
after  pretreatment  of  SCCs  with  a  Fas/Fc  chimera  (150  ng/ml)  for  I  h,  followed  by  the 
indicated  concentrations  of  SDG  or  p-XSC  for  16  h.  As  a  positive  control,  cells  were  also 
treated  with  soluble  Fas-L  (sFasL). 
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Cell  lysates  were  then  prepared  and  run  on  SDS- 
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tion  in  SIDS/polyacrylamide  gels  after  Western  blotting  (31).  How- 
ever,  no  activation  of  ERK5  by  EGF  was  found  with  either  NOMCs 
or  SCCs,  whereas  ERK5  activation  was  readily  observed  in  parallel 
experiments  with  HcLa  cells  (Fig.  40,  as  others  have  reported  (31). 
Induction  of  Stress  Kinases  by  SE  Compounds.  We  next  inves- 
tigated  whether  the  SE  compounds  induced  the  JNK  and  p38  stress 
kinase  pathways  because  they  have  been  strongly  implicated  in  in- 
duction  of  growth  arrest/apoptosis  by  a  wide  variety  of  signals  (40). 
Both  SDG  and  p-XSC  caused  activation  of  JNK  and  p38  in  both 
normal  and  carcinoma  cells  under  conditions  in  which  apoptosis  was 
induced  (Fig.  6).  There  was  no  significant  differences  between 
NOMCs  and  SCCs  in  the  extent  of  induction  of  JNK  and  p38  kinase 
by  p-XSC  (Fig.  6).  However,  SDG  was  reproducibly  more  efficient  at 
activatingJNK  and  p38  in  SCCs  than  NOMCs  (Fig.  6),  thus  mirroring 
the  greater  sensitivity  of  SCCs  to  induction  of  apoptosis  by  SDG 
(Fig.  2). 
To  test  whether  the  JNK  or  p38  pathways  were  functionally  im- 
portant,  we  performed  experiments  to  determine  whether  preventing 
the  activation  of  JNK  and/or  p38  reduced  the  extent  of  apoptosis 
induced  in  SCCs  by  SDG  or  p-XSC.  In  the  first  approach,  we 
exploited  the  known  differential  sensitivities  of  p38  kinase,  JNK,  and 
ERKs  1&2  to  two  chemical  inhibitors  of  the  MAPK  family, 
SB202190  and  S13203580.  LA)w  concentrations  (up  to  -10  jim)  se- 
lectively  inhibit  p38  kinase;  at  30  Am,  both  p38  and  JNK  are  inhibited, 
whereas  ERKs  1&2  are  not  affected  until  even  higher  concentrations 
(42-44).  We  therefore  tested  whether  concentrations  of'  SB202190 
affected  induction  of  Fas-L  and  apoptosis  by  SDG  or  p-XSC  in  SCCs. 
Control  experiments  confirmed  that  10  ýLm  SB202190  prevented 
SI)G-  or  p-XSC-induced  activation  of  p38  kinase  (measured  by 
activation  of  its  downstream  kinase  MAPKAPK-2  in  an  immunopre- 
cipitation/kinase  assay)  but  not  activation  of  JNK  (measured  by  phos- 
phorylation  of  c-Jun  at  Ser63)  or  ERKs  1&2  (measured  using 
phospho-specific  antibodies),  whereas  30  tLm  SB202190  prevented 
activation  of  both  p38  kinase  and  JNK  but  did  not  affect  activation  of 
ERK-s  1&2  (Fig.  7A).  Parallel  experiments  indicated  that  30  ýtm 
SB202190  prevented  SDG  and  p-XSC  induction  of  Fas-L  (Fig.  7B) 
and  apoptosis  (for  SDG,  Pý0.033;  for  p-XSC,  P=0.04  1;  Fig.  7C), 
whereas  10  tLm  SB202190  had  no  effect  (Fig.  7,  B  and  Cý.  This 
strongly  suggests  that  activation  of  the  JNK  pathway  is  primarily 
responsible  for  the  induction  of  Fas-L  and  apoptosis  by  SDG  and 
PASC. 
Using  phospho-spccific  c-Jun  antibodies,  we  found  that  the  SE 
compounds  induced  phosphorylation  of  c-Jun  at  Ser  63/73,  residues 
known  to  be  phosphorylated  by  JNK  (Fig.  7A  and  data  not  shown). 
Phosphorylation  of'c-Jun  at  Ser63/73  is  known  to  he  associatcd  with 
increased  transcriptional  activity  (45),  and  induction  of'  Fas-1.  is 
known  to  be  dependent  on  c-Jun  transcriptional  activity  (46,47). 
Thus,  our  data  provide  a  plausible  explanation  as  to  how  induction  of' 
JNK  by  SDG  and  p-XSC  leads  to  induction  of'  Fas-1,  and  apoplosis. 
To  confirm  the  l'unctional  importance  ot  the  JNK/c-Jun  pathway 
directly,  we  also  performed  experiments  interfering  with  C-JUu  t'unc- 
tion  using  a  dominant  negative  mutant  of'  c-Jun,  TAM67  (48).  Bc- 
cause  the  primary  oral  cultures  are  extremely  difficult  to  Iransfect  in 
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Fig.  5.  Effect  of  treatment  of  SCCs  with  the  P-1-3  kinase/Akt  pathway  inhibitor 
(LY294002)  or  the  ERKs  1  &2  pathway  inhibitor  (PD98059)  on  induction  of  apoptosis  by 
selenium  compounds.  A.  SCCs  were  pretreated  with  50  jim  LY294002  or  50  ji'm  PD98059 
and  then  treated  with  8  tim  SIX;  or  30  ttm  p-XSC  for  18  h,  and  the  effect  on  activatiori 
of  FRKs  l&2  or  Akt  was  determined  bv  Western  blotting  using  antibodies  that  reco  iz  gn  c 
phospho-spccific  or  total  Akt  or  FRK.  Ii,  induction  of  apoptosis  under  (lie  same  conditions 
measured  by  TUNFI.  staining  as  described  in  Fig.  2. 
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Fig.  6.  Activation  of  JNK  and  p38  stress  kinases  by  SDG  and  p-XSC.  NO  MCs  or  SCCs 
were  left  untreated  (0  or  treated  with  the  indicated  concentrations  of  SD(;  or  p-XSC  for 
Ih  or  30  min,  respectively,  and  cell  lysates  were  prepared  and  analyzed  by  SDS-PAGE 
and  Western  blotting  with  antibodies  against  the  activated  forms  of  p38  or  JNK  (p38*  and 
JNK-).  As  loading  controls,  the  blots  were  then  stripped  and  Western  blotted  with 
antibodies  against  total  p38  or  JNK.  The  figures  below  the  blots  indicate  the  relative  levels 
of  p38,  JNKI,  or  JNK2  expression  after  normalization  to  the  loading  control  levels. 
sufficient  numbers,  this  experiment  was  performed  using  HeLa  cells 
because  they  were  found  to  resemble  SCCs  in  terms  of  the  effects  of 
SDG  and  p-XSC  on  JNK,  p38,  ERKs  1&2,  and  Akt  (data  not  shown). 
Thus,  a  population  of  HeLa  cells  expressing  TAM67  was  obtained  by 
transiently  cotransfecting  HeLa  cells  with  a  GFII  vector  together  with 
the  TAM67  expression  vector  and  analyzing  the  transfected  cells  in 
the  GFII-positive  fraction  by  cell  sorting  (see  "Materials  and  Meth- 
ods"  for  details);  the  transfectants  obtained  had  a  level  of  TAM67 
expression  at  least  as  high  as  the  endogenous  Jun  level  (Fig.  K4).  The 
level  of  induction  of  apoptosis  by  SDG  in  TAM67-expressing  cells 
was  reduced  by  40%  (11  <  0.001)  compared  with  cells  transfected 
with  a  vector  alone  (Fig.  8,  B  and  C).  TAM67-expressing  cells  were 
only  marginally  protected  (by  -  15"/(,  )  from  induction  of  apoptosis  by 
p-XSC,  although  this  was  statistically  significant  (P  -  0.01;  Fig.  8,  B 
and  C).  Experiments  were  also  performed  to  test  whether  inhibiting 
both  the  JNK  and  p38  kinase  pathways  together  (by  treating  TAM67- 
transfected  cells  with  SB203580  to  inhibit  p38  kinase  activity)  was 
more  effective  at  protecting  cells  from  apoptosis  by  SDG  and  p-XSC. 
However,  the  extent  of  protection  was  identical  to  that  afforded  by 
TAM67  overexpression  alone  (Fig.  8C).  TAM67  expression  in  HeLa 
also  reduced  the  level  of  induction  of  Fas-L  by  SDG,  but  not  p-XSC 
(Fig.  8D),  and  this  correlates  with  the  ability  of  a  dominant  negative 
FADD  construct  (49)  to  reduce  the  extent  of  apoptosis  induced  by 
SDG  more  than  that  induced  by  p-XSC  (Fig.  8E),  though  both 
reductions  were  statistically  significant  (P  ý  0.014  and  P=0.034, 
respectively).  Overall,  these  functional  transfection  experiments  with 
HeLa  cells  support  the  conclusion  from  our  data  with  SCCs  based  on 
the  use  of  different  concentrations  of  SB202190  that  induction  of  JNK 
appears  to  be  the  main  stress  signal  transduction  pathway  functionally 
required  for  induction  of  Fas-L  and  apoptosis  by  SDG  and  p-XSC 
(although  the  protection  from  p-XSC-induced  apoptosis  by  c-Jun 
inhibition  by  TAM67  transfection  in  HeLa  cells  is  not  as  convincing 
as  that  afforded  by  JNK  inhibition  by  SB202190  in  SCCs,  for  reasons 
that  are  presently  unclear). 
The  main  purpose  of  this  work  was  to  identify  the  signal  transduc- 
tion  mechanisms  responsible  for  apoptosis  induced  by  cancer-protec- 
tive  SE  compounds  using  a  relevant  human  model.  Our  experimental 
rationale  was  based  on  previous  work  by  ourselves  and  others  that  SE 
compounds  with  the  strongest  cancer-protective  properties  in  vivo, 
such  as  p-XSC,  and  metabolites  of  selenite,  such  as  SDG,  are  also  the 
most  effective  inducers  of  growth  arrest  and  apoptosis  in  vitro. 
Our  first  novel  finding  is  that  human  SCCs  are  more  sensitive  to 
induction  of  apoptosis  by  the  SDG  than  NOMCs.  This  is  clearly  of 
considerable  relevance  to  understanding  the  cancer-protective  effect 
of  SE  compounds,  particularly  selenite.  It  is  not  clear  why  p-XSC 
does  not  show  the  tumor-selectivity  exhibited  by  SDG  but  may  reflect 
the  relative  importance  of  JNK/c-Jun  pathway  in  mediating  the  effects 
of  the  two  SE  compounds  (see  below).  Since  the  current  work  and 
manuscript  were  completed,  a  recent  report  has  also  shown  that  the 
LNCaP  prostate  carcinoma  cell  lines  are  more  sensitive  to  growth 
inhibition  and  induction  of  apoptosis  by  selenite  or  selenomethionine, 
than  primary  prostate  cells,  though  the  molecular  signal  transduction 
mechanisms  responsible  were  not  explored  (50). 
The  second  novel  point  of  interest  is  that  induction  of  apoptosis  by 
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Fig.  7.  Fftect  of  inhibition  of  p38  kinase  and  JNK 
activation  by  SB202190  on  induction  of  Fas-1,  and 
apoptosis  by  SDG  and  p-XSC  in  SCCs  (A  and  B). 
Fltect  of  varying  concentrations  of  SB202190  on  the 
activation  of  p38  kinase,  JNK,  and  F,  RKs  1  &2  (A)  and 
induction  of  Fas-1.  by  8  /im  SIX;  (B)  or  30  gm  p-XSC. 
In  A,  p38  kinasc  activity  was  measured  by  activation 
of  its  direct  substrate  MAPKAPK-2  in  an  immunopre- 
cipitation  kinase  assay  using  IIsp2-5  as  MAPKAPK-2 
substrate.  Activation  of  JNK  and  ERKs  l&2  was  as- 
saycd  by  phosphorylation  using  a  Ser63-phospho- 
specific  ami-Jun  or  F,  RKs  1&2  antibodies.  Total  p38 
levels  were  used  as  loading  controls.  B  and  C,  SCCs 
were  pretreated  for  30  min  with  the  indicated  concen- 
trations  of  S13202190,  followed  by  8  ttm  SDG  or  30 
gm  p-XSC  for  16  It.  In  B,  Fas-I.  levels  were  measured 
by  Western  blotting  as  in  Fig.  IA.  Me  figures  below 
the  blots  indicate  the  fold  increase  in  Fas-1,  expression 
above  control  level  after  SF  treatment.  In  C,  apoptosis 
was  measured  by  TUNFI.  staining. 
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Fig.  8.  Effect  of  overexpressing  dominant  negative  c-Jun  (TAM67)  on  induction  of  apopiosis  and  Fas-I.  by  SI:  compounds.  I  te  Iz  cc  I  Is  were  transient  IvI  rans  I  ccled  ý  it  haI  AM()7 
expression  vector  (T)  or  empty  vector  (V)  together  with  a  GFP-expression  vector  and  the  C&P-positive  cells  purified  by  cell  sorting.  In  A,  Western  Wolfing  experiments  with  a  pan  Jul] 
antibody  showed  that  the  cells  transfected  with  the  TAM67-expression  vector  express  TAM67  at  as  least  as  high  a  level  as  endogenous  normal  Jun.  In  A  cells  wcre  then  trcatcd  with 
5  jim  SDG  or  50  Am  p-XSC  for  18  h,  and  the  percentage  of  apoptotic  cells  was  determined  by  measuring  the  percentage  of  sub-6,  G,  cells.  Similar  differences  bemecii  vector-  and 
TAM67-expressing  cells  were  found  in  two  other  experiment%,  using  annexin  V  staining  as  the  criterion  for  apoptosis  (data  not  shown).  InC.  I'AM07-traiisicctcd  cells  were  preincubatcd 
with  10  tLm  SB203580  for  30  min  followed  by  5  ýcm  SDG  or  50  pLm  p-XSC  for  18  h,  and  the  percentage  of  apoptotic  cells  was  determined  as  in  B.  In  1),  vector  (V)-  or  I'AM67 
(7)-transfected  cells,  cotransfected  with  a  GFP-expression  vector,  were  treated  with  the  indicated  concentrations  of  SDG,  or  p-XSC  for  8  or  18  It,  respectively,  and  then  analyzed  for 
Fas-l-  expression.  The  percentages  of  transfected  cells,  determined  from  the  percentage  of  GFP-expressing  cells,  were  85  and  83%,  for  vector  and  I'AM07  translections.  The  figures 
below  the  blots  indicate  the  fold  increase  in  Fas-1,  expression  above  control  level  after  SE  treatment.  In  E,  an  "empty"  expression  vector  or  the  same  vector  encoding  a  dominant  negative 
FADD-GFP  fusion  protein  was  transiently  transfected  into  HeLa  cells  and  treated  with  the  SE  compounds  indicated  for  16  It,  and  the  GFP-positivc  population  was  assayed  for  apoptosis 
by  the  proportion  of  sub-G,,  -G,  cells. 
both  SE  compounds  is  associated  with  a  large  induction  in  Fas-L 
expression  above  the  low  basal  level  in  untreated  cells;  the  form  of 
Fas-L  produced  is  the  soluble  form  which  could  therefore  be  secreted 
and  act  intercellularly.  The  extent  of  Fas-L  induction  by  the  SE 
compounds  correlates  closely  with  the  level  of  apoptosis  induced  in 
normal  mucosa  or  carcinomas,  and  inhibition  of  the  Fas  pathway  in 
SCCs  by  a  Fas/Fc  chimera  attenuates  the  induction  of  apoptosis  by 
SDG  and  p-XSC.  Fas-L  expression  in  biopsies  of  squamous  carcino- 
mas  of  the  head  and  neck  has  also  been  demonstrated  recently  in 
another  report  and  shown  to  be  biologically  active  in  inducing  apo- 
ptosis  in  cocultivated  activated  T  lymphocytes  (51).  This  is  of  con- 
siderable  interest  because  the  Fas-L/Fas  receptor  interaction  is  one  of 
the  major  pathways  initiating  apoptosis  by  a  variety  of  agents  (46), 
including  alkylating  agents  (52)  and  drugs  used  in  chemotherapy  (53, 
54).  Because  both  NOMCs  and  SCCs  express  the  Fas  receptor  con- 
stitutively  (data  not  shown),  induction  of  Fas-L  may  explain  why  SE 
compounds  induce  apoptosis  in  human  oral  cells.  In  vivo,  the  soluble 
Fas-L  produced  by  carcinoma  cells  could  also  enhance  immunological 
responses  that  could  target  the  carcinoma  cells  (55).  Activation  of  Fas 
pathway  by  SE  compounds  could  therefore  be  a  factor  explaining  their 
effects  in  enhancing  antitumor  immune  responsiveness  (1,56).  Our 
data  show  that  Fas-L  induction  by  the  SE  metabolite,  SDG,  is  readily 
detectable  at  a  SE  concentration  within  the  range  of  plasma  concen- 
trations  found  in  humans,  although  higher  than  the  average  level  (57). 
The  concentrations  ofthe  synthetic  SE  derivative,  p-XSC,  required  for 
Fas-L  induction  are  higher  than  for  SDG,  but  it  is  well  established  in 
animal  models  that  p-XSC  has  a  higher  chemopreventive  index  than 
selenite,  exerting  its  maximum  cancer-protective  effect  at  high  dietary 
levels  (about  30  ppm  compared  with  2  ppm  for  selenite)  because  of  its 
lower  toxicity  (58). 
Thirdly,  both  SDG  and  p-XSC  induce  activation  of  the  p38  and 
JNK  stress  kinase  pathways  at  conccntrat  ions  that  induce  ý11)01)1()Sis, 
confirming  and  extending  a  previous  report  demonstrating  activation 
of  JNK  by  p-XSC  (59).  SDG  and  p-XSC  also  induce  FRKs  1&2  and 
Akt,  but  these  effccts  are  relatively  small  (except  for  the  significant 
effect  of  p-XSC  on  ERKs  1&2).  Our  functional  intervention  cxl)cri- 
ments  show  that  activation  of  the  JNK  pathway  seems  to  be  most 
important,  because  inhibition  of  the  JNK  pathway,  but  [lot  the  p38 
kinase  pathway,  with  appropriate  concentrations  of  SB202190  or 
using  a  dominant  negative  c-Jun  construct,  reduces  SF-induced  ap- 
optosis,  especially  with  SDG.  Conversely,  inhibition  of  the  P-1-3 
kinase  pathway  by  LY294002  did  not  reduce  the  sensitivity  of'  SCCs 
to  induction  of  apoptosis  by  the  SF  compounds,  in  fact,  it  increased 
the  extent  of  apoptosis  induced  by  SDG,  suggesting  that  the  observed 
induction  of  AM  in  response  to  SDG  was  an  (unsuccessful)  protective 
response  of  cells  to  induction  of  apoptosis  by  SDG.  Finally,  PD98059, 
a  specific  inhibitor  of  ERKs  1&2  activation,  (lid  not  affect  the  sensi- 
tivity  of  SCCs  to  induction  ofapoptosis  by  SDG  or  p-XSC.  Moreover, 
our  experiments  exclude  the  possibility  that  SDG  or  p-XSC  act  by 
inhibiting  activation  ofthe  ERKs  1&2  or  Akt  pathways  by  mitogens, 
such  as  EGIF  or  serum  which  would  have  biased  cells  toward  cell 
death. 
Induction  of  JNK  by  SDG  in  SCCs  is  somewhat  more  marked  than 
in  NOMCs,  which  may  therefore  explain  the  increased  sensitivity  of 
SCCs  to  induction  of'  Fas-L/apoptosis  by  SDG.  This  effect  of  micro- 
molar  levels  of  SE  in  inducing  apoptosis  via  activation  of'  the  JNK 
pathway  has  to  be  distinguished  from  the  ability  of'  subinicromolar 
levels  of  selenite  to  inhibit  UV-induced  apoptosis  and  activation  of 
JNK  (60),  presumably  by  increasing  the  dcloxificalion  of'  reactive 
oxygen  species  by  increasing  the  activities  of'  one  or  more  of  the 
known  selenoproteins. 
The  final  point  of  interest  is  our  evidence  indicating  that  induction 
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of  Fas-L  by  selenium  compounds  is  at  least  partially  dependent  on 
induction  of  JNK  because  concentrations  of  SB202190  that  inhibit 
both  JNK  and  p38  kinase,  but  not  p38  kinase  alone,  reduce  the  extent 
of  Fas-L  induction  in  SCCs  by  SDG  and  p-XSC,  and  expression  of  the 
dominant  negative  Jun  construct,  TAM67,  in  HeLa  cells  reduces  the 
induction  of  Fas-L  by  SDG.  There  is  other  evidence  in  the  literature 
also  indicating  that  the  JNK/c-Jun  pathway  is  mechanistically  up- 
stream  of  Fas-L  in  other  contexts,  e.  g.,  after  treatment  with  anticancer 
drugs  or alkylating  agents  (46,47).  However,  this  is  not  necessarily 
the  case  (recently  reviewed  in  Ref.  45);  e.  g.,  there  is  evidence  that  the 
Fas/Fas-L  interaction  induces  JNK  activation,  rather  than  the  reverse 
(61,62),  and  that  activation  of  JNK  by  Fas  is  not  necessarily  required 
for  induction  of  apoptosis  (63-65).  Fas  activation  has  also  been 
shown  to  activate  both  JNK  and  p38  activation  in  Jurkat  cells;  how- 
ever,  in  this  case,  activation  of  the  MKK3/p38  pathway  appeared  to  be 
important  as  a  downstream  target  for  Fas-induced  ICEICED-3  family 
proteases  (66).  Moreover,  targeted  disruption  of  FADD,  the  adaptor 
protein  required  for  Fas-induced  apoptosis,  does  not  eliminate  stress- 
induced  apoptosis  (67).  This  may  be  because  the  Fas  death  domain  of 
Fas  binds  independently  to  two  effector  molecules:  FADD,  which 
couples  Fas  to  pro-caspase-8,  and  Daxx,  which  couples  Fas  to  the 
JNK  pathway  (62). 
Exactly  how  SE  compounds  induce  the  stress  kinase  pathways  is 
not  yet  clear.  It  has  been  postulated  that  SE  compounds  induce 
oxidative  stress  by  production  of  superoxide  radicals  or  hydrogen 
peroxide  (68-70).  However,  we  have  previously  presented  evidence 
that  SE  compounds  do  not  induce  apoptosis  in  the  same  way  as 
hydrogen  peroxide  (71).  More  recently,  we  have  shown  that  the 
apoptosis-inducing  effects  of  SDG  and  p-XSC  in  animal  cell  lines  are 
prevented  by  antioxidants,  such  as  NH2-acetylcysteine  and  GSH; 
however,  putative  hydroxyl  radical  scavengers,  such  as  mannitol  and 
pyrrolidine  dithiocarbamate,  are  more  effective  in  protecting  against 
apoptosis  induced  by  p-XSC  than  SDG  (33).  This  is  another  sugges- 
tion  that  SDG  and  p-XSC  do  not  act  by  precisely  the  same  mecha- 
nism.  One  hypothesis  to  explain  induction  of  apoptosis  by  SDG  is  that 
it  may  alter  the  redox  status  of  the  cells  by  manipulating  the  level  of 
a  cellular  reducing  agent,  such  as  thioredoxin,  which  has  been  impli- 
catcd  in  growth  control  in  various  contexts  and  is  overexpressed  in 
many  tumors  (reviewed  in  Ref.  72).  This  may  be  a  plausible  idea 
because  SDG  has  been  shown  to  be  a  specific  inhibitor  of  thioredoxin 
and  thioredoxin  reductase  in  cell-free  systems  (73,74).  Alternatively, 
continuously  high  dietary  levels  of  SE  result  in  a  reduction  in  thiore- 
doxin  reductase  activity,  postulated  to  be  attributable  to  the  formation 
of  an  irreversible  diselenide  "trap"  at  the  selenocysteine  in  its  active 
site  (19);  this  would  also  result  in  a  reduction  in  the  level  of  reduced 
thioredoxin.  Of  particular  interest  in  this  context  is  the  fact  that  ASK1, 
one  of  the  upstream  activators  of  both  JNK  and  p38  (75),  is  inhibited 
by  binding  of  reduced  thioredoxin  to  its  NHI-terminal  region  (76); 
thus,  depletion  of  reduced  thioredoxin  by  SE  compounds  by  one  of  the 
mechanisms  described  above  might  be  expected  to  activate  ASK1  and 
induce  apoptosis.  ASKI  is  also  regulated  by  the  level  of  intracellular 
GSH  (77),  which  may  also  be  affected  by  the  level  of  SE  metabolites. 
We  are  currently  attempting  to  test  both  these  hypotheses. 
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Glasgow,  G61  1BD,  Scotland,  UK.  Email:  p.  r.  haffison@beatson.  gla.  ac.  uk. Abstract:  Based  on  the  observed  correlation  between  the  ffiectiveness  of  a  variety 
of  selenium  compounds  as  chemopreventive  agents  in  animal  models  and  their  ability 
to  inhibit  cell  growth  and  induce  apoptosis  in  vitro,  one  hypothesis  to  explain  the 
cancer  protective  effects  of  selenium  compounds  is  that  they  reduce  the  outgrowth  of 
tumour  cells  in  vivo.  Our  recent  work  has  therefore  investigated  the  effects  of 
selenium  compounds  on  signalling  pathways  responsible  for  growth  and  apoptosis  in 
biopsies  of  normal  oral  mucosa  and  oral  carcinomas,  using  a  primary  culture  system. 
Interestingly,  oral  carcinomas  are  signiflcantly  more  sensitive  than  normal  oral 
mucosa  to  induction  of  apoptosis  by  a  natural  selenium  metabolite 
(selenodiglutathione,  SDG)  and  this  is  associated  with  induction  of  Fas  ligand  (Fas- 
L),  a  well  known  mediator  of  apoptosis  in  other  contexts,  and  activation  so-called 
stress  kinase  signalling  pathways,  of  which  the  Jun  terminal  kinase  (JNIC)  pathway 
appears  to  most  important,  as  judged  by  functional  intervention  experiments.  Heme 
oxygenase  (HO),  another  marker  of  stress  responses,  is  also  induced  by  selenite  and 
SDG.  The  selective  activation  of  the  Fas  pathway  in  carcinomas  could  be  responsible 
directly  for  their  destruction  by  apoptosis  or  target  them  for  attack  by  immunological 
responses.  In  contrast,  although  the  potent  pharmacological  selenium 
chemopreventive  agent,  1,4-phenylenebis(methylene)selenocyanate  (p-XSQ,  also 
induces  Fas-L,  HO  and  stress  kinase  pathways,  the  mechanism  of  is  clearly  different 
to  that  of  SDG  since  apoptosislFas  induction  is  not  JNK-dependent  and  p-XSC  does 
not  show  tumour-selectivity.  These  differences  in  mechanism  between  SDG  andp-XSC 
may  be  due  to  the  manner  in  which  they  induce  redox  changes  in  the  cells,  since, 
although  the  effects  of  SDG  and  p-XSC  are  both  prevented  by  anti-oxidants  such  as 
glutathione  or  N-acetyl  cysteine(NAC),  hydroxyl  radical  scavengers  such  as  mannitol 
or  pyrrolidine  dithiocarbamate  (PDTC)  only  protect  against  the  effects  ofp-XSC. 
2 Animal  evidence  for  a  cancer  protective  effect  of  selenium 
There  is  very  convincing  evidence  that  a  high  dietary  level  of  naturally-occurring 
selenium,  usually  in  the  form  of  sodium  selenite,  substantially  reduces  the  incidence 
of  a  wide  variety  of  animal  cancers  under  conditions  where  animal  growth  and  health 
are  not  affected  (1-3).  Most  studies  have  observed  the  maximu  m  cancer-protective 
effect  at  non-toxic  levels  considerably  higher  than  normal  nutritional  levels  but  there 
is  also  more  limited  evidence  that  sub-nutritional  selenium  deprivation  increases 
cancer  risk  (recently  reviewed  by  Ip  (4)  and  Combs  &  Gray  (5))'.  In  animal  models,  the 
most  effective  chernopreventive  agents  seem  to  be  those  that  are  metabolised  directly 
to  selenols  (6-9),  including  aliphatic  or  benzYI  selenocyanates  (10-12),  particularly  p- 
XSC  (13-15),  and  Se-methylselenocysteine,  which  may  be  the  major  non-volatile  form 
of  selenium  in  plant  foods  (16).  In  particular,  selenium  derivatives  like  p-XSC  are 
effective  in  animal  carcinogenesis  models  in  which  selenite'is"  not  so  effective,  for 
example,  NNK-induc'ed  lung  cancers  (13). 
Epidemiological  evidence  for  a  cancer  protective  effect  of  selenium 
Human  epidemiological  evidence  also  indicates  a  statistically  significant  inverse 
relationship  between  selenium  level  and  risk  of  cancer  overall,  particularly  in  men 
(17-28;  recently  reviewed  in  (5)).  In  terms  of  individual  cancer  types,  the  evidence 
ftom  the  largest  studies  is  strongest  for  upper  respiratory  tract,  prostate,  oesophageal 
and  stomach  cancers  (27,29-32)  but  there  is  little  evidence  of  any  link  with  colon 
(23,27,28,32)  or  breast  (34-36)  cancer  risk  in  such  cohort  studies,  although  the  length 
of  follow-up  in  some  of  these  studies  was  quite  short.  Three  intervention  trials  have 
also  investigated  whether  selenium  supplementation  reduces  the  risk  of  cancer.  An 
early  randomised  intervention  trial  in  China,  with  about  1000  subjects  in  each  of  the 
3 treatment  and  placebo  arms,  reported,  that  dietary  supplementation  with  200  [tg/d 
selenium  as  selenised  yeast  for  2y  reduced  the  incidence  of  liver  cancer  in  a  high  risk 
area  by  45%  (p  =  0.05)  (37).  A  joint  Chinese/US 
Irandomised 
factorial  design  study  in 
a  nutritionally  poor  population  in  Linxian  County,  China,  showed  that  dietary 
supplementation  for  5y  with  a  cocktail  of  three  antioxidants  (P-carotene, 
-vitamin 
E 
and  selenium)  at  about  twice  their  RDA  values  produced  a  statistically  significant 
reduction  in  overall  cancer  rate  of  13  %  and  a  21  %  reduction  in  stomach  cancer  rate, 
whereas  supplementation  with  other  cocktails  of  vitamins  or  trace  elements  had  no 
effect  (38,39).  It  seems  plausible  that  selenium  was  responsible  for  the  effect  of  the 
antioxidant  cocktail  since  evidence  from  intervention  trials  suggests  that  neither  P- 
carotene  nor  vitamin  E  reduce  cancer  risk  generally  (40-43):  indeed,  although  there 
may  be  a  significant  inverse  relationship  between  prostate  cancer  and  vitamin  E  intake 
(44,45),  P-carotene  supplementation  was  consistently  associated  with  a  higher  risk  of 
lung  cancers  in  subjects  who  were  current  smokers  (46-48).  But  the  case  for  selenium 
supplementation  reducing  cancer  risk  has  received  greatest  support  from  the  recent 
randomised  placebo-controlled  intervention  trial  by  Dr.  Larry  Clark  and  his  colleagues 
involving  1312  men  with  a  prior  history  of  skin  basal  or  squamous  cell  carcinoma 
(49,50):  although  this  found  no  evidence  for  a  reduction  in  risk  of  recurrence  of  skin 
cancer  with  200  [tg/d  selenium  as  selenised  yeast,  total  cancer  rates  in  the  treatment 
arm  were  reduced  significantly  (by  37  %),  as  were  the  individual  rates  of  lung, 
colorectal  and  prostate  cancers  (49,50).  The  strongest  treatment  effect  was  observed  in 
subjects  with  the  lowest  plasma  selenium  levels  prior  to  supplementation. 
4 Possible  molecular  mechanisms 
The  molecular  mechanism(s)  responsible  for  reductiodin  cancer  risk  by  selenium 
are  presently  unclear.  The  early  hypothesis  that  the  chernopreventive  effect  of 
selenium  might  be  mediated  by  selenoproteins,  such  as  the  glutathione  peroxidases, 
eliminating  tumor-promoting  reactive  oxygen  species  now  seems  unlikely  since  the 
activities  of  known  selenoproteins  seem  to  be  saturated  in  animals  at  a  much  lower 
dietary  selenium  level  (0.1-0.4  p.  p.  m.  )  (51-53)  than  that  required  for  the  maximum 
chemopreventive  effect  of  selenium  (2-4  p.  p.  m.  )  (1-4).  There  is  further  evidence  that 
at  least  the  cytosolic  glutathione  peroxidase  (GPX1)  is  not  involved  iince  GPX1-null 
mice  do  not  show  any  abnormal  histopathologies  up  to  15  months  age  (54,55) 
(although  they  are  more  sensitive  to  exogenous  oxidative  stress  (56))  and  GPXI- 
tran,  s'g'-e;  n'ic  mice  are  actually  more  sensitive  to  DMBA/TPA-induced  skin  cancer, 
r.  ather  than  the  - rever  . se,  hypoth  etically  ;  býcause  the  generation  of  turnour-promoting 
lipoxyie-nase'-derived  peroxides  is  increased  (57).  However,  thioredoxin  reductase 
remains  a  possible  candidate  ''since  it  hasý  been  shown  to  be  inhibited  by  continuous 
high  selenium  levels,  possibly  due  to  diselenide  bond  formation  at  the  selenocysteine 
in  the  active  site  (58).  New  selenoproteins  have  recently  been  discovered  (59,60)  but 
their  functions  and  selenium  saturation  leyels  are  presently  unknown. 
Although  selenite  and  p-XSC  can  reduce  DNA  damage  by  carcinogens  (4,61-.  63), 
they  are  also  effective  if  given  after  carcinogen  in  the  early  phase  of  tumour 
progression  (1,4),  suggesting  that  they  may  act  primarily  as  anti-promotion  agents. 
This  is  also  suggested  by  the  fact  that,  in  general,  the  relative  efficacies  of  selenium 
derivatives  as  chernopreventive  agents  in  vivo  parallel  their  growth  inhibitory  effects 
in  vitro  and  their  ability  to  induce  apoptosis  (64-68).  Moreover,  induction  of  apoptosis 
5 by  selenium  metabolites  in  vitro  is  readily  detectable  at  levels  towards  the  upper  limit 
of  plasma  concentrations  found  in  humans,  i.  e.  about  5  tLM,  although  higher  than  the 
average  level  (Figure  1).  Thus,  understanding.  the  mechanisms  mediating  the  growth 
inhibitory  effects  in  vitro  may  be  relevant  to  the  mechanism  of  chemopFevention  in 
vivo  and  so  identifying  the  molecular  target(s)  of  selenium  action  may  suggest 
avenues  for  devising  novel  compounds  that  may  be  useful  as  cancer-protective  agents, 
for  example  in  high-risk  groups.  We  have  previously  shown  that  treatment  of  cells 
with  the  selenite  metabolite,  selenodiglutathione  (SDG)  induces  p53  accumulation  in 
cells  containing  wild  type  p53  (65).  However,  as  we  and  others  have  shown,  selenium 
compounds  induce  growth  arrest/apoptosis  of  cells  expressing  mutant  p53  (65)  or 
lacking  p53  completely  (69):  thus,  the  mechanism  whereby  selenium  compounds 
inhibit  cell  growth  and  induce  apoptosis  does  not  necessarily  require  a  functional 
wild-type  p53  pathway.  Recent  work  showing  that  both  inorganic  and  organic  forms 
of  selenium  induce  gadd34,  gadd45  and  gaddl.  53  (69)  suggests  that  interference  with 
cell  cycle  checkpoint  controls  is  associated  with  growth  affestlapoptosis  induced  by 
selenium  compounds. 
Induction  of  stress  responses  by  interference  with  redox  control 
The  main  purpose  of  our  recent  work  has  been  to  identify  the  signalling  mechanisms 
responsible  for  apoptosis  induced  by  cancer-protective  selenium  compounds.  Our 
experimental  rationale  was  based  on  previous  work  by  ourselves  and  others  that 
selenium  compounds  with  the  strongest  cancer-protective  properties  in  vivo,  such  as 
p-XSC,  and  metabolites  of  selenite,  such  as  SDG,  are  also  the  most  effective  inducers 
of  growth  arrest  and  apoptosis  in  vitro.  The  reason  for  using  SDG  is  based  on  our 
observation  that  selenite  freshly  added  to  cells  only  inhibited  their  growth  after  a  lag 
6 period  of  24  h,  whereas  conditioned  medium  from  such  cells  transferred  to  fresh  cells 
to  give  the  same'selenium  6oncentration  inhibited  their  growth  rapidly  and  the  active 
agent  was  shown  to  be  IOW'molecular  weight  by  passage  through  filters  with  different 
pore  sizes  (data'not  shown).  The  lag  period  'was  also  reduced  by  the  addition  of 
glutathione  (GSH)  together  with  selenite  (Figure  2).  Both  these  findings  suggested 
that  the  active  inhibitor  might  be  SDG,  which  would  be  formed  by  reaction  of  selenite 
with  GSH  either  intra-  or  extra-cellularly  and  this  was  consistent  with  the  fact  that 
purified  SDG  inhibited  cell  growth  without  a  significant  lag  period  (Figure  2).  This 
growth  arrest  was  also  shown  to  be  associated  with  apoptosis  as  determined  by  the 
TUNEL  assay  (data  not  shown). 
Exactly  how  selenium  compounds  induce  apoptosis,  is  not  yet  clear.  It  has  been 
postulated  that  selenium  compounds  induce  oxidative  stress  by  production  of 
superoxide  radicals  or  hydrogen  peroxide  (70-72),  although  our  previous  work 
suggested  that  SDG  does  not  induce  apoptosis  in  the  same  way  as  hydrogen  peroxide 
(73)  and  this  is  supported  by  our  new  evidence  that  selenium  compounds  do  not 
induce  the  same  large  scale  changes  in  phosphorylation  of  tyrosine  residues  in  proteins 
characteristic  of  oxidants  such  as  hydrogen  peroxide,  and  diamide  (Figure  3). 
Nevertheless,  selenite,  SDG  and  p-XSC  induce  herne  oxygenase  (HO)  (Figure  4),  a 
well-established  indicator  of  a  variety  of  cellular  stresses,  for  example  by  oxidants, 
irradiation  and  sulphydryl  reagents,  as  well  as  heme  (74)  and  this  occurs  at  selenite 
and  SDG  concentrations  of  3-5  [tM,  which  is  within  the  -range  of  plasma 
concentrations  found  in  humans  (Figure  1).  We  also  present  further  evidence  here  that, 
although  the  growth-inhibitory  effects  of  both  SDG  and  p-XSC  in  animal  cell  lines  are 
prevented  by  the  antioxidant  N-acetylcysteine  (NAC),  -putative  hydroxyl  radical 
7 scavengers,  such  as  mannitol  and  PDTC  are  more  effective  against  p-XSC  than  SDG 
(figure  5).  This  suggests  that  SDG  and  p-XSC  do  not  act  by  precisely  the  same 
mechanism.  One  hypothesis  to  eiýplain  induction  of  growth  arrest/apoptosis  by  SDG  is 
that  it  may  alter  the  redox  status  of  the  cells  by  manipulating  level  of  a  cellular 
reducing  agent,  such  as  thioredoxin  which  has  been  implicated  in  growth  control  in 
various  contexts  and  is  over-expressed  in  many,  tumours  (recently  reviewed  in  (75)). 
Tumour-selective  induction  of  apoptosis  by  the  selenium  metabolite,  SDG. 
In  view  of  the  fact  that  lung  and  esophageal  cancers  are  two  of  the  cancer  types  in 
which  the  epidemiological  evidence  for  a  cancer  protective  effect  of  selenium  is 
strongest,  in  our  recent  work  (76)  we  have  focussed  on  human  oral  cancers  since  they 
share  similar  risk  factors  to  lung  and  other  head  and  neck  cancers  and  represent  one  of 
the  few  experimental  models  where  biopsies  of  both  normal  tissue  and  lesions  at 
various  stages  of  cancer  progression'can  be  obtained  and  studied  in  primary  culture 
(77,78).  One  of  the  novel  findings  to  emerge  from  this  work  (76)  is  that  human  oral 
carcinomas  are  more  sensitive  to  induction  of  apoptosis  by  the  SDG  than  normal  oral 
mucosa  cells.  This  is  clearly  of  considerable  relevance  to  understanding  the  cancer- 
protective  effect  of  selenium  compounds.  '  p-XSC  does  not  show  this  tumour- 
selectivity:  the  reasons  for  this  difference  between  SDG  and  p-XSC  are  unclear  but 
appears  to  be  connected  with  the  relative  importance  of  the  various  kinase  signalling 
pathways  that  mediating  the  effects  of  the  two  selenium  compounds  (discussed  further 
below).  Another  recent  report  has  also  shown  that  the  LNCaP  prostate  carcinoma  cell 
lines  is  more  sensitive  to  growth  inhibition  and  induction  of  apoptosis  by  selenite  or 
selenomethionine  than  primary  prostate  ''cells,  though  the  molecular  signalling 
mechanisms  responsible  were  not  explored  (79). 
8 Involvement  of  the  Fas  and  stress  kinase  pathways  in  induction  of  apoptosis  by 
selenium  comýounds. 
Another  important  finding  we  have  made  is  that  induction  of  apoptosis  by  both  SDG 
and  p-XSC  is  associated  with  a  large  induction  in  Fas-L  expression  above  the  low 
basal  level  in  untreated  cells  (76):  the  form  of  Fas-L  produced  is  the  soluble  form 
'which  could  therefore  be  secreted  and  act  inter-cellularly.  The  extent  of  Fas-L 
induction  by  the  selenium  compounds  correlates  closely  with  the  level  of  apoptosis 
induced  in  normal  mucosa  or  carcinomas.  Fas-L  expression  in  biopsies  of  squamous 
carcinomas  of  the  head  and  neck  has  also  been  demonstrated  recently  in  another  report 
and  shown  to  be  biologically  active  in  inducing  apoptosis  in  co-cultivated  activated  T 
lymphocytes  (80).  Since  both  normal  oral  mucosa  and  oral  carcinomas  express  the  Fas 
receptor  constitutively  (data  not  shown),  induction  of  Fas-L  may  explain  why 
selenium  compounds  induce  apoptosis  in  human  oral  cells.  In  vivo,  the  soluble  Fas-L 
produced  by  carcinoma  cells  could  also  enhance  immunological  responses  that  could 
target  the  carcinoma  cells  (81).  Activation  of  Fas  pathway  by  selenium  compounds 
could  therefore  be  a  factor  explaining  their  effects  in  enhancing  anti-tumor  immune 
responsiveness  (5,82).  Pur  data  show  that  Fas-L  induction  by  the  selenium  metabolite, 
SDG,  is  readily,  detectable  at  a  concentration  which  is  within  the  range  of  plasma 
concentrations  found  in  humans,  although  higher  than,  the  average  level  (Figure  1). 
The  concentrations  of  the  synthetic  selenium  derivative,,  p-XSC,  required  for  Fas-L 
induction  are  higher  than  for  SDG  but  it  is  well  established  in  animal  models  that  p- 
XSC  is  less  toxic  and  exerts  its  maximum,  cancer-protective  effect  at  high  dietary 
levels  (about  30  p.  p.  m.  compared  to  2  p.  p.  m.  for  selenite  (83)). 
9 Another  recent  finding  is  that  induction  of  the  so-called  JNK  and  p38  stress  kinases, 
members  of  the  MAP  kinase  family  of  kinases,  is  associated  with  induction  of 
apoptosis  by  SDG  and  p-XSC  (76).  However,  functional  intervention  experiments 
show  that  the  JNK  stress  kinase  pathway  specifically  is  most  important  for  induction 
of  Fas-L  by  SDG  (76)  (but  this  is  not  the  case  for  p-XSC,  for  reasons  that  remain 
unclear  (76)).  There  is  other  evidence  in  the  literature  also  indicating  that  the  JNK/c- 
Jun  pathway  is  mechanistically  upstream  of  Fas-L  in  other  contexts,  for  example  after 
treatment  with  anticancer  drugs  or  alkylating  agents,  but  this  is  not  necessarily  the 
case  (recently  reviewed  in  (84)).  How  selenium  metabolites,  such  as  SDG,  might 
activate  the  JNK/Fas-L  pathway  is  not  yet  clear  but  one  possibility,  in  view  of  our 
evidence  that  changes  in  redox  balance  may  be  important  (Fig.  4),  is  that  redox 
regulation  of  the  upstream  kinase  (ASK1)  that  regulates  JNKjp38  kinases  (85)  is 
involved  since  ASK1  is  known  to  be  inhibited  by  reduced  thioredoxin  (86)  and 
glutathione  (87)  and  SDG  has  been  shown  to  inhibit  of  thioredoxin_  and  thioredoxin 
reductase  (58,88,89).  We  are  currently  attempting  to  test  this  hypothesis. 
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23 LEGENDS  TO  FIGURES 
Figure  1.  Range  of  selenium  levels  in  vivo  (compiled  from  data  in  Longnecker  et 
al.  (90)).  Plotting  the  selenium  intake  of  people  ([tg/day)  living  in  seleniferous,  areas 
against  the  measured  serum  selenium  levels  ([tM)  revealed  that  serum  concentrations 
of  3-5  ttM  selenium  can  be  achieved,  in  vivo,  by  people.  taking'high  doses  of  selenium 
without  any  apparent  adverse  effects. 
Figure  2.  Potentiation  of  the  growth  inhibitory  effects  of  selenite  by  glutathione: 
comparison  with  SDG.  Growth  of  C57  cells,  a  mouse  mammary  epithelial  cell  line,  in 
response  to  treatment  with  50  IAM  sodium  selenite  (Na  Se),  50  pM  glutathione  (GSH), 
50  [M  Na  Se  plus  50  VM  GSH  and  5  VM  SDG  for  1-4  days.  Cell  viability  was 
assayed  using  the  MIT  assay  (Promega,  UK)  according  to  the  Manufacturer's 
protocol. 
Figure  3.  Tyrosine  phosphorylation  patterns  in  response  to  treatment  with  oxidants 
and  selenium  compounds.  Cells  were  treated  as  indicated  with  H202,  diamide, 
selenite,  SDG  or  p-XSC,  protein  extracts  prepared  and  immunoblot  analysis 
performed  using  a  phospho-tyrosine  specific  antibody  (Santa  Cruz  Biotech.,  CA). 
Figure  4.  Induction  of  HO  mRNA  by  selenium  compounds.  C57  cells  were  treated 
with  the  indicated  concentrations  of  sodium  selenite  (Na  Se),  SDG  or p-XSC  for  4,6 
or  18  h,  RNA  extracted  and  analysed  by  Northern  transfer  and  hybridisation  with  a 
HO-1  cDNA  probe  (74)  or  7S  ribosomal  RNA  probe  as  a  loading  control. 
24 Figure  5.  Effects  of  antioxidants  on  inhibition  of  growth  by  selenium  compounds. 
Cells  were  pretreated  for  18h  with  20  mM  NAC  or  100  mM  mannitol;  or  for  2h  with 
80  [tM  PDTC  and  then  with  the  indicated  concentrations  of  SDG  or  p-XSC  in 
continued  presence  of  antioxidant  for  4h  (NAC  or  PDTC)  or  18  h  (mannitol).  Cells 
were  then  washed  in  PBS  and  cell  growth  measured  using  the  NITT  assay.  The  results 
are  expressed  relative  to  the  cells  treated  with  antioxidant  alone. 
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